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GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
1A history of Q fever
What’s in the name?
Q fever was first documented in 1937 in abattoir workers in Queensland, Australia 
[1]. The non-specific symptoms of fever, intense headache, malaise and anorexia 
led to search of infectious causes like typhus, typhoid and paratyphoid fever, and 
leptospirosis. When all the tests for these infections were negative, the hitherto 
unknown disease was designated Query (Q) fever [1]. This name has stuck to the 
disease ever since, even though the causative agent Coxiella burnetii was identified 
in the subsequent years by Cox and Burnet [2, 3]. The term ‘Q fever’ does not cover 
the differential clinical manifestations of the disease, but surely this name 
resonates well and the uncommon initial letter makes it stand out in lists of 
(infectious) diseases.
Coxiella burnetii, I presume?
Along with the first documentation of Q fever, the causative agent of the disease 
was isolated from the blood and urine of symptomatic Q fever patients, by serial 
passage in guinea pigs [2]. It appeared to be typical Rickettsiae in smears from the 
spleens of infected mice [2]. This investigation of the bacterium in Australia 
coincided with the isolation of a previously unknown agent from ticks collected in 
Nine Mile (Montana, USA) during a field study on Rocky Mountain spotted fever. 
The initial American reports on the organism rejected it as a ‘true’ bacterium and 
assigned it viral characteristics, since it was easily filterable and unable to grow in 
cell-free culture [3]. After injection into guinea pigs, it produced a febrile illness 
that was different from Rocky Mountain spotted fever [3]. The link between the 
Harald Cox [Montana, USA] (Left) and Frank Marfarlane Burnet [Queensland, Australia] (Right)
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Australian and American researchers was made coincidently when an NIH 
Director visiting the Rocky Mountain Laboratory contracted infection with the 
Nine Mile agent [4]. In the report about this patient ‘X’, written by the NIH director 
himself, the author describes how he experienced signs and symptoms strikingly 
similar to Q fever. Subsequent cross protection studies confirmed that the Q fever 
and the Nine Mile agent were very likely the same pathogen [5]. It was proposed to 
name the organism Coxiella burnetii to credit both groups for their research. First 
being placed in the family Rickettsiaceae, C. burnetii has been reclassified after 
that, following advancing techniques of classifying organisms based on rRNA and 
genome sequencing. It was moved to the order Legionellales being genetically 
more related to members in this order, becoming a member of the family 
Coxiellaceae. The complete genome of the first isolate of C. burnetii in the USA, 
called the “Nine Mile strain”, obtained from a tick, has been sequenced in 2003 [6].
The bacterium
Coxiella burnetii is a Gram-negative coccobacillus and its life-cycle contains two 
morphologically distinct forms [7]. The small-cell variant (SMV) is the extracellular 
form that resists environmental stress such as desiccation, heat and chemical 
exposure [8]. The SCV is metabolically inactive, with tightly packed chromatin. 
These characteristics make the bacterium able to survive for prolonged periods in 
the environment and spread easily, both in a natural outbreak [9], as in hypothetical 
circumstances when it would be used as a biological weapon [10]. In contrast, the 
large-cell variant (LCV) is metabolically and divisionally active, and develops after 
SCV has infected the host’s immune cells, inside the monocytes or macrophages. 
The trigger for this differentiation seems to be the low pH inside the cytoplasmic 
Dr Livingstone, I presume?
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1vacuole in which C. burnetii survives [11], which is described below in more  detail.To complicate the matter, C. burnetii displays antigenic phase variation, having a 
phase I and phase II form, based on the structure of the lipopolysaccharide (LPS) 
molecules on the outer membrane of the bacterium. C. burnetii isolated from 
natural sources such as patients and animals have full-length LPS molecules with 
O antigen, and are referred to as phase I bacteria. Phase shift can occur in the 
laboratory when serial in-vitro passages of phase I bacteria in embryonated eggs or 
tissue culture results in a truncated LPS molecule on the membrane of C. burnetii. 
This form is referred to as the phase II bacterium. The phase II LPS molecule has 
the same lipid A as phase I, but lacks the C. burnetii-specific O antigen sugars 
virenose and dihydrohydroxystreptose [12]. In the Nine Mile strain, this aberrant 
phase II LPS is caused by large chromosomal deletion of genes involved in 
O-antigen sugar biosynthesis [13].
Chemical structure of LPS phase II from Coxiella burnetii in avirulent phase II. 
Abbrevations: Man, D-mannose; Hep, D-glycero- D-manno-heptose; Kdo, 3-deoxy-D-manno-oct-2-ulosonic acid. 
GlcN, D-glucosamine. (Adapted from Toman et al. Coxiella burnetii glycomics and proteomics--tools for linking 
structure to function. Ann N Y Acad Sci. 2009;1166:67-78)
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 This phase shift is associated with loss of virulence: phase I bacteria are 
virulent in humans and in animal models, while phase II bacteria do not cause 
disease in immune-competent animals [14]. Moreover, vaccines that are made from 
inactivated phase II bacteria do not protect against subsequent infection; so phase I 
bacteria are used in vaccines  [15-17].
 The impact of this phase variation in C. burnetii on serological response of the 
infected host needs to be mentioned here. Serology of Q fever concerns with 
antibodies against both phase I and phase II bacteria. Counter-intuitively, during 
an acute infection, antibodies against phase II are first detected, later followed by 
antibodies against phase I antigens. In chronic infection, antibody titres to phase I 
antigens are persistently present, which has important consequences for the 
diagnosis of chronic Q fever, as discussed later.
Q fever as a zoonosis
C. burnetii is prevalent worldwide, with the exception of New-Zealand [18, 19], and 
human Q fever outbreaks are reported in many countries [20-25]. The recent outbreak 
in the Netherlands from 2007 to 2010 was the largest ever described, with more than 
4,000 human cases notified, and estimates of 40,000 infected individuals, based on 
C. burnetii seroprevalence numbers among screened patients at high-risk for chronic 
Q fever [26].
 Q fever is a zoonosis, with natural reservoirs in a wide range of wild and 
domestic animals. The most common reservoirs leading to human outbreaks, 
however, are domestic ruminants, mostly goats and sheep [20, 27, 28]. These 
animals do not suffer from overt disease, but C. burnetii can replicate massively in 
placentas of pregnant animals, often resulting in abortion, premature birth or 
stillbirth. During parturition, high amounts of bacteria spread into the environment, 
potentially leading to human infections. Inhalation of aerosols containing C. burnetii, 
derived from birth products, are the main route of transmission [19]. Moreover, 
C. burnetii is shed in milk, urine and faeces of infected animals and human infections 
from ingestion of contaminated dairy products has been described [29]. Traditionally, 
farmers, veterinarians and abattoir workers are most at risk for Q fever. The Dutch 
outbreak in goat farms occurred in densely-populated urban areas, affecting 
people living or recreating in the vicinity of the infected farms.
Q fever, the disease
Acute Q fever
Initial infection with C. burnetii can lead to symptoms of acute Q fever, but is 
asymptomatic in >50%  of people, in which case it is detected retrospectively by the 
presence of anti-C. burnetii antibodies [20, 30]. Acute Q fever usually presents as a 
15
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1self-limiting flu-like illness, after 7-21 days of incubation, and can be accompanied by other symptoms such as headache, fatigue, myalgia and respiratory symptoms. 
C. burnetii DNA can be detected in serum in the early acute phase of the disease, 
using poly- merase chain reaction (PCR). However, serology plays a central role in 
diagnosing acute Q fever. As described before, C. burnetii exhibits antigenic 
variation with phase I and phase II LPS, and antibodies against both phases are 
detected separately in serological assays. Antibodies are detectable within 1-2 
weeks after start of symptoms of acute Q fever. The appearance of anti-phase II 
IgM (and IgG) antibodies accompanied by lower levels of anti-phase I antibodies 
are considered diagnostic of acute Q fever. Immunofluorescense (IFA) is the 
reference method, but other techniques are also used, i.e. complement fixation 
(CFT) and enzyme-linked immunosorbent assay (ELISA).
 The diagnosis is often missed because symptoms are non-specific and can 
resolve without treatment. Antibiotics, preferably doxycycline 200 mg/day for 2 
weeks, can be administered to shorten duration of symptoms [31]. A more serious 
presentations of acute Q fever is that of an atypical pneumonia, for which hospital 
admission can be necessary, and is estimated to occur in 2% of cases [30]. It should 
be noted that the necessity for hospital admission was much higher in the 
beginning of the epidemic in the Netherlands [32]. An overall mortality rate of 
acute Q fever of 1% is reported in France [19, 33]. Other rare manifestations of acute 
Q fever, including severe acute hepatitis, pericarditis, myocarditis and menin-
go-encephalitis have been described [19]. One of the important long-lasting 
sequelae of acute Q fever is (post-) Q fever fatigue syndrome (QFS) [34, 35], which 
is reported in over 20% of patients with acute Q fever [36, 37]. These patients suffer 
from incapacitating fatigue that lasts at least 6 months after the acute episode, 
which can be accompanied by a complex of other complaints among which are 
nausea, headache, dizziness, blurred vision, joint and muscle pain, (night)sweats 
and dyspnoea during exercise [38]. Conventional laboratory or microbiological 
parameters, however, do not discriminate QFS from an uncomplicated past Q fever 
episode. The clinical presentation of QFS resembles chronic fatigue syndrome 
(CFS) and fatigue after infection with pathogens like Borrelia burgdorferi. The 
aetiology of QFS is not elucidated yet, although it has been suggested that 
non-viable Coxiella antigens persisting in bone marrow after infection result in 
chronic immune stimulation [39, 40], definite proof of this is lacking. Moreover, 
cytokine dysregulation in individuals with predisposing genetic polymorphisms 
in immune-related genes has been linked to QFS [41, 42].
Chronic Q fever
Regardless of the initial presentation, C. burnetii can establish a persistent infection 
that may present after months to years and cause chronic disease (chronic Q fever). 
16
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Common manifestations of chronic Q fever are endocarditis, mycotic vascular 
aneurysm, and vascular prosthesis infection; all of these are life-threatening 
conditions. The diagnosis of chronic Q fever is often difficult. Symptoms are 
non-specific and can include low-grade fever, weight loss, night sweats, hepato-
splenomegaly and a persistently raised erythrocyte sedimentation rate (ESR) and 
C-reactive protein (CRP). Laboratory diagnosis of persistent infection relies on 
serology, polymerase chain reaction (PCR) and culture. While PCR and culture on 
valvular or vascular tissue are highly sensitive, tissue is only obtained when 
conventional surgery is carried out. On blood specimens, PCR and culture have a 
low sensitivity for chronic Q fever. Serology is therefore essential for diagnosis. 
Persisting high IgG antibody titres against C. burnetii phase I, and to a lesser extent 
phase II, are indicative of chronic C. burnetii infection. Cut-off anti-phase I IgG titre 
of >1:800 or 1:1600 based on a French in-house IFA, and >1:1024 based on a 
commercially available IFA (Focus Diagnostics), are considered for the diagnosis 
of chronic Q fever [43-45]. High phase I titres along with presence of definite 
endocarditis according to the modified Duke criteria [46] are considered 
confirmative of chronic Q fever endocarditis [47, 48]. Infected aneurysms or 
vascular prostheses can be identified by imaging techniques, most notably computed 
tomography (CT) and 18F-fluorodeoxyglucose positron emission tomography 
(FDG-PET/CT) [49, 50].
 Treatment of chronic Q fever is long and cumbersome. Antibiotics should be 
administered for at least 18 months or, in case of a valvular/vascular prosthesis, for 
at least 24 months [51]. Surgical intervention to replace an infected vascular 
aneurysm/graft or cardiac valve is often necessary, either in the acute situation of 
symptomatic aortic aneurysm or heart failure, or when a patient does not improve 
on antibiotics [52-54].
Host factors predisposing to chronic Q fever
Individuals at risk for developing chronic Q fever after infection with C. burnetii 
are patients with pre-existing cardiac valvulopathy (including prosthetic valve) 
and vascular aneurysms or grafts. Other reported risk factors are pregnancy, older 
age and renal insufficiency [52, 54-58]. In the large Dutch Q fever outbreak, it 
became apparent that only a minority (7.8%) of patients with cardiac valvular 
risk-factors developed chronic Q fever after (serological evidence of) infection with 
C. burnetii [59]. For patients with pre-existing vascular aneurysms or prosthesis, 
this proportion was substantially higher (30.8%) [60]. It can be speculated that 
immunological host factors play an important role to prevent development of 
chronic Q fever in most individuals, but predispose a minority to clinical 
manifestations of chronic Q fever. Inefficient early recognition of the bacterium by 
the innate immune system followed by incomplete eradication and/or inadequate 
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1initiation of adaptive immune responses may be pivotal factors in the development of chronic Q fever.
 Indeed, immunosuppression is stated in the literature as a risk factor for 
chronic Q fever. Case studies describe chronic Q fever in patients with (haema-
tologic) malignancies, or with liver- and bone marrow transplantation [58, 61-63]. 
A retrospective study of 102 Q fever endocarditis patients, reveals cancer as a risk 
factor [55], which may be related to the use of immuno-modulating cytotoxic 
treatment. A association between Q fever and the use of immunosuppressive 
drugs, including corticosteroids and methotrexate, is mentioned in three case 
reports [64-66], one of which describes a patient with chronic Q fever endocarditis 
[66]. It has also been suggested, based on animal and in-vitro experiments, that the 
persistence of C. burnetii in monocytes/macrophages is related to increased IL-10 
[67-71]. This cytokine is able to down-modulate the microbicidal activity of 
macrophages. Capo et al. showed that peripheral blood mononuclear cells (PBMCs) 
from chronic Q fever patients spontaneously produced elevated levels of IL-10 [67]. 
In addition, Honstettre et al monitored cytokine production by PBMCs from acute 
Q fever patients and found that the amount of IL-10 correlated to the risk of 
development of chronic Q fever [68]. IL-10 was found to induce C. burnetii replication 
in naive human monocytes, probably mediated by decreased TNF production [69]. 
Neutralizing IL-10 in in-vitro cultured monocytes of chronic Q fever patients, 
restored the microbicidal activity of these cells [70]. It has been shown that 
transgenic mice that over-express IL-10 in the macrophage compartment fail to kill 
the bacteria and develop a persistent C. burnetii infection with similar pathology to 
human chronic Q fever patients [71].
Immune response in Q fever
C. burnetii is an obligate intra-cellular bacterium that replicates in immune cells of 
the host, specifically cells of the mononuclear phagocyte lineage: monocytes and 
macrophages. After aerosol inhalation of the SCV form of C. burnetii, the bacterium 
targets the alveolar macrophages [72]. In an acute Q fever model in guinea pigs, 
immunohistochemistry confirmed the presence of C. burnetii organisms in infected 
animals in the lungs, liver, and spleen. Bacteria were most prominent in monocytes 
and macrophages but were also noted in other cell types, mainly pneumocytes in 
the lungs [73]. In human acute Q infection, dougnut granulomas consisting of 
macrophages and lymphocytes have been found in liver and bone marrow biopsy 
specimens [19].
 It is likely that C. burnetii is trafficked by infected monocytes/macrophages to 
other tissue than the lungs. Interestingly, cardiac valves, aneurysmatic vascular 
wall or prosthesis and placenta are predilection sites for outgrowth and persistence 
of C. burnetii. In chronic Q fever, no granulomas are found in C. burnetii-infected 
18
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tissue such as heart valves, liver and aneurysms [19, 74]. In valvular tissues, C. 
burnetii is detected intracellularly, clustered as a single intracytoplasmic mass, 
almost exclusively in local macrophages [74]. Vegetations are difficult to detect 
using echocardiography in Q fever endocarditis [30, 75]. Somewhat contradictory, 
a recent histological study on C. burnetii-infected vascular wall tissue showed a 
necrotizing granulomatous response in four of seven patients with vascular 
chronic Q fever [76].
 It has been demonstrated that C. burnetii phase I enters monocytes/macrophages 
using αvβ3-integrin (CD51/CD61) as binding receptor [77, 78]. Binding to Toll-like 
receptor (TLR)4 has been proposed to be involved in actin rearrangement and 
phagocytosis [79]. TLR4 knockout mice showed only transient granuloma formation 
after inoculation with C. burnetii, in contrast to wild-type mice. However, TLR4 
knockout mice did not show increased C. burnetii survival inside macrophages in 
vitro, or a defect in bacterial clearance in vivo [79].
 Interestingly, Zamboni et al. have shown that phase I LPS of C. burnetii is a 
poor immunogenic stimulus and functions as an antagonist of TLR4-dependent 
Transmission electron micrographs of phase II Coxiella-infected Vero cells.
Cells were infected for 2 days (A) or 6 days (B–D), then examined via transmission electron microscopy. Panel A 
shows a spacious PV at 2 days post infection (dpi) harbouring a few Coxiella organisms (arrow). Multilamellar 
bodies (arrowhead) are also present that may result from PV fusion with autophagosomes. By 6 dpi (B and C), the 
PV has enlarged to occupy a large portion of the host cell and contains numerous Coxiella that have entered the 
stationary phase of their growth cycle (Coleman et al., 2004). (Adapted from Voth&Heinzen, Lounging in a 
lysosome: the intracellular lifestyle of Coxiella burnetii. Cell Microbiol 2007;9(4):829-40)
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1signalling in macrophages [80]. This results from the fact that the lipid A portion of C. burnetii LPS is a tetra-acylated structure, in contrast to e.g. Escherichia coli LPS 
which has a hexa-acylated lipid A portion which is a thousand times more potent 
as an endotoxin [81-83]. It has been suggested that the full-length LPS molecule of 
phase I C. burnetii serves as a shielding molecule, which masks antigens on its 
surface from immune recognition by other pattern recognition receptors (PRRs) of 
the host’s immune cells [84], i.e., TLR2. Indeed, C. burnetii phase II - with short LPS 
molecules - stimulate macrophages through TLR2 [80]. Macrophages from TLR2 
knockout mice were highly permissive to C. burnetii phase II growth, compared to 
either TLR4 knockout or wild-type mice [80].
 Once inside cells, C. burnetii resides in an cytoplasmic vacuole – the parasito-
phorous vacuole (PV) – which closely resembles a phagolysosome, containing 
lysosomal enzymes and having a low pH (<5.0). During maturation of the PV, the 
vacuole increases in size till it almost completely fills the host cell cytoplasm [85]. 
During this process, the SCV converts to the LCV and becomes metabolically 
active and replicates. It is quite unique that C. burnetii can withstand the active acid 
hydrolases and degradative activity inside the PV [86]. It even replicates to high 
numbers and thrives in this hostile environment in which other bacteria are 
degraded [87]. C. burnetii promotes vacuole biogenesis and maintenance to survive, 
and is able to inhibit apoptosis of the host cell [88]. Authophagy, normally a 
mechanism of the innate immune system to remove intracellular pathogens, is 
induced by C. burnetii favouring the generation and maturation of the PV and 
thereby actually promoting intracellular replication [89, 90].
It is known that antibodies can provide protection against intracellular pathogens 
via a number of different mechanisms, including direct bactericidal activity, 
complement activation, opsonization, cellular activation via Fc or complement 
receptors, and antibody-dependent cellular cytotoxicity [91, 92].
 However, the role of humoral responses in Q fever are not clear. Early studies 
on C. burnetii have shown that passive transfer of antibody protects guinea pigs 
against subsequent challenge with C. burnetii [93]. Other studies in mice confirmed 
that passive immunization of naïve mice with serum from vaccinated mice fully 
protected against challenge [17]. However, immune sera or B-cells of immunized 
mice that were transferred to SCID mice, conferred no protection against C. burnetii 
challenge, while T-cells did [17], emphasizing the importance of T cell-mediated 
immunity.
 The high antibody titres that are found in chronic Q fever to phase I and 
phase II antigens are apparently not effective for C. burnetii clearance. It has even 
been made plausible that these high antibody titres are potential detrimental 
during chronic Q fever, because immune complexes can cause pathology such as 
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glomerulonephritis or vascular leukocytoclastic lesions [62]. In addition, conflicting 
results have been obtained on the effect of antibody opsonisation on the intracellular 
fate of C. burnetii. Desnues et al demonstrated that C. burnetii that was opsonized 
with IgG antibodies purified from chronic Q fever patients, favoured C. burnetii 
replication within human macrophages [94]. Shannon et al., however, found 
increased uptake of antibody-opsonized C. burnetii by macrophages, but did not 
observe subsequently impact on growth rate intracellularly [92, 95]. They found, 
however, that antibody- opsonization of C. burnetii led to increased maturation of 
dendritic cells and increased cytokine production. Surprisingly, both the Fc 
receptor, as well as complement receptors were redundant for passive immunization 
in vivo, as shown by equal protection of wildtype mice compared to FcR knockout 
as well as several different strains of complement-deficient mice [95].
Cell-mediated immune responses are important for the defence against intracellular 
bacteria, as shown for Mycobacterium tuberculosis, Mycobacterium leprae, Listeria 
monocytogenes, and Legionella pneumophila [92]. These intracellular bacteria infect 
professional antigen-presenting cells, resulting in antigen presentation on a MHC 
II molecule on the surface of the cells. In combination with T cell co-stimulatory 
molecules on the surface and the production of cytokines, this leads to activation 
of antigen-specific T cells, which are recruited to the site of infection. The latter 
produce pro-inflammatory cytokines such as interferon-gamma (IFN-γ) and 
 tumour-necrosis factor (TNF), in turn leading to activation of macrophages to 
perform anti-microbial effector mechanisms that are able to kill the intracellular 
bacteria. In this process, granulomas are formed in infected tissue.
 For C. burnetii, it has been shown in a series of experiments that when the 
cell-mediated immunity was suppressed in guinea pigs and mice by whole body 
irradiation, cortisone injection or pregnancy, the infection reactivated [96-98]. 
Andoh et al showed in a mouse model of acute Q fever that T cell-deficient mice 
and IFN-γ knockout mice were very susceptible to C. burnetii infection [99]. IFN-γ 
knockout succumbed to infection in an early stage, while T-cell deficient mice were 
not able to clear the infection within 4 weeks. Read et al reconstituted immuno-
deficient SCID mice with CD4+ or CD8+ T cells, and depleted immunocompetent 
Balb/c mice of T cell subsets, thereby showing that CD4+ cells or CD8+ cells alone 
were able to control a primary infection with C. burnetii [100]. This suggests that 
both CD4+ and CD8+ T cells play an important role in host defense against 
C. burnetii, at least in the mouse.
 In-vitro studies have shown that IFN-γ induces killing of C. burnetii in THP-1 
monocytic cells, and inhibits growth of C. burnetii in mouse fibroblasts [101, 102]. 
Induction of reactive oxygen and nitrogen species (ROS and RNS, respectively) 
have been shown to be involved in the control of C. burnetii replication by IFN-γ 
21
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1stimulation of primary mouse macrophages [103]. In humans, lymphocytes of vaccinees and people with a past infection proliferate in response to C. burnetii 
antigens in vitro, indicating long-lasting cell-mediated immune responses [104, 
105]. IFN-γ production by T cells upon in-vitro C. burnetii stimulation was observed 
in immunized individuals [106].
 Thus, cell-mediated immune responses contribute to clearance of C. burnetii 
infection and IFN-γ plays a key role in the control of C. burnetii replication.
Q fever vaccination
Development of a safe and effective Q fever vaccine started almost from the 
moment that the micro-organism was identified. These vaccine projects were not 
only initiated to protect people with occupational exposure to C. burnetii – the 
main focus was on workers in slaughterhouses in Australia – but were also the 
result from governmental concerns of C. burnetii as a biothreat [10]. Several attempts 
were unsuccessful sofar, including a live-attenuated phase II vaccine in Russia 
(107), a chloroform-methanol residue (CMR) extract vaccine in the USA [108, 109], 
and a trichloroacetic (TCA) extract in Slovakia [110]. These vaccines were either 
unsafe or found to be reactogenic [108, 110-112]. In addition, development of 
sub-unit protein vaccine had no success. A number of potential protective protein 
subunits were identified, but recombinant protein antigens expressed in E. coli 
showed limited efficacy [113-115].
 The only commercially available vaccine has been licensed for use in Australia 
since 1989. This is a formaldehyde-inactivated whole-cell phase I vaccine (Q-vax; 
CSL Biotherapies, Australia), produced from the Henzerling strain of C. burnetii 
[116-118]. Studies have shown 97-100% protection in slaughterhouse workers for at 
least five years post-vaccination [116, 119, 120]. However, Q-vax induces side-effects 
in a significant proportion of vaccinees, similarly to the CMR and TCA extract 
vaccines. The most reported side-effects are swelling, erythema and tenderness at 
the site of vaccination, but also systemic mild symptoms such as headache and 
flu-like symptoms [118]. Individuals who had previous contact with C. burnetii 
need to be excluded from vaccination with Q-vax, because it has been reported that 
vaccination of people with pre-existing immunity against C. burnetii may lead to 
serious adverse reactions such as sterile abcesses and systemic hypersensitivity 
reactions [38, 121]. To identify pre-existing immunity, serology and skin testing is 
performed in all potential vaccinees before vaccination with Q-vax, according to 
the manufacturer’s instruction [116]. A positive result in either one or both tests 
precludes vaccination.
 A recent report on passive surveillance of the Australian national Q-fever 
vaccination campaign 2001-2004 in slaughterhouses, showed a very low number of 
reported adverse events after immunization (86/48,986;0.002%). These included 
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mostly local reactions, with only one serious adverse event [122]. There are only 
few reports of severe local reactions after Q-vax vaccination [123, 124]. It should be 
taken in account that all the data comes from vaccination of a predominantly 
young and healthy group of male slaughterhouse workers.
The Q fever outbreak in the Netherlands, which was related to dairy goat farms, 
spread among the human population living in close proximity to the farms with 
infected goats [125, 126]. The most important measures to prevent morbidity and 
mortality of human Q fever were taken in the veterinary sector, aiming at reducing 
the spread of C. burnetii. In the Netherlands, these included obligatory hygienic 
measures for farms with small ruminants, mandatory notification of C. burnetii- 
infected dairy goat and sheep farms, vaccination of all dairy goats and sheep on 
farms with more than 50 animals, bulk tank milk monitoring for C. burnetii DNA 
by PCR and culling of pregnant goats on infected farms [21]. Human vaccination 
with the Australian Q-vax vaccine, however, was decided to be of additional value 
in individuals particularly at high-risk for serious complications of Q fever, namely 
those with risk factors for development of chronic Q fever living in the Q fever 
high-incidence area [127]. This target population included patients with underlying 
cardiac valvulopathy (including prosthesis), a history of endocarditis, known 
(aortic) aneurysm or vascular prosthesis [127, 128]. The size of these target groups 
Q fever notifications in the Netherlands 2007-2011 and measures taken. 
(Adapted from Isken et al. Implementation of a Q fever vaccination program for high-risk patients in the Netherlands. 
Vaccine  31(23):2617-22)
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1was unknown and no attempts were made to estimate the number to be expected. Pre-vaccination screening – with C. burnetii serology and skin test – and vaccination 
took place at one municipal health centre in the high-incidence area between 
January and April 2011, with some catch-up vaccinations in June. The much larger 
than expected number of referred people overloaded the system and made 
implementation of the campaign difficult, forcing an up-scaling of staff. In the end, 
a total of 1786 patients were screened, of which 1370 were  vaccinated.
Outline and aims of the thesis
In this thesis, we study the immune response to Coxiella burnetii in the light of 
chronic Q fever and Q fever vaccination, in order to define important aspects of the 
host’s immunological defence against C. burnetii. The major goal of our research is 
to improve prevention, diagnosis and treatment of (chronic) Q fever.  In addition, 
elucidating immunological aspects of the pathogenesis of Q fever disease opens up 
the possibilities of adjunctive immunosupportive treatment in selected patients. 
Knowledge on the applicability and immunogenicity of vaccination against 
C. burnetii in people with risk factors for chronic Q fever will help in future 
decisions on C. burnetii vaccination in outbreak situations.
• In Part I we look more closely into the recognition and response to C. burnetii 
by the immune system in humans and the association between disease outcome 
and genetic polymorphisms in immune-related genes. We investigated the 
specific interferon-gamma (IFN-γ) response pathway is investigated in chronic 
Q fever patients.
• In Part II we asked the question whether measurement of cell-mediated 
immune responses can be used as a diagnostic tool for Q fever.
• In Part III we investigated whether the use of frequently described drugs that 
suppresses the cell-mediated immune response in rheumatoid arthritis (RA) 
patients increases the risk of developing (acute or chronic) Q fever.
• In Part IV, we addressed the question to what extent Q fever vaccination is safe 
and immunogenic; in addition we investigated the coverage of the Dutch Q 
fever vaccination campaign.
PART I.  Studies on the immune response against C. burnetii in 
(chronic) Q fever
The innate immune system provides the first line of host defense against 
microorganisms. After adequate recognition of the invading pathogen, host-defense 
mechanisms are activated, such as cytokine signaling and phagocytosis, which are 
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needed to eliminate the bacteria. We hypothesized that chronic Q fever patients 
have inadequate innate immune recognition of C. burnetii. In Chapter 2, we used 
functional in-vitro analysis to explore how C. burnetii is initially recognized by 
 pattern-recognition receptors of the host immune cells. In Chapter 3, we investigated 
the association between chronic Q fever and genetic polymorphisms in these pattern- 
recognition receptors and their adaptor molecules. In Chapter 4 we focussed on 
the IFN-γ response in chronic Q fever. IFN-γ is pivotal for microbicidal activity of 
monocytes and macrophages against the intracellular C. burnetii. Previous research 
has led to the conclusion that this pathway is defective in chronic Q fever patients. 
We started with a systems biology approach, using a gene expression microarray, to 
investigate the IFN-γ response in patients and healthy individuals. We investigated 
this further by functional and genetic analysis in chronic Q fever patients.
PART II.  Detection of C. burnetii infection using cell-mediated 
immune responses
The standard immunological method to detect Q fever is measurement of specific 
antibodies against phase I and phase II C. burnetii. Assessment of T-lymphocyte 
immunity might be an additional and even superior method, given the fact that 
defence against C. burnetii mainly depends on cell-mediated immunity, which 
includes IFN-γ mediated macrophage activation. Hence, a skin test can be done 
to assess delayed-type hypersensitivity to intradermally injected inactivated 
C. burnetii. The skin test, however, is cumbersome, lacks a well-defined cut off, and 
depends on trained personnel to perform. Its use is limited to pre-vaccination 
screening to exclude potential vaccinees with pre-existing immunity against 
C. burnetii. We developed an in-vitro IFN-γ production assay, in which IFN-γ 
production is measured in blood after in-vitro exposure to C. burnetii antigens, 
using similar principles as those of the Quantiferon test for tuberculosis. In 
Chapter 5, we described how we investigated the applicability of our novel assay, 
by measuring the IFN-γ production in a large group of vaccination candidates who 
were screened by Q fever serology and skintest.
 In Chapter 6 we asked ourselves the very relevant question whether the 
measurement of IFN-γ production, in combination with other cytokines in a whole 
blood assay, could be used to differentiate an ongoing infection (chronic Q fever) 
from a past (cleared) infection. Identifying a cytokine profile specific for chronic Q 
fever may aid in its timely diagnosis and early treatment to prevent severe 
morbidity and death.
 In Chapter 7 we investigated whether cell-mediated immune responses can 
be used as a biomarker to monitor treatment of chronic Q fever. For this, we 
longitudinally performed whole blood assays in fifteen chronic Q fever patients on 
antibiotic treatment for at least 18 months.
25
GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
1 Other IFN-γ release assays have recently been developed and are based on a technique of enzyme-linked immunosorbent spotting (Elispot), which detect 
 antigen-specific IFN-γ secreting cells by making them visible at a single-cell 
level. In Chapter 8, we compared the results of our IFN-γ production assay with 
the results of a Coxiella Elispot in a group of Q fever patients and healthy control 
individuals.
 In Chapter 9 we asked the question whether the C. burnetii -specific IFN-γ 
responses could be a useful tool for diagnosis of acute Q fever. We challenged im-
munocompetent BALB/c mice with aerosols containing virulent phase I C. burnetii, 
and evaluated the timing and extent of IFN-γ responses. Other cytokines were 
also measured in an effort to identify other potential diagnostic markers.
PART III.  Immunosuppressive drugs for rheumatoid arthritis as a 
risk factor for chronic Q fever
Although immune-suppression is a stated risk factor for development of chronic 
Q fever, based on case series and case reports, definition of the type of immune- 
suppression is poor and systematic studies are absent. Anti-TNF therapy increases 
the risk of infections with intracellular bacteria such as M. tuberculosis. Clinical 
data on the risk of C. burnetii infection in patients on anti-TNF therapy are lacking. 
In view of the widespread use of TNF-blockers in patients with rheumatoid 
arthritis (RA) or other inflammatory conditions, we decided to perform a controlled 
cohort study to examine the risk of Q fever in RA patients with and without 
anti-TNF therapy. Chapter 10 describes the results of this study. In Chapter 11 we 
described the history of an RA patient who had an episode of acute Q fever while 
being treated with anti-TNF agents, and who developed chronic Q fever over the 
subsequent two years while using the anti-B-cell monoclonal antibody rituximab. 
The case highlights the importance of cellular and humoral immune response 
modifying agents in the natural course of C. burnetii infections and the possible 
pitfalls of the use of serological methods to detect the stage of disease.
PART IV. Prevention of Q fever by vaccination against C. burnetii
Following the large Q fever outbreak in the Netherlands between 2007 and 2011, 
the Dutch government decided to vaccinate people with risk-conditions for 
development of chronic Q fever. The only available whole-cell vaccine Q-vax 
required pre-vaccination screening – skin-testing and serology – to exclude 
sensitized individuals with presumably more risk for immune-mediated adverse 
events following immunization. There was no experience worldwide with this 
vaccine in this specific old age risk group with its many co-morbidities and 
medication. Another special aspect of this vaccination campaign was that the 
IFN-γ release assay was performed during pre-vaccination screening. This 
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supplied additional information about pre-existing T-cell immunity in vaccinees 
as it did not influence the decision to vaccinate.
 In Chapter 12, we describe the safety and adverse events after skin test and 
vaccination in this specific patient-group, and relate this to characteristics of 
the vaccinees and pre-vaccination screening outcomes. We also analyzed the 
association between local adverse events after skin test or vaccination, patient 
characteristics and pre- and post-vaccination immunological parameters. In 
Chapter 13, we assessed the immune responses to C. burnetii at 6 and 12 months 
after vaccination in this relevant population.
 Chapter 14 focuses on the skin test which, as an in-vivo test, elicits an immune 
response itself and may influence subsequent measurements of immune response. 
In Chapter 15, we retrospectively aimed to obtain prevalence rates of the risk- 
conditions for chronic Q fever in the high-incidence area, in order to estimate 
coverage of the Q fever vaccination campaign. To this end, we extracted data on 
the specific risk-conditions from the Integrated Primary Care Information (IPCI)-
database, a large longitudinal population-based general practice research database 
in the Netherlands. We described the procedure we followed to arrive at an 
estimate of the coverage of the Q fever vaccination campaign in the Netherlands 
2011.
Finally, Chapter 16 provides a summary, general discussion and recommendations 
for future research.
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Abstract
Background. Infection with Coxiella burnetii can lead to acute and chronic Q fever. 
Toll-like receptor 1 (TLR1), TLR2, TLR4, TLR6, nucleotide-binding oligomerization 
domain receptor 1 (NOD1), NOD2, and the mitogen-activated protein kinases are 
central in the innate immune response against microorganisms, but little is known 
about their role in the recognition of C. burnetii in humans.
Methods. Human peripheral blood mononuclear cells (PBMCs) were stimulated 
with C. burnetii Nine Mile and the Dutch outbreak isolate C. burnetii 3262. TLRs 
were inhibited using specific antibodies or antagonists. Additionally, the influence 
of human polymorphisms in TLRs and Nod-like receptors (NLRs) on C. burnetii–
induced cytokine production was assessed.
Results. Inhibition of TLR2, p38, JNK, and ERK led to decreased cytokine responses 
in C. burnetii–stimulated human PBMCs. Humans with polymorphisms in TLR1 
and NOD2 had reduced cytokine production, compared with humans with 
wild-type genotypes, after stimulation. Interestingly, polymorphisms in TLR6 led 
to decreased cytokine production after C. burnetii 3262 stimulation but not after 
C. burnetii Nine Mile  stimulation.
Conclusions. The TLR1/TLR2 heterodimer and NOD2 are important recognition 
receptors for the induction of cytokine responses against C. burnetii in humans. 
Furthermore, an interesting finding was the divergent recognition of C. burnetii 
Nine Mile and C. burnetii 3262.
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Introduction
Coxiella burnetii is the causative agent of Q fever and can cause either acute or 
chronic infection in humans. Acute Q fever is associated with inflammation, 
hepatitis, and pneumonia. Chronic Q  fever, defined as a cardiovascular chronic 
infection, develops over several months to years following an initial infection and 
is characterized primarily by endocarditis or endovascular infection [1]. Even 
though only a small proportion (2%–5%) of the infected individuals develop 
chronic Q fever, the burden for patients is significant, as long-term antimicrobial 
drug treatment is necessary, with mortality reaching >60% when infection is 
left untreated [1, 2]. In the Netherlands, one specific C. burnetii genotype,  referred 
to as C. burnetii 3262, dominated the Q fever outbreak, which resulted in several 
thousands of cases and chronic infection in >250 patients [3].
 The innate immune system provides the first line of host defense against 
microorganisms. Unique pathogen-associated molecular patterns (PAMPs) on the 
surfaces of microorganisms are recognized by the pattern-recognition receptors 
(PRRs) of the host immune cells to activate host-defense mechanisms, such as 
phagocytosis and cytokine signaling [4]. The main PRRs involved in recognition of 
bacteria are Toll-like receptors (TLRs; TLR1, TLR2, TLR4, and TLR6) and nucleo-
tide-binding oligomerization domain receptor 1 (NOD1) and NOD2. Previous 
studies in mice and reporter cell lines have demonstrated TLR2 as an important 
regulator of immune responses against C. burnetii [5–7]. The TLR2 receptor is able to 
form heterodimers with either TLR1 or TLR6; TLR1/TLR2 heterodimers mainly 
recognize triacylated lipopeptides, whereas TLR2/TLR6 heterodimers recognize 
diacylated lipopeptides [8, 9]. Polymorphisms in TLR1 and TLR6 have been associated 
with increased susceptibility to candidemia, invasive aspergillosis, impaired myco- 
bacterial signaling, and innate immune responses in sepsis [10–13]. NOD1 and 
NOD2 recognize the bacterial peptidoglycan structures g-D-glutamyl- meso-
diaminopimelic acid (iE-DAP) and muramyl dipeptide (MDP), respectively [14]. They 
are associated with the recognition of a broad range of bacteria and interact with 
TLR2 through receptor-interacting protein (RIP)-like interacting caspase-like 
apoptosis regulatory protein kinase (RICK) as the central signaling molecule [15].
 Two unknown issues involve how C. burnetii is initially recognized by the 
immune system in humans and how C. burnetii evades these mechanisms and 
leads to acute and chronic Q fever in patients. Previously, it has been shown that 
the defective immune response that accompanies chronic Q fever is associated 
with the failure of C. burnetii to induce lymphocyte proliferation, the absence of 
granulomas, and cytokine dysfunction [1, 16]. However, our group recently showed 
that patients with chronic Q fever have high T-cell–derived interferon γ (IFN-γ) 
production upon contact with C. burnetii [17]. This finding may indicate that 
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defective innate immune recognition of C. burnetii and subsequent induction of 
appropriate cytokines are important for the pathogenesis of chronic Q fever and 
may not be due to the failure to activate lymphocytes. To investigate this hypothesis, 
more fundamental knowledge is needed about the PRRs involved in sensing 
C. burnetii. Therefore, this study investigated the role of TLR1, TLR2, TLR4, TLR6, 
NOD1, NOD2, and the downstream mitogen-activated protein kinases (MAPKs) 
p38, JNK, and ERK in the recognition of two C. burnetii phase I strains, the reference 
strain C. burnetii Nine Mile and the Dutch outbreak isolate C. burnetii 3262. The study 
will provide better insight into the recognition of C. burnetii by PRRs in general 
and could assist further investigations on immunological causes of chronic Q fever.
Material and Methods
C. burnetii Strains
Two C. burnetii strains were used: C. burnetii Nine Mile RSA493 (NM) phase I (a kind 
gift from the Bundeswehr Institute for Microbiology; Munich, Germany) and 
C. burnetii X09003262 (3262) phase I, isolated from the placenta of an aborted goat 
in the Netherlands [3]. Both strains were cultured on buffalo green monkey cells, 
and the numbers of Coxiella DNA copies was determined using Taqman real-time 
polymerase chain reaction as described previously [18]. Lipopolysaccharide (LPS) 
phase determination was performed by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis and silver staining, using purified phase I (RSA493) and phase 
II (RSA439) C. burnetii NM LPS (kindly provided by R. Toman) as controls [19, 20]. 
Both C. burnetii strains were inactivated by heating for 30 minutes at 99°C.
Study Population
Peripheral blood mononuclear cells (PBMCs) were derived from buffy coats from 
blood donors (Sanquin, Nijmegen, the Netherlands) and from whole-blood specimens 
from volunteers (for single-nucleotide polymorphism [SNP] analyses). All were 
healthy Dutch volunteers of European descent. Donor blood specimens were not 
serologically screened for C. burnetii infection, and the individuals were not 
immunized [21]. In the SNP experiment with C. burnetii 3262, cells were isolated 
from 85 volunteers (age, 23–73 years; 23% were women, and 77% were men). In the 
experiment with C. burnetii NM, cells were isolated from 123 volunteers (age, 22–70 
years; 16% were women, and 84% were men). The NOD2-deficient individuals had 
the homozygous NOD2 3020insC polymorphism. The 3020insC polymorphism 
was analyzed as described previously [22]. Venous blood specimens were collected 
after informed consent was obtained. The experiments were conducted according 
to the principles expressed in the Declaration of Helsinki.
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Isolation of Human PBMCs and Stimulation
PBMCs from healthy and NOD2-deficient individuals were isolated as described 
previously [23]. A volume of 100 µL containing 5 × 105 cells was added to a 
round-bottomed 96-well plate (Corning, Amsterdam, the Netherlands) and 
incubated with C. burnetii NM or C. burnetii 3262 (range, 1 × 106 – 1× 107 bacteria/
mL) in the presence of 10% human serum. After 24 hours, supernatants were 
harvested and stored at −20°C. In some experiments, PBMCs were preincubated 
for 60 minutes with antagonizing or inhibiting agents. Monoclonal antibodies for 
blocking TLR2 (clone TL2.1) and mouse immunoglobulin G2a isotype were used at 
a concentration of 5 µg/mL (InvivoGen, Toulouse, France). Highly purified 
Bartonella quintana LPS (100 ng/mL) was used as a TLR4 antagonist [24]. p38 was 
inhibited using 1 mmol/L p38 inhibitor SB202190 (Sigma-Aldrich, Zwijndrecht, the 
Netherlands) [25]. JNK and ERK1/2 were inhibited by 20 μmol/L JNK SP600125 
(AG Scientific, San Diego, California) and 10 μmol/L MEK U0126 (Promega, 
Madison, Wisconsin), respectively.
Cytokine  Measurement
Cytokine production was measured using an enzyme-linked immunosorbent assay 
(ELISA). The following kits were used: interleukin 6 (IL-6; Sanquin, Amsterdam, 
the Netherlands), tumor necrosis factor-α (TNF-α), interleukin 1β (IL-1β; R&D Systems, 
Minneapolis, Minnesota), and mouse IL-6 (Invitrogen, Carlsbad, California). Absorption 
was measured at 450 nm (Bio-Rad Laboratories, Veenendaal, the Netherlands).
Genomic DNA Isolation and SNP Analysis
DNA was isolated using the Gentra Pure Gene Blood kit (Qiagen, Valencia, California) 
according to the manufacturer’s protocol for whole-blood specimens. Polymorphisms 
were identified using a predesigned TaqMan SNP genotyping assay (Applied Bio- 
systems, Foster City, California) or an Illumina Immunochip. The following SNPs 
were analyzed: for TLR1: rs5743611, rs4833095, and rs5743618; for TLR2: rs5743704; 
for TLR4: rs4986790/rs4986791; for TLR6 P249S: rs5743810; for NOD2: rs2066842, 
rs5743293, rs2066845, rs2066844, rs9302752, rs7194886, rs8057341, rs751271, and 
rs3135499; and NOD1 insertion/deletion polymorphism NOD1 + 32656 (Table 1).
Animals
TLR1, TLR2, and TLR6 knockout mice were kindly provided by Prof S. Akira 
(Department of Host Defense, Osaka University, Osaka, Japan) and are fully 
backcrossed to the C57BL/6 background. Age- and sex-matched control C57BL/6 
mice were obtained from Charles River Wiga (Sulzfeld, Germany). Mice were 
housed in filter-top cages, and water and food were provided ad libitum. Wild-type, 
NOD1, NOD2, and NOD1/2 knockout mice were bred and maintained in the St. 
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Jude Children’s Research Hospital (Memphis, Tennessee). Bone marrow–derived 
macrophages (BMDMs) were used in all experiments. After dissection of mouse 
legs, the bone marrow was flushed out using sterile phosphate-buffered saline 
(PBS). Differentiation into macrophages occurred in 7 days at 37°C and 5% CO2 in 
Dulbecco’s modified Eagle’s medium/nutrient mixture F-12 (Gibco, Invitrogen, 
Carlsbad, CA, USA) supplemented with 30% L929 medium, 10% heatinactivated 
filtered fetal bovine serum (Invitrogen, Carlsbad, CA, USA), 1% nonessential 
amino acids, and 1% 100 U/mL penicillin and 100 mg/mL streptomycin. On day 6, 
the BMDMs were counted and added to either a 24-well plate at  a concentration  of 
1 × 106 cells/mL or a 96-well plate at a concentration of 1 × 105 cells/mL. After 
24 hours of resting at 37°C, the cells were stimulated with medium, C. burnetii 
NM (1 × 106 bacteria/mL), C. burnetii 3262 (1 × 106–1 × 107 bacteria/mL), Pam3Cys 
(10 µg/ mL), and Escherichia coli LPS (10 ng/mL).
 The experiments were approved by the Ethics Committee on Animal Experiments 
of the Radboud University Medical Center, and protocols were approved by the 
St. Jude Children’s Research Hospital Committee on the Use and Care of  Animals.
Statistical Analysis
The data are expressed as mean ( ± standard error of the mean) unless indicated 
otherwise. Differences between experimental groups were tested using the Mann–
Whitney U test. In experiments using antagonists or inhibitors, the Wilcoxon 
matched-pairs signed rank test was used. GraphPad Prism 5 software was used. 
Differences with a P value of < .05 were considered statistically significant.
Results
Role for TLR2, but not TLR4, in C. burnetii–Induced Cytokine 
Response in Humans
TLR4 is an important receptor for LPS. Because C. burnetii phase I possesses 
tetra-acylated LPS [27], TLR4 could play a role in cytokine production by C. burnetii. 
Upon TLR4 blockade by the TLR4 antagonist Bartonella LPS, the IL-1β, IL-6, and 
TNF-α responses of PBMCs after E. coli LPS stimulation were effectively inhibited. 
However, this potent TLR4 antagonist was unable to inhibit C. burnetii NM–
induced and C. burnetii 3262–induced cytokine responses in PBMCs (Figure 1A).
 PBMCs preincubated with an antagonistic antibody directed against TLR2 
produced less IL-1β and IL-6 after encounter with C. burnetii NM and C. burnetii 
3262 (Figure 1B). TNF-α levels were decreased after stimulation with C. burnetii 
3262; conversely, this was not observed after stimulation with C. burnetii NM and 
the TLR2 ligand Pam3Cys (Figure 1B). Additionally, the role of TLR4 and TLR2 in 
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Figure 1. Recognition of Coxiella burnetii by Toll-like receptor 2 (TLR2), but not by TLR4, in 
humans and mice. A and B, Peripheral blood mononuclear cells (PBMCs) were pretreated 
with medium or Bartonella lipopolysaccharide (LPS; 100 ng/mL; A) or with isotype control 
immunoglobulin G2B or anti-TLR2 (B) for 1 hour and subsequently stimulated with Roswell 
Park Memorial Institute (RPMI) medium (striped bar), C. burnetii Nine Mile (NM; 1 × 106 
bacteria/mL), C. burnetii 3262 (1 × 106 bacteria/mL), Escherichia coli LPS (10 ng/mL), or 
Pam3Cys (10 µg/mL) in the presence of serum (n = 5–9). Mean values ( ± standard error of the 
mean [SEM]) are shown. *P < .05 and **P < .01, by the 2-tailed Wilcoxon matched-pairs signed 
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C. burnetii recognition was investigated using PBMCs from volunteers with or 
without SNPs in these genes. Polymorphisms in TLR4 (D299G and T399I) did not 
result in decreased cytokine responses (Figure 1C). PBMCs from volunteers 
homozygous for a SNP in TLR2 (P631H) showed significantly decreased IL-1β 
responses after stimulation  with C. burnetii 3262 only (Figure 1D). An explanation 
can be that the location of the TLR2 SNP is more important for the binding of 
C. burnetii 3262 than for C. burnetii NM or Pam3Cys.
 Finally, we investigated the role of TLR2 in the cytokine induction by C. burnetii in 
murine BMDMs. BMDMs derived from TLR2 knockout mice produced less IL-6, 
compared with those from wild-type mice, after stimulation with C. burnetii NM 
and C. burnetii 3262 (Figure 1E ).
Cytokine Induction by C. burnetii NM Stimulation of Human 
PBMCs Depends on TLR1, While C. burnetii 3262 Recognition Is 
Mediated by Both TLR1 and TLR6
The finding that TLR2 plays an important role in the recognition of C. burnetii led to 
the question whether this response is mainly mediated by TLR1/TLR2 or TLR2/
TLR6 heterodimers [28].
 PBMCs from individuals bearing the homozygous mutant variant of TLR1 
(S609I) and TLR1 (N248S) produced significantly less IL-1β and TNF-α after 
stimulation with C. burnetii NM and C. burnetii 3262 than individuals who were 
heterozygous for these particular SNPs or had the wild-type variant (Figure 2A). 
The same trend was observed for the TLR1 (R80T) SNP, of which only a few 
individuals in the cohort carried the homozygous variant. Decreased cytokine 
responses were also observed in these individuals after stimulation with the 
purified TLR2 ligand Pam3Cys (data not shown). Among the individuals carrying 
the TLR6 (P249S) SNP, the cytokine responses induced by the two C. burnetii strains 
differed from each other. C. burnetii NM stimulation did not result in decreased 
IL-1β and TNF-α production, while stimulation with C. burnetii 3262 revealed 
significantly lower IL-1β and TNF-α production, compared with individuals who 
were heterozygous or had the wild-type variant (Figure 2B). However, stimulation 
by the Mann–Whitney U test. Interleukin 1β (IL-1β), tumor necrosis factor α (TNF-α), and 
interleukin 6 (IL-6) were measured in the supernatant by an enzyme-linked immunosorbent 
assay (ELISA) after 24 hours of incubation. E, Bone marrow–derived macrophages from 
wild-type (WT) and TLR2 knockout mice were stimulated with Dulbecco’s modified Eagle’s 
medium, C. burnetii NM (1 × 106 bacteria/mL), C. burnetii 3262 (1 × 106 bacteria/mL), Pam3Cys 
(10 µg/mL), and E. coli LPS (10 ng/mL). The murine IL-6 (mIL-6) level was measured using 
ELISA after 24 hours of incubation. Data are combined results of 2 separate experiments 
containing 3 mice in each group (Pam3Cys stimulation, 1 experiment only). The mIL-6 
production of the WT mice is set at 100%. Abbreviations: HE, heterozygote; HO, homozygote; 
NS, not significant.
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Figure 2. Recognition of Coxiella burnetii by Toll-like receptor 1 (TLR1) and TLR6 in humans 
and mice. A and B, Peripheral blood mononuclear cells from healthy individuals genotyped 
for the TLR1 S602I, TLR1 N248S, and TLR1 R80T single-nucleotide polymorphisms (SNPs; A) 
and the TLR6 P249S SNP (B) were stimulated with Roswell Park Memorial Institute medium 
(RPMI) (striped bar), C. burnetii Nine Mile (NM; 3 × 106 bacteria/mL), and C. burnetii 3262 
(3 × 106 bacteria/mL) in the presence of serum. Interleukin 1β (IL-1β) and tumor necrosis 
factor α (TNF-α) levels were measured in the supernatant by an enzyme-linked immuno -
sorbent assay (ELISA) after 24 hours of incubation. *P < .05, **P < .01, and ***P < .001, by the 
Mann–Whitney U test. C, Bone marrow–derived macrophages from wild-type (WT), TLR1 
knockout, and TLR6 knockout mice were stimulated with medium only, C. burnetii NM 
(1 × 106 bacteria/mL), and C. burnetii 3262 (1 × 106–1× 107 bacteria/mL). After 24 hours of 
stimulation, mouse IL-6 levels were measured by ELISA. White bars represent the WT mice, 
gray bars represent the TLR1 knockout mice, and black bars represent the TLR6 knockout 
mice. Experiments were performed in duplicate (3–4 mice in each group), and mean values 
(± standard error of the mean) are depicted. IL-6 production by the WT mice is set at 100%. 
*P < .05 and **P < .01, by the Mann–Whitney U test. Abbreviations: DMEM, Dulbecco’s 
modified Eagle’s medium; HE, heterozygote; HO, homozygote; mIL-6, mouse interleukin 6.
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with fibroblast stimulating ligand 1 (FSL-1), a TLR2/6 agonist, did not result in 
lowered cytokine responses (data not shown).
 In mice, BMDMs derived from TLR1 knockout mice produced less IL-6 after 
stimulation with C. burnetii NM, while this was not observed after C. burnetii 3262 
stimulation. On the other hand, IL-6 production by BMDMs from TLR6 knockout 
mice was strongly diminished after stimulation with both C. burnetii NM and 
C. burnetii 3262 (Figure 2C).
The Role of NOD2 in the C. burnetii–Induced Cytokine Response 
NLRs are involved in initiating an immune response against microorganisms 
through recognition of bacterial peptidoglycan. As shown in Figure 3A, PBMCs from 
individuals heterozygous and homozygous for the NOD1 insertion-deletion + 32656 
polymorphism displayed similar IL-1β and TNF-α production after C. burnetii NM 
and C. burnetii 3262 stimulation as individuals bearing the wild-type genotype.
 In contrast, PBMCs from NOD2-deficient individuals produced significantly less 
IL-1β and IL-6 than PBMCs from healthy controls after C. burnetii 3262 stimulation 
(Figure 3B). The same trend was observed after C. burnetii NM stimulation (Figure 
3B) and for TNF-α production (data not shown). The effect of 9 NOD2 SNPs was 
further analyzed. Stimulation with C. burnetii NM resulted in decreased yet not 
statistically significant TNF-α production in 6 of these 9 analyzed NOD2 SNPs, 
while 4 of these SNPs modulated stimulation with C. burnetii 3262, resulting in 
lower TNF-α and IL-1β production. Figure 3C shows these TNF-α responses of the 
NOD2 1007finsC, NOD2 G908R, and NOD2 R702W SNPs after C. burnetii NM and 
C. burnetii 3262 stimulation.
 In mice, C. burnetii NM stimulation of BMDMs led to a 35% reduction of IL-6 
production in NOD1 knockout mice, compared with wild-type mice, while in 
NOD2 knockout mice and double-knockout mice, IL-6 production was reduced by 
>50% (Figure 3D). Unfortunately, stimulation of the BMDMs with C. burnetii 3262 
resulted in low production of IL-6 and was not useful for comparing the different 
groups (data not shown).
P38, JNK, and ERK Are Downstream Mediators of C. burnetii–
Induced Cytokine Production 
MAPKs such as p38, JNK, and ERK have been proven to be downstream of TLRs, 
and their activation eventually leads to cytokine production, proliferation, and 
apoptosis [29]. We confirmed this function of MAPKs upon C. burnetii  stimulation, 
as inhibition of p38 and ERK led to significantly decreased IL-1β, TNF-α, and IL-6 
production by PBMCs (Figure 4). PBMCs preincubated with a specific JNK inhibitor 
also produced less IL-1β and TNF-α after C. burnetii stimulation, but IL-6 production 
was not altered in comparison to the dimethyl sulfoxide control (Figure 4).
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Figure 3. Nucleotide-binding oligomerization domain receptor 2 (NOD2) is involved in the 
recognition of Coxiella burnetii, while NOD1 is not. A, Peripheral blood mononuclear cells 
(PBMCs) from healthy volunteers genotyped for the NOD1 single-nucleotide polymorphism 
(SNP) ND1 + 32656 were stimulated with Roswell Park Memorial Institute (RPMI) medium 
(striped bar), C. burnetii Nine Mile (NM; 3 × 106 bacteria/mL), and C. burnetii 3262 (3 × 106 
bacteria/mL). B, PBMCs from individuals with a homozygous NOD2 3020insC mutation and 
PBMCs from healthy controls were stimulated with RPMI medium, C. burnetii NM (1× 106–2× 
106 bacteria/mL), C. burnetii 3262 (1× 106–2× 106 bacteria/mL), and muramyl dipeptide (MDP; 
5 µg/mL). Interleukin 1β (IL-1β) and interleukin 6 (IL-6) production by the healthy controls is 
set at 100%. C, PBMCs from healthy volunteers genotyped for the NOD2 SNPs 1007finsC, 
NOD2 G908R, and NOD2 R702W were stimulated with RPMI medium (striped bar), C. burnetii 
NM (3 × 106 bacteria/mL), and C. burnetii 3262 (3 × 106 bacteria/mL). In all experiments, 
PBMCs were stimulated in the presence of human serum. Interleukin 1β (IL-1β), interleukin 
6 (IL-6), and tumor necrosis factor α (TNF-α) levels were measured in the supernatant by an 
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Discussion
In the present study, we investigated the role of TLRs and NLRs in the recognition 
of C. burnetii. Using different approaches, we found clear evidence for involvement 
of TLR1, TLR2, and NOD2 but not for TLR4 and NOD1. An additional   important 
finding was the divergent recognition of C. burnetii NM and the Dutch outbreak 
isolate C. burnetii 3262. C. burnetii NM was mediated by TLR1/TLR2 only, while C. 
burnetii 3262 was recognized by both the TLR1/TLR2 and TLR2/TLR6 heterodimers. 
Interestingly, recognition of these two strains also differed with respect to the role 
of TLR6 in men and mice.
enzyme-linked immunosorbent assay (ELISA) after 24 hours of incubation. *P < .05 and **P < .01, 
by the Mann–Whitney U test. D, Bone marrow–derived macrophages from wild-type (WT), 
NOD1 knockout, NOD2 knockout, and NOD1/2 knockout mice were stimulated with 
medium only and C. burnetii NM (1 × 107 bacteria/mL). After 24 hours of stimulation, mouse 
IL-6 levels were measured by ELISA. White bars represent the WT mice, light gray bars 
represent the NOD1 knockout mice, dark gray bars represent the NOD2 knockout mice, and 
black bars represent the NOD1/2 knockout mice. Experiments were performed in duplicate 
(n = 2–3), and mean values ( ± standard error of the mean) are depicted. IL-6 production by 
the WT mice is set at 100%. *P < .05 and **P < .01, by the Mann–Whitney U test. Abbreviations: 
DMEM, Dulbecco’s modified Eagle’s medium; HE, heterozygote.
Figure 4. Involvement of mitogen-activated protein kinases in Coxiella burnetii–induced 
cytokine production. Peripheral blood mononuclear cells from 8 healthy volunteers were 
pretreated with dimethyl sulfoxide (control), p38 inhibitor, JNK inhibitor, or ERK inhibitor 
for 1 hour and subsequently stimulated with Roswell Park Memorial Institute (RPMI) 
medium (striped bar), C. burnetii Nine Mile (NM; 1 × 106 bacteria/mL), and C. burnetii 3262 
(1 × 106 bacteria/ mL) in the presence of human serum. Interleukin 1β (IL-1β), tumor necrosis 
factor α (TNF-α), and interleukin 6 (IL-6) were measured in the supernatant by an 
enzyme-linked immunosorbent assay after 24 hours of incubation. Mean values ( ± standard 
error of the mean) of 3 separate experiments are shown. *P < .05 and **P < .01, by the 2-tailed 
Wilcoxon matched-pairs signed rank test.
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 We found no important role of TLR4 in mediating in vitro cytokine production 
by human PBMCs after C. burnetii encounter. Although Honstrette et al [30] reported 
that TLR4 knockout mice exhibited a defect in cytokine production and granuloma 
formation, our observation that C. burnetii–induced cytokine production in 
humans was not mediated by TLR4 is not surprising. As reported before, LPS with 
a tetra-acylated lipid A component, as expressed by bacteria such as Rhodobacter 
sphaeroides or the lpxL2 mutant of Neisseria meningitidis H44/76, is found to be a 
very weak cytokine inducer and even to act as a TLR4 antagonist [31, 32]. 
Accordingly, an antagonistic effect of C. burnetii phase I lipid A has been 
demonstrated [7]. 
 We observed an important role of TLR2 in C. burnetii recognition in mice, and, 
moreover, our study revealed that TLR2 is also important for C. burnetii recognition 
by human   PBMCs. C. burnetii NM and C. burnetii 3262 are both able to induce 
cytokine production via TLR2 signaling, which suggests that both strains have 
PAMPs that can activate TLR2. C. burnetii phase II activation of TLR2 has previously 
been reported by Zamboni et al [7]. They showed that macrophages from TLR2 
knockout mice were highly permissive to C. burnetii growth, compared with either 
TLR4 knockout or wild-type mice. Furthermore, they found that macrophages 
from TLR2 knockout mice produced lower levels of TNF-α and IL-12 [7]. While 
Zamboni et al used the avirulent C. burnetii phase II, we used the virulent 
C. burnetii phase I, which is the infective phase that is found in the  environment.
 We additionally investigated the role of TLR1 and TLR6 in cytokine induction 
by C. burnetii, because TLR2 forms heterodimers with either TLR1 or TLR6. We 
addressed the issue by performing experiments with PBMCs from individuals 
with known SNPs in TLR1 and TLR6. We found that individuals carrying 
polymorphisms in TLR1 showed a diminished cytokine response against C. 
burnetii NM and C. burnetii 3262. Our findings suggest that the TLR1/TLR2 
heterodimer plays a role in C. burnetii recognition. BMDMs from TLR1 knockout 
mice stimulated with C. burnetii NM produced less IL-6, compared with BMDMs 
from wild-type mice. Conversely, stimulation with C. burnetii 3262 did not lead to 
lower cytokine production in TLR1 knockout BMDMs.
 The role of TLR6 in the induction of a cytokine response against C. burnetii is 
less clear. Our analyses of human PBMCs suggested that C. burnetii 3262 is 
recognized by TLR6, while this is not the case for C. burnetii NM. This can be 
explained by a different binding site of C. burnetii 3262 to TLR6, compared with C. 
burnetii NM and FSL-1. In mice, it seemed that TLR6 plays a major role in cytokine 
induction by C. burnetii for both the reference strain and the Dutch outbreak isolate. 
We observed a different role for TLR1 and TLR6 in mice and humans in our 
experiments, showing that innate immune recognition of C. burnetii can differ 
between mice and humans. However, much of the data published to this point on 
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innate immune recognition of C. burnetii is derived from murine experiments. We 
can conclude that assumptions about immune recognition of C. burnetii in humans 
based on murine studies alone should be made carefully [33, 34].
 The shared intracellular localization of the NOD2 receptor and C. burnetii, 
together with the confirmed role of TLR2 in the recognition of C. burnetii, made the 
investigation of NOD2 of interest. Our study in humans revealed that NOD2 plays 
a major role in cytokine induction upon C. burnetii encounter, as individuals 
bearing the NOD2 3020insC mutation (which causes a loss of function of the NOD2 
gene [22]) had significant lower cytokine responses. This finding was further 
strengthened by our observation in individuals bearing SNPs in NOD2. The 
important role for both TLR2 and NOD2 signaling in the induction of cytokines 
has been demonstrated for other bacteria, such as Borrelia burgdorferi and 
Mycobacterium paratuberculosis [23, 35]. So far, only one other research group has 
investigated the role of NOD2 in C. burnetii infection [36]. They concluded that 
NOD2 is not essential for the control of C. burnetii infection in mice, although they 
observed lower TNF-α and MCP-1 messenger RNA responses in C. burnetii–
stimulated BMDMs from NOD2 knockout mice, compared with those from 
wild-type mice. We found lower IL-6 responses in C. burnetii–stimulated BMDMs 
from NOD1 knockout mice, compared with those for wild-type mice, but even a 
larger decrease was observed in NOD2 knockout mice. As the IL-6 response was 
not further decreased in the NOD1/2 knockout mice, we suggest that the role of 
NOD2 is more important.
 The strain C. burnetii 3262 was the predominant genotype found during the Q 
fever outbreak in the Netherlands. This single genotype of C. burnetii caused the 
largest  outbreak of Q fever ever reported worldwide. Besides increased exposure 
of humans to this pathogen due to intensive goat herding, it may be hypothesized 
that this strain is less effectively recognized by the human immune system and is 
therefore more virulent than other strains. However, our study showed that, 
similar to C. burnetii NM, C. burnetii 3262 in humans was recognized by TLR1, 
TLR2, and NOD2 and induced a robust proinflammatory cytokine response. 
Interestingly, we observed a possible role for TLR6 in cytokine induction by C. 
burnetii 3262, while this was not seen for C. burnetii NM. It can be questioned 
whether extended activation of the immune response is beneficial for the infected 
individual, as enhanced uptake of C. burnetii by monocytes and macrophages can 
favor the intracellular replication of C. burnetii, leading to a possible infection. 
However, it has to be further investigated whether the recognition of C. burnetii 
3262 by TLR6 can lead to increased virulence.
 It is not completely clear why chronic Q fever only develops in a small 
proportion of infected individuals. Although patient-related factors such as the 
presence of valvular pathology or atherosclerotic vascular disease are a 
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contributing factor, poly-morphisms in PRR genes may also predispose to the 
development of chronic Q fever. Studies performed in our group show associations 
between polymorphisms in TLR1, TLR2, and TLR6 and increased susceptibility to 
complicated skin and skin structure infections [37]. In addition, others observed 
associations between the TLR6 SNP and malaria and between invasive aspergillosis 
and overrepresentation of TLR2 in patients with tuberculosis [13, 38, 39]. Therefore, 
it would be interesting for future studies to investigate whether polymorphisms in 
TLR1, TLR2, TLR6, and NOD2 are observed more often in patients with chronic Q 
fever and whether these polymorphisms are related to the severity of infection due 
to any C. burnetii strain or to specific C. burnetii strains.
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Abstract
Background. Q fever is an infection caused by Coxiella burnetii. Persistent infection 
(chronic Q fever) develops in 1%–5% of patients. We hypothesize that inefficient 
recognition of C. burnetii and/or activation of host-defense in individuals carrying 
genetic variants in pattern recognition receptors or adaptors would result in an 
increased likelihood to develop chronic Q fever.
Methods. Twenty-four single-nucleotide polymorphisms in genes encoding Toll-like 
receptors, nucleotide-binding oligomerization domain–like receptor-2, αvβ3 integrin, 
CR3, and adaptors myeloid differentiation primary response protein 88 (MyD88), 
and Toll interleukin 1 receptor domain-containing adaptor protein (TIRAP) were 
genotyped in 139 patients with chronic Q fever and in 220 controls with 
cardiovascular risk-factors and previous exposure to C. burnetii. Associations 
between these single-nucleotide polymorphisms and chronic Q fever were 
assessed by means of univariate logistic regression models. Cytokine production 
in whole-blood stimulation assays was correlated with relevant genotypes. 
Results. Polymorphisms in TLR1 (R80T), NOD2 (1007fsX1), and MYD88 (−938C>A) 
were associated with chronic Q fever. No association was observed for poly -
morphisms in TLR2, TLR4, TLR6, TLR8, ITGAV, ITGB3, ITGAM, and TIRAP. No 
correction for multiple testing was performed because only genes with a known 
role in initial recognition of C. burnetii were included. In the whole-blood assays, 
individuals carrying the TLR1 80R-allele showed increased interleukin 10 
production with C. burnetii  exposure.
Conclusions. Polymorphisms in TLR1 (R80T), NOD2 (L1007fsX1), and MYD88 
(−938C>A) are associated with predisposition to development of chronic Q fever. 
For TLR1, increased interleukin 10 responses to C. burnetii in individuals carrying 
the risk allele may contribute to the increased risk of chronic Q fever.
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Introduction
Q fever is an infection with the intracellular gramnegative bacterium Coxiella burnetii. 
Although most symptomatic individuals experience only mild flulike symptoms or 
pneumonia (acute Q fever), some patients develop a persistent infection with severe 
complications including endocarditis and vascular (prosthesis) infection (chronic Q 
fever). Persistent infection occurs in 1%–5% of C. burnetii–infected subjects and 
develops insidiously, which contributes to its late diagnosis and high mortality rates. 
It is well established that the main risk factors for chronic infection are preexisting 
abnormalities of cardiac valves (including valvular prosthesis), vascular aneurysms, 
vascular prosthesis, and immuno suppression [1, 2]. However, in a large outbreak in 
the Netherlands from 2007 to 2010, only a minority of patients with these risk factors 
developed chronic Q fever after (serological evidence of) infection with C. burnetii [3, 4]. 
Inefficient early recognition of the bacterium by the innate immune system followed by 
incomplete eradication and/or inadequate initiation of adaptive immune responses 
may be a contributing factor in the development of chronic Q fever.
 The innate immune system provides the first barrier against C. burnetii infection. 
In general, pattern recognition receptors (PRRs) on innate immune cells recognize 
molecular moieties of microorganisms. Toll-like receptors (TLRs) and nucleotide- 
binding oligomerization domain (NOD) proteins are the main PRRs involved in 
the recognition of bacteria. TLRs interact with various adaptor proteins, including 
myeloid differentiation primary response protein 88 (MyD88) and Toll interleukin 
1 receptor domaincontaining adaptor protein (TIRAP), to activate transcription factors, 
leading to production of proinflammatory cytokines, activation of antimicrobial 
mechanisms, and subsequent initiation of adaptive immune responses. MyD88 is 
also required for the production of interleukin 1, 18, and 33, which emphasizes its 
importance for host defense against  microorganisms.
 We recently demonstrated that C. burnetii–induced cytokine production by human 
innate immune cells is mediated through the heterodimer TLR1/TLR2 on the cell 
membrane and by cytoplasmic NOD2 [5]. TLR6 seems to be involved specifically in 
the recognition of the C. burnetii strain 3262 that was isolated during the outbreak 
in the Netherlands [5]. Microorganisms such as C. burnetii use phagocytosis as an 
efficient mechanism of entry into monocytes/macrophages, where they can 
survive intracellularly in a parasitophorous vacuole (PV) [6]. An important role in 
C. burnetii uptake has been described for leukocyte response integrin (αvβ3 
integrin) and complement receptor 3 (CR3 [αMβ2, CD11b/CD18]). Virulent phase I 
C. burnetii uptake is mediated by αvβ3 integrin, whereas phagocytosis of avirulent 
phase II C. burnetii also involves CR3 [7, 8].
 Genetic variants in immune cell receptors such as TLRs and NODs and their 
adaptors have been associated with increased susceptibility to bacterial infections 
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[9–16]. Thus, it is tempting to speculate that inefficient recognition of C. burnetii and 
activation of host defense in individuals carrying genetic variants in these receptors 
or adaptors would result in ineffective early clearance of the bacterium and an 
increased likelihood to develop chronic Q fever. No study so far has been able to 
investigate this possibility, due to the low prevalence of the disease. The recent 
Q fever outbreak in the Netherlands led to >4000 reported acute Q fever cases and >250 
chronic Q fever cases [17], offering an unique opportunity to study this question.
 We hypothesized that certain polymorphisms in the host’s PRR genes or in 
genes encoding their adaptor proteins influence the risk of persistent C. burnetii 
infection and hence the development of chronic Q fever. To test this hypothesis, we 
analyzed the prevalence of specific single-nucleotide polymorphisms (SNPs) in 11 
candidate genes —TLR1, TLR2, TLR4, TLR6, TLR8, MYD88, TIRAP, NOD2, ITGAV, 
ITGB3, and ITGAM (CD11b)— in a cohort of 139 patients with chronic Q fever and 
a control cohort of 220 individuals, living in the same area and with valvular or 
vascular predisposing factors for chronic Q fever, who had contracted C. burnetii 
(based on positive serological results) but did not develop chronic Q fever. The 
genetic study was complemented with functional assays investigating the effect of 
the specific polymorphisms on the in vitro cytokine production in C. burnetii–
stimulated whole blood.
Material and Methods
Ethics Statement
The study was approved by the Ethical Committee of Radboud University Medical 
Center, Nijmegen, the Netherlands. Subjects were enrolled after providing written 
informed consent (or waiver when deceased [n = 5], as approved by the Ethical 
Committee). Institutional review boards of participating hospitals approved the 
inclusion of patients and controls in this study. The study has been performed in 
accordance with the Declaration of  Helsinki.
Subjects
All patients who visited the outpatient clinic at the internal medicine departments 
of the participating hospitals with probable or proven chronic Q fever, as defined 
by the Dutch consensus on chronic Q fever (Table 1), were asked to participate in 
the study. Recruitment of patients took place between July 2011 and July 2014 at 
Radboud University Medical Center, Canisius-Wilhelmina Hospital (Nijmegen), 
Catharina Hospital (Eindhoven), Elkerliek Hospital (Helmond), Atrium Medical 
Center (Heerlen), Elisabeth Hospital (Tilburg), Bernhoven Hospital (Oss), and 
Jeroen Bosch Hospital (’s-Hertogenbosch). Demographic and clinical characteristics 
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(classification based on serological titers and imaging results, cardiovascular risk 
factors, immunosuppressive comorbid condition, or medication) were retrieved 
from the patients’ medical records.
 The population-matched control group consisted of individuals from the 
same area who had valvular or vascular abnormalities predisposing to chronic 
Table 1   Classification of Chronic Q Fever According to the Dutch Consensus 
Guidelinesa
Classification Criteria
Proven chronic 
Q fever
1. Positive Coxiella burnetii PCR findings in blood or tissueb
OR
2.  IFA titer ≥1:800 or ≥1:1024 for C. burnetii phase I IgGc 
AND
–  definite endocarditis according to modified Duke criteria [18] 
OR
–  proven large vessel or prosthetic infection shown by imaging 
studies (FDG-PET, CT, MR imaging, or AUS)
Probable chronic 
Q fever
IFA titer ≥1:800 or ≥1:1024 for C. burnetii phase I IgGc
AND
≥1 of the following:
–  Valvulopathy not meeting major criteria of modified Duke criteria [18]
–  Known aneurysm and/or vascular or cardiac valve prosthesis 
without signs of infection shown by TEE/TTE, FDG-PET, CT, MR 
imaging, or AUS
–  Suspected osteomyelitis, pericarditis, or hepatitis as manifestation 
of chronic Q fever
–  Pregnancy
–  Symptoms and signs of chronic infection (e.g., as fever, weight loss 
and night sweats, hepatosplenomegaly, or persistently raised ESR 
and CRP level)
–  Granulomatous tissue inflammation, proved histologically
–  Immunocompromised state
Possible chronic 
Q fever
IFA titer ≥1:800 or ≥1:1024 for C. burnetii phase I IgGc without 
manifestations meeting criteria for proven or probable chronic  
Q fever
Abbreviations: AUS, abdominal ultrasound; CRP, C-reactive protein; CT, computed tomography; ESR, 
erythrocyte sedimentation rate; FDG-PET, fluorodeoxyglucose positron emission tomography; IFA, 
 immunofluorescence assay; IgG, immunoglobulin G; MR, magnetic resonance; PCR, polymerase chain 
reaction; TEE, transesophageal echocardiography; TTE, transthoracic echocardiography.
a The consensus guidelines are described by Wegdam-Blans et al [19].
b In the absence of acute infection.
c  Cutoff is dependent on the IFA technique used (≥1:800 for a technique developed in house and ≥1:1024 
for a commercial IFA technique).
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Q fever and serological evidence of exposure to C. burnetii (anti–C. burnetii phase II 
immunoglobulin G antibody titer ≥1:32) but no clinical symptoms or serological 
evidence of chronic Q fever. These individuals were recruited in the Q fever 
prevaccination screening campaign in January– April 2011 [20, 21] and in a Q fever 
screening of patients with vascular risk factors living in the Q fever outbreak 
area [22].
Genotyping
From patients who came to the outpatient clinic or to the Q fever prevaccination 
screening, venous blood was collected and stored at −80°C. DNA was isolated 
from these blood samples using standard  methods  [23].  Other  participants, both 
patients and controls, received a buccal swab kit (Isohelix) to obtain epithelial cells 
for DNA isolation. DNA was isolated using a buccal DNA isolation kit (Isohelix), 
according to the manufacturer’s protocol. SNPs were selected based on known 
effects on protein function or gene expression, published associations with human 
diseases, and/or haploview data. In total, 25 SNPs in TLR1, TLR2, TLR4, TLR6, 
TLR8, TIRAP, MYD88, NOD2, ITGAV, ITGB3, and ITGAM were genotyped with a 
Sequenom mass spectrometry genotyping platform. Quality control was performed 
by duplicating 5% of the samples within and across plates, incorporating positive and 
negative control samples, and sequencing samples to verify the various genotypes.
In Vitro Whole-Blood Stimulation and Cytokine Measurements 
In a subgroup of control subjects—those who participated in the Q fever 
prevaccination screening study, as described elsewhere [24] —whole-blood assays 
were performed, and C. burnetii–induced cytokines were measured (n = 93). 
In short, venous blood was drawn into endotoxin-free lithium-heparin tubes 
(Vacutainer; BD Biosciences), and samples were processed within 12 hours. Blood 
was aliquoted in separate tubes and incubated at 37°C for 24 hours with heat- 
inactivated (30 minutes at 99°C) C. burnetii Nine Mile RSA493 phase I [25] (bacteria 
count, 107/mL) or mitogen (positive control) or without stimulus (negative control), 
as described elsewhere [24]. After incubation, blood cultures were centrifuged at 
4656 g for 10 minutes, and supernatants were collected. Supernatants were stored 
at −20°C until concentrations of cytokines—including interleukin 1β (IL-1β), tumor 
necrosis factor (TNF), interleukin 2 (IL-2), interleukin 6 (IL-6), and interleukin 10 
(IL-10)—were measured with a magnetic bead multiplex assay (Merck Millipore), 
according to the manufacturer’s  instructions.
Statistical Analyses
The presence of Hardy–Weinberg equilibrium was analyzed for all 24 SNPs 
separately in the control cohort [26]. For the 2 TLR8 SNPs on the X chromosome, 
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only the female subjects were included in the Hardy–Weinberg equilibrium 
analysis, and relative allele frequencies were subsequently compared between 
female and male subjects. The difference in genotype frequencies between patients 
and controls were analyzed by means of a gene dosage model, using the Fisher 
exact test to test for significance. Subsequent dominant and recessive model 
analysis was performed using univariate logistic regression, for which odds ratios 
(ORs) and their 95% confidence intervals (CIs) were reported. Because the choice of 
the genetic variants was based exclusively on genes with an established or 
suspected role in C. burnetii recognition, rather than exploratory, no correction for 
multiple testing was performed. Statistical analyses were performed with SPSS 
software (version 20). Cytokine concentrations from the whole-blood stimulation 
assays were stratified according to genotype and compared by means of Mann–
Whitney U tests, using GraphPad Prism software (version 5; GraphPad). Overall, 
statistical tests were 2 sided, and differences were considered statistically 
significant at P < .05.
Results
Baseline Characteristics
In total, 139 (92 proved and 47 probable) patients with chronic Q fever and 220 
control subjects without chronic Q fever but with serological evidence of C. burnetii 
exposure and a risk factor for chronic Q fever were included in the study. 
Demographic and clinical characteristics of patients and controls are summarized 
in Table 2. Patients were slightly older than controls (2.4-year difference in median 
age). In both groups, vascular risk factors were more prevalent than cardiac 
valvular risk factors. Valvular risk factors, however, were more prevalent in the 
controls than in the patients. Patients with chronic Q fever were more likely than 
control subjects to be  immunocompromised.
Association of SNPs in MYD88, NOD2, and TLR1 With  
Chronic Q Fever
Genotyping of patients and controls was successful for all polymorphisms in genes 
encoding TLRs, NOD2, MyD88, TIRAP, αvβ3 integrin, and CR3 presented in Table 3. 
For each polymorphism, >94% of the subjects were genotyped. All SNPs were 
in Hardy–Weinberg equilibrium in the control group, except for ITGB3 rs4642 
(χ2 = 6.18); this SNP was excluded from further analysis.
 In the analysis of all patients with chronic Q fever, a significantly different 
distribution of 1 NOD2 and 1 MYD88 polymorphism was revealed in the dominant 
model: NOD2 L1007fsX1 (P = .02; OR, 3.34; 95% CI, 1.22–9.14) and MYD88 −938C>A 
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(P = .04; OR, 2.15; 95% CI, 1.05–4.39) (Table 4). Compared with controls, patients 
were more often heterozygous for the allelic variant of these SNPs.
 When only patients with proven chronic Q fever were considered, TLR1 R80T 
was distributed significantly different among patients and controls in the dominant 
model (P = .03; OR, 0.48; 95% CI, .24–.95) (Table 5), whereas it was marginally 
significant (P = .08; OR, 0.61; 95% CI, .35–1.06) when all patients (including those 
with probable Q fever) were included. Patients were less often heterozygous or 
homozygous for the allelic variant of this SNP. The distributions of NOD2 L1007fsX1 
and MYD88 −938C>A showed a trend toward significance among patients and 
controls (P = .07 and P = .09, respectively) when only patients with proven chronic 
Q fever were included in the analysis. No associations were observed between 
polymorphisms  in  TLR2, TLR4,  TLR6, TIRAP,  ITGAV,  ITGB3, or ITGAM and the 
development of chronic Q  fever.
Table 2   Baseline Patient Characteristics in Patients With Chronic Q Fever and 
Controls
Characteristic Chronic Q Fever 
Cohort (n = 139)
Control Cohort 
(n = 220)
P 
Valuea
Age median (IQR), y 70.0 (63.0–75.6) 67.6 (58.3–74.3) .02
Male sex, No. (%) 114 (82) 169 (77) .29
Classification of chronic Q fever, No. (%)
Proven (%) 92 (66.2) 0
Probable (%) 47 (33.8) 0
Cardiovascular risk factor for chronic Q fever, No. (%)b
Vascular  aneurysm/prosthesis 95 (68.3) 129 (58.6) .07
Valvular  defect/prosthesis 39 (28.1) 111 (50.5) <.001
Immunocompromised statec 21 (15.1) 14 (6.4) .01
Abbreviation: IQR, interquartile range.
a  P values based on Fisher exact test for categorical variables and Mann–Whitney U test for continuous 
variables.
b  Nine case patients and 22 controls had both vascular and valvular risk conditions.
c  In case patients, immunocompromised states included autoimmune disease with immunosuppressive 
drug treatment (n = 14), renal insufficiency (n = 1), renal transplantation (n = 1), cancer (n = 3), and 
prednis(ol)one use (n = 1); in controls, autoimmune disease with immunosuppressive drug treatment 
(n = 5), renal transplantation (n = 2), cancer (n = 4); and prednis(ol)on use (n = 4).
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Table 3   Genotyped SNPs in genes encoding immune receptors and adaptor 
molecules
Gene SNP ID Gene  
region
Nucleotide 
changea
Amino Acid Change
TLR1 rs4833095 Exon 4 T > C  S248N
 rs5743611 Exon 4 G > C R80T
TLR2 rs111200466 5’ UTR ins > del NA
 rs5743704 Exon 3 C > A P631H
 rs5743708 Exon 3 G > A R753Q
TLR4 rs4986790 Exon 3 A > G D299G
 rs1927911 Intron 1 C > T NA
TLR6 rs1039559 Intron 1 T > C NA
 rs5743818 Exon 2 T > G Synonymous (A644A)
TLR8 rs3747414 Exon 3 C > A Synonymous (I751I)
 rs3764880 Exon 1 A > G M1V affects protein start
NOD2 rs1077861 Intron 10 A > T NA
 rs2066847 Exon 11 – > C frameshift and stopcodon 
(L1007fsX1)
 rs2066844 Exon 4 C > T R702W
MYD88 rs4988453 Promoter C > A NA
 rs6853 3’ UTR A > G NA
TIRAP rs8177348 Intron 1 C > T NA
 rs8177374 Exon 5 C > T S180L
ITGAV rs3738919 Intron 17 C > A NA
 rs9333288 Intron 3 A > G NA
ITGB3 rs3809865 3’ UTR A > T NA
 rs4642 Exon 10 G > A Synonymous (E511E) 
ITGAM rs1143679 Exon 3 G > A R77H
 rs1143678 Exon 30 C > T P1146S
Abbreviations: SNP, single nucleotide polymorphism; ID, identification number; Ins, insertion; NA, not 
applicable; SNP, single-nucleoide polymorphism; UTR, untranslated region.
a The first nucleotide is the most common nucleotide.
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CHAPTER 3
Effect of TLR1 SNP R80T on In Vitro IL-10 Production by  
C. burnetii–Stimulated Whole Blood
The functional consequences of TLR1 R80T, NOD2 L1007fsX1 and MYD88 −938C>A 
were studied using C. burnetii stimulation of whole blood obtained from 93 control 
subjects with different TLR1 R80T, NOD2 L1007fsX1, and MYD88 −938C>A genotypes. 
Figure 1. Association between TLR1 R80T genotypes and cytokine production after 
whole-blood stimulation with Coxiella burnetii. IL-1β, interleukin 1β; IL-2, interleukin 2; IL-6, 
interleukin 6; IL-10, interleukin 10; TNF, tumor necrosis factor. Stimulation was performed 
for 24 hours with heat-killed C. burnetii Nine Mile phase I (RSA 493) (bacteria count, 1 × 107/mL). 
Data are presented as medians and interquartile ranges, and groups were compared with 
the Mann–Whitney U test. 
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Production of IL-1β, TNF, IL-2, IL-6, and IL-10 was measured after 24 hours of stimulation. 
Decreased IL-10 production was observed after stimulation with C. burnetii by 
blood cells with TLR1 80T containing genotypes, which is associated with lower 
susceptibility to chronic Q fever. Proinflammatory cytokine production, including 
IL-1β, IL-6, TNF, and IL-2, did not differ among TLR1 R80T genotypes (Figure 1).
Figure 2. Association between NOD2 and MYD88 genotypes and cytokine production after 
whole-blood stimulation with Coxiella burnetii. Subjects were stratified by genotype for 
NOD2 1007fsX1 (A, C, and E ) and MYD88 −938C>A (B, D, and F ). Stimulation was performed 
for 24 hours with heat-killed C. burnetii Nine Mile phase I (RSA 493) (bacteria count, 1 × 107/
mL). Data are presented as medians and interquartile ranges, and groups were compared 
with the Mann–Whitney U test. Abbreviation: IL-1β, interleukin 1β; IL-10, interleukin 10; 
TNF, tumor necrosis factor.
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 There were no significant differences in the association between NOD2 
L1007fsX1 and MYD88 −938C>A polymorphisms and the production of IL-1β, TNF, 
and IL-10 in response to C. burnetii (Figure 2). Findings for IL-6 and IL-2 are not 
shown (P = .78 and P = .58 respectively, with stratification by NOD2 1007fsX1 
genotype; P = .51 and P = .52 with stratification by MYD88 −938C>A genotype).
Discussion
In the present study, we investigated whether genetic variants in PRRs and adaptor 
proteins were associated with chronic Q fever in C. burnetii–infected individuals 
with vascular or valvular risk factors. Our results showed that TLR1 R80T 
(rs5743611), NOD2 L1007fsX1 (rs2066847) and MYD88 −938C>A (rs4988453) are 
linked to the development of chronic Q fever. In addition, blood cells from 
individuals carrying the TLR1 80T variant that led to decreased susceptibility to 
chronic Q fever showed lower IL-10 production with C. burnetii stimulation. We 
observed no influence of TLR2, TLR4, TLR6, TLR8, TIRAP, ITGAV, ITGB3, and 
ITGAM SNPs on the susceptibility to chronic Q fever.
 To our knowledge, this is the first genetic study investigating the role of SNPs 
in PRR and adaptor molecule genes in the development of chronic Q fever, the 
most severe complication of C. burnetii infection. Our study comprises the largest 
chronic Q fever cohort ever described. Previous studies on genetic predisposition 
to Q fever either concerned small cohorts of patients or focused on other clinical Q 
fever manifestations (acute Q fever or Q fever fatigue syndrome). Everett et al [27] 
studied susceptibility to acute Q fever by focusing on TLR2 and TLR4 SNPs, for 
which they demonstrated no correlation in 89 patients with acute Q fever and 162 
controls. Helbig et al [28] investigated association between variants in HLA, IFNG, 
IL10, and TNFR genes and chronic Q fever or post–Q fever fatigue in 22 and 31 
patients, respectively; they described significant differences in the frequencies of 
IL10 promoter microsatellites in chronic Q fever compared with findings in 181 
individuals without Q fever exposure. Vollmer-Conna et al [29] demonstrated that 
functional polymorphisms in IFNG and IL10 affect disease severity and duration 
after serologically confirmed acute Q fever. 
 We focused on polymorphisms in immune genes involved in the initial 
recognition of C. burnetii, based on the assumption that chronic Q fever develops 
only after inefficient early recognition resulting in inadequate early clearance of 
the bacterium. Previous studies have shown that patients with chronic Q fever 
exhibit a different cytokine response to C. burnetii [30–32], but it is not clear whether 
this different response is specific for the myeloid cells of these individuals or due 
to the persistent presence of the bacteria in monocytes/macrophages. Deciphering 
73
SNPS IN PRR GENES IN CHRONIC Q FEVER
3
genetic polymorphisms in immune genes of the innate response to C. burnetii may 
give more insight into the  mechanism.
 In genetic association studies, the choice of the control group is of pivotal 
importance. We deliberately chose a control cohort of subjects living in the same Q 
fever–endemic area, with both past C. burnetii infection (as shown by positive 
anti–C. burnetii serological results) and cardiovascular risk factors for chronic Q 
fever, who did not develop chronic Q fever. When a different distribution of genetic 
polymorphisms is observed between patients and these controls, it indicates that 
these polymorphisms modify the risk of developing chronic Q fever, and not that 
of contracting C. burnetii infection or any underlying predisposing factors. The 
control cohort, however, was somewhat younger, had significantly more valvular 
risk factors, and was less immunocompromised than the patient  cohort.
 Notably, antimicrobial drug treatment at the time of acute Q fever might 
decrease the risk of chronic Q fever. Although information on previous treatment 
for acute Q fever was not obtained from the controls in this study, we assume that 
the majority of controls did not receive antibiotic treatment for acute Q fever 
because they participated in screening programs to detect previous C. burnetii 
infection.
 The patient cohort included patients with proven or probable diagnosis of 
chronic Q fever; possible cases were left out. Given that the diagnosis of chronic Q 
fever is difficult—because direct detection of the bacterium is not possible in many 
cases—a probable chronic Q fever diagnosis is based on indirect evidence of 
persistent C. burnetii infection. These patients also receive long-term antibiotic 
treatment, with treatment and follow-up protocols identical to those used for 
proven chronic Q fever, but some of these patients may have no persistent infection. 
However, we also performed an analysis including only the subset of patients with 
proven chronic Q fever, which increased the level of diagnostic certainty for 
chronic Q fever in the case patients but decreased the power to detect associations.
 We identified a significant association between the TLR1 R80T polymorphism 
and the risk of chronic Q fever. This TLR1 SNP has been described as a risk factor 
for invasive aspergillosis after hematopoietic stem cell transplantation [16], 
candidemia [33], and inflammatory bowel disease [34]. TLR1 S248N, which is not 
linked to TLR1 R80T, did not show an association with the development of chronic 
Q fever. We studied the functional consequences of the TLR1 R80T polymorphism 
in a subset of controls. The presence of TLR1 80T allele resulted in significantly 
lower production of the anti-inflammatory cytokine IL-10 but did not affect TNF, 
IL-1β, or other proinflammatory cytokines, as reported elsewhere [5]. The TLR1 
80T allele was significantly less frequent in the patients with proven Q fever than 
in  the control cohort. This suggests that having lower IL-10 production on contact 
with C. burnetii may protect against chronic Q fever. This finding is in line with the 
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role of the anti-inflammatory cytokine IL-10 in the development of human chronic 
Q fever, which has been extensively reported [30, 35–37]. In short, IL-10 induces C. 
burnetii replication  in  naive  monocytes  [35].  In  addition, IL-10 production in 
unstimulated peripheral blood mononuclear cells was increased after C. burnetii 
infection in individuals who subsequently developed chronic endocarditis relative 
to those who did not [36]. Moreover, transgenic mice that constitutively overexpress 
IL-10 is the only efficient model for chronic Q fever so far  [38].
 NOD2 is a cytoplasmic receptor involved in bacterial peptidoglycan sensing. 
The intracellular localization of NOD2 and the survival of C. burnetii in the 
intracellular PV may lead to ongoing interaction between them. The active secretion 
of bacterial proteins by C. burnetii through the PV membrane, demonstrated to 
occur by a type IV secretion apparatus [39], may play a role in this process. Genetic 
variation in NOD2 has previously been linked to autoinflammatory diseases, such 
as Crohn disease and Blau syndrome [40]. An association with susceptibility to 
tuberculosis and leprosy has also been described [41, 42]. The NOD2 L1007fsX1 
SNP, leading to a frame shift and a premature stop codon, has a large effect on the 
protein. Its association with Crohn disease has been extensively described [43, 44]. 
Ammerdorffer et al [5] showed that C. burnetii– induced cytokine production by 
human mononuclear cells is mediated through NOD2, with NOD2-deficient 
individuals having strongly decreased IL-1β and IL-6 responses. In the present 
study, we were unable to show a significant effect on C. burnetii–induced cytokine 
responses when we stratified for the polymorphism NOD2 L1007fsX1, most likely 
because of the rare occurrence of heterozygotes for the allelic variant and absence 
of homozygotes.
 To our knowledge, the role of the adaptor molecule MyD88 in C. burnetii 
infection has not been studied previously. We found that MYD88 −938C>A was 
significantly associated with susceptibility to chronic Q fever. In general, MyD88 
plays a central role in innate immune responses, being downstream of all TLRs 
(except TLR3) and the interleukin 1 receptor. MyD88 deficiency leads to recurrent 
infections with pyogenic bacteria in early childhood but seems redundant for most 
other infections [15]. The MYD88 −938C>A SNP has been shown to decrease 
promoter activity [45] and was found to be associated with development of 
sarcoidosis [46].
 TLR2 is a receptor for bacterial lipopeptides, which are recognized by either 
TLR2/TLR1 or TLR2/TLR6 heterodimers. Although multiple studies have shown 
that TLR2 is involved in the host’s immune response against C. burnetii [5, 47–49], 
we found no association between the TLR2 SNPs included in this study and 
development of chronic Q fever. This could indicate either that TLR2 has no 
prominent role in the elimination of C. burnetii or that the consequences of these 
genetic variants for the protein function in C. burnetii defense are limited. We also 
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did not observe any association of chronic Q fever with TLR4, TLR6, TLR8, or 
TIRAP polymorphisms. Genetic polymorphisms in the genes for the receptors 
αvβ3 integrin and CR3, which have been reported to be involved in C. burnetii 
uptake and TNF production [7, 50], were also not distributed significantly 
differently between patients with chronic Q fever and controls.
 Our study has some limitations that need to be taken into account. Although 
this is the largest cohort of patients with chronic Q fever ever described, it is still 
relatively small for a study of the genetic associations of an infectious disease. We 
tried to overcome this limitation by using a control group almost similar in sex, 
age, and cardiovascular risk factors and with exposure to the same virulent C. 
burnetii strain. Another important consideration is that no correction for multiple 
testing was performed, because only candidate genes with a known or suspected 
role in C. burnetii recognition were investigated, and not randomly selected genes. 
It has to be taken into account that when correction for multiple testing is applied, 
the statistical significance of the NOD2, MYD88, and TLR1 SNPs association with 
susceptibility to chronic Q fever is lost. To confirm our current findings, they need 
to be replicated in another cohort of patients with chronic Q fever.
 In conclusion, our current findings suggest an association between TLR1, 
NOD2, and MYD88 polymorphisms and the risk or developing chronic Q fever 
after infection with C. burnetii. Interestingly, we found that the protective TLR1 
80T allele was associated with decreased C. burnetii–induced IL-10 production. 
Further research is warranted to elucidate the exact role of these receptors and the 
adaptor molecule in host defense against C. burnetii in humans, which could be 
used to strategize approaches to risk assessment, prophylactic treatment, or 
targeted therapy of chronic Q fever.
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Abstract
Background: Q fever is caused by Coxiella burnetii, an intracellular bacterium that 
infects mononuclear phagocytes. In some individuals, it causes a persistent cardio-
vascular infection: chronic Q fever. The aim of the present study was to investigate 
whether the C. burnetii-induced IFN-γ response was defective in chronic Q fever 
patients.
Methods: IFN-γ was measured in supernatants of C. burnetii-stimulated peripheral 
blood mononuclear cells (PBMCs) of chronic Q fever patients (n=17) and healthy 
individuals (n=17). To assess whether the IFN-γ-induced effects are intact, expression 
profiles of IFN-γ-induced genes of C. burnetii-stimulated PBMCs were compared 
between 6 patients and 4 healthy individuals. Neopterin, a marker of cellular 
immune response, was measured in PBMC culture supernatants and in sera of 
patients and healthy individuals. In a genetic association study, polymorphisms in 
genes involved in the Th1-cytokine response were analysed in patients (n=139) and 
at risk controls (n=220).
Results: IFN-γ production in vitro by C. burnetii-stimulated PBMCs of chronic Q 
fever patients, was significantly higher than in controls. In gene-expression analysis, 
genes downstream of IFN-γ were also strongly up-regulated in patients. Neopterin 
levels were significantly higher in supernatants of C. burnetii-stimulated PBMC of 
chronic Q fever patients than of controls. In addition, high serum levels of neopterin 
were found in patients. The IL12B polymorphisms rs3212227 and rs2853694 were 
associated with chronic Q fever. There was no association for polymorphisms in 
IFNG, IFGR1, IL18 or IL12RB1.
Conclusion: IFN-γ production, as well as the response to IFN-γ, appears to be 
intact in chronic Q fever patients. Genetic analysis showed that polymorphisms in 
the IL-12p40 gene are associated with chronic Q fever.
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Introduction
Q fever is a zoonosis caused by the Gram-negative coccobacillus Coxiella burnetii. 
The infection is transmitted to humans by inhalation of aerosols that contain 
bacteria derived from dried animal manure or birthing fluids [1]. During infection, 
more than 50% of the individuals remain asymptomatic, but in some acute Q fever 
develops [1, 2]. Regardless of initial manifestations, a minority of individuals 
develops a chronic infection that may become apparent months or years after 
initial exposure [3, 4]. Chronic Q fever mainly develops in people with pre-existing 
valvular disease, aortic aneurysm or vascular prostheses [5-7], and may present as 
endocarditis, a mycotic aneurysm, or vascular prosthesis infection, life-threaten-
ing conditions that need long-term antibiotics and sometimes surgical intervention 
[6, 8]. An immunosuppressed state as well as older age, pregnancy and renal 
insufficiency are also associated with increased risk for chronic Q fever [5, 9-11].
 During the 2007-2011 Q fever outbreak in the Netherlands, the majority of 
patients with valvular/vascular risk factors for chronic Q fever apparently cleared 
the infection [12, 13]; however, more than 250 patients did develop chronic Q fever 
[14]. It is unknown what explains this difference in susceptibility to develop a 
chronic infection.
As an obligate intracellular pathogen, C. burnetii proliferates in mononuclear 
phagocytes, i.e., monocytes and tissue macrophages. C. burnetii uniquely replicates 
in an intracellular acidic vacuole that harbours late endosome markers, containing 
lysosomal enzymes and having a low pH [15-17]. In general, containment of 
intracellular infection by the host’s immune system requires a pro-inflammatory 
response with granuloma formation and intracellular killing or control of the 
bacterium in activated monocytes/macrophages. The key cytokine in this process is 
interferon-γ (IFN-γ), a well-studied proinflammatory T helper (Th)-1 cytokine, which 
activates macrophages, and is able to eliminate or control intracellular pathogens 
[18]. IFN-γ production is induced by type-1 cytokines secreted by monocytes/
macrophages or dendritic cells,, most notably interleukin (IL)-12 and IL-18 [19, 20].
The important role of IFN-γ in the defense against C. burnetii is supported by the 
high mortality observed in IFN-γ -/- mice infected with C. burnetii [21]. In-vitro 
studies have also shown that recombinant IFN-γ induces killing of C. burnetii 
by THP-1 monocytic cells, and inhibits growth of C. burnetii in mouse fibroblasts 
[22-24]. It has been reported that chronic Q fever is associated with a defective 
antigen-driven lymphocyte proliferation to C. burnetii antigens, with intact response 
to other antigens [25]. A substantial amount of C. burnetii-specific IFN-γ is produced 
by healthy individuals after vaccination with killed C. burnetii and after natural 
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infection [26]. Based on these observations, it has been assumed that chronic Q 
fever patients have an inadequate IFN-γ response to C. burnetii that in turn leads to 
persistent infection [21, 23, 27], but direct evidence for this hypothesis is lacking. 
The aim of present study is to investigate the IFN-γ response to C. burnetii in 
chronic Q fever patients.
Materials and Methods
Ethics statement
The study was approved by the Ethical Committee of Radboud university medical 
center, Nijmegen, the Netherlands. Subjects were enrolled after providing written 
informed consent (or waiver when deceased [n=5], as approved by the Ethical 
Committee). Institutional Review Boards of participating hospitals approved the 
inclusion of patients and controls in this study. The study has been performed in 
accordance with the Declaration of Helsinki.
Subjects
For the peripheral blood mononuclear cells (PBMC) stimulation experiments and 
serum measurements as described below, 17 proven chronic Q fever patients, who 
visited the outpatient clinic at the department of internal medicine of the 
participating hospitals, were included. Chronic Q fever was diagnosed based on 
the guidelines by the Dutch chronic Q fever consensus group [28]. Seventeen 
healthy individuals without known history of Q fever, were included as controls 
in these experiments. Serum of patients and controls was collected and stored in 
aliquots at -80°C until use.
 For the genetic analysis study, all probable or proven chronic Q fever patients 
[28], who visited the outpatient clinic at the departments of internal medicine of 
the participating hospitals, were asked to participate. The recruitment took place 
as described before [29], and 139 patients were included. The control group 
consisted of 220 individuals from the same area with valvular or vascular 
abnormalities predisposing to chronic Q fever, who had serological evidence of 
exposition to C. burnetii (anti-C. burnetii phase II IgG antibodies ≥1:32) without 
clinical symptoms or serological evidence of chronic Q fever. These individuals 
were recruited as described previously [29].
Bacteria
C. burnetii Nine Mile (NM) phase I (RSA 493) – a reference strain isolated from a 
tick [30] – and C. burnetii 3262 – isolated from the placenta of a spontaneously 
aborted goat in the Netherlands [31] – were cultured in Buffalo Green Monkey cells 
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in a BSL-3 facility at the Central Veterinary Institute, as described previously [32]. 
The number of Coxiella DNA copies was determined using a Taqman real-time 
polymerase chain reaction [32]. The C. burnetii strains were inactivated by heating 
for 30 minutes at 99°C and stored at -80°C until use. Furthermore, Q-vax® vaccine 
(CSL Biotherapies, Victoria, Australia) [33] contains formaldehyde-inactivated C. 
burnetii Henzerling strain phase I in 50 µg/ml, and was used in a end-concentration 
of 100 ng/ml.
Isolation and stimulation of PBMCs
PBMCs from chronic Q fever patients and healthy individuals were isolated as 
previously described [34]. In short, venous blood was drawn from the cubital vein 
of all participants into 10 ml EDTA tubes. PBMCs were isolated from whole blood 
using density gradient centrifugation on Ficoll-Hypaque (GE Healthcare, Uppsala, 
Sweden). The cells from the interphase were aspirated and washed twice in sterile 
PBS and resuspended in RPMI 1640 Dutch modification culture medium (Sigma-
Aldrich, St Louis, MO, USA) supplemented with 1% L-glutamine, 1% pyruvate and 
1% gentamicin. Cells were counted in a Coulter Counter Z® (Beckman Coulter, 
Fullerton, CA, USA), and adjusted to required concentration. The PBMCs [2.5 x 106/
ml] were incubated in a round-bottom 96-wells plate (volume 200 µl/well) at 37°C 
and 5% CO2  with either heat-killed C. burnetii NM [107/ml and 106/ml], heat-killed 
C. burnetii 3262 [106/ml], Q-vax [100 ng/ml] or heat-killed C. albicans (ATCC 
MYA-3573; UC820) [105 /ml] or culture medium alone. After 48 hours, supernatants 
were collected and stored at -20°C until being assayed.
IFN-γ and neopterin measurements
IFN-γ production was measured in the supernatants by enzyme-linked immuno -
sorbent assay (ELISA; Pelikine compact, Sanquin, Amsterdam, the Netherlands), 
according to the manufacturer’s instruction.
 Neopterin was also measured in supernatants of eight patients and four 
healthy individuals by ELISA (IBL International, Hamburg, Germany), according 
to the manufacturer’s instruction. Neopterin in serum was measured likewise, 
using stored sera of 21 chronic Q fever patients and 11 healthy controls.
Gene expression analysis
To assess gene expression, PBMCs of six patients and four healthy individuals 
were incubated for 8 hours in a flat-bottom 24-wells plate (volume 1 ml/well) at a 
concentration of [107 cells/ml] at 37°C and 5% CO2 with heat-killed C. burnetii NM 
[107/ml], E. coli LPS [10 ng/ml] or culture medium alone.
 RNA was extracted using the RNeasy Mini kit (Qiagen) and DNAse treatment. 
The quality of the RNA preparation was assessed using the 2100 Bioanalyzer and 
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the RNA 6000 Nano LabChip kit (Agilent Technologies), and its quantity was 
assessed using a Nanodrop. The PBMC gene expression was analyzed using Whole 
Human Genome 4×44K microarrays (Agilent Technologies, Massy, France), 
representing 45,000 probes and One-color Microarray Based Gene Expression 
Analysis kit, as previously described [35]. RNA samples of stimulated or 
unstimulated PBMCs from 6 chronic Q fever patients and 4 healthy individuals 
were included in the analysis.
 The data were analyzed with R and the Bioconductor software suites. Raw 
data were preprocessed and quality-checked with Agi4x44PreProcess library and 
normalized through quantile normalization. Differential expression was assessed 
using Limma library. To explore IFN-γ pathway modulation in this dataset, nodes 
in the pathway were color-coded according to the ratio of gene expression in 
stimulated cells to gene expression in unstimulated cells.
 Graphical representation of the pathway were drawn with Cytoscape [36]. 
Minimum Information About a Microarray Experiment (MIAME)-compliant data 
were submitted to the Gene Expression Omnibus (GEO) of the National Center for 
Biotechnology Information (http://www.ncbi.nlm.nih.gov/geo/) and can be assessed 
with the GEO series accession number GSE66476.
Genotyping of type-1 cytokine (receptor) polymorphisms and 
measuring IFN-γ response in whole blood according to genotype
From patients who came to the outpatient clinic, venous blood was drawn and 
stored at -80°C until use. DNA was isolated from these blood samples using 
standard methods [37]. Other participants, both patients and controls, received a 
buccal swab kit (Isohelix, Cell Projects Ltd., Harrietsham, Kent, UK) to obtain 
epithelial cells for DNA isolation. DNA was isolated using a buccal DNA isolation 
kit (Isohelix), according to the manufacturer’s protocol. Single nucleotide 
polymorphisms (SNPs) were selected based on known functional effects on protein 
function or gene expression, published associations with human diseases and/or 
haploview data. In total, nine SNPs in IFNG, IFNGR1, IL18, IL12B and IL12RB1 
were genotyped with a Sequenom mass-spectrometry genotyping platform. 
Quality control was performed by duplicating 5% of the samples within and across 
plates, by the incorporation of positive and negative control samples and by 
sequencing samples to verify the various genotypes.
 In a subgroup of the genotyped control subjects, whole blood assays were 
performed and C. burnetii-induced IFN-γ was measured, as described earlier [38]. 
In short, venous blood was drawn into 5 ml endotoxin-free lithium-heparin tubes 
(Vacutainer, BD Biosciences). Heat-killed C. burnetii NM RSA 493 phase I [10^7 
bacteria/ml] was used as stimulus. After incubation, blood cultures were centrifuged 
and supernatants were stored at -20ºC until assayed.
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Statistical analysis
Median IFN-γ and neopterin concentrations were compared using Mann-Whitney 
U-tests, using GraphPad Prism (GraphPad software Inc., version 5). Statistical tests 
were two-sided and a P-value below 0.05 was considered statistically significant.
Presence of Hardy-Weinberg equilibrium (HWE) was analysed for all nine SNPs 
separately in the control cohort [39]. The difference in genotype frequencies 
between the patients and the control group were analyzed by means of a gene 
dosage model, with Fisher’s exact test to determine significance. Subsequent 
dominant and recessive model analysis was performed by means of univariate 
logistic regression, for which odds ratios (ORs) and their 95% confidence intervals 
(95% CI) were reported. Because the choice of the genetic variants was based 
exclusively on genes products with an established role in response to C. burnetii 
recognition, rather than exploratory, no correction for multiple testing was 
performed. Statistical analyses were carried out with the IBM SPSS software 
(version 20).
Results
Intact C. burnetii–induced IFN-γ production by PBMCs of chronic 
Q fever  patients  
The ability of PBMCs of chronic Q fever patients to mount a recall response to C. 
burnetii was investigated by stimulation of PBMCs in the absence of serum for 48 
hours with various C. burnetii-strains and subsequent measurement of IFN-γ in 
the supernatants. Figure 1 shows that a high IFN-γ production was induced in 
PBMCs of patients with all C. burnetii-strains and that this was significantly different 
from the response in PBMCs of healthy individuals. Interestingly, inactivated 
C. albicans, known to induce IFN-γ in PBMCs of healthy individuals, led to significant 
less IFN-γ production in chronic Q fever patients.
Transcriptome analysis reveals C. burnetii-induced upregulation of 
genes downstream of IFN-γ in chronic Q fever patients
Since chronic Q fever patients produce high amounts of IFN-γ upon C. burnetii 
stimulation, we wondered whether the pathway downstream of IFN-γ would be 
defective in chronic Q fever patients. In a whole-transcriptome microarray approach, 
the transcriptional responses of PBMCs to C. burnetii and, for comparison, to E. coli 
LPS were investigated.
 Performing principal component analysis, the gene expression profiles overall 
showed a different activation pattern in patients and controls, and for patients also 
different between C. burnetii and E. coli LPS stimulation (not shown). For the 
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purpose of this study, we focused on the gene expression related to the IFN-γ 
downstream pathway. In Figure 2, the median gene modulation in inflammatory 
responses of PBMCs of six patients and four healthy controls is shown, in which 
the IFN-γ downstream pathway can be evaluated. As can be seen from this figure, 
PBMCs from patients show up-regulation of genes downstream of IFN-γ signaling 
when stimulated with C. burnetii, while this was not the case in healthy individuals.
Stimulation with E. coli LPS, however, led to up-regulation of IFN-γ pathway in 
healthy individuals, which was less pronounced in chronic Q fever patients 
(Supplementary figure 1).
Neopterin levels are increased in chronic Q fever patients
Neopterin is a highly stable low molecular weight molecule that belongs to the 
chemical group known as pteridines. Its biosynthesis can be seen as a general 
marker of activation of the cellular immune system, in particular by IFN-γ action. 
In the course of a cellular immune reaction, neopterin can be measured in serum. 
It is produced in vitro by macrophages after stimulation with IFN-γ. We found 
significantly higher concentrations of neopterin in serum of chronic Q fever 
patients than in controls (Figure 3a). In addition, in the supernatant of C. burnetii 
NM-stimulated PBMCs of chronic Q fever patients, neopterin levels were 
significantly higher than of healthy individuals (Figure 3b), while in supernatant 
of C. albicans-stimulated PBMCs, neopterin concentrations were similar.
Figure 1. C. burnetii-induced IFN-γ production differs between chronic Q fever patients 
and healthy individuals. IFN-γ was measured in supernatant of PBMCs stimulated for 48 
hours with inactivated C. burnetii Nine Mile [10^6/ml], C. burnetii 3262 [10^6/ml], C. burnetii 
Henzerling [100 ng/ml] (all phase I) and Candida albicans [10^5/ml]. Values are expressed as 
mean ± standard error. P values are calculated using Mann-Whitney U-test.
**P<0.01, ***P<0.001.
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Figure 2. Differential expression of inflammatory response pathways, including the 
IFN-γ pathway, in C. burnetii stimulated PBMCs. PBMCs of six chronic Q fever patients 
(A) four healthy individuals (B) were stimulated with heat-inactivated C. burnetii Nine Mile 
[10^7/ml] for 8 hours. The median ratio of gene expression in stimulated PBMCs to the 
unstimulated PBMCs are color-coded from blue (Fold change [FC]= -4) to red (FC= +4) at each 
receptor or transcription factor.
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Genetic polymorphisms in IL12B are differently distributed 
between chronic Q fever patients and at risk controls and are 
associated with decreased IFN-γ production
We investigated whether subtle, common genetic variations in the type-1 cytokine 
pathway, that affect IFN-γ production or response, are associated with the risk for 
development of chronic Q fever. We performed a genetic association study using a 
cohort of chronic Q fever patients and appropriate control subjects as described 
Figure 3. C. burnetii-induced neopterin is significantly different between chronic Q fever 
patients and healthy individuals. (A) Neopterin was measured in serum of healthy controls 
(n=11) and chronic Q fever patients (n=21). (B) Neopterin was measured in supernatant of 
PBMCs of patients (n=8) and of healthy individuals (n=4) stimulated for 48 hours with 
inactivated C. burnetii Nine Mile (NM) phase I [10^7/ml], C. burnetii NM phase I [10^6/ml] 
and C. albicans [10^5/ml]. Medians of healthy individuals and patients are compared by 
Mann-Whitney U-test. ** P<0.01.
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previously [29]. In total, 139 (92 proven and 47 probable) chronic Q fever patients 
and 220 control subjects without chronic Q fever but with serological evidence of 
C. burnetii exposure and a risk factor for chronic Q fever were included. Genotyping 
of patients and controls was successful for all polymorphisms in genes encoding 
IFN-γ (IFNG), IFN-γ receptor chain 1 (IFNGR1), IL-18 (IL18), IL-12p40 (IL12B) and 
the IL-12 receptor β1 chain (IL12RB1) presented in Table 1. For each polymorphism, 
>92% of the subjects were genotyped. All SNPs were in Hardy-Weinberg equilibrium 
in the control group.
 In the gene dosage analysis, genotyping revealed an association between 
chronic Q fever and both IL12B polymorphisms: IL12B rs2853694 (Fisher’s exact 
P=0.006) and IL12B rs3212227 (P=0.004). No associations were observed between 
polymorphisms in IFNG, IFNGR1, IL18, IL12RB1 and the presence of chronic Q 
fever (Table 2). Subsequently, IL12B rs2853694 was found to be significantly 
differently distributed in a recessive model analysis, with two C alleles leading to 
increased risk of chronic Q fever (P = 0.001; OR, 2.18 [95% CI, 1.35-3.53]). IL12B 
rs3212227 distribution was significantly different in a dominant model analysis, 
with protective effect of the C allele (P = 0.004; OR, 0.50 [95% CI, 0.31-0.80]) (Table 2). 
These two polymorphisms are not strongly linked (r2=0.248).
Table 1   Genotyped SNPs in genes encoding IFN-γ (IFNG), IFN-γ receptor 
chain 1 (IFNGR1), interleukin-18 (IL18), interleukin-12p40 (IL12B), and 
interleukin-12 receptor chain β1 (IL12RB1)
Gene SNP ID Gene region Nucleotide 
changea
Amino Acid Change
IFNG rs2069718 Intron 3 C > T
rs1861494 Intron 3 T > C
IFNGR1 rs1327474 Promoter A > G
rs2234711 5’ UTR T > C
IL18 rs549908 Exon 4 T > G Synonymous (S35S)
IL12B rs2853694 Intron 4 A > C
rs3212227 3’ UTR A > C
IL12RB1 rs436857 Exon 1 G > A P40L
rs11575934 Exon 7 A > G R214Q
Abbreviations: SNP, single nucleotide polymorphism; ID, identification number.
a The first nucleotide is the most common nucleotide.
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 Next we investigated the functional consequences of these two genetic 
variations by assessing the C. burnetii induced IFN-γ production in whole blood 
samples from control subjects stratified for IL12B rs2853694 and rs3212227 
genotypes. IFN-γ production was measured in supernatants after 24 hours of 
culture. These control subjects were stratified for genotype either in a recessive 
model (rs2853694; low-risk AA/AC versus high-risk CC) or in a dominant model 
(rs3212227; high-risk AA versus low-risk AC/CC) (Figure 4). The mean IFN-γ 
production by C. burnetii-stimulated blood cells in subjects with rs2853694 CC 
genotype was 243 pg/mL and in subjects with AA/AC genotype 563 pg/mL. a 
difference that was not significant (P=0.13). Subjects with rs3212227 AC/CC low-risk 
genotypes and CC genotypes neither showed statistically different mean IFN-γ 
production (573 pg/mL versus 428 pg/mL: P=0.40).
Figure 4. IL12B rs2853694 and rs3212227 genotypes and C. burnetii-induced IFN-γ in 
whole blood. In vitro stimulation of whole blood was performed for 24 hours with heat- 
inactivated C. burnetii Nine Mile phase I [1x 107 bacteria/mL]. Subjects were stratified by 
genotype (A) IL12B rs2853694 AA/AC versus CC, (B) IL12B rs3212227 AA versus AC/CC. 
Data are presented as means ± standard error of the mean. Groups were compared by 
Mann-Whitney U-test.
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Discussion
In this study we investigated the C. burnetii-induced IFN-γ production in chronic 
Q fever patients. We show that immune cells of chronic Q fever patients are not 
only capable of a high IFN-γ production in response to C. burnetii, but also display 
up-regulation of genes downstream of the IFN-γ receptor in addition to production 
of neopterin, which is highly IFN-γ-dependent. We found that genetic 
polymorphisms in IL12Bmare associated with the development of chronic Q fever.
 Previously, it has been assumed that chronic Q fever patients have an 
inadequate T-cell derived IFN-γ production in response to C. burnetii infection. 
Our study could not confirm this assumption, and our findings provide evidence 
that C. burnetii induced IFN-γ production in chronic Q fever is rather increased. In 
a previous study, Koster et al [25] found that lymphocytes of chronic Q fever 
patients with endocarditis fail to proliferate in vitro in response to C. burnetii 
antigens. In one of these patients, this was demonstrated five years after the 
endocarditis was treated with antibiotics and cardiac valve replacement. This un-
responsiveness was antigen-specific, since lymphocyte proliferation in response to 
Candida antigens was preserved [25]. The method of studying C. burnetii-specific 
adaptive immune responses used by Koster et al., i.e., lymphocyte proliferation, is 
different from our recent studies in which we showed increased IFN-γ production 
by ex-vivo C. burnetii-stimulated whole blood of chronic Q fever patients [40, 41]. In 
our present study, we confirmed these findings in PBMCs of chronic Q fever 
patients cultured for 48 hours in the presence of either one of three different C. 
burnetii strains. The absence of autologous serum in these cultures show that the 
IFN-γ production observed is not dependent on anti-C. burnetii antibodies.
 Surprisingly, we found decreased IFN-γ response to Candida albicans in chronic 
Q fever patients compared to healthy individuals. This seems to indicate that 
PBMCs of patients with an active chronic Q fever infection are strongly responsive 
to C. burnetii in a specific fashion, at the expense of responsiveness to other stimuli. 
More research is necessary to unravel this mechanism.
 The transcriptome analysis revealed that genes downstream of the IFN-γ 
receptor are upregulated in PBMCs of chronic Q fever patients upon stimulation 
with C. burnetii. In addition, IFN-dependent transcription factors were specifically 
upregulated in C. burnetii stimulated PBMCs of patients, and not in healthy 
individuals (data not shown). This shows that the IFN-γ signaling pathway is 
intact in chronic Q fever. The high neopterin levels in vivo – the measurements in 
serum – and in vitro – in C. burnetii-stimulated PBMC cultures – indicate that 
macrophages of chronic Q fever patients are activated by IFN-γ. This confirms that 
the IFN-γ signaling pathway is intact. In a previous study, mean neopterin levels 
in plasma of 13 acute and 23 chronic Q fever patients were increased (5.4 and 5.1 
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ng/mL, respectively) compared to 17 healthy individuals (2.1 ng/mL), although 
these differences were not significant [42].
 Interestingly, our findings that the IFN-γ pathway in response to C. burnetii is 
intact in chronic Q fever patients can be added to the observation that anti-C. 
burnetii antibody titers are high in chronic Q fever patients [43] . Taken together, we 
may conclude that we have not found evidence for an impaired adaptive immune 
response in these patients. Since they are not able to kill the pathogen, apparently 
the antibody response and the strong IFN-γ response do not lead to adequate 
bactericidal effects. Why these hosts fail to eliminate the bacterium is still 
enigmatic.
 It has been shown that IL-23 is the critical first signal from the antigen-presenting 
cells after recognition of pathogen-associated molecular patterns (PAMPs) by 
pattern recognition receptors (PRRs). IL-23 signals through binding to the IL-23 
receptor on T-cells, and stimulates cellular proliferation and early production of 
IFN-γ and TNF. IFN-γ in turn binds to the IFN-γ receptor on macrophages and 
activates, in synergy with TNF, various microbicidal pathways as well as 
production of IL-12. Subsequently, IL-12 drives, in synergy with IL-18, activation, 
differentiation and proliferation of T-cells along to the Th1-cells to produce more 
IFN-γ [44]. An essential component of both IL-12 and IL-23 is IL-12p40. In the 
present study, we found that the presence of SNPs in the promoter region 
(rs2853694) and at the 3’UTR (rs3212227) of the IL-12p40 gene, IL12B, were associated 
with the development of chronic Q fever. For both SNPs, association with leprosy, 
another disease caused by an intracellular pathogen, has been described [45, 46]. 
We found that subjects with the risk genotype of the polymorphisms did not 
significantly differ with regard to IFN-γ production. Hence we were unable to 
prove that these polymorphisms have an impact on the susceptibility to C. burnetii 
through production of IFN-γ. The high IFN-γ production upon C. burnetii 
stimulation that is seen in chronic Q fever patients is measured during an active 
chronic infection and most likely results from an ongoing stimulation of adaptive 
immune responses. In this light it would be interesting to compare initial IFN-γ 
responses between acute Q fever patients who eventually develop a chronic 
infection and those who do not. Honstettre et al. previously measured IL-12p40 
release by PBMCs of patients with acute Q fever. They describe a trend of reduced 
IL-12p40 release during acute Q fever in patients with valvulopathy, of which 50% 
subsequently developed chronic Q fever [47].
 There are, however, some considerations that should be taken into account 
when interpreting our results. First of all, we studied the immune response of 
circulation blood mononuclear cells to C. burnetii. It may be more relevant to study 
the local immune response in C. burnetii infected vascular walls or valvular tissue. 
Both vascular and valvular chronic C. burnetii infection are mostly low-grade 
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infections in which systemic immune activation is apparently not effective in 
clearing the local infection. The local immunological processes are likely crucial 
for survival of C. burnetii at predilection sites such as defective cardiac valves and 
aneurysmatic vascular wall. Immunohistochemical studies of C. burnetii-infected 
cardiac valves showed small, focal collections of infected mononuclear phagocytes 
[48, 49]. Further identification of these cells and their immunological environment 
could help us to better understand the local persistence of C. burnetii.
 Second, the model that we used to study the IFN-γ response to C. burnetii, i.e., 
in-vitro stimulation of PBMCs with heat-inactivated bacteria, might not reflect the 
immunological processes in vivo. In particularly, relatively high doses of C. burnetii 
were used to stimulate the PBMCs in culture, compared to the low antigen load in 
serum during Q fever infection.
In conclusion, the present study shows that IFN-γ production and the response to 
IFN-γ appear to be intact in chronic Q fever patients and does not explain the 
failure to clear the infection. Although our genetic analysis showing that poly -
morphisms in the IL-12p40 gene are associated with chronic Q fever also points to 
the IFN-γ pathway, the functional consequences of these polymorphisms in Q fever 
are unclear.
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Supplementary Figure 1. Differential expression of inflammatory response pathways, 
including IFN-γ pathway, in E. coli LPS stimulated PBMCs. PBMCs of six chronic Q fever 
patients (A) and four healthy individuals (B) were stimulated with E. coli LPS [10 ng/ml] for 
8 hours. The median ratio of gene expression in stimulated PBMCs to the unstimulated 
PBMCs are color-coded from blue (Fold change [FC]= -4) to red (FC= +4) at each receptor or 
transcription factor.
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Abstract
Background. Current practice for diagnosis of Q fever, caused by the intracellular 
pathogen Coxiella burnetii, relies mainly on serology and, in prevaccination assessment, 
on skin tests (STs), which both have drawbacks. In this study, C. burnetii–specific 
interferon γ (IFN-γ) production was used as a new diagnostic tool for previous 
 Q fever, circumventing most of these drawbacks. Our aim was to compare this test 
to serology and ST.
Methods. One thousand five hundred twenty-five individuals from an endemic 
area with a risk for chronic Q fever were enrolled. IFN-γ production was measured 
after in vitro stimulation of whole blood with C. burnetii antigens. Various formats 
using different C. burnetii antigens were tested. Serology and ST were performed 
in all individuals.
Results. In all assay formats, C. burnetii–specific IFN-γ production was higher 
(P < .0001) in seropositive or ST-positive subjects than in seronegative and ST- 
negative subjects. Whole blood incubated for 24 hours with C. burnetii Nine Mile 
showed optimal performance. After excluding subjects with equivocal serology 
and/or borderline ST results, IFN-γ production was 449 ± 82 pg/mL in the positive 
individuals (n = 219) but only 21 ± 3 pg/mL in negative subjects (n = 908). Using 
Bayesian analysis, sensitivity and specificity (87.0% and 90.2%, respectively) were 
similar to the combination of serology and ST (83.0% and 95.6%, respectively). 
Agreement with the combination of serology and ST was moderate (84% 
concordance; κ = 0.542).
Conclusions. Specific IFN-γ detection is a novel diagnostic assay for previous 
C. burnetii infection and shows similar performance and practical advantages over 
serology and ST. Future studies to investigate the clinical value in practice are 
warranted.
Editorial Commentary by Graves on pages 1752-53.
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Introduction
Acute Q fever, caused by Coxiella burnetii, is often not recognized because it may 
have an asymptomatic or a mild course [1]. Chronic life-threatening endovascular 
infection may, however, develop, particularly in patients with valvulopathy or 
aneurysmas [1, 2]. A correct diagnosis of C. burnetii infection is crucial for patient 
care, as well as for vaccination and epidemiological studies.
 The standard method to detect Q fever is measurement of specific antibodies 
[3, 4]. However, assessment of T-lymphocyte immunity might be an additional and 
even superior method because defense against this intracellular pathogen mainly 
depends on cellular immunity, including interferon γ (IFN-γ)–mediated macrophage 
activation [5–7]. Hence, a skin test (ST) can be done to assess delayed-type hyper-
sensitivity to intradermally injected C. burnetii. The ST is almost exclusively used 
for prevaccination screening. Its disadvantages are variability, lack of a well-defined 
cutoff, and dependence on trained personnel to perform a ST. Therefore, we 
developed an in vitro IFN-γ production assay, in which IFN-γ production in blood 
after exposure to C. burnetii antigens is measured, similar to the quantiferon test 
for tuberculosis [8, 9].
 Between 2007 and 2010, the Netherlands experienced the largest outbreak of 
Q fever worldwide [10], with an estimated >40 000 infected individuals and >250 
patients with chronic Q fever [11, 12]. In 2010, the health authorities decided to offer 
vaccination with the C. burnetii whole-cell vaccine Q-vax [13] to inhabitants of the 
endemic area at risk for chronic Q fever (ie, those with preexisting heart valve 
lesion, prosthetic valve, congenital heart anomalies, aortic aneurysm, or vascular 
graft). Vaccine candidates were screened by serology and ST to exclude preexisting 
sensitization to C. burnetii antigens that may cause hypersensitivity reactions upon 
vaccination [14]. This prevaccination screening presented a unique opportunity to 
explore the applicability of our novel assay. We tested different formats of the assay 
and assessed its accuracy in diagnosing previous Q fever.
Methods
Study Population and Sampling Procedure
The study population consisted of vaccine candidates in the Dutch Q fever 
vaccination campaign from 21 January 2011 to 20 April 2011; the campaign coincided 
with a 30-fold decrease of new human Q fever cases in the spring compared with 
the peak in 2009, probably related to veterinary measures, including culling of all 
pregnant goats on infected farms. The target population consisted of individuals 
living in the highly endemic area based on surveillance data available. Voluntariness 
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and application by general practitioners were required. One week before the 
planned vaccination, candidates were invited to the Municipal Health Service in 
‘s-Hertogenbosch. Blood was collected for serology followed by the ST. All 
candidates were asked to participate in the study by donating 5 mL of heparinized 
blood for the IFN-γ assay. This sample was obtained simultaneously with the 
serological sample and processed within 12 hours, as previous experiments had 
shown that samples assessed at 2 or 12 hours did not affect the assay results. IFN-γ 
production was not relevant for the decision whether or not to vaccinate. The study 
was performed according to the guidelines of the local ethics committee, and 
written informed consent was obtained. Demographic details were collected 
anonymously.
C. burnetii IFN-γ Production Assay
IFN-γ production was measured after in vitro stimulation of whole blood incubated 
under 2 different conditions (A or B) described below. Also, 2 C. burnetii antigens 
were used separately for stimulation. In parallel, stimulation with phytohemag-
glutinin was performed as a positive control and incubation with no reagent as a 
negative control.
 In format A, undiluted whole blood was incubated in a closed tube at 37°C for 
24 hours. In format B, the blood was diluted 1:5 in medium (Roswell Park Memorial 
Institute 1640 Dutch modification supplemented with glutamax [2 mM], pyruvate 
[1 mM], and gentamicin [1 mg/mL]) and incubated in 24-wells plates at 37°C and 
5% carbon dioxide for 48 hours.
 The 2 C. burnetii antigens were the Q-vax vaccine [15] and the heat-inactivated 
laboratory strain C. burnetii Nine Mile RSA 493 (C. burnetii–NM) [16], kindly 
provided by Dr D. Frangoulidis (Bundeswehr Institute of Microbiology, Munich, 
Germany).
 Q-vax vaccine contains formaldehyde-inactivated C. burnetii Henzerling strain 
phase 1 in 50 µg/mL. Previous dose–response experiments in Q fever patients 
showed optimal IFN-γ production in the range of 100–500 ng/mL. A single lot (No. 
0980– 07 201) was used and diluted to 100 ng/mL.
 C. burnetii–NM phase 1 was cultured in a biosafety level 3 facility at the Central 
Veterinary Institute, using Buffalo Green Monkey cells in Earle’s Modified Eagle 
Medium supplemented with 10% fetal calf serum, 1% nonessential amino acids, 
and 1% L-glutamine. The concentration of C. burnetii DNA was determined by 
real-time polymerase chain reaction. The supernatant was centrifuged for 15 
minutes at 1000 × g and stored in aliquots at −80°C. Killing was done by heating for 
30 minutes at 99°C. For stimulation C. burnetii–NM was used in an end concentration 
of 107 bacteria/mL, previously shown to be optimal in Q fever patients. The same 
batch was used for all assays.
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After incubation of blood samples with either C. burnetii antigens, phytohemagglu-
tinin (PHA), or nil, cultures were centrifuged and supernatants were stored at 
−20°C.
 IFN-γ was measured by enzyme-linked immunosorbent assay. Serological 
and ST results were unknown to those performing the assay. Net IFN-γ production 
was expressed as the concentration of IFN-γ in stimulated samples minus that in 
negative controls. If either IFN-γ production in the negative control exceeded 24 
pg/mL (thrice the lower detection limit of the ELISA) or the IFN-γ production after 
PHA stimulation was <24 pg/mL without the C. burnetii–stimulated aliquots 
exceeding 24 pg/mL, the assay was considered inconclusive.
Serology and Skin Testing
Antibodies against C. burnetii were determined in serum by indirect immuno-
fluorescence measuring immunoglobulin M and immunoglobulin G against 
C. burnetii–NM phase 1 and 2. Seropositivity was defined as anti–C. burnetii titers 
≥1:32. A solitary  weak  reactivity  of  immunoglobulin  G  against  phase 2 antigens 
below the cutoff level of 1:32 was defined as equivocal because this was considered 
possible false positive or crossreacting. Seropositivity led to exclusion from 
vaccination.
 Q-vax skin tests [15] were  performed by professionals. In short, the local 
response to 0.1 mL intradermally injected Q-vax ST (containing the same C. burnetii 
antigens as Q-vax vaccine, but in a lower concentration) in the forearm was 
measured after 7 days. Only participants with negative or equivocal serological 
results were invited for ST reading. The ST results were classified as positive 
(induration ≥5 mm), borderline (induration 1–4 mm or any swelling and/or 
redness), or negative (no induration, swelling, or redness). Positive and borderline 
results led to exclusion from vaccination.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 5 and SAS version 9.2. 
Mann–Whitney U tests were performed to test statistical significance of IFN-γ 
production differences between groups. Association between inconclusiveness of 
specific IFN-γ production and demographics was assessed with a generalized 
linear model with identity link function [17]. Receiver operating characteristics 
(ROC) curves were created to assess accuracy (area under the curve [AUC]) of the 
different IFN-γ assay formats. Spearman’s r was calculated to report correlation. 
Subsequently, a Bayesian model [18], in which no test is considered to be the gold 
standard, was used to determine the sensitivity and  specificity  of  the  IFN-γ 
assay  of  the  best  performing format. Using this method [18], adapted for several 
cutoffs, the ROC curve was estimated. The proportionate agreement and the 
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Cohen’s κ were calculated to assess agreement [19]. The McNemar test was used to 
compare the proportion of positive results between tests. The level of significance 
was set at P ≤ .05.
Results
During the prevaccination visit, 1786 individuals were screened. No subject had 
signs of acute Q fever (no immunoglobulin M level compatible with acute Q fever), 
whereas 12 had a serological profile compatible with chronic Q fever and were 
referred for further analysis [20]. Blood samples from 1525 individuals were 
obtained for IFN-γ production. Assay format A was performed on all 1525 samples; 
format B was discontinued after 1306 samples. Table 1 shows the characteristics of 
the vaccine candidates.
 Results of the IFN-γ measurements in format A and B were conclusive for 
1278 (83.8%) and 1223 (93.6%) individuals, respectively. After excluding individuals 
with equivocal serology or borderline ST results, 1127 (73.9%) and 1087 (83.2%) 
individuals were left with a conclusive outcome for all 3 tests (Figure 1).
 Assay format A showed inconclusive results in 247 (16.2%) individuals; format B 
had only 83 (6.4%) inconclusive results. Inconclusiveness in format A was associated 
with age and sex (P = .02 and P = .0008 respectively; no interaction, P = .40), being 
most frequent in female subjects aged >80 years (29%; 95% confidence interval [CI], 
Table 1   Characteristics of the Total Population Participating in the Q Fever 
Prevaccination Screening and the Study Population
All individuals in 
pre-vaccination 
screening (n=1786)
Study population 
(n=1525)
Mean agea ± SD (years) 63.5 ± 14.7 64.0 ± 14.2
Female sex (%) 668 (37.4) 558 (36.6)
Exclusion of vaccination based on:
positive serology (%) 181 (10.1) 158 (10.4)
positive/borderline ST (%) 210 (11.8) 190 (12.5)
Serology indicating chronic Q fever infec-
tion
12 (0.7) 9 (0.6)
Abbreviations: ST, skin test.
a Age at 01-01-2011.
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21–38) and least frequent in male subjects aged <80 years (13%; 95% CI, 11–15). Only 
41 of the 247 inconclusive results in format A were due to high background IFN-γ 
production in the control sample; these were judged as technical errors or low-grade 
inflammation. Two hundred six results were inconclusive because of absent PHA 
response in  the  absence  of  a clear antigen-specific response ( judged as anergy). 
However, 157 of 206 (76%) had an adequate PHA response in the corresponding 
sample in format B.
 Subjects with conclusive results for all 3 tests were divided, based on the 
combined outcome of serology and ST, in seropositive or ST-positive (previous 
C. burnetii exposure) or seronegative and ST-negative (no C. burnetii exposure) groups. 
In the 1127 subjects with conclusive results in format A, 218 were seropositive or 
ST-positive, and 908 were seronegative and ST-negative. In the 1087 subjects with 
conclusive results in format B, 190 were seropositive or ST-positive, and 897 were 
seronegative and ST-negative. The IFN-γ production (mean ± standard error) was 
compared between these groups in both formats separately (Figure 2A and 2B). 
Figure 1. Flow diagrams of individuals included in the specific interferon γ (IFN-γ) 
production measurement. The numbers of individuals are shown separately for the IFN-γ 
assay in format A and format B. Format A: IFN-γ production assay in undiluted whole blood 
incubated 24 hours; format B: IFN-γ production assay in 1:5 diluted blood incubated 48 
hours. Abbreviations: IFN-γ, interferon γ; ST, skin test
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conclusive IFN-γ production
assay results 
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 conclusive serology and
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PHA-induced IFN-γ production did not distinguish between individuals with 
previous and no C burnetii exposure. However, C. burnetii antigen–specific IFN-γ 
production was significantly higher in subjects with previous exposure. IFN-γ 
production in assay format A stimulated with C. burnetii–NM distinguished best 
between seropositive or ST-positive individuals and negative individuals; IFN-γ 
production was 449 ± 82 pg/mL in the sero- or ST-positive individuals and 21 ± 3 
pg/mL in the seronegative or ST-negative individuals, respectively.
 The ROC curves (Figure 3), combining serology and ST as (surrogate) gold 
standard, revealed the highest AUC for format A with C. burnetii–NM (AUC, 0.8452). 
The correlation between C. burnetii–NM– and Q-vax–induced IFN-γ production in 
format A and between the C. burnetii–NM– induced IFN-γ production in format A 
and format B are shown in a scatter plot (Figure 4). The Spearman’s rank correlations 
were 0.5410 and 0.637, respectively (P < .0001).
Figure 2. Coxiella burnetii–specific interferon γ (IFN-γ) production ( pg/ mL) in seronegative 
and skin test (ST)–negative individuals (white bars) compared with seropositive or 
ST-positive individuals (gray bars). A, IFN-γ production (undiluted whole blood incubated 
24 hours) in 908 seronegative and ST-negative individuals compared with 219 seropositive or 
ST-positive individuals. B, IFN-γ production (1:5 diluted blood incubated 48 hours) in 897 
seronegative and ST-negative individuals compared with 190 seropositive or ST-positive 
individuals. Values are expressed as mean ± standard error. P values are calculated using 
Mann–Whitney U test. ***P < .0001. Abbreviations: C.B.-NM, Coxiella burnetii Nine Mile; 
IFN-γ, interferon γ; NS, not significant; PHA, phytohemagglutinin; ST, skin test.
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Comparison With Serology and Skin Testing
We focused on format A using C. burnetii–NM for further analysis. Figure 5 shows 
the data of 1278 individuals with conclusive results in format A, stratified according 
to the outcome of serology and ST, including equivocal serology and borderline ST 
results (see also Supplementary Table 1, showing the other IFN-γ assay formats). 
Specific IFN-γ (mean ± standard error) production was calculated in each group. 
This was highest in positive serology outcome, followed by positive ST outcome in 
combination with equivocal or negative serology. IFN-γ production was lowest in 
seronegative and ST-negative subjects. In borderline ST outcome, IFN-γ production 
Figure 3. Comparison of the receiver operating characteristic (ROC) curves of the interferon 
γ (IFN-γ) production assay in different formats considering positive serology or skin test 
(ST) outcome as case and negative serology and ST outcome as control. ROC curves of the 
IFN-γ production assay in 2 different formats (A and B) and with two Coxiella burnetii 
antigens are shown. A, IFN-γ production in undiluted whole blood incubated 24 hours. B, 
IFN-γ production in 1:5 diluted blood incubated 48 hours. The area under the curve indicates 
the accuracy of the IFN-γ production assay. Abbreviations: AUC, area under the curve; NM, 
Nine Mile.
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Figure 4. Scatter plots showing the correlation in interferon γ (IFN-γ) production between 
Q-vax and Coxiella burnetii–Nine Mile (NM) stimulation within IFN-γ assay format A (upper 
plot) and the correlation in IFN-γ production induced by C. burnetii–NM between assay 
format B and A (lower plot). The Spearman’s rank correlations were 0.5410 and 0.637, 
respectively (P < .0001). Every dot represents 1 subject, sofar as dots are not overlapping. 
Abbreviations: IFN-γ, interferon γ; NM, Nine Mile.
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was not significantly different between those with equivocal and negative serological 
findings (P = .07).
 Using Bayesians statistics, we determined sensitivity and specificity of the 
IFN-γ assay at predefined cutoff values from 16 to 80 pg/mL, equivalent to 2–10 
times the lower detection limit for the enzyme-linked immunosorbent assay. For 
the 1127 individuals with conclusive results for the IFN-γ assay, serology and ST 
were analyzed. A noninformative prior distribution was used for all parameters. 
The prior prevalence of C. burnetii infection was given a flat prior distribution over 
the range 0–0.5.
 The prior sensitivity and specificity of the tests were given a flat prior 
distribution over the range 0–1. The data of the performance of the IFN-γ measurement 
at different cutoffs are shown in Table 2. The resulting ROC curve for the IFN-γ 
assay (Figure 6) shows an accuracy (AUC) of 0.9239 (95% credible interval [CrI], 
0.8466–0.9756). Choosing an optimal cutoff value of 32 pg/mL, sensitivity and 
specificity of the IFN-γ assay were 87.0% and 90.2% (95% CrI, 72.2–98.8 and 
86.0–94.5, respectively). The sensitivities and specificities of combined serological 
and ST, as calculated in this analysis, were 83.0% and 95.6% (95% CrI, 70.1–98.7 and 
93.3–99.4, respectively). The prevalence of past Q fever was estimated in this 
Figure 5. Distribution of serology and skin test outcome and interferon γ (IFN-γ) production 
in the study population with conclusive IFN-γ production results in assay format A (n = 1278). 
The upper boxes indicate the number (%) of individuals. The lowest boxes indicate the 
specific IFN-γ production (mean ± standard error; pg/mL) in whole blood incubated for 
24 hours and stimulated with Coxiella burnetii Nine Mile. Abbreviation: IFN-γ, interferon γ.
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analysis to be 19.3% (95% CrI, 14.9–25.0). In comparison, available data on blood 
donors in the high-incidence area in 2009, based on serological screening alone, 
show a C. burnetii immunoglobulin G prevalence of 12.2% [21].
 Agreement between the dichotomized IFN-γ assay (with cutoff of 32 pg/mL) 
and the combination of the other 2 tests is shown in Table 3. Overall agreement was 
84%  (949 of 1127) with κ = 0.542 (P < .0001), which is considered moderate [22]. The 
proportion of individuals with past or present C. burnetii infection identified  by 
the  IFN-γ assay, but not by serology or ST, was significantly higher (118   of 178 = 
0.66) than the proportion identified by serology and ST but not by the IFN-γ assay 
(60 of 178 = 0.34) (McNemar χ2 = 18.90; P < .0001).
Performance in Equivocal Serology
We examined more closely the data in the 101 individuals with equivocal serology 
to know if the ST and the IFN-γ production assay (at cutoff level of 32 pg/mL) data 
revealed agreement in identifying individuals with and without previous Q fever 
(Figure 7). In 16 of 20 individuals with positive ST, IFN-γ production was above the 
Table 2   Sensitivity and Specificity With Concomitant 95% Credible Interval  
of the Specific Interferon γ Production at Cutoff Values in the Range  
of 16–80 pg/mL
Cutoff value for  
specific IFN-γ production 
(pg/ml)
Sensitivity  
(%)
95% CrI  
(%)
Specificity 
(%)
95% CrI 
(%)
16 91.8 78.4-99.7 82.4 78.1-86.7
24 87.9 73.7-98.6 87.1 82.8-91.5
32 87.0 72.2-98.8 90.2 86.0-94.5
40 82.3 67.8-94.9 92.5 88.4-96.7
48 79.2 65.0-92.4 94.0 90.4-98.0
56 78.3 63.9-91.4 94.9 91.3-98.7
64 76.3 62.1-89.3 95.9 92.4-99.4
72 73.0 58.9-85.4 96.1 92.7-99.5
80 70.3 56.3-83.1 96.9 93.6-99.8
A Bayesian model was used with flat priors for prevalence and test parameters, including IFN-γ 
 production and the combination of serology and skin test. The IFN-γ production measurement was 
performed in 24 hrs incubated whole blood, stimulated with C. burnetii Nine Mile. Only individuals 
with conclusive results for all three tests were included (n=1127).  
Abbrevations: 95% CrI, 95% credible interval.
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Table 3   Relationship Between the Interferon γ Production Outcome and the 
Combination of Serology and Skin Test Outcome
Combination of serology  
and ST outcomeb
Total
positive negative
IFN-γ production measurement outcomea
Positive 159 118 277
Negative 60 790 850
Total 219 908 1127
The IFN-γ production measurement was performed in 24 hrs incubated whole blood, stimulated with 
C. burnetii Nine Mile. Only individuals with conclusive results for all three tests were included (n=1127). 
Overall agreement was 84% (949/1127), κ=0.542 (P < 0.0001). Abbreviations: ST, skin test.
a  IFN-γ production measurement was considered positive at value > 32 pg/mL and considered  negative 
at value ≤ 32 pg/mL.
b  Combination of serology and ST was considered positive if either one was positive and considered 
negative if both were negative.
Figure 6. Receiver operating characteristic curve of the best performing interferon γ (IFN-γ) 
production assay at cutoff values ranging from 16 to 80 pg/mL using a Bayesian model 
without taking serology and skin test (ST) as gold standard. The IFN-γ production 
measurement was performed in whole blood incubated 24 hours and stimulated with 
Coxiella burnetii Nine Mile. Only individuals with conclusive results for all 3 tests were 
included (n = 1127). The area under the curve with concomitant 95% credible interval 
indicates the accuracy of the IFN-γ production measurement. Abbreviations: AUC, area 
under the curve; CrI, credible interval.
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cutoff, whereas in 55 of 63 individuals with negative ST the IFN-γ production was 
below the cutoff. Excluding those individuals with borderline ST, agreement 
between IFN-γ assay and ST was 71 of 83 (85.6%) in cases with equivocal serology. 
In borderline ST results (n = 18), the IFN-γ results were clearly separated in high 
and low IFN-γ clusters. Thus, the IFN-γ assay has additional value in identifying 
(past) Q fever in individuals with equivocal serology and  borderline ST results.
Figure 7. Interferon γ (IFN-γ) production ( pg/mL) according to skin test results in individuals 
with equivocal serology. The individuals with conclusive results in the IFN-γ production 
assay in format A stimulated with Coxiella burnetii Nine Mile with equivocal serology are 
included (n = 101). The dotted line indicates the cutoff of 32 pg/mL. Abbreviation: IFN-γ, 
interferon γ.
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Discussion
In a sample of >1500 individuals at risk for chronic Q fever, we demonstrated that 
an assay that measures antigen-specific IFN-γ production in vitro is a valuable tool 
in the diagnosis of Q fever. The accuracy of this test is similar to the traditional 
serology and ST. The test is easy to perform: no advanced personnel or equipment 
are required for incubation, and read-out and the data are available the next day. 
It is patient friendly by excluding the need for in vivo testing, which, in sensitized 
individuals, can be troublesome.
 The IFN-γ production assay was analyzed in individuals with a specific risk 
for development of chronic Q fever and considerable C. burnetii exposure. The 
assay was carried out in 2 formats with different incubation periods and 2 different 
C. burnetii antigens. The results of the 4 assay conditions were consistent, showing 
higher IFN-γ production in individuals with positive serology or ST response, 
whereas PHA stimulation was not specific. Thus, C. burnetii–specific IFN-γ production 
seems to be a useful diagnostic aid in determining previous Q fever infection.
 The IFN-γ production in undiluted blood exposed to C. burnetii–NM for 24 
hours showed the highest AUC, using serology and ST as the putative gold 
standard. This format performed better than in 1:5 diluted blood. This may be 
because of higher concentrations of serum factors, the 5× higher inoculum, and the 
shorter incubation in the undiluted assay. Stimulation  with C. burnetii–NM 
performed better than Q-vax. In the ROC curves, Q-vax stimulation reached 
maximal sensitivity of 53%. The scatter plot data support this finding by showing 
no Q-vax–induced IFN-γ in many samples with C. burnetii–NM– induced IFN-γ 
production. The sensitivity of the assay may be strain dependent; the Henzerling 
strain of Q-vax may be less potent than C. burnetii–NM in inducing IFN-γ in the 
Dutch setting. Formaldehyde in Q-vax may have led to a greater loss of antigen 
than heat inactivation. Lastly, 0.49 µM thiomersal in Q-vax may lead to a T helper 
2 cell response, thereby reducing IFN-γ production [23].
 A major advantage of the IFN-γ production assay is its internal positive and 
negative control. Consequently, 16.2% of the findings in format A were inconclusive. 
These were mainly because of low PHA response, suggesting anergy. However, in 
76%, PHA did elicit an IFN-γ response, albeit in format B. In the commercial IFN-γ 
production assays for tuberculosis, indeterminate results are rarely addressed, 
but low mitogen responses may be as high as 21% [24]. Although inconclusive 
observations  are  a  limitation  of  our assay,  false-negative or false-positive results 
are identified, whereas serology and ST lack internal controls.
 Because an imperfect gold standard does not allow a realistic estimation of the 
accuracy of a novel test, we used a Bayesian model (without taking serology and 
ST as surrogate gold standards). Bayesian models allow the evaluation of the true 
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accuracy of tests and do not require that any test or combination of tests be perfect 
[25, 26]. Each unknown parameter in the model should have a prior distribution, 
based on previous findings. However, data on prevalence of Q fever exposure in 
the Netherlands are based on serology alone. Moreover, little is known about 
sensitivity and specificity of serology and STs in Q fever diagnosis. Therefore, we 
chose to use noninformative priors, which resulted in broad 95% CrI of posterior 
parameters. With these rough estimates, we found a good performance of the 
IFN-γ test, similar to the combination of serology and ST.
 Specific IFN-γ testing provides data different from serology and ST when used 
in practice. The discordant results were mainly because of positive IFN-γ production 
in seronegative and ST-negative individuals. Obviously, the absence of a gold 
standard makes it impossible to assess definitely whether the IFN-γ assay was 
more sensitive or less specific than the combination of serology and ST. Bayesian 
analysis seems to indicate both: somewhat higher sensitivity (87.0% vs 83.0%) and 
somewhat lower specificity (90.2% vs 95.6%). Moreover, previous studies on immunity 
to C. burnetii after Q fever vaccination, using both lymphocyte proliferation assays 
and IFN-γ based assays, reveal a higher sensitivity of measurement of cellular 
immunity than serology [27, 28].
 The IFN-γ assay might replace ST in the prevaccination setting because both 
tests measure cellular immunity to C. burnetii. The IFN-γ assay has important 
operational advantages: the data are available in <2 days, and no follow-up visit is 
required. Furthermore, the assay can be used repeatedly, whereas ST may affect 
subsequent (serological) tests by boosting C. burnetii–specific immunity [29]. The 
IFN-γ assay also offers advantages over serology because it is a controlled test with a 
continuous parameter as read-out, not using titers. In contrast to immunofluorescence 
serology, there is no inter-reader variability. Moreover, it bypasses the ongoing 
discussion on phase 1/phase 2 antibodies and optimal cutoff [4, 30, 31]. We are 
hesitant to state that the IFN-γ production assay could replace serology; we rather 
see it as being complimentary, with added value in cases with equivocal serology. 
The additional value in active Q fever disease, both the acute and chronic form, is 
currently being addressed.
Supplementary Data
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Abstract
Infection with Coxiella burnetii may lead to life-threatening chronic Q fever endocarditis 
or vascular infections, which are often difficult to diagnose. The present study 
aims to investigate whether measurement of in-vitro interferon-gamma (IFN-γ) 
production, a key cytokine in the immune response against C. burnetii, differentiates 
chronic from a past cleared infection, and whether measurement of other cytokines 
would improve the discriminative power. First, C. burnetii-specific IFN-γ production 
was measured in whole blood of 28 definite chronic Q fever patients and compared 
with 135 individuals with past Q fever (seropositive controls) and 908 seronegative 
controls. IFN-γ production was significantly higher in chronic Q fever patients 
than in controls, but with overlapping values between patients and seropositives. 
Secondly, the production of a series of other cytokines was measured in a subset 
of patients and controls, which showed that interleukin (IL)-2 production was 
significantly lower in patients than in seropositive controls. Subsequently, measuring 
IL-2 in all patients and all controls with substantial IFN-γ production showed that an 
IFN-γ/IL-2 ratio >11 had a sensitivity and specificity of 79% and 96%, respectively, 
to diagnose chronic Q fever. This indicates that a high IFN-γ/IL-2 ratio is highly 
suggestive for chronic Q fever. In an additional group of 25 individuals with 
persistent high anti-Coxiella phase I IgG titres without definite chronic infection, 
all but six showed an IFN-γ/IL-2 ratio <11. In conclusion, these findings hold promise 
for the often difficult diagnostic work-up of Q fever and the IFN-γ/IL-2 ratio may 
be used as an additional  diagnostic marker.
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Introduction
Q fever is caused by the intracellular bacterium Coxiella burnetii. Some 1–5% of the 
infected individuals present with Q fever endocarditis or infection of an aneurysm 
or vascular prosthesis (‘chronic Q fever’), months to years after primary infection 
[1,2]. If left untreated, these conditions are often fatal. Timely diagnosis is therefore 
warranted, and treatment should be started before irreversible damage has 
occurred. However, diagnosis of Q fever endocarditis or vascular infection is not 
easy, as culture is cumbersome and specific polymerase-chain reaction (PCR) lacks 
sensitivity [3,4]. To date, serology is a key factor in early detection of persistent 
infection, based on measurement of antibodies against the two antigenic forms of 
C. burnetii, phase I and II organisms, with high phase I anti-C. burnetii IgG titres (in 
the absence of acute Q fever) indicative for chronic Q fever [5]. The appropriate 
cut-off titre that differentiates it from a past cleared infection is debated; the 
currently proposed cut-offs 1:1024 or 1:1600 have low specificity [5–7].
 Appropriate cytokine production is pivotal for the cellular defence against the 
intracellular bacterium C. burnetii [8, 9], with interferon-γ (IFN-γ), derived from 
T-cells and NK-cells, stimulating macrophage microbicidal activity [10]. IFN-γ is 
under the control of type I interferons and interleukin-12 (IL-12), IL-18 and IL-23 
[11]. Other cytokines also play a role: in Q fever endocarditis, up-regulation of 
monocyte-derived tumour necrosis factor-a (TNF-α), IL-1β and IL-6 from patients 
has been reported [12], as well as overproduction of IL-10 [13,14]. Benoit et al. showed 
that C. burnetii induces M2 polarization of macrophages in vitro with up-regulation 
of IL-1Receptor antagonist (IL-1Ra) and IL-6, and down-regulation of TNF-α [15]. In 
the adaptive immune response to C. burnetii, cytokines such as IL-2, stimulating 
lymphocyte proliferation and development of memory responses [16], could also 
be important.
 We recently showed that measurement of the cellular immune response (i.e. in-vitro 
C. burnetii-specific IFN-γ production in whole blood) identifies individuals who 
have been previously exposed to C. burnetii [17]. In the present study, we assessed 
the production of IFN-γ, in combination with other cytokines mentioned above, in 
patients with chronic Q fever, with the aim of identifying a cytokine profile that 
may aid in the timely diagnosis of Q fever endocarditis or vascular infection.
Materials and Methods 
Ethics statement
The study was approved by the Medical Ethical Committee Arnhem-Nijmegen 
and written informed consent was obtained from all subjects.
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Study population
Twenty-eight Q fever endocarditis or vascular patients were recruited from 
participating hospitals. At the time of diagnosis, all patients had phase I IgG titres 
≥1:1024 (in the absence of acute Q fever), with either a positive C. burnetii PCR in 
serum (n = 9) or tissue (n = 8) or both (n = 3) and/or signs of endocarditis as defined 
by the modified Duke criteria, or undisputable evidence of vascular (prosthetic) 
infection on positron emission tomography/computed tomography (PET/ CT)-scan 
or ultrasound (n = 8). Nine were diagnosed with Q fever endocarditis and 19 had a 
vascular (prosthesis) Q fever infection. They fulfilled the criteria for ‘proven 
chronic Q fever’ of the Dutch consensus group on chronic Q fever diagnostics [18].
 Individuals screened in the Dutch Q fever vaccination campaign from January 
to April 2011, as previously described, were used as controls [17]. They all had 
pre-existing valvular or vascular risk factors for Q fever endocarditis or vascular 
infection [19]. Control individuals were classified as seronegative if both serological 
testing and the Q-vax® skin test (CSL, Parkville, Australia) were negative (n = 908). 
Controls were classified as seropositive when serological tests showed anti-C. 
burnetii antibodies (phase I or II IgG ≥1:32) without signs or symptoms of persistent 
Q fever infection, and without a serological profile suggesting chronic Q fever 
infection (phase I IgG ≤1:512), more than 1 year after the Q fever epidemic (n = 135).
 In a second stage of our study, an additional group of 25 patients was included, 
in whom the diagnosis of chronic C. burnetii infection was suspected based on 
serology, all having persistent phase I IgG ≥1:1,024, but could not be confirmed 
with PCR, or definite valvular or vascular focus of infection on echocardiography 
or PET/CT. Fourteen of them had pre-existing valvular or vascular risk factors.
Measurement of C.burnetii-specific antibodies and detection  
of C. burnetii DNA 
IgG-antibodies against C. burnetii phase I and phase II were measured by a commercially 
available immunofluorescence assay (IFA; Focus Diagnostics, Cypress, CA, USA).
 Coxiella burnetii DNA in blood (serum/plasma) and tissue was obtained using 
real-time PCR targeting the IS1111a insertion element [20].
In-vitro whole blood stimulation
Cytokine production was measured in whole blood stimulation, based on previous 
findings [17]. Venous blood was drawn into 5-mL endotoxin-free lithium-heparin 
tubes (Vacutainer, BD Biosciences) and samples were processed within 12 h. 
Incubation was performed as previously described [17]. Coxiella burnetii Nine Mile 
(NM) RSA 493 phase I [21] was used as well as Q-vax vaccine, containing formalde-
hyde-inactivated C. burnetii Henzerling strain phase I. The mitogen phytohaemag-
glutinin (PHA, Sigma-Aldrich, St Louis, MO, USA) was used as positive control. 
129
IFN-γ/IL-2 RATIO TO DIAGNOSE CHRONIC Q FEVER
6
One aliquot was incubated with only culture medium as negative control. After 
incubation, blood cultures were centrifuged at 4656 g for 10 min and supernatants 
were stored at -20°C until assayed.
Cytokine measurements
IFN-γ concentration was measured in all samples, using a commercial enzyme- 
linked immunosorbent assay (ELISA; Pelikine compact, Sanquin, Amsterdam, the 
Netherlands) as previously described [17].
 To find out if other cytokines would improve the discrimination between 
patients and controls, a series of other cytokines was measured in a subset of 
patients and samples: TNF-α, IL-1β, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-10 were 
measured using a multiplex beads assay (Merck Millipore, Billerica, MA, USA). 
IL-12p70, IL-23 and IL-18 were measured simultaneously in a magnetic beads 
multiplex assay (Merck Millipore) according to the manufacturer’s instructions.
Statistical analysis
Graphpad Prism (Graphpad Software Inc., version 5) was used to analyze the data. 
Cytokine results were displayed as individual values or expressed as medians 
with interquartile range. The Mann–Whitney U-test was used to determine differences 
between groups. Spearman’s rho correlation coefficient was used to calculate 
correlation. Receiver operator characteristic (ROC) curves were constructed, and 
the area under the curve (AUC) was assessed for the accuracy of measuring (a ratio 
of) cytokine production. p <0.05 was considered significant.
Results
Patients and controls
From January 2011 until January 2012, blood samples were obtained from 28 
patients with Q fever endocarditis or vascular infection. Their mean age (± standard 
deviation) was 66.2 (± 11.8) years; 78.6% were male. At the time of blood sampling, 
ten patients did not yet receive antibiotics. The median duration of antibiotic 
therapy among patients on treatment (n = 18) was 7.5 months (range 1–26 months). 
Patient characteristics at the time of blood sampling are shown in Table 1.
 Of   the   control   individuals,   908   individuals  (aged 63.6 ± 14.0, 61.6% male) 
were seronegative; 135 individuals (aged 60.8 ± 15.1, 77.8% male) were seropositive. 
None of the seropositive controls had detectable IgM antibodies without IgG, 
suggesting the absence of acute Q fever.
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Interferon-gamma production in 24 h-stimulated whole blood
We measured the IFN-γ production (stimulated–unstimulated) in undiluted whole 
blood incubated for 24 h with PHA, Q-vax or C. burnetii-NM in all patients and all 
controls (Fig. 1). Aspecific PHA-induced IFN-γ production did not differ between 
groups. In contrast, both C. burnetii-antigens induced significantly more specific 
IFN-γ in patients (median 151 pg/mL and 2486 pg/mL by Q-vax and C. burnetii-NM, 
respectively) than in seropositive controls (3.0 pg/mL and 120 pg/mL) (p <0.001) 
and seronegative controls (0.0 and 0.0 pg/mL) (p <0.001). Of interest, longer 
incubation shows higher mitogen-induced IFN-γ production than C. burnetii- 
specific production (data not shown). Apparently, the specific response is more 
rapid than the mitogen response.
 ROC curves for C. burnetii-induced IFN-γ for patients vs. seropositive controls 
showed an accuracy (AUC) of 0.8664 (95% CI, 0.7933–0.9395; p <0.0001) (Fig. 2a); 
Q-vax-stimulated IFN-γ production showed lower accuracy (0.8484; 95% CI, 
Figure 1. Coxiella burnetii-induced IFN-γ production is higher in patients than in seropositive 
and seronegative controls. Net IFN-γ production (stimulated minus unstimulated) is shown 
after 24 h incubation of whole blood with phytohaemagglutinin (PHA) or C. burnetii-specific 
antigens (Q-vax and C.b.-NM). Median ± IQR are shown. The Mann– Whitney U-test was 
used to compare medians. C.b.-NM, C. burnetii Nine Mile; ns = not significant, ***p <0.001.
Seronegative controls (n=908)
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0.7639–0.9330; p <0.0001) (Figure S1). Therefore, further analyses were performed 
only with C. burnetii-NM-stimulated samples. There was a considerable overlap 
between IFN-γ production in seropositive controls and Q fever patients (Fig. 2b). 
Choosing 500 pg/mL as the optimal cut-off, 75.0% (21/28) of the patients and 17.8% 
(24/135) of the seropositive individuals had a value above this cut-off.
 Interestingly, the height of IgG anti-phase I antibody titre was significantly 
correlated with the amount of IFN-γ produced. Spearman’s rho in the total of 
seropositive controls and Q fever patients was 0.3069 (p <0.001).
 Further analyses of IFN-γ production did not show significant differences 
between untreated (n = 10) and treated (n = 18) Q fever patients (p 0.11); duration of 
treatment (in months) did not correlate with IFN-γ production (p 0.37).
Cytokine profiles in 48-h C. burnetii Nine Mile-stimulated diluted 
blood in a subset of patients and  controls
To find out whether measurement of one or more additional cytokines would help 
to distinguish chronic Q fever from past infection, both conditions showing high 
IFN-γ production, we measured the production of TNF-α, IL-1β, IL-1Ra, IL-4, IL-5, 
IL-6, IL-10, IL-12p70, IL-23, IL-18 and IL-2. Because not all cytokines were expected 
to be detectable in the first 24 h, 48-h C. burnetii-NM-stimulated diluted blood 
samples were used. Cytokine production in samples of 16 patients (obtained in the 
first 10 months of the study), 18 seropositive controls with substantial (≥32 pg/mL) 
IFN-γ production in 24 h and 18 seronegative controls with low IFN-γ production, 
were compared. The results for IFN-γ, IL-2, IL-1β, TNF-α, IL-10 and IL-1Ra are 
shown as Figure S2 in the supporting information. As expected, the median IFN-γ 
production did not differ significantly between patients and the selected seropositive 
individuals. Most interestingly, production of IL-2 was significantly lower in 
patients (median 5.0 pg/mL) than in these seropositive controls (median 39.5 pg/
mL) (p <0.001).
 The production of the monocyte-derived cytokines IL-1β and TNF-α was high 
in both chronic Q fever patients and in seropositive individuals, but not significantly 
different (p 0.24 and p 0.16 for IL-1β and TNF-α, respectively). However, both were 
significantly higher than in seronegative controls. The same pattern was seen for 
IL-6 (not shown).
 The anti-inflammatory cytokine IL-10 production also did not differ between 
patients and seropositive controls. However, patients had significantly higher IL-10 
production than seronegative individuals (p <0.01). IL-1Ra did not differ between 
groups.
 The C. burnetii-NM-stimulated production of IL-4, IL-5, IL-18 and IL-23 remained 
below detection limit. IL-12p70 levels were very low and did not discriminate.
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IFN-γ/IL-2 ratio for diagnosis of chronic Q  fever
In previous subset, patients with chronic Q fever showed high IFN-γ and low IL-2 
production, whereas seropositive controls with high IFN-γ production showed 
high IL-2.
 Next, we assessed IL-2 production in all patients and all 102 seropositive 
controls  with  substantial  IFN-γ production ≥32 pg/mL. The IFN-γ/IL-2 ratio was 
calculated for each individual (Fig. 2d). The AUC of the ROC-curve for patients vs. 
seropositive controls was 0.8873 (95% CI, 0.7983–0.9762; p <0.0001) (Fig. 2c). In 22/28 
(78.6%) patients, the ratio was  above 11, compared with only 6/102 (5.9%) 
seropositive controls with an IFN-γ production ≥32 pg/mL and 6/135 (4.4%) of all 
seropositives. So, the number of high values in the seropositive controls diminished 
by 75% (from 24 to 6) at cut-off 11 for IFN-γ/IL-2 ratio compared with the cut-off 500 
pg/mL for IFN-γ production alone (Fig. 2e).
 The IFN-γ/IL-2 ratio did not correlate with the duration of antibiotic treatment 
in patients (p 0.44), neither was there a significant difference between treated and 
untreated patients (p 0.55). However, patients with positive C. burnetii PCR in 
serum or plasma at the moment of blood sampling (n = 10), had a significantly 
higher IFN-γ/IL-2 ratio than those with negative PCR (n = 18) (median IFN-γ/IL-2 
ratio of 92.9 and 15.9, respectively, p <0.01).
IFN-γ/IL-2 ratio in individuals with high phase I IgG without 
definite chronic Q  fever
Subsequently, the IFN-γ/IL-2 ratio was determined in the group of 25 individuals 
(aged 63.7 ± 13.9, 72.0% male) in whom chronic Q fever was suspected based on 
persistent high IgG anti-C. burnetii phase I ≥1:1024, but without definite diagnosis 
of chronic C. burnetii infection based on PCR, echocardiography or PET/CT-scan. 
The results are shown separately for those with and those without pre-existing 
cardiovascular risk factors for chronic infection (Fig. 3). All but six had an IFN-γ/
IL-2 ratio below the cut-off. A high IFN-γ/IL-2 ratio was found in 2/11 (18%) in the 
group without and 4/14 (29%) in the group with risk factors. The details of these six 
patients are shown in Table 2. Interestingly, patient 1, without pre-existing risk 
factors but persistent high phase I IgG and a high IFN-γ/IL-2 ratio of 39, was a 
veterinarian with non-specific complaints and a newly diagnosed cardiac murmur. 
Echocardiography and PET/CT-scan were normal and PCR on serum negative. 
After discontinuation of 1.5 years treatment with doxycycline and hydroxychloro-
quine without decreasing antibody titres, titres rose again. It cannot be excluded 
that this veterinarian experienced ongoing exposure to C. burnetii. Patient 2, 
having no valvular or vascular risk factors for chronic Q fever but persistent high 
phase I IgG and IFN-γ/IL-2 above the cut-off, was immunocompromised (prednisone 
use after kidney transplantation). He was started on antibiotics because of suspected 
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(Previous page) Figure 2. IFN-γ production discriminates between patients with chronic 
Q fever and seropositive controls, but the ratio of IFN-γ and IL-2 production discriminates 
better. (a) Receiver operator characteristics (ROC) curve of the Coxiella burnetii-NM- 
stimulated IFN-γ production after 24 h in whole blood of chronic Q fever patients vs 
seropositive controls. The area under the curve (AUC) is 0.8664 (95% CI, 0.7933–0.9395; 
p <0.0001). The arrow indicates the optimal cut-off of IFN-γ production (500 pg/mL) with 
best combination of sensitivity and specificity. (b) The individual IFN-γ production is shown 
for chronic Q fever patients (n = 28) and seropositive controls (n = 135), plotted against phase 
I IgG titres. Each dot indicates one individual. The horizontal line indicates the cut-off at 500 
pg/ml. The vertical line distinguishes patients (closed circles) from controls (open circles). 
(c) ROC curve of the IFN-γ/IL-2 ratio in Q fever patients vs seropositive controls. AUC is 
0.8873 (95% CI, 0.7983–0.9762). The arrow indicates the optimal cut-off of IFN-γ/IL-2 ratio at 
11. (d) The individual IFN-γ/IL-2 ratio is shown for chronic Q fever patients (n = 28) and 
seropositive controls with IFN-γ production ≥32 pg/mL (n = 102), plotted against phase I 
IgG. Each dot indicates one individual. The horizontal line indicates an IFN-γ/IL-2 ratio 
cut-off at 11. The vertical line distinguishes patients (closed circles) from controls (open 
circles). (e) Comparison between IFN-γ alone and the ratio of IFN-γ/IL-2 to identify patients. 
IFN-γ plotted against IL-2 production shows patients (black dots) and seropositive controls 
(open dots). All patients (n = 28) and all seropositive controls with IFN-γ production ≥32 pg/
mL (n = 102) were included. The horizontal line indicates the cut-off of IFN-γ at 500 pg/mL. 
The sloping line indicates the cut-off IFN-γ/IL-2 ratio at 11.
Figure 3. The ratio of IFN-γ and IL-2 production in individuals with high phase I IgG, 
without definite chronic Q fever. These 25 individuals were diagnosed with persistent phase 
I IgG ≥1:1024, but no definite chronic Q fever based on PCR, echocardiography or PET/
CT-scan. Eleven had no pre-existing cardiovascular risk factors for chronic Q fever, while 
the other 14 had pre-existing valvular or vascular defects. The horizontal dotted line 
indicates the previous established cut-off IFN-γ/IL-2 ratio at 11.
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mitral valve involvement based on PET/CT, which was considered inconclusive for 
endocarditis by the nuclear medicine physician and could not be confirmed by 
echocardiography. Likewise, patient 3 was treated for suspected Q fever vascular 
infection; however, the PET/CT was interpreted to be inconclusive because of 
diffuse uptake in the recently inserted vascular prosthesis. Patients 5 and 6 had 
cardiac predisposition but no evidence of persistent infection based on PCR, echo-
cardiography or PET/CT-scan. Both, however, were started on long-term antibiotics 
because of the high risk of Q fever endocarditis. Only patient 4 did not receive 
antibiotics and had spontaneously decreasing phase I IgG titre, which persisted at 
1:512 without signs or symptoms of chronic active infection.
Discussion
In the present study, we show that Q fever endocarditis or vascular patients exhibit 
high in-vitro IFN-γ production and low IL-2 production, while individuals with a 
past infection showed both high IFN-γ and high IL-2 production. The production 
of monocyte-derived pro-inflammatory cytokines IL-1β, TNF-α and IL-6 was high 
in patients as well as in individuals with past infection and did not discriminate. 
Similarly, anti-inflammatory cytokines IL-10 and IL-1Ra were not significantly 
different in Q fever patients and individuals with a past infection. In this 
population, the IFN-γ/IL-2 production ratio >11 had a sensitivity and specificity of 
79% and 96%, respectively, to diagnose chronic Q fever.
 Interestingly, we found that Q fever endocarditis and vascular patients display 
high C. burnetii-specific IFN-γ production in whole blood, while it is commonly 
assumed that chronicity of Q fever infection is due to T-lymphocyte unresponsiveness 
and impaired IFN-γ production [22,23]. We show here that C. burnetii-specific 
IFN-γ production in these patients is even higher than in individuals with past C. 
burnetii infection. We obtained the same results when using isolated peripheral 
blood mononuclear cells from chronic patients and controls (unpublished data). 
This is in accordance with the findings of Limonard et al. [24] reporting higher 
numbers of IFN-γ-positive cells in three chronic Q fever patients compared with 
nine convalescent controls, using a Coxiella ELISPOT assay. Apparently, this high 
IFN-γ production by peripheral blood cells is not sufficient to activate C. bur-
netii-infected monocytes/macrophages at the site of infection, to such an extent 
that the infection is cleared. We hypothesize that downstream of IFN-γ, the 
response to this cytokine is aberrant in patients with persistent C. burnetii infection.
 The measurement of the production of monocyte-derived cytokines did not 
aid in differentiation between chronic active Q fever patients and individuals 
previously exposed to C. burnetii. Nevertheless, both groups had higher production 
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than naive controls. From this it can be concluded that restimulation with C. 
burnetii in primed individuals leads to enhanced production of cytokines by 
monocytes. With regard to the production of anti-inflammatory cytokines in 
chronic Q fever patients, only that of IL-10 was higher than in seronegative controls. 
This is in line with previous reports on patients with Q fever endocarditis [13,14]. 
The latter studies also reported low IL-10 in individuals with Q fever without 
chronic evolution. IL-10 appeared to induce C. burnetii replication and its 
neutralization inhibits bacterial replication in monocytes from patients with Q 
fever endocarditis [25]. Thus, IL-10 may be important in the development of chronic 
Q fever, but we found that measurement of C. burnetii-specific IL-10 production is 
not a useful diagnostic marker.
 Our finding that IL-2 production was significantly lower in chronic Q fever 
patients than in seropositive controls may be to do with the types of T cell involved 
in the C. burnetii-specific immune responses. In chronic infection, we assume that 
increased numbers of circulating C. burnetii-specific effector T cells produce IFN-γ 
and low amounts of IL-2 upon activation. In seropositive controls, it is probably the 
central memory T cell that dominates and produces mainly IL-2 [26]. We showed 
that the ratio of IFN-γ to IL-2 production is more specific than IFN-γ production 
alone (96% vs 82%), and has a slightly higher sensitivity (79% vs 75%) to distinguish 
patients from seropositive controls. The relative high specificity of the IFN-γ/IL-2 
ratio suggests that seropositive individuals with a ratio above the cut-off merit 
thorough follow-up for the progression to Q fever endocarditis or vascular infection.
 In tuberculosis, measurement of specific IL-2 production in addition to IFN-γ 
also helps to differentiate between active and latent infection. Here too, a high 
specific IFN-γ and low IL-2 production is found in active infection, and both high 
IFN-γ and high IL-2 production indicate latent tuberculosis [27,28]. A shift from T 
cells secreting only IFN-γ and IFN-γ/IL-2 to T cells secreting IFN-γ/IL-2 and only 
IL-2 is reported during treatment of active tuberculosis [29].
 Ten of the 28 patients were not yet on antibiotic treatment at the moment of 
blood sampling. The absence of a significant difference in cytokine profile between 
untreated and treated patients suggests that the cytokine profile observed is not 
affected by the use of antibiotics. Still, the IFN-γ/IL-2 ratio seems to be related to 
the load of C. burnetii, because patients with positive PCR for C. burnetii DNA in 
serum or plasma have a significantly higher ratio than patients with negative PCR. 
Longitudinal studies are needed to assess the applicability of the IFN-γ/IL-2 ratio 
in follow-up during treatment of patients with chronic Q fever.
 All 28 patients included in the first part of the study to evaluate the performance 
of cytokine(s) production measurements, had definite Q fever endocarditis or 
vascular infection. We subsequently performed the measurements of IFN-γ/IL-2 
in a group of 25 individuals with an uncertain diagnosis (i.e. having high phase I 
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IgG without definite diagnosis of chronic C. burnetii infection based on clinical 
criteria, PCR or definite focus of infection on diagnostic imaging). It shows the 
difficulties in assessing the value of a new marker in a group of patients with 
uncertain diagnosis, some of whom are highly suspected of having chronic Q 
fever, but not fulfilling the criteria for definite chronic Q fever, neither those of 
Raoult et al. nor those of the Dutch consensus [18,30]. In the great majority of these 
difficult cases (19/25), the IFN-γ/IL-2 ratio was low. This may imply absence of 
chronic C. burnetii infection or a more low-grade infection. In some, the diagnosis 
remains unclear because PCR and imaging techniques may have lacked sensitivity 
to make a definite diagnosis before long-term antibiotic treatment was started.
 In conclusion, we found that a high IFN-γ/IL-2 ratio is highly suggestive for 
chronic Q fever. This finding holds promise for the often difficult diagnostic 
work-up of Q fever patients and may be used as an additional diagnostic marker.
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Supplementary Figures
Figure S1. Receiver operator characteristics (ROC) curve of the Q-vax stimulated IFN-γ 
production after 24 hours in whole blood of chronic active Q fever patients versus seropositive 
controls. The Area Under the Curve (AUC) is 0,8484 (95% CI; 0.7639-0.9330, P<0.0001).
(Next page) Figure S2. C. burnetii induced cytokine profile in patients with chronic Q fever, 
compared to seronegative and seropositive controls. Cytokines interferon (IFN)-γ, interleukin 
(IL)-2, IL-1β, tumor necrosis factor (TNF)-α, IL-10 and IL-1Receptor antagonist (IL-1Ra) in 
48 hours C. burnetii-NM stimulated blood are shown for a selection of seronegatives (n=18), 
seropositives (n=18) and Q fever endocarditis or vascular patients (n=16). Horizontal lines 
indicate the median value of the respective population. The dotted line represents 
the lower detection limit of the assay. Mann-Whitney U test was used to compare medians. 
ns = not significant, * P<0.05, **P<0.01, *** P<0.001.
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CHAPTER 7
Abstract
Background: Antibiotic treatment of chronic Q fever is cumbersome and of long 
duration.To monitor treatment, there is a need for alternative biomarkers. Coxiella 
burnetii-specific interferon (IFN)-γ and interleukin (IL)-2 production reflect the 
type of effector and memory T-cell response. In chronic Q fever, C. burnetii-specific 
IFN-γ production is higher and IL-2 production is lower than in individuals with 
past Q fever. Here we explore whether C. burnetii-specific IFN-γ and IL-2 production 
correlate to treatment response.
Methods: We studied the longitudinal C. burnetii-specific IFN-γ/IL-2 ratio in 
fifteen proven chronic Q fever patients. All patients were followed for at least 18 
months during antibiotic treatment. Treatment was considered successful when 
clinical recovery was observed, a positive PCR for C. burnetii DNA in blood became 
persistently negative, anti-phase I IgG showed a fourfold decrease or more, and 
imaging techniques showed disappearance of infectious foci.
Results: Overall, the IFN-γ/IL-2 ratio declined when patients experienced a 
successful treatment outcome. When treatment failed, IFN-γ/IL-2 ratios did not 
significantly decrease. The median (±IQR) slope of the longitudinal IFN-γ/IL-2 
ratio with successful treatment was −2.10 (−7.02 to −0.06),  and −0.15  (−1.13  to 0.25) 
with unsuccessful  treatment (P = 0.19). Q fever endocarditis patients had higher 
IFN-γ/IL-2 ratios than patients with endovascular infections.
Conclusion: We propose that the IFN-γ/IL-2 ratio can be used as an additional 
biomarker for monitoring chronic Q fever treatment, with declining ratios being 
indicative of successful treatment.
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Introduction
Q fever is a zoonosis, caused by the Gram-negative, intracellular bacterium Coxiella 
burnetii (Raoult et al., 2005; Parker et al., 2006). Following primary infection, 1–5% 
of patients develop chronic infection, which can become clinically overt months to 
years later (Maurin and Raoult, 1999). Endocarditis and infection of a vascular 
aneurysm or prosthesis are the most common manifestations of chronic Q fever 
(Botelho-Nevers et al., 2007; Million et al., 2010). Pre-existent cardiac valvular 
abnormalities, aortic aneurysms, vascular grafts, and immune-compromised state 
are risk factors (Raoult et al., 2000; Fenollar et al., 2001; Landais et al., 2007).
 Clinical symptoms of chronic Q fever are often non-specific, and the diagnosis 
relies on identifying pre-existing risk-factors, the results of anti-C. burnetii serology 
and PCR for C. burnetii DNA on blood or tissue, and results of imaging techniques 
(Wegdam-Blans et al., 2012a; Anderson et al., 2013). Untreated chronic infection 
leads to severe morbidity,  with a mortality up to 60% (Million et al., 2010). 
Long-term antibiotics, preferably doxycycline combined with hydroxychloroquine 
(Raoult et al., 1999; Kersh, 2013), are required to eliminate C. burnetii. Antibiotics 
should be administered for at least 18 months or, in case of a valvular/vascular 
prosthesis,  for at least 24 months (Million et al., 2010).  Surgical intervention to 
replace an infected vascular  aneurysm/graft or cardiac valve is often necessary, 
either in the acute situation of a symptomatic aortic aneurysm or heart failure, or 
when a patient does not improve on antibiotics (Botelho-Nevers et al., 2007; 
Kampschreur et al., 2012; Wegdam-Blans et al., 2012b).
 The discontinuation of antimicrobial therapy strongly depends on the results 
of follow-up imaging. In case of vascular infection focus, 18F-fluorodeoxyglucose 
Positron Emission Tomography/Computed Tomography (FDG-PET/CT) is 
preferred, which has high sensitivity and specificity for low-grade vascular 
infections (Merhej et al., 2012; Barten et al., 2013). In cases of Q fever endocarditis, 
vegetations are difficult to detect on echocardiography, and a negative 
echocardiogram does not rule out endocarditis (Maurin and Raoult, 1999). 
Therefore, serology is an important tool during the antibiotic treatment of chronic 
Q fever. Chronic infection is characterized by high titres of anti-phase I IgG 
anti-bodies. It is assumed that antibiotic treatment should be continued until these 
titres have declined at least fourfold, or until titres are below 1:800 in immunofluo-
rescence assay [IFA, or below 1:1024 in a commercial available IFA (Focus 
Diagnostics)]; (Million et al., 2010). In daily practice, the slow serological decline 
requires longer treatment, and titres often remain above 1:800 (or above 1:1024 
respectively) for a prolonged time.
 These limitations show the need for additional biomarkers to monitor treatment of 
chronic Q fever. In this respect, laboratory tests measuring cell-mediated immune 
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responses may be of value. Interferon-gamma (IFN-γ) plays a pivotal role in the 
immune response against the  intracellular C. burnetii (Dellacasagrande et al., 1999; 
Andoh et al., 2007). Analogous to IFN-γ release assays (IGRAs) that are widely 
used in Mycobacterium tuberculosis infection (Pai et al., 2004), we previously used 
whole-blood assays to show that the C. burnetii-specific IFN-γ production is 
significantly increased in people that have been exposed to C. burnetii (Schoffelen 
et al., 2013). The interpretation of IFN-γ production in chronic Q fever is 
complex, since IFN-γ production is a marker of both immunity and infection. 
We demonstrated, by measuring a broad panel of cytokines, that ex-vivo C. burnetii- 
specific IFN-γ production is higher and interleukin (IL)-2 production is lower in 
chronic Q fever patients than in patients with past Q fever (Schoffelen et al., 2014), 
and concluded that a high IFN-γ/IL-2 ratio has a high specificity to discriminate 
between these two groups.
 The present study follows the hypothesis that the IFN-γ/IL-2 ratio will decline 
during effective treatment of chronic Q fever. To test this, we followed 15 chronic 
Q fever patients for at least 18 months during antibiotic treatment and performed 
whole-blood stimulation assays with measurement of IFN-γ and IL-2 on a regularly 
basis. This study is the first evaluation of a cell-mediated immunity biomarker for 
treatment of chronic Q fever.
Materials and Methods
Patients and follow-up
Fifteen chronic Q fever patients, recruited from participating hospitals, were 
followed in this study for at least 18 months. The study was approved by the 
Medical Ethical Committee Arnhem-Nijmegen and written informed consent was 
obtained from all subjects. At the time of diagnosis, all patients had a positive PCR 
in blood, serum and/or tissue, and anti-phase I IgG titres ≥ 1:1024 (in the absence of 
acute Q fever). Four patients were diagnosed with endocarditis according to the 
modified Duke criteria (n = 4), and eleven had vascular infection. All fulfilled the 
criteria of ‘proven chronic Q fever’ of the Dutch consensus group on chronic Q 
fever (Wegdam-Blans et al., 2012a). Patients were included at different time points 
after start of treatment. The start of antibiotic treatment was designated t = 0. The 
three patients that were included at the start of treatment or within 2 months after 
start of treatment are described in more detail. Treatment was considered successful 
when clinical recovery was observed, a positive PCR for C. burnetii DNA on blood 
became persistently negative, antiphase I IgG showed a fourfold decrease or more 
(related to the maximum titre), and imaging techniques showed disappearance of 
any (vascular or valvular) infectious foci.
149
IFN-γ/IL-2 BIOMARKER FOR CHRONIC Q FEVER
7
Whole  blood incubation
Venous blood drawn into 5 mL endotoxin-free lithium-heparin tubes (Vacutainer, 
BD Biosciences) was processed within 12 h. Blood was aliquoted in separate tubes 
and incubated at 37◦C for 24 h with heat-inactivated C. burnetii Nine Mile (NM) 
RSA493 phase I (Seshadri et al., 2003), mitogen (positive control) or without 
(negative control).
 C. burnetii NM was used in an end-concentration of 107 bacteria/mL. Bacteria 
were cultured in a BSL-3 facility at the Central Veterinary Institute (Lelystad, the 
Netherlands) as previously described (Schoffelen et al., 2013) and kindly provided 
by Dr. H. J. Roest. The same batch was used for all assays. The mitogen phytohem-
agglutinin (PHA, Sigma-Aldrich, St. Louis, MO, USA; 10 μg/mL) was used as a 
positive control. After incubation, blood cultures were centrifuged at 4656 g for 10 
min and supernatants were stored at −20◦C until assayed.
Cytokine measurements
Interferon-γ concentration in supernatants was measured using a commercial 
enzyme- linked immunosorbent assay (ELISA; Pelikine compact, Sanquin, Amsterdam, 
the Netherlands) as previously described (Schoffelen et al., 2014). The background 
IFN-γ response of the negative control aliquot was subtracted from the stimulated 
aliquots for each individual sample. In all negative control aliquots, the highest 
IFN-γ concentration was 46 pg/mL, which was considered acceptable. In addition, 
all samples showed a net IFN-γ production >24 pg/mL in either the positive control 
aliquot or in the C. burnetii-stimulated aliquot. Thus, all samples were considered 
valid. IL-2 concentrations in supernatant of the C. burnetii-stimulated aliquots 
were measured using luminex magnetic beads assay (Merck Millipore, Billerica, 
MA, USA) according to the manufacturer’s instructions.
Analysis
Graphpad Prism (Graphpad software Inc., version 5) was used to make the graphs 
and to analyze the data. Non-linear regression to a straight line with least square 
fit was performed to obtain the best-fit slope of the IFN-γ/IL-2 ratio of each patient 
over time. Median ± interquartile range (IQR) slope was compared between groups.
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Results
Case 1: a patient with C. burnetii-infected vascular prosthesis  
with  successful treatment
A 30-years-old man with a medical history of traumatic rupture of the thoracic 
aorta, for which he had undergone vascular surgery receiving an endoprosthesis, 
suffered from new symptoms of malaise, night sweats,  weight loss,  and chills. 
Because of the preceding Q fever epidemic, serology for C. burnetii was performed, 
revealing chronic infection with very high IgG titers against phase I and II (both 
1:65536). PCR on serum for C. burnetii DNA was positive. He was not aware of a 
preceding acute Q fever episode. FDG-PET/CT showed no signs of infection at the 
thoracic aortic prosthesis, nor elsewhere. Transesophageal echocardiogram (TEE) 
showed mild aortic valve insufficiency without vegetations. Although infection of 
the vascular prosthesis could not be detected with FDG-PET/CT, it was considered 
the most likely focus of infection. The patient started antimicrobial therapy with 
doxycycline and hydroxychloroquine after which he made a quick clinical 
recovery.  PCR  in  serum  became  permanently negative 5 months after start of 
therapy. Although anti-phase I IgG titers had decreased from 1:131072 to 1:8192 in 
24 months, titers did not decrease further and moxifloxacin was added to the 
therapy. This regimen was continued for another 14 months, after which it was 
decided to stop treatment and continue follow-up 3-monthly. The follow-up –6 
months so far– was uneventful. This patient, having a good response on the 
antimicrobial therapy, showed peaking of the IFN-γ/IL-2 ratio during the first 9 
months. Thereafter, the ratio declined and was stable at lower values during the 
last phase of the treatment, analog to the anti-phase I antibody titers (Figure 1A).
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Case 2: a patient with C. burnetii endocarditis with successful 
treatment
A 66-years-old man had a history of aortic valve stenosis with valvular replacement 
(homograft) 11 years before. He presented with symptoms of cardiac failure, for 
which a TEE was performed, which showed vegetations on the valvular prosthesis. 
Screening for C. burnetii revealed chronic Q fever infection with anti-phase I and II 
Figure 1. Detailed overview of immunological parameters in (A) patient 1 (B) patient 2, 
and (C) patient 3 from start of antibiotic treatment to end of study follow-up. The IFN-γ 
and IL-2 concentrations (dotted lines) and the IFN-γ/IL-2 ratio (black diamant) are shown on 
the left y-axis, the anti-phase I IgG antibody-titer (black triangle) is shown on the right y-axis. 
The course of antibiotic treatment is depicted above each graph.
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IgG 1:131072 and a positive C. burnetii PCR in blood. Therapy with doxycycline and 
hydroxychloroquine was started and the patient underwent valvular replacement. 
PCR on valve tissue was positive for C. burnetii DNA. After 2 months therapy, PCR 
on blood was negative and remained so in the follow-up. The patient recovered 
well. Although he suffered from side effects (mainly photo-sensitivity), the 
antimicrobial therapy could be continued for 27 months, after which 3-monthly 
follow-up continued. By that time, the anti-phase I IgG had declined  to  1:2048. 
After stop of antimicrobial therapy, the follow-up has been uneventful (13 months 
so far).
 The IFN-γ/IL-2 ratio showed an initial increase, but from 5 months after start 
of treatment onward, the IFN-γ/IL-2 ratio declined to very low values (Figure 1B).
Case 3: a patient with C. burnetii-infected vascular prosthesis  
with failure of  treatment
In the aftermath of the Q fever epidemic, a 64-years-old man presented with an 
acute aneurysm of  the abdominal aorta.  In the preceding weeks, he had back 
pain, fatigue, malaise, and weight loss. He underwent surgery with placement of  a 
vascular prosthesis, and PCR on aorta tissue was positive for C. burnetii. Serology 
revealed elevated titers of anti-phase I and phase II IgG both 1:8192. PCR for C. 
burnetii DNA in blood was negative. He could not recall a preceding episode of 
fever or pneumonia. Doxycycline and hydroxychloroquine treatment was started. 
A transthoracic echocardiogram (TTE) showed thickening of the aortic valve. The 
patient refused to undergo TEE. He recovered well after the operation. However, 
anti-C. burnetii IgG titers did not decrease in the subsequent 2 years. PCR for 
C. burnetii DNA on blood, performed 3-monthly, remained negative. Moxifloxacin 
was added to the therapy after 23 months. FDG-PET/CT showed increased uptake 
at the vascular prosthesis, indicating a persistent infection. This patient showed an 
unsuccessful treatment of a chronic Q fever vascular infection. The IFN-γ/IL-2 
ratio was relatively low from the start of therapy in this patient. The ratio showed 
an increase after the operation after which it remained mildly elevated, with no 
tendency to decline (Figure 1C). This was the result of neither decrease in IFN-γ 
production nor increase in IL-2 production over time.
An overview of the IFN-γ/Il-2 ratio in follow-up of 15 
chronic Q fever patients
We studied the longitudinal IFN-γ/IL-2 ratio in fifteen chronic Q fever patients 
(Table 1). All were followed for at least 18 months during antibiotic treatment. 
In some cases, this included a period after completion of the treatment. For the 
purpose of this study, the data of all patients were analyzed according to start of 
antimicrobial therapy (t = 0), which was up to 35 months before inclusion. We 
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divided the group in patients with successful treatment (n = 8) and those with 
unsuccessful treatment (n = 7; Figure 2). The latter  group did not fulfill the success- 
criteria because of  persistent PCR positivity for C. burnetii in blood (patient 9), less 
than a fourfold decrease in anti-phase I IgG titer (patient 3, 8, 11, 14), and/or 
persistent uptake on FDG-PET/CT (patient 3, 6, 7, 8, 14). As can be seen in Figure 2, 
Figure 2. Interferon-γ/IL-2 ratio in C. burnetii-stimulated whole blood of chronic Q fever 
patients during the study follow-up period, separately shown for (A) patients with 
successful and (B) patients with unsuccessful treatment. t = 0 is start of antibiotic treatment. 
Treatment was considered successful when 18 months of antibiotic treatment (or 24 months 
when a prosthesis remained in situ) was completed, and clinically recovery was observed, 
and a positive PCR for C. burnetii DNA on blood became persistently negative, and anti-phase I 
IgG showed a fourfold decrease or more (related to the maximum titer), and imaging 
techniques showed disappearance of any (vascular or valvular) infection focus. Circles 
indicate a positive PCR on blood/serum, squares indicate positive PCR on tissue. Vertical 
lines indicate stop of antimicrobial treatment.
Figure 3. Non-linear regression to straight curves of the longitudinal IFN-γ/IL-2 ratios of 
chronic Q fever patients. Patients with successful treatment are shown in green, patients 
with unsuccessful treatment are shown in red. The median (±IQR) slope of the patients with 
successful treatment was −2.10 (−7.02 to −0.06), compared to −0.15 (−1.13 to 0.25) in patients 
with unsuccessful treatment (P = 0.19).
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Figure 4. Follow-up IFN-γ/IL-2 ratio from chronic Q fever patients during the study 
follow-up period, separately shown for (A) patients with endocarditis and (B) patients 
with vascular (prosthesis) infection. t = 0 is start of antibiotic treatment.
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the patients with successful treatment had higher maximum IFN-γ/IL-2 ratios 
than those with unsuccessful treatment. Moreover, the IFN-γ/IL-2 ratio of the 
patients with successful treatment showed a more pronounced decrease, each with 
an individual pattern, compared to the patients with unsuccessful treatment. We 
performed non-linear regression of the longitudinal IFN-γ/IL-2 ratios of each 
patient to a best-fit straight line (Figure 3). The median (±IQR)  slope  of the patients 
with successful treatment was −2.10 (−7.02 to −0.06),  compared to −0.15 (−1.13 to 
0.25) in patients with unsuccessful treatment (P = 0.19). Because the two main 
clinical manifestations of chronic Q fever may differ immunologically, the patients 
with endocarditis were also depicted separately from the patients with vascular 
(prosthesis) infection (Figure 4). Q fever endocarditis patients had overall higher 
IFN-γ/IL-2 ratios than the vascular Q fever patients.
Discussion
In the present study, we evaluated the usefulness of longitudinal measurements of 
cell-mediated immune responses against C. burnetii for treatment monitoring of 
chronic Q fever. We measured the C. burnetii-specific IFN-γ and IL-2 production in 
a whole-blood stimulation assay during a period of at least 18 months follow-up of 
proven chronic Q fever patients. We observed a trend in which the IFN-γ/IL-2 ratio 
declined when patients experienced a successful outcome of treatment. Patients in 
whom treatment failed, had overall lower IFN-γ/IL-2 ratios, which did not 
significantly decrease.
 The IFN-γ/IL-2 ratio reflects the type of effector and memory CD4+ T-cell 
response (Sallusto et al., 1999). Memory T lymphocytes can broadly be defined as 
two distinct populations of effector memory T-cells and central memory T-cells. 
IFN-γ is predominately produced by effector T-cells and effector memory T-cells, 
while IL-2 is predominately produced by central memory T-cells. It is postulated 
that high IFN-γ/IL-2 ratio indicates predominance of effector T-cells and effector 
memory T-cells, resulting from ongoing immunological stimulation by a persistent 
infection.
 The relevance of measuring IFN-γ/IL-2 production profiles, as diagnostic 
correlate of memory T-cell responses, has been studied outside the field of Q fever, 
specifically in a number of viral infections (Younes et al.,  2003;  Semmo  et al., 
2005), and in Mycobacterium tuberculosis infection (Sargentini et al., 2009; Biselli et 
al., 2010; Casey  et al., 2010;  Sester  et al., 2011; Essone et al., 2014). These studies, as 
summarized by Lalvani and Millington (2008), show that in acute and chronic 
infections with a high antigen concentration, e.g., in chronic progressive HCV 
infection (Semmo et al., 2005) or untreated tuberculosis (Millington et al., 2007), 
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CD4+ T-cells predominately secrete IFN-γ. In infections with persistently low 
antigen concentrations, e.g., latent asymptomatic cytomegalovirus infection, CD4+ 
T-cells secreting IFN-γ only, IFN-γ/IL-2, or IL-2 only are detected (Harari et al., 
2005). In cleared infections, IL-2 secreting CD4+ T-cells predominate (Harari et al., 
2004, 2005; Correa et al., 2007; Millington et al., 2007). Our finding that the IFN-γ/
IL-2 ratio declines during successful treatment of chronic Q fever, assuming a 
decrease in antigen load, is in accordance with these studies.
 The group of patients that was included in our study was inevitably hetero -
geneous with regard to morbidity, infection status, treatment course and treatment 
response. Likewise, the inter-individual variation in IFN-γ and IL-2 responses was 
large. We considered it therefore not feasible to combine individual results for a 
grouped analysis, and chose to describe patients separately. Three patients were 
described in more detail, because they were followed (almost) from the start of 
antibiotic treatment. Strikingly, in two of these patients (patients 1 and 2), who 
seemed to respond well to treatment, the IFN-γ production and the IFN-γ/IL-2 
ratio initially increased,  but decreased thereafter.  It is tempting to speculate that 
this initial increase reflects an adequate immune response. A similar initial 
increase of the specific IFN-γ response is seen in patients during treatment for 
tuberculosis (Sahiratmadja et al., 2007). The patient that still showed signs of 
infection after more than 2 years of antibiotic treatment (patient 3), had markedly 
high IL-2 secretion and a low IFN-γ/IL-2 ratio from the start, which fluctuated in 
the follow-up but did not decrease. This might suggest bacterial persistence with 
low antigen concentrations; an assumption that is supported by the notion that C. 
burnetii DNA was not detectable in blood, even before start of antimicrobial 
therapy. The results of the total group of patients with unsuccessful treatment 
show the same pattern: overall lower IFN-γ/IL-2 ratio from the start of follow-up 
in this study, with no C. burnetii DNA detectable in blood. An exception to  this rule 
is patient 9, who failed on antibiotic treatment by having C. burnetii DNA detectable 
in blood after 20 months of antimicrobial therapy. The lower IFN-γ/IL-2 ratio we 
observed in  patients with endovascular infections compared to endocarditis 
patients suggests that these manifestations of chronic Q fever differ with respect to 
antigen concentrations; vascular infections might be a more low-grade infection 
than endocarditis.
 Our study has some limitations. First of all, we studied a relatively small 
number of patients. Longer follow-up with additional time points after completion 
of treatment need to be incorporated into future studies to evaluate success of 
treatment. Moreover, the method we used, in vitro measurement of IFN-γ and IL-2 
production, does not clearly differentiate whether these cytokines are produced by 
effector T-cells (producing only IFN-γ) or effector memory T-cells (producing 
IFN-γ and IL-2) or central memory T-cells (producing predominantly IL-2). The 
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ratio IFN-γ/IL-2 merely reflects the overall result and might be influenced by the 
total number of circulating T-cells and their viability in vitro. To increase our 
insight in the matter, detection of cytokine production on single-cell level, e.g., by 
flow cytometry with intra-cellular cytokine staining (Harari et al., 2005), would be 
a valuable addition in future research.
 The central position of serology in Q fever diagnostic is undisputable, and 
serology has hitherto been the most widely used immunological measurement for 
C. burnetii infection. It continues to be extensively validated in Q fever research 
(Frankel et al., 2011; van der Hoek et al., 2011; Edouard et al., 2013; Herremans et al., 
2013). Nevertheless, the immunological importance of measuring antibodies in 
response to this intracellular bacterial infection is questionable. Specifically, the 
use of antibody titers to monitor the effect of antibiotic treatment on C. burnetii 
infection and disease needs further research. The definition of serological cure as 
anti-phase I IgG below 1:800 (or 1:1024 when a commercial IFA  is used) is based on 
expert opinion  (Million et al., 2010).  The definition of absence of a fourfold decrease 
in antibody titers as a poor prognostic factor, is based on a smallsized retrospective 
study of Q fever endocarditis (Million et al., 2010), and is not yet confirmed by 
other studies. In the light of this limited evidence  of  serology  as  a  biomarker,  it 
would be valuable to also focus on the more relevant cell-mediated immune 
response. Especially when the decision to continue or stop treatment has to be 
made in an individual patient, the availability of other relevant biomarkers may be 
of help. Our study shows a promising role for the IFN-γ/IL-2 production profile, 
although the large variation in IFN-γ/IL-2 ratio between patients in this study 
makes it difficult to formulate general recommendations for the application of 
these biomarkers at the current time.
 In conclusion, existing clinical, imaging and microbiological parameters to 
monitor the response to treatment have several limitations. We propose that the 
IFN-γ/IL-2 production profile can be used as an additional immunological 
biomarker for treatment monitoring of chronic Q fever.
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Abstract
Diagnosis of ongoing or past infection with Coxiella burnetii, the causative agent 
of Q fever, relies heavily on serology: the measurement of C. burnetii-specific 
antibodies, reflecting the host’s humoral immune response. However, cell-mediated 
immune responses play an important, probably even more relevant, role in 
infections caused by the intracellular C. burnetii bacterium. Recent studies have 
investigated interferon-gamma (IFN-γ) based assays, including a whole-blood 
IFN-γ production assay and a Coxiella enzyme-linked immunospot (Coxiella 
ELISPOT), as potential diagnostic tools for Q fever diagnosis. Both are in-house 
developed assays using stimulating antigens of different origin. The main objective 
of this study was to compare the test performance of the IFN-γ production assay 
and the Coxiella ELISPOT for detecting a cellular immune response to C. burnetii in 
Q fever patients, and to assess the correlation between both assays. To that end, 
both tests were performed in a well-defined patient group of chronic Q fever 
patients (n = 16) and a group of healthy seronegative individuals (n = 17). Among 
patients, both the Coxiella ELISPOT and the IFN-γ production assay detected 
positive response in 14/16. Among controls, none were positive in the Coxiella 
ELISPOT, whereas the IFN-γ production assay detected positive results in 1/17 and 
3/17, when using Henzerling and Nine Mile as stimulating antigens, respectively. 
These results suggest the Coxiella ELISPOT has a somewhat higher specificity than 
the IFN-γ production assay when Nine Mile is used as antigen stimulus. The assays 
showed moderate correlation: the Spearman correlation coefficient r ranged between 
0.37–0.60, depending on the antigens used. Further investigation of the diagnostic 
potential for C. burnetii infection of both assays is warranted.
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Introduction
Q fever is a zoonotic disease that occurs worldwide and is caused by the gram- 
negative, intracellular bacterium Coxiella burnetii. The Netherlands experienced a 
major Q fever outbreak between 2007 and 2010, with over 4,000 reported human 
infections [1]. Acute Q fever mostly presents as a flu-like illness, pneumonia or 
hepatitis, but initial infections can be asymptomatic in more than 50% of cases [2]. 
Chronic Q fever is a rare but serious complication that occurs in approximately 5% of 
all patients following the acute infection. This persisting infection typically presents 
with endocarditis or vascular infection, and has significant mortality rates, 
especially in case of diagnostic and therapeutic delay [3].
 Evaluating chronic C. burnetii infection is challenging. Measurement of serum 
antibodies against C. burnetii is currently the ‘gold standard’ for Q fever diagnosis 
[3]. Diagnosis of chronic Q fever relies heavily on detection of high IgG antibody 
titers against phase  1  C.  burnetii.  This  serological  criterion  is  combined  with 
PCR  for  C.  burnetii  DNA  on  blood  or  tissue  (if  available)  and clinical assessment 
of any nidus of chronic infection [4,5].
 Both humoral and cell-mediated immune responses  are involved in the host’s 
immunity against the intracellular C. burnetii bacterium [6–8]. Therefore, it makes 
sense to explore the value of complementing conventional serology with an assessment 
of host specific cell-mediated immune responses to detect a chronic infection with 
C. burnetii. To this end, new immunological blood tests have been developed that 
are based on cellular immunity, measuring T-cell derived interferon-γ (IFN-γ) 
production in response to stimulation with C. burnetii. The first, the whole-blood 
IFN-γ production assay, was extensively investigated during a Q fever vaccination 
campaign and for the diagnosis of chronic Q fever [9–11]. The second, the Coxiella 
enzyme-linked immunospot (Coxiella ELISPOT), was explored in a small series of 
patients with past or chronic Q fever [12]. The IFN-γ production assay measures 
the amount of C. burnetii specific IFN-γ production, while the Coxiella ELISPOT 
measures the number of C. burnetii specific IFN-γ producing cells. These IFN-γ 
based assays are not yet routinely used for Q fever diagnosis. Both are in-house 
assays, using different stimulating antigens. The IFN-γ production assay uses 
in-house cultured Nine Mile phase 1 and the Q-vax vaccine containing Henzerling 
phase 1, while the Coxiella ELISPOT uses commercially available Nine Mile phase 
1 and phase 2 antigens. 
 In the aftermath of the Dutch Q fever outbreak, we had the opportunity to use 
both IFN-γ based tests in parallel in a group of well-defined chronic Q fever 
patients. Volunteers with no history of Q fever and with negative Q fever serology 
served as a control group.
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 The purpose of this study was to compare the test performance (sensitivity 
and specificity) of the IFN-γ production assay and the Coxiella ELISPOT for 
detecting a cellular immune response to C. burnetii in Q fever patients and to 
determine the correlation between the assays.
Materials and Methods
Patients and control subjects
Chronic Q fever patients (n = 16) were recruited from the outpatient clinics of 
the participating hospitals. All fulfilled the criteria for probable (n = 4) or proven 
(n = 12, of which 3 Q fever endocarditis and 9 Q fever vascular infection) chronic 
Q fever according to the Dutch consensus statements on chronic Q fever [4]. 
Fourteen of the 16 patients were on long-term antibiotic treatment at inclusion. 
The median duration of  antibiotic treatment at the time of blood collection was 
21 months (range 0–59 months). The control individuals (n = 17) were similar with 
respect gender, somewhat younger, but had no history of Q fever and had negative 
Q fever serology as measured by immunofluorescence assay (Focus Diagnostics, 
Cypress, CA, USA) (Table 1). Informed consent was obtained from all subjects 
before blood donation and the study was approved by the local ethics committee 
(CMO regio Arnhem-Nijmegen).
IFN-γ production assay
The IFN-γ production assay was performed as previously described [9]. In short, 
heparinized whole blood was aliquoted into four separate 1.5 mL tubes at 0.5 mL per 
tube.  The  tubes were  inoculated  with  either  10 μg/mL  PHA  (Sigma,  St.  Louis, MO), 
100 ng/ml  Q  vax  vaccine  (see  below),  10^7/mL  heat- inactivated C. burnetii Nine 
Mile phase I (see below), or nothing. The tubes were incubated in-vitro for 
24 hours at 37ºC and 5% CO2. The IFN-γ production was measured in the 
supernatant by ELISA (Pelikine compact, Sanquin, Amsterdam). Net IFN-response 
was expressed as the concentration of IFN-γ in the stimulated sample minus that 
in the unstimulated   sample.
 The Q-vax vaccine (CSL Biotherapies, Vic., Australia), contains formalin- 
inactivated whole cell phase 1 Henzerling  strain.
 Heat-inactivated phase 1 C. burnetii Nine Mile (NMI, RSA493) was kindly 
provided by H.I. Roest (Central Veterinary Institute, Lelystad, the Netherlands). 
Details about culture and preparation of this stimulating antigen are described 
elsewhere  [9].
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Coxiella ELISPOT
The Coxiella ELISPOT was performed on peripheral blood mononuclear cells 
(PBMCs) isolated from heparinized blood and stimulated for 16–20 hours, as 
described before  [12].
 In precoated wells of PVDF strip plates (ELISpotpro; Mabtech) 100 μL of 
mononuclear cells were seeded at a density of 250,000 cells per well, and incubated 
with 50 μL of antigens, PHA (2.5 μg/ mL) or nothing. As stimulating antigens, 
commercially available formalin-inactivated phase 1 and phase 2 Nine Mile (NMI 
and NMII, Virion-Serion Immunodiagnostica GmbH, Würzburg, Germany) were 
used. After incubation, the resulting number of spots, representing the number of 
individual T-cells producing IFN-γ following stimulation with C. burnetii antigens, 
were detected and enumerated using an ELISpot reader (Auto Immun Diagnostika 
GmbH, Strassberg,  Germany).
Statistics
Statistical  analysis  was  performed  using  GraphPad  Prism  5. Median (6 interquartile 
range) IFN-γ production and number of spots  were  compared  between  groups 
using  Mann-Whitney  U-tests.  Receiver  Operating  Characteristics  (ROC)  curves 
analysis were used to derive a cutoff for positivity of either assay. The cutoff was 
determined from the ROC curve by choosing the value that yielded empirical 
optimal sensitivity and specificity.
 Correlation was reported by calculating the Spearman’s r with 95% Confidence 
Interval.
Table 1   Characteristics of chronic Q fever patients and control individuals
Patients (n = 16) Controls (n = 17)
Age in yrs, median (range) 68 (31–80) 46 (25–64)
Males, number (%) 13 (81) 14 (82)
IgG anti-phase I titera, median (range) 2048 (128–32768) <16 (n.a.)
IgG anti-phase II titera, median (range) 3072 (256–32768) <16 (n.a.)
Duration of antibiotic treatment in 
monthsa, median (range)
21 (0–59) n.a.
n.a., not applicable.
a At the time of bloodsampling. 
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Results and Discussion
The amount of IFN-γ as measured in the IFN-γ production assay and the spot 
count obtained in the Coxiella ELISPOT were evaluated. The individual values are 
shown in Figure 1 for patients and control subjects separately. The median IFN-γ 
response to the Henzerling antigen in the patients was 440 pg/mL (IQR 62–612 pg/
mL), whereas in control subjects, this was 0 pg/mL (IQR 0–0 pg/mL). The median 
IFN-γ response to the NMI antigen in the patients was 3238 pg/mL (IQR 534–6564 
pg/mL), whereas in control subjects, this was 126 pg/mL (IQR 14–250 pg/mL). The 
median ELISPOT spot count after NMI stimulation was 44 (IQR 15–94) in patients 
and 0 (IQR 0–0) in controls, and after NMII stimulation 71 (IQR 23–100) in patients 
and 0 (IQR 0–0) in controls. In both assays, the differences between patients and 
control subjects were significant for each stimulating antigen. All of the samples 
tested responded to PHA  mitogen.
 To establish a cutoff for a positive response in both assays for each of the 
antigens, ROC curves were constructed (Figure 2). Cutoffs were derived from ROC 
curve analysis to yield empirical optimal sensitivity and specificity. For the IFN-γ 
production assay, this resulted in a cutoff of 45 pg/mL or 365 pg/mL when using 
Figure 1. Results of the IFN-γ production assay and Coxiella ELISPOT in chronic Q fever 
patients and control subjects. In vitro IFN-γ production by whole blood in response to 
Henzerling and Nine Mile phase 1 antigens was measured in the IFN-γ production assay. 
The number of IFN-γ positive cells in response to Nine Mile phase 1 and Nine Mile phase 2 
antigens was measured in the Coxiella ELISPOT. Individual values of patients and controls 
are shown separately, and the lines indicate the medians. Patients and controls were 
compared using the Mann-Whitney U-test.
***P,0.001, **P,0.01. Abbreviations: NMI, Nine Mile phase 1; NMII, Nine Mile phase 2; IFN-γ, 
interferon-gamma. 
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the Henzerling or the NMI as stimulating antigen respectively. For the Coxiella 
ELISPOT, this resulted in a cutoff of 5 spots to both NMI and NMII. Given these 
cutoffs, the IFN-γ production assay detected positive response in 14/16 and  the 
Coxiella ELISPOT was positive in 14/16 among the patients. Among the controls, 
the IFN-γ production assay detected positive response in 1/17 and 3/ 17, when 
using Henzerling and Nine Mile as stimulating antigens respectively, whereas 
none were positive in the Coxiella ELISPOT. These results suggest that the assays 
have comparable sensitivity in this population, but the Coxiella ELISPOT has a 
higher specificity than the IFN-γ production assay with Nine Mile as an antigen 
stimulus. This might be due to different antigens being exposed after heat-inacti-
vation of the NMI strain as compared to the antigens present on the formalin-inac-
tivated bacteria.
 Furthermore, it is very well possible that the IFN-gamma production assay 
and the Coxiella ELISPOT assay do not measure the same features of the immune 
response. Although both tests measure Coxiella specific IFN-gamma production, 
the Coxiella ELISPOT assay singles out and quantifies the T lymphocyte 
compartment, whereas whole blood stimulation also includes blood IFN-gamma 
producing NK cells, reflecting also the innate part of the immune response. 
Figure 2. ROC curves of the IFN-γ production assay and the Coxiella ELISPOT. ROC curves 
are shown for each assay with each stimulating antigen separately. Abbreviations: NMI, 
Nine Mile phase 1; NMII, Nine Mile phase 2; IFN-γ, interferon-gamma. 
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However, true positives in the control group cannot be excluded which in turn 
may underestimate specificity. A seroprevalence study in the Q fever epidemic 
area among patients with a valvular risk factor for chronic Q fever found 20.4% of 
the people to be seropositive for C. burnetii [13]. As the control subjects lived close 
to or in the epidemic area, although not having a Q fever history or detectable 
anti-C. burnetii antibodies, it is not unthinkable that any of the control subject 
could have a past exposure to C. burnetii that was not picked up by serology. Of 
note, two of the three control subjects that produced substantial amounts of IFN-γ 
Figure 3. Correlation between the amount of C. burnetii-specific IFN-γ production and 
the number of  IFN-γ  positive  cells.  The individual values of chronic Q fever patients 
(n = 16) were used to determine the correlation between the IFN-γ production as measured 
with the IFN-γ production assay, and the number of IFN-γ positive cells as measured with 
the Coxiella ELISPOT. Each graph shows the correlation between the resulting values of the 
two assays, with either one of the stimulating antigens. On the Y-axes, the IFN-γ production 
is shown after stimulation with NMI (upper graphs) and Henzerling antigens (lower graphs). 
On the X-axes, the spot count is shown after stimulation with NMI (left graphs) and NMII 
(right graphs) antigens. The Spearman’s correlation coefficient r (95% Confidence Interval) is 
given for each comparison. Abbreviations: NMI, Nine Mile phase 1; NMII, Nine Mile phase 
2; IFN-γ, interferon-gamma. 
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after NMI antigen stimulation, also showed minimal response below the cutoff in 
the Coxiella ELISPOT.
 In the patient samples, we determined the correlation between the amount of 
IFN-γ produced in the IFN-γ production assay and the number of IFN-γ-produc-
ing cells in the Coxiella ELISPOT (Figure 3). The correlation between the values 
obtained in the two assays, each employing two stimulating antigens, was 
determined separately, resulting in a total of four comparisons. The Spearman 
correlation coefficient r ranged between 0.37–0.60, indicating a moderate to strong 
correlation. The discrepancies between both types of assays can be explained by 
the different origins and concentrations of stimulating antigens, the different 
phase variation, or, as mentioned previously, the method of inactivation of the 
antigen stimuli. Moreover, it may well be true that the amount of IFN-γ released is 
not directly related to the number of IFN-γ positive cells. IFN-γ based assays are 
used for detection of immunity to Mycobacterium tuberculosis and commercial kits 
are available for the two types of assays, e.g. the QuantiFERON-TB and the T Spot 
TB [14]. These assays have been reported to be at least as accurate as the tuberculin 
skin test to detect exposure to M. tuberculosis. The correlation between the two 
types of IFN-γ based assays for tuberculosis as previously reported in the literature, 
are better (r = 0.69 and r = 0.80) than what we observed evaluating these diagnostic 
platforms in C. burnetii infection  [15,16].
 In conclusion, the two IFN-γ based assays had a similarly high sensitivity for 
detecting C. burnetii infection and the correlation between both test was moderate. 
The IFN-γ production assay in whole blood has the practical advantage of relative 
technical simplicity over the more laboriously intensive Coxiella ELISPOT. The 
Coxiella ELISPOT, however, seemed to be more specific with Nine Mile as an 
antigen stimulus. These observations, and previous studies of these IFN-γ based 
assays in C. burnetii infection, show the potential of measuring cell-mediated 
immune response in Q fever and warrant further investigation of these assays in 
larger cohorts of Q fever patients.
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Abstract
Coxiella burnetii, a Gram-negative intracellular bacterium, can give rise to Q fever 
in humans and is transmitted mainly by inhalation of infected aerosols from 
animal reservoirs. Serology is commonly used to diagnose Q fever, but the early 
cellular immune response—i.e., C. burnetii–specific interferon γ (IFN-γ) production 
in response to antigen challenge—might be an additional diagnostic. Detection of 
IFN-γ responses has been used to identify past and chronic Q fever infections, but 
the IFN-γ response in acute Q fever has not been described. By challenging 
immuno competent BALB/c mice with aerosols containing phase I C. burnetii, the 
timing and extent of IFN-γ recall responses were evaluated in an acute C. burnetii 
infection. Other cytokines were also measured in an effort to identify other 
potential diagnostic markers. The data show that after initial expansion of bacteria 
first in lungs and then in other tissues, the infection was cleared from day 10 
onwards as reflected by the decreasing number of bacteria. The antigen-induced 
IFN-γ production by splenocytes coincided with emergence of IgM phase II 
antibodies at day 10 postinfection and preceded appearance of IgG antibodies. 
This was accompanied by the production of proinflammatory cytokines including 
interleukin (IL) 6, keratinocyte-derived cytokine, and IFN-γ–induced protein 10, 
followed by monocyte chemotactic protein 1, but not by IL-1β and tumor necrosis 
factor α, and only very low production of the anti-inflammatory cytokine IL-10. 
These data suggest that analysis of antigen-specific IFN-γ responses could be a 
useful tool for diagnosis of acute Q fever. Moreover, the current model of C. burnetii 
infection could be used to give new insights into immunological factors that 
predispose to development of persistent infection.
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Introduction
Infection with Coxiella burnetii, a Gram-negative intracellular bacterium, causes 
Q fever in humans. The common route of infection is through inhalation of 
C. burnetii–infected aerosols spread from animals, usually sheep or goats (McQuiston 
and Childs, 2002). Acute Q fever presents as a flu-like illness but can be asymptomatic 
in over 50% of infections. A minority of cases presents as pneumonia or hepatitis 
(Parker et al., 2006). Generally, acute Q fever is self-limiting, yet early recognition 
and antibiotic treatment may shorten duration (Benenson and Tigertt, 1956). In some 
cases, however, C. burnetii infection leads to a chronic infection (chronic Q fever), 
mostly Q fever endocarditis or vascular infection (Million et al., 2010). These 
conditions are life-threatening if left untreated. Prevention of evolution from acute 
to chronic Q fever, by prolonged antibiotic treatment following initial infection, is 
suggested for risk groups, but the value of this intervention is debated (Limonard 
et al., 2011; Million et al., 2013).
 In the initial phase of the infection, cytokines and chemokines produced by 
monocytes and macrophages are central to recruit and activate other immune 
cells, promote pathogen disposal, and develop adaptive immunity. Cell-mediated 
adaptive immune responses are essential for control of acute C. burnetii infection, 
probably even more important than B-cell responses (Andoh et al., 2007; Read et 
al., 2010; Sidwell et al., 1964). C. burnetii–specific T cells produce interferon-γ (IFN-γ) 
and activate monocytes/macrophages to produce inflammatory cytokines and 
control intracellular C. burnetii growth (Brennan et   al., 2004; Ghigo et al., 2002).
 Currently, detection of acute Q fever infection in humans mainly relies on 
measurement of C. burnetii–specific serum antibodies. Measurements of T-cell 
immune responses might be of additional value in acute Q fever but, so far, have 
not been investigated in this context. To obtain data on early adaptive immune 
responses, human studies are of limited value, since patients are identified fairly 
late in the course of overt clinical disease. Animal models that mimic human acute 
Q fever can be used instead.
 Animal models for Q fever usually include guinea pigs or mice (Maurin and 
Raoult, 1999). In mice, as in humans, C. burnetii infection can cause disease, with 
different mouse strains showing divergent vulnerability for infection, with 
mortality only in the most sensitive strains (Scott et al., 1987). The incubation time 
till development of symptoms depends on the inoculation dose (Benenson and 
Tigertt, 1956), the route of infection, and the phase of C. burnetii. The virulent form 
is the so-called phase I C. burnetii that possesses a full-length lipopolysaccharide 
(LPS) and is isolated from infected humans or animals (Russell-Lodrigue et al., 
2009). Phase II, obtained after several passages of phase I organisms in vitro, 
displays a truncated LPS molecule lacking the terminal O-antigen sugars (Amano 
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et al., 1987) and does not lead to disease even when administered in high inocula 
in experimental animals (Andoh et al., 2005, 2007; Moos and Hackstadt, 1987). The 
route of infection is of importance with a shorter incubation time in animals 
infected intraperitoneally as compared to the natural route of respiratory infection 
(Tigertt et al., 1961). Clearly, aerosol infection resembles most closely the natural 
route of infection in humans and should be preferred for studying the disease 
(Stein et al., 2005).
 The main purpose of this study was to investigate the development of cellular 
immunity—i.e., C. burnetii–specific IFN-γ production in response to antigen 
challenge—and to compare this with the timing of IgM and IgG antibody responses 
against phase I and II bacteria. In addition, we investigated the specific production 
of early inflammatory mediators—a panel of monocyte-/macrophage-derived 
cytokines and chemokines—in an effort to identify other potential diagnostic 
markers. To facilitate analysis and mimic the mode of transmission for human 
acute Q fever most closely, we used a mouse model of aerosol infection with phase I 
C. burnetii in immunocompetent BALB/c mice.
Materials and methods
Animals
A total of 50 male BALB/c mice, 9 weeks of age, were purchased from The Jackson 
Laboratory (Bar Harbor, ME, USA). This mouse strain is known to be intermediately 
sensitive to infection with C. burnetii (Scott et al., 1987; Stein et al., 2005). Mice were 
housed in a Tecniplast Isocage system (Tecniplast, Exton, PA, USA) in an ABSL3 
facility and given food and water ad libitum. The animal experiments were 
performed according to an animal protocol approved by the CDC Institutional 
Animal Care and Use Committee.
Bacteria
The strain used for this study was C. burnetii Nine Mile (NM) phase I (RSA493). 
This reference strain, isolated from a tick in 1935 (Maurin and Raoult, 1999), can 
cause Q fever in humans (Benenson and Tigertt, 1956) and grows well in mouse 
models (Russell-Lodrigue et al., 2009). It was grown in chicken eggs and purified 
by sucrose gradient centrifugation (Miller and Thompson, 2002). Stockswere kept 
frozen at−80 °C in sucrose phosphate glutamate buffer until use.
Mouse infections
On day 0, 40 mice were inoculated using the Biaera aerosol management platform 
(AeroMP; Biaera Technologies, Hagerstown, MD, USA). Ten milliliters of phosphate- 
buffered saline (PBS) containing NM phase I bacteria (at 108 organisms/mL) was 
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placed in a nebulizer, and the aerosolized bacteria were introduced into the 
chamber containing the 40 mice for a 10-minute exposure period. Sixty liters of air 
from the chamber was sampled in an impinger containing 10-mL PBS. Quantitative 
PCR detected 1.68 × 107 C. burnetii organisms in the impinger, suggesting that the 
air in the chamber contained 280 organisms permilliliter of air. Based on a tidal 
volume of 0.15mL and a respiratory rate of 163/min for mice, it is estimated that 
each mouse inhaled 6.8 × 104 C. burnetii organisms. Ten mice served as a negative 
control group and were left uninfected. The infected and uninfected mice were 
maintained in separate high efficiency particulate air-filtered isolator cages.
 On day 1, 3, 7, 10, and 14, groups of 8 infected and 2 uninfectedmice were 
euthanized by exsanguination under isoflurane anesthesia, after which the 
euthanasia was verified by cervical dislocation. Blood was harvested by cardiac 
puncture and collected in heparinized tubes, and blood from pairs of mice was 
pooled. Lungs, spleen, and liver were aseptically removed. Spleens  were  weighed 
before  further processing.
Quantitative PCR
For analysis of the quantity of C. burnetii DNA in blood and tissue, blood and 
spleens from the 8 infected and 2 uninfected mice at each time point were pooled 
into 5 pairs. Spleens were homogenized into single cell suspensions by grinding 
the tissues between frosted ends of ground glass slides before pooling. For liver 
and lung, the organs from each mouse were tested independently. To quantify the 
C. burnetii, total genomic DNA was extracted from 100-μL blood, lung/liver tissue, 
or spleen cell suspensions using the QIAamp DNA mini kit (Qiagen, Valencia, CA, 
USA), according to the manufacturer’s instructions. On all these samples, quantitative 
PCR for IS1111a was performed as described (Kersh et al., 2010).
Serology
Serum  titers  of  IgM  and  IgG  antibodies  against  phase  I  and II C. burnetii were 
determined by indirect immunofluorescence antibody test (IFA). Plasma was 
obtained from heparinized blood through centrifugation at 1200 × g. Slides coated 
with either NM phase I (RSA 493) or NM phase II (RSA 439) strains were incubated 
with titrations of plasma samples. After washing, they were treated with fluorescein 
isothiocyanate–conjugated goat anti-mouse antibody, and binding was visualized
using a fluorescence microscope. The greatest dilution of plasma that resulted in 
unambiguous antibody binding is reported as titer.
Splenocyte stimulation
Splenocytes were isolated by homogenizing the spleens by grinding the tissue 
between the frosted ends of a pair of ground glass slides, creating single-cell 
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suspensions in sterile PBS. Splenocytes from pairs of mice were pooled. After 
centrifugation at 300 × g for 10 minutes at 20 °C, red blood cells were lysed by 
osmotic shock followed by resuspension in PBS. After passage through a 100-μm 
cell strainer to filter debris, cells were centrifuged again at 300 × g for 10 minutes at 
20 °C and resuspended in RPMI culture media supplemented as described. Cells 
were plated at 3× 106 cells/well in a 24-well plate, in a final volume of 1 mL per  well.
 Splenocyteswere stimulated with medium alone (negative control), the mitogen 
concanavalin A (conA) (2.5 μg/mL), or heat-killed (60 minutes, 80 °C) (Enright et 
al., 1957) phase I NM at either 1 × 106/mL or 1 × 107/mL. After 48 h incubation at 
37 °C and 5% CO2, 400 μL of splenocyte supernatant was collected from each well. 
Supernatantswere stored at−80 °C until cytokines were measured.
Cytokine analysis
Supernatant samples were gamma-irradiated (2 × 106 rads) before handling. Cytokine 
concentrations—including mouse interleukin (IL) 1β, IL-6, tumor necrosis factor 
(TNF) α, IL-10, keratinocyte-derived cytokine (KC), monocyte chemotactic protein 
(MCP) 1, IFN-γ–induced protein (IP) 10, and IFN-γ—were measured using a 
Luminex bead– based multiplex assay (R and D Systems, Minneapolis, MN, USA), 
in accordance with the manufacturers’ instructions. Samples were analyzed using 
a Bio-Plex Luminex 100 (Bio-Rad, Hercules, CA, USA).
Statistical analysis
Data are expressed as mean ± SD (for weight and genome copies) or median ± IQR 
(for cytokine data). Differences between uninfected and infected mice at different 
time points after infection were tested using analysis of variance (ANOVA) test or 
Kruskal–Wallis test, as appropriate. GraphPad Prism 5.0 software (GraphPad) was 
used. A difference was considered significant if the P value was ≤0.05.
Results
C. burnetii infection in mice
All infected mice showed some signs of lethargy and ruffled fur for 2–7 days, with 
onset between day 7 and day 14 postinfection. Infected mice developed splenomegaly 
from day 3 onwards (Fig. 1). None of the mice died before being sacrificed.
Detection of C. burnetii DNA
The bacterial DNA copy numbers in the lungs of infected mice increased from day 
1 to day 7 and declined thereafter. In plasma, amplification products were obtained 
at day 3 (only in 1 of 4 pairs of mice) and reached maximum at day 7 (all pairs of 
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9mice). In liver and spleen, C. burnetii DNA was detected at day 7 and reached 
maximum at day 10 afterwhich it declined (Fig. 2). At day 14, of the tissues examined, 
spleens contained the highest load of C. burnetii DNA. No bacterial DNA was 
detected in plasma and tissue of uninfected mice.
Serological response
Serological responses, asmeasured by IFA, are shown in Fig. 3. A positive response 
in infected mice was first detectable at day 10, with low titers (ranging from 1:32 to 
1:64) for IgMphase II. These titers increased to 1:256 to 1:2048 at day 14. IgG phase 
II and IgMphase Iwere also positive in all infectedmice (range 1:256 to 1:512 and 
range 1:64 to 1:256, respectively). At day 14, all infected mice had developed anti- 
bodies against NMphase I and II C. burnetii, and all control mice remained sero -
negative. IgG against phase I was only lowpositive in 2 of 4 mouse pairs (maximum 
1:32) at day 14.
Cytokine production
Cytokinesweremeasured in supernatants of splenocytes stimulated for 48 h in 
vitro. Splenocytes of infected mice produced substantial amounts of cytokines, 
with different stimulus-dependent, time postinfection patterns. The pattern of an-
tigen-induced IFN-γ production, reflecting a specific cell-mediated immune 
response, was of special interest (Fig. 4). conA-induced IFN-γ production was 
Figure 1. Spleen weight after aerosol infection with C. burnetii in immunocompetent BALB/c 
mice. Spleen-to-body weight (mean ± SD) is shown for 10 uninfected mice (t = 0) and 8 
infected mice per time point postinfection. ANOVA test followed by Dunn’s multiple com-
parison test was used to compare infected mice at different time points with uninfected 
mice. **P ≤ 0.01; ***P ≤ 0.001.
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similarly high in uninfected and infected mice. Unstimulated splenocytes produced 
some IFN-γ at day 10. NM-induced IFN-γ production, absent in all uninfected 
mice and in infected mice at days 1, 3, and 7, was significantly increased at day 10 
and 14 postinfection.
 Regarding the other cytokines, NM stimulation induced significant IL-6, KC, 
and IP-10 from day 10 onwards, while MCP-1 production and low levels of IL-10 
were observed on day 14 (Fig. 5). In addition, con A-stimulated splenocytes showed 
significantly increased IL-6 and IP-10 production at day 14. Unstimulated 
splenocytes produced IL-6 at day 10, but otherwise, no substantial amounts of 
any other cytokines at any time point. IL-1β and TNF-α production were below 
Figure 2. Number of C. burnetii DNA copies in lung, plasma, liver, and spleen after aerosol 
infection with C. burnetii in immunocompetent BALB/c mice. The mean ± SD numbers of 
genomic equivalents per gram of tissue or milliliter of plasma are shown of 8 infected mice 
per time point. Uninfected mice were negative at every time point in all tissues. Samples that 
were negative were assigned a value of 200 genomic equivalents per gram (or milliliter). This 
is the limit of detection of the assay. P values were calculated by 1-sample t-test with a 
hypothetical value of 0. *P < 0.05, **P < 0.01, ***P < 0.001.
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detection limits at all time points with all stimuli. Supplementary Table 1 contains 
all data on all the cytokines measured.
Figure 3. Antibody responses to C. burnetii after aerosol infection with C. burnetii in immu-
no-competent BALB/c mice. IgM and IgG titers to NM phase I and phase II were measured 
in plasma by IFA. The median ± range reciprocal titers are shown of 4 pairs of infected mice 
per time point. The control mice were seronegative at every time point (not shown). Negative 
results in the IFA were assigned a value 1:8.
Figure 4. Early IFN-γ production by stimulated splenocytes of C. burnetii–infected immu-
no-competent BALB/c mice. Splenocytes were stimulated for 48 h with conA (2.5 μg/mL), 
NM phase I (107/mL), NM phase I (106/mL), or left unstimulated (nil). The median ± 
interquartile range cytokine production is shown per time point of 4 pairs of infected mice. 
T = 0 shows the median ± interquartile range of 5 pairs of uninfected mice. P values were 
calculated by Kruskal–Wallis test followed by Dunn’s multiple comparison test comparing 
cytokine concentrations of infected mice at different time points with uninfected mice.
*P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: conA = concanavalin A; NMI = C. burnetii 
Nine Mile phase I.
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Figure 5. Early IL-6, KC,MCP-1, IP-10, and IL-10 production by stimulated splenocytes of C. 
burnetii–infected immunocompetent BALB/c mice. Splenocytes were stimulated for 48 h 
with conA (2.5 μg/mL), NM phase I (107/mL or 106/mL), or left unstimulated (nil). The 
median ± interquartile range cytokine production is shown per time point of 4 pairs of 
infected mice. T=0 shows the median ± interquartile range of 5 pairs of uninfected mice. 
IL-1β and TNF-α production were below the lowest detection limit at all time points for all 
stimulations (not shown). The dashed horizontal line represents the lowest standard in the 
Luminex assay; values below are extrapolated. P values were calculated by Kruskal–Wallis 
test followed by Dunn’s multiple comparison test comparing cytokine concentrations of 
infected mice at different time points with uninfected mice. *P < 0.05, **P < 0.01. Abbreviations: 
conA = concanavalin A; NMI = C. burnetii Nine Mile phase I.
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Discussion
In the present study, we observed effective early immune responses in immuno-
competent BALB/c mice infected with C. burnetii via the aerosol route. After initial 
expansion of bacteria in lungs and spread to other tissues, the infection was cleared 
from day 10 onwards as reflected by the decreasing number of bacterial DNA 
copies. Antigen-induced IFN-γ production by splenocytes, indicating a cell- 
mediated immune response, coincided with emergence of IgM phase II antibodies 
at day 10 postinfection. This was accompanied by the production of proinflammatory 
cytokines including IL-6, KC, and IP-10, followed by MCP-1, but not by IL-1β and 
TNF-α, and only very low production of the anti-inflammatory cytokine IL-10.
 Previous  studies in  humans have  looked  at the in  vitro IFN-γ response in 
people vaccinated against Q fever, people that have had a previous Q fever 
infection, and chronic Q fever patients (Izzo and Marmion, 1993; Kersh et al., 2013; 
Limonard et al., 2012; Schoffelen et al., 2013a, 2013b, 2014). However, the testing of 
in vitro IFN-γ responses in acute human Q fever has not been reported. Acute 
cytokine responses in mice have been studied previously. This has been done by 
infecting mice by either an intraperitoneal or intratracheal route and then 
measuring circulating cytokines in serum at single time points (Russell-Lodrigue 
et al., 2009). These studies have detected IFN-γ and other cytokines in mouse 
serum but have not looked at in vitro antigen-specific recall responses at different 
time points. Another study looked at some early time points and detected modest 
increases in IFN-γ recall responses after infection of mice by intraperitoneal or 
intravenous routes (Honstettre et al., 2006). The study reported here describes in 
vitro antigen-specific recall cytokine responses at multiple time points shortly 
after C. burnetii aerosol infection. The data show a very robust antigen-specific 
IFN-γ response that is detected at about the same time as antibody responses 
relative to infection and perhaps just   prior to detection of C. burnetii–specific IgG. 
Based these observations, specific IFN-γ production assays are worthwhile to 
investigate for detection of human acute Q fever.
 The aerosol infection route that was used in this study closely reflects the 
typical acquisition of human infection by inhalation. After an inoculum of 6.8 × 104 
bacteria, the number of C. burnetii DNA copies first increased in the lungs, after 
which the bacteria became detectable in plasma, with subsequent spread to the 
spleen and liver.
 After the initial expansion, bacterial numbers declined. Since we aimed to 
observe the very early immune response, later time points were not  studied.  A previous 
study of  intratracheal infection  with C. burnetii in BALB/c mice that continued to 
24 days postinfection also showed clearance of infection (Read et al., 2010). In that 
study, the genome copy numbers in the lungs sharply decreased between days 9 
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and 16, similar to our observations. Moreover, the spleen weight peaked at day 16 
postinfection but had decreased by day 24, another indication that infection was 
controlled.
 The time–response curves of the humoral immune response suggest that IgG 
antibodies are redundant for early clearance of C. burnetii. Due to the absence of 
cellular IgM receptors, IgM by itself—in contrast to IgG—is unable to influence 
cellular responses. In our model, IgG, against either phase I or phase II bacteria, 
became detectable only at day 14, whereas the clearance of bacteria from the lungs 
started between days 7 and 10. The decrease in bacterial DNA occurred, however, 
simultaneously with the increase of specific IFN-γ production by splenocytes. 
 A limitation of present study is that the results of cytokine production upon 
stimulation with recall antigens were obtained in splenocytes instead of peripheral 
blood cells, which would likely be used for testing in humans. Although there is 
not a specific reason to believe that IFN-γ production by peripheral blood cells 
would be completely different from splenocytes, there could be kinetic differences. 
In present study, stimulation of mouse whole blood in vitro was performed, but 
cytokine responses were difficult to detect due to technical limitations of whole 
blood stimulations in mice. IFN-γ could not be detected, while IP-10 was detectable 
only in low levels showing maximum levels at day 10 (not shown). Previous studies 
looking at past infection or vaccination against Q fever have found that human 
peripheral blood is a good source of cytokine-producing cells in response to C. 
burnetii antigen stimulation (Schoffelen et al., 2013a, 2013b).
 In addition to IFN-γ, we observed the production of IL-6, KC, MCP-1, and IP-10 
in C. burnetii stimulated splenocytes at days 10 and 14 after infection. These 
cytokines probably play an important role in the cell infiltration in C. burnetii–
infected tissues of immunocompetent BALB/c mice, which was observed by Read 
et al. (2010). The increased production of IL-6 has been described in the course of 
human acute Q fever, in which unstimulated peripheral blood cells showed 
increased production of pro-inflammatory cytokines including IL-6, TNF-α, IL-12, 
and the anti-inflammatory cytokine IL-10 (Honstettre et al., 2003). However, IL-6 
production by C. burnetii–stimulated blood cells was not increased in acute Q fever 
patients. Likewise, MCP-1 was found to be increased in unstimulated blood cells of 
acute Q fever patients, but not in C. burnetii–stimulated cells (Meghari et al., 2006). 
These human patients were, however, in a later stage of the infection than the mice 
in the current study.
 To our knowledge, IP-10 has not been studied in the context of C. burnetii 
infections before. IP-10 is a chemokine produced by monocytes/macrophages, 
mainly in response to IFN-γ but also other cytokines including type I interferons, 
IL-2, IL-23, and IL-17. IP-10 has shown a promising role as an additional marker of 
Mycobacterium tuberculosis infection (Ruhwald et al., 2012), being specifically 
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induced by tuberculosis (TB)–specific antigens in confirmed TB cases and not in 
healthy controls. These data from human patients infected with an obligate 
intracellular pathogen are in line with our observations in mice infected with C. 
burnetii. However, Ruhwald et al. (2012) showed that IP-10 levels after antigen 
stimulation are higher compared with IFN-γ levels in human peripheral blood. 
In our study, we found that IP-10 was induced in antigen-stimulated splenocytes, 
but levels of IP-10 (1400 pg/mL) were lower than levels of IFN-γ (5000 pg/mL).
 Previous studies have shown absent IL-1β production but substantial TNF-α 
production by C. burnetii–stimulated peritoneal macrophages of uninfected 
BALB/c mice (Ochoa-Repáraz et al., 2007). Other studies showed increased TNF-α 
production by peritoneal macrophages of C. burnetii–infected BALB/c mice 
(Honstettre et al., 2006). In our model, using the respiratory infection route,  we 
were unable to induce substantial IL-1β and TNF-α production in stimulated 
spleen cells of infected mice. The lack of TNF-α response in our system could be 
due to the route of infection used, the cell types present in our spleen preparations, 
or the antigen used.
 Of note, only minimal levels of IL-10 were produced by splenocytes after 
C. burnetii infection. IL-10 has been of special interest in previous studies, since it 
was linked to persistent infection in humans (Capo et al., 1996; Honstettre et al., 
2003) and chronic Q fever in mice overexpressing IL-10 (Meghari et al., 2008). Our 
findings show that clearance of C. burnetii in the early stage is accompanied by only 
a very low antigen-specific IL-10 production by splenocytes. Earlier studies in in-
traperitoneally C. burnetii–infected BALB/c mice showed high levels of IL-10 
production by C. burnetii–stimulated peritoneal macrophages at day 7 postinfection, 
before bacterial load decreased (Honstettre et al., 2006). Similar to TNF-α, 
macrophages may be an important source of IL-10 in response to C. burnetii, 
although it is likely that regulatory T cells and Th2 lymphocytes also play a role.
 In conclusion, the model of C. burnetii infection used in this study demonstrates 
that detection of antigen-induced IFN-γ could be used to detect acute C. burnetii 
infection in mice, and this is likely to be the case in humans as well. Antigen-specific 
production of IFN-γ and IP-10 were both detectable prior to elevation of specific 
IgG antibodies. This study also showed antigen-specific induction of IL-6, KC, and 
MCP-1 from splenocyte cultures. If applied to immune-deficient mice or mice with 
anatomical risk factors for endocarditis or vascular infections, the model may offer 
wide opportunities to study the pathophysiological and immune derangements 
that occur during progression from acute to chronic Q fever.
 Supplementary data to this article can be found online at http://dx. doi.org/ 
10.1016/j.diagmicrobio.2014.12.008.
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Abstract
Objectives: During the recent Dutch Q fever epidemic, many individuals became 
infected with the intracellular bacterium Coxiella burnetii. Initial infection is often 
asymptomatic, but can be complicated by chronic Q fever in 1-5% of cases, months 
to years later. We examined whether rheumatoid arthritis (RA) patients on 
anti-tumor necrosis factor α (anti-TNFα) therapy are at increased risk for chronic 
Q fever.
Methods: RA patients, living in the Q fever endemic area, were screened for anti- 
C. burnetii antibodies in two cohorts: 1. RA patients on anti-TNFα therapy and 2. 
anti-TNFα naive RA patients. Patients with phase I and/or II IgG titres ≥1:32 
were defined as seropositives, indicating previous exposure to C. burnetii. Chronic 
Q fever was diagnosed by a team of medical specialists.
Results: 57/361 (15.8%) patients on anti-TNFα therapy were seropositive, compared 
to 55/398 (13.8%) anti-TNFα naive patients (P=0.47). 10/112 (8.9%) seropositive 
patients were diagnosed with chronic Q fever: 7/57 (12.3%) patients on anti-TNFα 
therapy and 3/55 (5.5%) anti-TNFα naive patients (RR 2.25; 95% CI 0.61–8.27, P=0.32). 
Univariate analysis in all seropositive patients identified higher age, cardiac 
valvulo pathy/prosthetic valve or aneurysm/vascular prosthesis and corticosteroid 
use as significant risk factors for chronic Q fever.
Conclusions: The prevalence of chronic Q fever in seropositive RA patients was 
higher (8.9%) than previously reported in infected individuals in the general 
population, suggesting that patients with RA are at risk for development of chronic 
Q fever. However, we found no significant additional risk of anti-TNFα therapy.
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Introduction
Q fever is a zoonosis caused by the intracellular bacterium Coxiella burnetii. During 
the Dutch Q fever outbreak (2007-2010) an estimate of more than 40,000 individuals 
became infected [1,2]. Initial infection leads to a mostly self-limiting febrile disease 
in approximately 40% of cases; however, in at least 60% it remains asymptomatic 
and often unrecognized [3]. Chronic infection, mainly manifesting as endocarditis 
or vascular infection, presents in 1-5% of individuals months to years after initial 
infection [4,5]. These conditions are often fatal if left untreated and should therefore 
be diagnosed in an early stage. Individuals most at risk are those with pre-existing 
cardiac valvular disease or vascular aneurysm or prosthesis [6-10]. Immuno-
suppression is another stated risk factor for chronic fever, although definition of 
the type of immunosuppression is poor and statistical empowerment of the increased 
risk for chronic Q fever in immunocompromised patients is absent. Case studies 
describe chronic Q fever in patients with (haematologic) malignancies, or with 
liver- and bone marrow transplantation [11,12]. In addition, a retrospective study of 
102 Q fever endocarditis patients, reveals cancer as a risk factor, although the 
authors do not specify the use of immuno-modulating drugs[9]. An association 
between Q fever and the use of immunosuppressive drugs, including cortico-
steroids and methotrexate, is mentioned in three case reports: two with acute Q fever 
[13,14], one with Q fever endocarditis [15].
Tumor necrosis factor-α (TNFα) plays an important role in the defense against 
intracellular bacteria such as C. burnetii [16]: In-vitro studies show that TNFα 
mediates interferon-gamma-induced intracellular killing of C. burnetii in monocytes 
through apoptosis [17], while neutralizing TNFα in-vitro decreases C. burnetii 
 internalization in monocytes of Q fever endocarditis patients [18], and TNFα 
knock-out mice infected with C. burnetii develop early bacteraemia and severe 
heart lesions [19]. On the other hand, overproduction of TNFα by blood mononuclear 
cells of acute Q fever patients with valvulopathy is associated with development of 
chronic Q fever [20], and monocytes of Q fever endocarditis patients produce more 
TNFα than cells from cured patients or immunologically naive individuals.
Anti-TNFα therapy increases the risk of infections with intracellular bacteria such 
as mycobacterium tuberculosis [21,22]. Clinical data on the risk of C. burnetii 
infection in patients on anti-TNFα therapy are lacking. In view of the widespread 
use of TNFα-blockers in patients with rheumatoid arthritis (RA) or other 
inflammatory conditions, and the severe consequences of chronic Q fever, we 
decided to perform a controlled study to examine whether RA patients on 
anti-TNFα therapy are at increased risk of chronic Q fever. The regional Q fever 
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outbreak situation in the Netherlands served as a unique opportunity to perform 
such a study.
Methods
Patient enrollment
RA patients were selected from the rheumatology outpatient clinic of the Jeroen 
Bosch Hospital in ’s- Hertogenbosch, the Radboud University Nijmegen Medical 
Centre and the Sint Maartenskliniek in Nijmegen. All three hospitals are located in 
or near the Q fever epidemic area. The study was approved by the local medical 
ethics review committee in Nijmegen. All patients lived in the Q fever epidemic 
area at the time of inclusion according to postal code [23].
 Two cohorts were selected; The first cohort (anti-TNFα treated group) consisted 
of patients using TNFα-blockers, including adalimumab, etanercept and infliximab, 
for at least three months during the Q fever outbreak (between January 1st 2007 
and January 1st 2010). The second cohort (anti-TNFα naive controls) consisted of 
patients who did not use any of these TNFα-blockers or other biological disease 
modifying anti-rheumatic drugs (biological DMARDs) in this time frame nor 
thereafter.
 Exclusion criteria for both cohorts were age under 18 years, current pregnancy, 
lactation, lymphoproliferative disease and haematologic malignancies, chronic 
infections with HIV, hepatitis B or C, active mycobacterial disease and legal 
incapability.
 Medication details and medical history were retrieved from patients’ records 
and collected in an additional questionnaire.
Q fever diagnostics and disease definitions
From all participating patients, blood samples were obtained between December 
2011 and June 2012. Serum was screened for IgG against both C. burnetii antigenic 
phases, phase I and II, by means of immunofluorescence assay (IFA; Focus 
Diagnostics, Cypress, CA, USA), using a cutoff titre of ≥1:32. If screening was above 
this cutoff, exact titres of IgG and IgM antibodies against C. burnetii phase I and II 
were determined. In case of a phase I IgG ≥1:512, PCR for C. burnetii DNA was 
performed on plasma. Subjects were classified as seropositives when C. burnetii 
IgG antibodies were ≥1:32. All seropositive individuals were followed-up three to 
six monthly in the year after the initial screening by their rheumatologist or an 
infectious disease specialist. The end of the study-period was defined as one year 
after the last inclusion. Seropositive individuals with suspected chronic Q fever 
underwent further medical assessment including imaging, i.e. echocardiography 
and whole body positron emission tomography-computed tomography (PET-CT). 
201
Q FEVER IN RHEUMATOID ARTHRITIS PATIENTS
10
Chronic Q fever was diagnosed or excluded by a team of medical specialists, who 
were guided by the Dutch consensus on chronic Q fever diagnostics [24]. Chronic 
Q fever was considered as proven if PCR was positive, or if phase I IgG was ≥1:1024 
and endocardial involvement, large vessel or prosthetic infection was confirmed 
by imaging. All other chronic Q fever cases were classified as probable, since all 
had at least one stated risk factor, e.g. immunocompromised status. Past acute C. 
burnetii infection was defined by seropositivity at enrollment without the diagnosis 
of chronic Q fever during one year follow-up.
To prevent information bias, the cause of death was retrieved from the medical 
records of patients that had deceased after January 1st 2007 but before study 
enrollment, and possible relation of death to Q fever was determined. Patients with 
a known chronic Q fever infection who died of acute aneurysms or acute heart 
failure, were identified to have a cause of death ‘related to Q fever’. Patients who 
died of acute aneurysm, complications of vascular prosthesis, endocarditis or 
acute heart failure, but did not have a known chronic Q fever infection, were 
identified as patients with a cause of death ‘possibly related to Q fever’.
Statistical analyses
Clinical and microbiological data for all subjects were collected and analyzed in an 
SPSS database (version 18.0). For comparison of the baseline characteristics, data 
were expressed as mean values or percentages. Mean values were compared using 
independent samples t-test. Percentages were compared using Fisher’s exact test. 
The proportion seropositive patients and chronic Q fever patients was compared 
between both groups and the relative risk (RR) with 95% confidence intervals (95% 
CI) were calculated. In an univariate analysis of all seropositive patients, we aimed 
to identify other possible risk factors for chronic Q fever. Multivariate analysis 
could not be performed, due to the low number of cases. In all analyses, P<0.05 was 
considered significant.
Results
Study population
A total of 1319 RA patients were found eligible for inclusion in this study. Of the 
1319 selected patients, 86 had died before study enrollment but after January 1st 
2007. The cause of death of 56 of these patients could be retrieved from the medical 
records; none was rated related to Q fever, only four were possibly related.
 The 1233 remaining living patients were invited for microbiological screening. 
The response rate was 759/1233 (62%). Of the included subjects, 361 used TNFα- 
blockers for at least three months during the Q fever outbreak, while 398 were 
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anti-TNFα naive. Table 1 shows the baseline characteristics of the two cohorts. The 
cohort on anti-TNFα therapy during the epidemic was younger, and used significantly 
more often corticosteroids during the epidemic and currently (P<0.0001).
Diagnosis of Q fever in the anti-TNFα cohort and the anti-TNFα 
naive cohort
In total, 112/759 (14.8%) patients were seropositive: 57/361 (15.8%) in the anti-TNFα 
cohort and 55/398 (13.8%) in the anti-TNFα naive cohort, which was not significantly 
different (P=0.47). Three selected patients (two in the anti-TNFα therapy cohort 
and one in the anti-TNFα naive cohort) were already diagnosed with chronic Q 
fever before enrollment in this study.
 Overall, 10/112 (8.9%) seropositive patients were diagnosed with chronic Q fever: 
seven in the anti- TNFα group and three in the anti-TNFα naive group (see Table 2 
for details). Thus, 12.3% (7/57) of the seropositive RA patients using anti-TNFα had 
progressed into chronic Q fever after contact with C. burnetii, and 5.5% (3/55) of the 
anti-TNF naive patients (RR 2.25; 95% CI 0.61–8.27, P=0.32). Three of the ten patients 
had known pre-existing valvular and/or vascular risk factors for chronic Q fever, 
while the others had none. All were offered transesophageal echocardiogram 
(TEE); three patients refused TEE, yet underwent transthoracic echocardiogram 
(TTE). Two had echocardiographic signs of endocarditis. Two showed abnormalities 
on PET-CT, which revealed increased uptake in aortic valve in one and increased 
uptake in pleural effusion in another. Two patients treated for chronic Q fever had 
IgG titres against phase I below the threshold of 1:1024, one of whom had a positive 
Coxiella PCR in pleural effusion. The other was diagnosed with probable chronic 
Q fever based on fatigue and newly diagnosed abnormalities of the aortic valve 
on TEE. Blood cultures were negative. Although chronic C. burnetii infection could 
not be confirmed by PCR on blood (and no cardiac valve tissue was available, since 
cardiac surgery was not performed sofar), longterm antibiotic treatment for chronic 
Q fever was started in this patient.
Serological follow-up of seropositives
In the remaining 102 seropositive patients, no chronic Q fever was diagnosed in 
the follow-up period of one year. Upon screening, all of them had IgG against 
phase II antibodies. The serologic screening results are shown separately for the 
anti-TNFα cohort and the anti-TNFα naive cohort in table 3. The geometric mean 
titres of IgG against phase I and phase II were not significantly different between 
both groups (P=0.28 and P=0.061 respectively).
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Table 1   Baseline characteristics of all included patients.
Anti-TNF 
group  
n = 361 (%)
Anti-TNF 
naive group
n = 398 (%)
p-value
Mean age ± SDa 59.9 (±11.0) 62.1 (±12.2) 0.01
Male sex 109 (30.2) 128 (32.2) 0.58
Valvulopathy/prosthetic valve 14 (2.2) 19 (4.8) 0.60
Vascular aneurysm or prosthesis 4 (1.1) 8 (2.0) 0.39
Ischaemic heart disease 43 (11.9) 53 (13.3) 0.59
Peripheral vascular disease 7 (1.9) 15 (3.8) 0.19
Cerebral vascular disease 17 (4.7) 25 (6.3) 0.43
Dyslipidaemia 65 (18.0) 86 (21.6) 0.24
Hypertension 110 (30.5) 139 (35.0) 0.22
Diabetes mellitusb 27 (7.5) 45 (11.3) 0.08
Pregnancy (between 2007-2010)c 5 (1.4) 3 (0.8) 0.49
Malignancyd 8 (2.2) 14 (3.5) 0.39
Renal insufficiencye 19 (5.3) 26 (6.5) 0.54
Use of TNF-α blocker during epidemicf 361 (100) - n/a
Use of etanercept during epidemic 194 (53.6) - n/a
Use of adalimumab during epidemic 148 (40.9) - n/a
Use of infliximab during epidemic 70 (19.3) - n/a
Months of TNF-α blocker use (mean ±SD)g 26.0 (±11.6) - n/a
Use of DMARDh during epidemic 283 (78.2) 397 (100.0) n/a
Use of methotrexate during epidemic 225 (62.3) 297 (74.6) n/a
Months of DMARD use (mean ±SD) 24.4 (±15.2) 30.7 (±9.5) n/a
Use of corticosteroids during epidemic 103 (28.5) 63 (15.8) 0.000
Months of corticosteroid use (mean ±SD) 7.3 (±13.2) 3.2 (±9.1) 0.000
Use of DMARD or/and corticosteroids during 
epidemic
307 (85.0) 397 (100.0) n/a
Use of other biological during epidemic 29 (8.0) - n/a
Current use of TNF-α blocker 256 (70.9) - n/a
Current use of DMARD 248 (68.7) 366 (92.0) n/a
Current use of corticosteroids 81 (22.4) 40 (10.1) 0.000
Current use of other biologicali 61 (16.9) - n/a
SD, standard deviation; n/a, not applicable; DMARD, disease modifying anti-rheumatic drug
a  Age at November 1st 2011.
b  Diabetes mellitus (DM) is defined as DM type 1 or DM type 2.
c  Pregnant patients did not receive anti-TNF treatment during pregnancy.
d  Patients with a malignancy diagnosed after January 1st 2007, patients that were treated after January 1st 
2007 for malignancy or with metastatic disease. Basocellular carcinoma are not included because of 
diminutive clinical impact. There were no patients with haematological malignancies included in this 
study.
e  Renal insufficiency is defined as a GFR <60/min.
f  Epidemic is defined as the outbreak between January 1st
 2007 and January 1st 2010 in the Netherlands.
g  During the epidemic as defined; maximum of 36 months.
h  Use of DMARD: not including use of corticosteroids.
i  Other biologicals were golimumab, certolizumab, abatacept, anakinra, rituximab, tocilizumab.
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Univariate analysis of risk factors for chronic Q fever
To identify risk factors other than anti-TNFα treatment for development of chronic 
Q fever in RA, univariate analysis was performed, comparing the ten chronic Q 
fever cases with the 102 patients with past C. burnetii infection. Clinical data, 
anti-rheumatic medication use during Q fever epidemic, and known risk factors 
for chronic Q fever are listed for both groups in table 4. The RA patients with 
chronic Q fever were significantly older than those who did not develop chronic Q 
fever (P=0.02) and, as expected, had significantly more often pre-existing vascular 
or valvular risk factors for chronic Q fever (P=0.05). Moreover, corticosteroid use 
Table 2   Results of microbiological analysis and clinical assessment at initial 
screening and 2-4 months of follow-up of 10 patients diagnosed  
with probable or proven chronic Q fever.
Initial results Results after  
2-4 mo follow- up
Sex Cohort IgG titre 
against 
phase I
IgG titre 
against  
phase II
PCR
in blood
Valvular or vascular risk 
factors for chronic Q fevera
Anti-rheumatic 
medicationb
Clinical  
assessmentc
Antibiotic 
treatment
IgG titre 
against 
phase I
IgG titre 
against 
phase II
PCR
1 Male Anti-TNF 1:4096 1:4096 - Aortic valve stenosis, 
abdominal aortic aneurysm
Etanercept, methotrexate, 
hydroxychloroquine, 
prednisone
Endocarditis yes 1:1024 1:512 -
2 Female Anti-TNF 1:8192 1:8192 + Mitral valve repair Adalimumab, infliximab, 
prednisone
Endocarditis yes 1:4096 1:4096 +
3 Male Anti-TNF 1:16384 1:16384 - None Infliximab, sulfasalazine, 
prednisone
Focus unclear yes 1:8192 1:8192 -
4 Female Anti-TNF 1:1024 1:1024 - None Etanercept Focus unclear no 1:1024 1:1024 -
5 Male Anti-TNF 1:1024 1:4096 - None Etanercept, methotrexate, 
leflunomide, prednisone
Focus unclear yes 1:2048 1:2048 -
6 Female Anti-TNF 1:1024 1:2048 - None Adalimumab, methotrexate Focus unclear no 1:256 1:4096 -
7 Female Anti-TNF 1:256 1:512 - None Adalimumab, sulfasalazine Endocarditis yes 1:512 1:1024 -
8 Male TNF-naive 1:512 1:512 - None Methotrexate, sulfasalazine PCR+ pleural 
effusion
yes 1:512 1:512 -
9 Male TNF-naive 1:2048 1:1024 - Vascular prosthesis 
abdominal aorta
Methotrexate, prednisone Vascular prosthesis 
infection
yesd 1:2048 1:1024 -
10 male TNF-naive 1:2048 1:2048 - None Methotrexate, prednisone Focus unclear no 1:1024 1:1024 -
PCR, polymerase-chain reaction; TNF, tumor necrosis factor alpha. a valvulopathy, valvular prosthesis, 
aneurysms, vascular prosthesis. b during epidemic, at least 3 months. c based on anamnesis, physical 
examination and imaging (echocardiogram and whole body positron emission tomography-computed 
tomography). d in addition to surgical repair of endoleak vascular prosthesis.
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during the epidemic was identified as a predisposing factor for development of 
chronic Q fever (P=0.02), as well as its duration of use ( P=0.002). The use of metho -
-trexate, any DMARD or any biological DMARD (other than infliximab, adalimumab 
or etanercept) were not found to be a significant predisposing riskfactor.
Table 2   Results of microbiological analysis and clinical assessment at initial 
screening and 2-4 months of follow-up of 10 patients diagnosed  
with probable or proven chronic Q fever.
Initial results Results after  
2-4 mo follow- up
Sex Cohort IgG titre 
against 
phase I
IgG titre 
against  
phase II
PCR
in blood
Valvular or vascular risk 
factors for chronic Q fevera
Anti-rheumatic 
medicationb
Clinical  
assessmentc
Antibiotic 
treatment
IgG titre 
against 
phase I
IgG titre 
against 
phase II
PCR
1 Male Anti-TNF 1:4096 1:4096 - Aortic valve stenosis, 
abdominal aortic aneurysm
Etanercept, methotrexate, 
hydroxychloroquine, 
prednisone
Endocarditis yes 1:1024 1:512 -
2 Female Anti-TNF 1:8192 1:8192 + Mitral valve repair Adalimumab, infliximab, 
prednisone
Endocarditis yes 1:4096 1:4096 +
3 Male Anti-TNF 1:16384 1:16384 - None Infliximab, sulfasalazine, 
prednisone
Focus unclear yes 1:8192 1:8192 -
4 Female Anti-TNF 1:1024 1:1024 - None Etanercept Focus unclear no 1:1024 1:1024 -
5 Male Anti-TNF 1:1024 1:4096 - None Etanercept, methotrexate, 
leflunomide, prednisone
Focus unclear yes 1:2048 1:2048 -
6 Female Anti-TNF 1:1024 1:2048 - None Adalimumab, methotrexate Focus unclear no 1:256 1:4096 -
7 Female Anti-TNF 1:256 1:512 - None Adalimumab, sulfasalazine Endocarditis yes 1:512 1:1024 -
8 Male TNF-naive 1:512 1:512 - None Methotrexate, sulfasalazine PCR+ pleural 
effusion
yes 1:512 1:512 -
9 Male TNF-naive 1:2048 1:1024 - Vascular prosthesis 
abdominal aorta
Methotrexate, prednisone Vascular prosthesis 
infection
yesd 1:2048 1:1024 -
10 male TNF-naive 1:2048 1:2048 - None Methotrexate, prednisone Focus unclear no 1:1024 1:1024 -
PCR, polymerase-chain reaction; TNF, tumor necrosis factor alpha. a valvulopathy, valvular prosthesis, 
aneurysms, vascular prosthesis. b during epidemic, at least 3 months. c based on anamnesis, physical 
examination and imaging (echocardiogram and whole body positron emission tomography-computed 
tomography). d in addition to surgical repair of endoleak vascular prosthesis.
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Discussion
To our knowledge, this is the first systematic study on the risk on chronic Q fever 
in a clearly defined immunocompromised patient group living in an epidemic 
area. We found a prevalence of Q fever seropositivity in RA patients of 14.8%, 
approximately the same as the 12.2% previously reported for the general population 
living in the same area.[25] Despite this, the overall prevalence of chronic Q fever 
among seropositive RA patients was 8.9%, which is higher than what is described 
by others in an unselected population (1-5%). These figures suggest that RA 
patients may not be more susceptible for initial Q fever infection, but may be more 
prone for the development of chronic Q fever. However, in RA patients on 
anti-TNFα therapy, no significant additional risk for chronic Q fever was found 
(RR 2.25; 95% CI 0.61–8.27, P=0.32). In this respect, we were unable to show that 
anti-TNFα therapy increases the risk for progression to chronic Q fever.
An important finding of this study was a prevalence of chronic Q fever of 8.9% 
among C. burnetii seropositive RA patients, which is relatively high. Since we did 
Table 3   Titres of IgG against phase I and II C. burnetii in anti-C. burnetii 
 antibody-positive RA patients without development of chronic  Q fever; 
either with or without anti-TNF treatment during the Q fever 
epidemic.
Anti-TNF treated  
RA patients (n=50)
TNF-naive  
RA patients (n=52)
IgG against 
phase I
IgG against 
phase II
IgG against 
phase I
IgG against 
phase II
Negative 22 (44.0) 0 (0.0) 26 (50.0) 0 (0.0)
1:32 6 (12.0) 3 (6.0) 9 (17.3) 13 (25.0)
1:64 10 (20.0) 10 (20.0) 7 (13.5) 7 (13.5)
1:128 5 (10.0) 13 (26.0) 7 (13.5) 10 (19.2)
1:256 7 (14.0) 10 (20.0) 3 (5.8) 14 (26.9)
1:512 0 (0.0) 8 (16.0) 0 (0.0) 4 (7.7)
1:1024 0 (0.0) 4 (8.0) 0 (0.0) 4 (7.7)
1:2048 0 (0.0) 2 (4.0) 0 (0.0) 0 (0.0)
≥1:4096 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
RA, rheumatoid arthritis; TNF, tumor necrosis factor alpha. No. (%) of patients is indicated.
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not include a control cohort without RA and immunosuppressive medication in 
our study, the interpretation must be done cautiously. A previous study conducted 
in 2010 in 686 unselected individuals with an acute Q fever episode in 2007-2008, 
Table 4   Univariate analysis of risk factors for development of chronic Q fever 
in all Q fever seropositive RA patients.
Chronic 
Q fever 
infection  
n =10 (%)
Past Q fever 
infection
n = 102 (%)
p-value
Mean age ± SD (yr) 66.3 ± 8.5 58.3 ± 10.6 0.02
Male Sex 6 (60) 47 (46.1) 0.51
Vascular aneurysm/prosthesis or 
valvulopathy/prosthetic valvea
3 (30) 7 (6.9) 0.05
Current use of TNF-α blocker 4 (40) 40 (39.2) 1.00
TNF-α blocker during epidemicb 7 (70) 50 (49.0) 0.32
TNF-α blocker use > 1 year during epidemic 5 (50) 41 (40.2) 0.74
Months of TNF-α blocker use (mean ±SD)c 16.6 (±15.7) 12.5 (±15.1) 0.41
Current use of corticosteroids 3 (30) 13 (12.7) 0.15
Corticosteroids during epidemic 6 (60) 23 (22.5) 0.02
Corticosteroid use > 1 year during epidemic 4 (40) 15 (14.7) 0.06
Months of corticosteroid use (mean ±SD) 15.8 (±17.6) 4.3 (±9.9) 0.002
Current use of DMARDd 8 (80) 87 (85.3) 0.65
DMARD during epidemic 8 (80) 95 (93.1) 0.18
Methotrexate during epidemic 6 (60) 75 (73.5) 0.46
DMARD use > 1 year during epidemic 8 (80) 84 (82.4) 1.00
Methotrexate use > 1 year 6 (60) 67 (65.7) 0.74
Months of DMARD use (mean ±SD) 27.5 (±15.1) 27.5 (±12.3) 0.99
Months of methotrexate use (mean ±SD) 20.3 (±17.9) 21.6 (±15.7) 0.81
Current use of other biologicale 1 (10) 5 (4.9) 0.44
Other biological during epidemic 0 (0) 5 (4.9) 1.00
RA, rheumatoid arthritis; DMARD, disease modifying anti-rheumatic drug; SD, standard deviation
a  Known risk factors for progression to chronic Q fever infection.
b  Epidemic is defined as the outbreak between 1-1-2007  and 1-1- 2010 in the Netherlands.
c  During epidemic as defined; maximum of 36 months.
d  Use of DMARD does not include use of corticosteroids.
e  Other biologicals were golimumab, certolizumab, abatacept, anakinra, rituximab, tocilizumab.
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living in the same area as our RA patients, showed a prevalence of chronic Q fever 
of 1.6% [26]. Considering this population to be a historic control cohort, the 
prevalence of chronic Q fever in our  RA population is significantly higher ((RR 
5.57; 95% CI 2.42–12.81, P=0.0002).
Although we found an increased risk for the development of chronic Q fever in the 
anti-TNFα treated group compared to the anti-TNFα naive group (12.3 vs 5.5%), 
this difference was not significant, mainly due to the low number of identified 
cases, which could have resulted in a type II error.
 However, in univariate analysis, we found higher age and valvular/vascular 
defects or prosthesis to be risk factors for chronic Q fever, as described previously 
in a Dutch cohort of chronic Q fever patients [8], and the use of corticosteroids 
during the epidemic. Interestingly, the anti-TNFα group used significantly more 
often corticosteroids, which could partly explain the increased risk we found 
among anti-TNFα users. The finding of corticosteroids as a predisposing factor for 
chronic Q fever, could not be confirmed in multivariate analysis, because of the 
low number of chronic Q fever cases.
We expect to have detected most, if not all, of the chronic Q fever cases with our 
screening and follow-up strategy. The Q fever epidemics in the Netherlands subsided 
abruptly in 2010 after several veterinary interventions, and new infections after 
2010 were extremely rare.[27] Our screening was performed 2-3 years after the peak of 
the Q fever epidemic and patients found to be seropositive at the start of the study 
were followed up for one year during which none progressed to chronic Q fever.
 Even so, 75% of individuals who develop chronic Q fever after an acute Q fever 
episode, are diagnosed within one year [28]. Thus it is not to be expected that 
patients would develop chronic Q fever after the follow-up period.
We used the measurement of antibodies to detect Q fever. It should, however, be 
mentioned that in general immunosuppressive medication and immune-mediated 
diseases interfere with serologic responses, and antibody titres may be lower than 
in healthy individuals.[29] Influenza virus vaccination in anti-TNFα treated 
patients result in somewhat lower post-vaccination titres as compared to a control 
group on non-biological DMARDs [30,31]. Studies on pneumococcal polysaccharide 
vaccination, on the other hand, do not describe a negative impact of anti-TNFα use 
on vaccination outcomes [32]. Likewise, in our study, we did not find a significant 
difference in the level of anti-C. burnetii antibody titres between the seropositives 
in the anti-TNFα treated group and the anti-TNFα naive group. Therefore we 
assume that screening for antibodies is an appropriate tool to identify exposure to 
C. burnetii in our study groups, in spite of the background disease and medication.
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Of note, the screening identified one case with proven and one case with probable 
chronic Q fever, with maximum phase I IgG titres of 1:512, just below the cutoff of 
1:1024 [24]. The first patient used methotrexate and sulfasalazine during the Q 
fever epidemic and presented with a C. burnetii DNA positive pleural effusion. The 
second used adalimumab and sulfasalazine during the epidemic and was 
suspected for having Q fever endocarditis based on symptoms, elevated serum 
C-reactive protein and abnormalities on TEE. A recent publication showed that 
4/57 patients with Q fever endocarditis, confirmed by C. burnetii PCR of 
cardiovascular surgical samples, had phase I IgG antibody titres ≤1:800 [33], but 
the authors do not mention the immune status of these four individuals. Moreover, 
in a Dutch cohort of chronic Q fever patients, 3/93 PCR-positive patients had a 
phase I IgG titre of 1:512 at diagnosis, one of whom used immunosuppressive 
agents [34]. All in all, this emphasizes that an absolute cutoff for phase I IgG 
antibody titres should not be handled to rigid, when other clues for infection are 
present. Elevated phase I IgG titres below the cutoff 1:1024 do not rule out the 
possibility of chronic Q fever in immunocompromised patients.
Interestingly, of the ten chronic Q fever RA patients identified in this study, only 
three patients had pre-existing vascular or valvular defects as risk factor for 
development of chronic Q fever. In fact, two of them were already diagnosed with 
chronic Q fever at inclusion while participating in a screening program of 
individuals with pre-existing cardiac valve abnormalities [6] and vascular defects. 
The finding that 70% of the patients with chronic Q fever had no pre-existing 
vascular or valvular defects, stresses the importance of immunodeficiency in the 
risk of developing chronic C. burnetii infection [12].
With regard to the pathophysiology of chronic C. burnetii infection, it remains 
unclear whether immunosuppression at the moment of exposure leads to direct 
progression to chronic infection or if starting immunosuppression leads to 
reactivation of a latent infection. The latter has been shown in guinea pigs, that 
experienced reactivation after recovery of previous C. burnetii infection caused by 
cortisone injections [35]. In tuberculosis both pathophysiological pathways are 
described, with active tuberculosis after start of anti-TNFα treatment interpreted 
as reactivation of latent infection, and tuberculosis longer after start of anti-TNF 
treatment interpreted as a new infection, sometimes immediately progressing to 
active disseminated disease [36]. In our study, the anti-TNFα cohort used 
TNFα-blockers with a mean duration of 26 months during the 3-year epidemic, 
and the anti-TNFα naive cohort used DMARDs with a mean duration of 31 months 
during the epidemic. This suggests that the majority of the initial C. burnetii 
infections coincided with the use of immunosuppressives.
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In conclusion, our data suggests that RA patients are at increased risk for 
development of chronic Q fever. Therefore, careful evaluation for chronic Q fever 
is warranted after C. burnetii exposure in these patients. Since corticosteroid use 
during the outbreak was found in univariate analysis to be a specific risk factor for 
development of chronic Q fever, special attention should be paid to RA patients 
using corticosteroids. Anti-TNFα therapy, however, was not identified as an 
important risk factor for development of chronic Q fever.
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Abstract
Background: Q fever is caused by the intracellular bacterium Coxiella burnetii. 
Initial infection can present as acute Q fever, while a minority of infected 
individuals develops chronic Q fever endocarditis or vascular infection months 
to years after initial infection. Serology is an important diagnostic tool for both 
acute and chronic Q fever. However, since immunosuppressive drugs may hamper 
the humoral immune response, diagnosis of Q fever might be blurred when these 
drugs are used.
Case presentation: A 71-year-old Caucasian male was diagnosed with symptomatic 
acute Q fever (based on positive C. burnetii PCR followed by seroconversion) while 
using anti-tumor necrosis factor-α (anti-TNFα) drugs for rheumatoid arthritis 
(RA). He was treated for two weeks with moxifloxacin. After 24 months of 
follow-up, the diagnosis of probable chronic Q fever was established based on 
increasing anti-C. burnetii phase I IgG antibody titres in a immunocompromised 
patient combined with clinical suspicion of endocarditis. At the time of chronic 
Q fever diagnosis, he had been treated with anti B-cell therapy for 16 months. 
Antibiotic therapy consisting of 1.5 years doxycycline and hydroxychloroquine 
was started and successfully completed and no signs of relapse were seen after 
more than one year of follow-up.
Conclusion: The use of anti-TNFα agents for RA in the acute phase of Q fever did 
not hamper the C. burnetii-specific serological response as measured by immuno-
fluorescence assay. However, in the presented case, an intact humoral response did 
not prevent progression to probable chronic C. burnetii infection, most likely 
because essential cellular immune responses were suppressed during the acute 
phase of the infection. Despite the start of anti-B-cell therapy with rituximab after 
the acute Q fever episode, an increase in anti-C. burnetii phase I IgG antibodies was 
observed, supporting the notion that C. burnetii specific CD20-negative memory 
B-cells are responsible for this rise in antibody titres.
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Background
Q fever is caused by the intracellular growing bacterium Coxiella burnetii [1]. Acute 
Q fever is a (self-limiting) febrile illness, but can present as pneumonia or hepatitis. 
Chronic Q fever presents most often as an endovascular infection, i.e. endocarditis 
or mycotic aneurysm or infected vascular graft, which has a high mortality if left 
untreated [2,3]. Risk factors are underlying valvular defects, or pre-existing vascular 
aneurysm or   prosthesis.
 Immunosuppression is another stated risk factor for chronic Q fever, as some 
immuno suppressive drugs decrease protective cellular responses against intracellular 
growing bacteria. This risk factor has thus  far  been poorly documented, but recently 
we confirmed that patients with rheumatoid arthritis (RA) using immunosuppressive 
drugs are indeed at increased risk of developing chronic Q fever [4].
 Clinical signs of C. burnetii infection are often nonspecific, and the diagnosis 
of acute or chronic Q fever is heavily based on measurement of antibody titres [5,6], 
complemented by the direct detection of the micro-organism by polymerase chain 
reaction (PCR) [7,8]. Serologic criteria for Q fever consist of measurement of 
antibodies against the two antigenic forms of C. burnetii, phase I and II organisms, 
with high anti-C. burnetii  phase I IgG titres - in the absence of acute Q fever – 
pointing to a chronic infection. The appropriate cut-off titre that differentiates it 
from a past cleared infection is debated; currently proposed cut-offs are 1:1,024 or 
1:1,600 [6,9].
 The diagnosis of Q fever in hosts on immunosuppressive drugs may be 
complicated, because these drugs can inhibit antibody responses and therefore 
hamper correct diagnosis based on serologic results. Also the immunemediated 
disease itself, for which these drugs are prescribed, may contribute to inadequate 
immune responses to infection [10,11].
 Here we present a case history of a patient with  RA who had an episode of 
acute Q fever while being treated with anti-tumor necrosis factor-α (anti-TNFα) 
medication, and who developed probable chronic Q fever over the subsequent two 
years while using the anti-B-cell monoclonal antibody rituximab. The case high - 
lights the importance of cellular and humoral immune response modifying agents 
in the natural course of C. burnetii infections and the possible pitfalls of the use of 
serological methods to detect the stage of disease.
Case presentation
Acute Q fever
In May 2009, during the Dutch Q fever epidemic, a 71-years-old rheumatoid factor 
and anti-CCP positive RA patient living in the Q fever high incidence area, presented 
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with 8 days of fever and a non-productive cough. He was receiving anti-rheumatic 
treatment including etanercept (an anti-tumor necrosis factor-α [anti-TNFα] agent) and 
prednisone. He had a history of atrial fibrillation, but no underlying valvulopathy. 
Physical examination and a chest X-ray were compatible with a pulmonary infiltrate. 
No murmurs were heard upon cardiac auscultation. Laboratory  investigations 
revealed  increased  C-reactive protein (CRP, 285 mg/L), a normal leukocyte count 
(5.2×109/L) and normal values for renal function  and liver enzymes. PCR (real-time 
PCR targeting the IS1111a insertion element [12]) for C. burnetii on plasma turned 
out to be positive. However, serology (immunofluorescence assay [IFA, Focus 
Diagnostics, Cypress, USA]) was negative for IgM as well as for IgG against phase 
I and II Coxiella burnetii. The diagnosis of acute Q fever was made and treatment 
with moxifloxacin 400 mg daily for 14 days was started. Two weeks later, 
seroconversion was observed with anti-phase I and II IgM titres of 1:4096 and 
1:16384 respectively.
Diagnosis and treatment of probable chronic Q  fever
After quick recovery, the patient was followed-up to monitor for possible progression 
to chronic Q fever. During this period, the anti-rheumatic treatment had been 
switched by the rheumatologist from etanercept to adalimumab (another  anti-TNFα 
agent), and subsequently – 8 months after the acute Q fever episode – to rituximab. 
The latter, an anti-CD20 anti B-cell monoclonal antibody, had resulted in adequate 
suppression of the rheumatic activity.
 As can be seen in Figure 1, anti-phase I IgG antibodies titres had not decreased 
below 1:1024 after more than one year, and continued to increase to 1:4096 at 24 
months, suggesting development of chronic Q fever. At that moment, the patient 
had complaints of general fatigue but no fever, night-sweats or cardiac problems. 
On physical examination, however, a grade 2/6 aortic systolic murmur was audible. 
Transesophageal echocardiography (TEE) showed no signs of endocarditis, but an 
echogenic mitral annulus and a trace of mitral valve insufficiency. Laboratory 
investigation showed an ESR 40 mm/hr with CRP < 2 mg/L. PCR for C. burnetii in 
plasma was repeatedly negative. Abdominal ultrasound did not reveal an aortic 
aneurysm. Positron-emission tomography (PET)-scanning showed hilar lymph-
adenopathy but no other abnormalties. Endobronchial biopsy of the hilar lymph 
nodes was PCR negative for C. burnetii and showed no signs of malignancy. Because 
of the increasing anti-phase I IgG titres in this immunocompromised patient, in 
combination with nonspecific complaints and the new cardiac murmur, the 
diagnosis of ‘probable chronic Q fever’ was made [13] and the patient was started 
on doxycycline 200 mg daily combined with hydroxychloroquine 200 mg three 
times daily for 1.5 years. Intermittent courses with rituximab were continued as 
anti-rheumatic treatment, in combination with azathioprine. During antibiotic 
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treatment, the antiphase I IgG titres decreased from 1:8192 to 1:1024. The patient 
experienced improvement from his fatigue. After 1.5 years treatment, PET-scanning 
and TEE were unchanged. After discontinuation of antibiotics, the serological and 
clinical follow-up was pursued and is still continuing, with no relapse after more 
than one year.
Discussion
We report on an immunocompromised patient, followed-up from the start of a 
symptomatic acute Q fever episode to the development and treatment of probable 
chronic Q fever. Our case illustrates three interesting aspects of diagnosis and 
treatment of Q fever in an  immunocompromised host. First, we noticed that, 
despite the presence of RA and use of anti-TNFα agents, the humoral response to 
the initial C. burnetii infection was not impaired. Secondly, in spite of adequate 
treatment, the acute Q fever progressed to  probable chronic Q fever endocarditis, 
Figure 1. Q fever serology during follow-up after acute Q fever in a patient with anti- 
rheumatic drugs. Serological titres of anti-Coxiella burnetii phase I and phase II IgG (as measured 
by immunofluorescence assay) during follow-up after acute Q fever (t = 0) of a patient using 
subsequently etanercept, adalimumab and rituximab as biological disease-modifying anti- 
rheumatic drugs. Rituximab was given with 7 months intervals, each time two dosages with 
two weeks interval. At t = 24 the diagnosis probable chronic Q fever was established followed 
by anti-microbial treatment with doxycycline and hydroxychloroquine for 1.5 years.
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which suggests incomplete clearance of the infection during the acute stage. 
Finally, the increase in phase I IgG titres, which serves as a marker for chronic Q 
fever, occurred under treatment with anti B-cell immunotherapy which was 
started after the acute Q fever episode.
 In the presented case, a definite diagnosis of chronic Q fever could not be 
made. C. burnetii DNA was not detected in blood on several occasions and  echo-
cardiography did not show major signs of endocarditis. Nevertheless, chronic Q 
fever was clinically highly suspected. The patient was followed-up after acute Q 
fever, and we observed that the antibody titres were falling after they had peaked 
following the acute Q fever episode, only to rise again after 18 months. This 
increase in antibody titres was accompanied by aspecific complaints of fatigue and 
a newly diagnosed cardiac murmur. According to the Dutch guidelines, this was a 
diagnosis of probable chronic Q fever [13], and the patient received antibiotic 
treatment as considered  appropriate.
 Interestingly, we observed a normal antibody response in the acute phase of 
the Q fever infection under anti-TNFα therapy. This is in line with previous studies 
which have shown that anti-TNFα therapy does not prevent serologic responses to 
influenza vaccination [14,15], although titres may be somewhat lower. Clearly, in 
our case, this normal antibody response did not prevent the development of 
persistent C. burnetii infection, as complete clearance might depend more on 
cellular immune responses.
 Indeed, to constrain intracellular C. burnetii  infections, a cellular immune 
response is crucial and TNFα is a key cytokine in this response. In-vitro studies 
showed that TNFα mediates interferon-gamma induced intracellular killing of 
C. burnetii in monocytes  through  apoptosis [16]. TNF knock-out mice infected 
with C. burnetii develop early bactaeremia and severe heart lesions [17]. Infection 
risk due to decreased cellular immunity in anti-TNFα treated patients, has been 
shown for other intracellular infections, most notably Mycobacterium tuberculosis, 
but also Listeria monocytogenes and Salmonella enterica, and for herpesviridae [18-21].
 Rituximab, an anti-CD20 monoclonal antibody, is used for the treatment of RA 
patients failing on  TNFα blockers. Rituximab depletes circulating CD20-positive 
B-cells for a period of six to nine months [22]. As a consequence, patients on 
rituximab therapy have an impaired antibody response to neo-antigens. Existing 
plasma cells and memory B-cells, which do not express CD20, are not affected by 
rituximab [23]. During the development from acute to chronic Q fever, there is  an 
ongoing infection with presumably increasing concentrations of C. burnetii 
antigens. Because plasma cells do not express B-cell receptors at their surface, 
which makes them incapable to respond to alterations in antigen concentrations, 
we assume that the rise of anti-C. burnetii IgG titres in our patient originated from 
stimulation of memory IgG B-cells by increased concentrations of recall antigens. 
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This intact response to recall antigens after rituximab has been observed for 
patients receiving vaccinations [24], but has never been documented after natural 
infection.
 Our results indicate that anti-C. burnetii phase I IgG antibody titres can be 
used as a marker for progression to chronic Q fever and the subsequent  response 
to therapy in patients in whom B-cell depleting therapy is started after initial 
exposure. However, it is likely that B-cell depleting medication during first contact 
with neo-antigens of C. burnetii will seriously hamper the development of an 
antibody response and  the  diagnosis of Q fever based on serological   titres.
Conclusions
The use of anti-TNFα agents for RA in the acute phase of Q fever does not seem to 
impede the C. burnetii-specific serological response. However, in the  presented 
case, an intact humoral response did not prevent progression to probable chronic 
C. burnetii infection, most likely because essential cellular immune responses were 
suppressed in the acute phase of the infection. Even though anti-B-cell therapy 
with rituximab was started after the acute Q fever episode, an increase in anti-C. 
burnetii phase I antibodies was observed, supporting the notion that C. burnetii 
specific CD20-negative memory B-cells are responsible for this rise in antibody 
titres.
Consent
Written informed consent was obtained  from  the  patient for publication of this 
Case report.
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Abstract
Background: Following a large Q fever outbreak in the Netherlands, patients at 
risk for chronic Q fever received a whole-cell Q fever vaccine. Sensitized people 
were excluded based on pre-vaccination screening with skin test (ST) and serology. 
An investigational IFN-γ-production assay was added. No previous experience 
existed for Q fever vaccination in this patient risk-group with predefined cardiac 
valvular anomalies or aortic aneurysm/prosthesis and many co-morbidities. We 
studied the adverse events (AE) and their association with patient characteristics 
and immunological parameters.
Methods: AE registration covered the week after skin test and 90 days following 
vaccination, with the use of diaries, interviews and spontaneous reports. Serious 
(S)AE were assessed immediately to ensure safety. We coded AE according to 
reported severity. Univariate and multivariate analysis addressed associations.
Results: Pre-vaccination screening led to exclusion of 182 patients with positive 
serology and 207 patients with positive skin test-reading. The skin test did not lead 
to any causally related SAE. Subsequent vaccination of 1370 patients did not reveal 
unexpected AE; however, 80% of vaccinees reported local AE (in 26% of these 
pronounced or extensive). The two causally related SAE (0.1%) both concerned a 
persistent subcutaneous injection site mass. AE were more frequent in women, 
younger patients, and those without immunosuppressive co-morbidity/medication. 
The occurrence of local AE after skin test was associated with pre-vaccination 
positive serology and high IFN-γ production. This was also true for local AE 
following vaccination, with a strong association with local AE after skin test as 
well. The proportion of vaccinees with positive serology and positive IFN-γ values 
6 months after vaccination was higher in those with local AE after skin test or after 
vaccination (non-significant, probably due to small  numbers).
Conclusion: Q fever vaccination was safe but reactogenic in this high-risk patient- 
group. Rates of local AE were higher in women, younger age groups and in those 
with positive immunological parameters. Vaccinees with local AE after skin test 
or after vaccination appear to have more pronounced post-vaccination immune 
responses.
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Introduction
Human acute Q fever infection, caused by Coxiella burnetii, is asymptomatic in over 
50% of cases. In symptomatic cases, clinical presentation ranges from self-limiting 
febrile illness to pneumonia or hepatitis for which prompt treatment with 
antibiotics shortens duration [1,2]. Chronic Q fever develops in about 5% of patients, 
often resulting in endocarditis and vascular infection [3]. In contrast to acute 
infection, chronic Q fever has high lethality if untreated. Long-term antibiotic 
therapy, and often surgical intervention, are necessary [4].
 In spring 2007, an attentive rural family general practitioner (GP) noticed 
several cases of atypical community-acquired pneumonia in young adults [5,6]. 
This proved to be one of the first signals of the largest Q fever outbreak ever [7]. 
Nearby goat farms were the sources of human infections. Retrospectively, this 
livestock epidemic started in 2005, following years of intensive goat farming [8]. 
From 2007 to 2011, 4107 acute Q fever patients were reported, with peak incidence 
in 2009. Numbers of infected people are estimated to have been ten times as high 
[9]. Numbers of chronic Q fever increased thereafter, amounting to over 200 cases 
identified until 2011 with a 13% lethality [10,11]. From 2009 onwards, consecutive 
measures to curtail the livestock epidemic included mandatory vaccination and 
culling of carrying animals on infected farms [8]. Some preventive measures, like 
avoiding human proximity to infected farms, were not feasible due to the dense 
population.
 Several risk-groups for chronic Q fever have been identified, notably those 
with structural cardiac (valvular) anomalies, prosthetic valves or aortic aneurysms/
prostheses [12,13]. The value of antibiotic prophylaxis after initial infection for the 
prevention of chronic Q fever in these patients has been debated [14,15]. An effective 
Q fever vaccine is registered in Australia, where – mostly healthy young – people 
at occupational risk are vaccinated [16].
 In 2010, the Netherlands Health Council (HC) advised to vaccinate specific 
chronic Q fever risk-groups, focusing on the high-incidence area in south-eastern 
Netherlands [17]. A vaccination campaign was conducted between January and 
April 2011, with some catch-up vaccinations in June [18]. A centralized approach to 
screening and vaccination was chosen as the vaccine was not registered in the 
Netherlands and experience with this vaccine and the required skin test in this 
specific patient-group was lacking. Pre-vaccination screening was considered 
essential because previous C. burnetii infection is assumed to increase the risk of 
adverse events (AE) to this whole-cell vaccine [19]. If outcomes of serology or skin 
test were positive, no vaccination was given [20]. The skin test, however, by 
intradermal deposition of killed bacterial suspension, may provoke a local reaction. 
AE following skin test and vaccination were monitored intensively, with follow-up 
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for 90 days. An investigational whole-blood interferon-gamma (IFN-γ) production 
assay, measuring cell-mediated immunity in vitro, was added to the screening 
[21,22]. While its outcome was irrelevant for the decision to vaccinate, it gave an 
opportunity to analyze AE in vaccinees with possibly  pre-existing  cell-mediated 
immunity.
 This article describes vaccinees’ characteristics, pre-vaccination screening 
outcomes, and reported AE after skin test and after vaccination in this  specific 
patient-group.  We  also  analyzed the association between local AE after skin test 
or vaccination, patient characteristics and pre- and post-vaccination immunological 
parameters [23].
Patients and methods
Target population
Q fever vaccination targeted specific risk conditions, based on the HC advice, with 
defined exclusion criteria (Box 1). Efforts to reach target populations were most 
intensive in the high-incidence area. GPs identified and referred patients [18].
Screening and vaccination
Intake and screening took place at a municipal health centre in the high-incidence 
area, where eligible patients came for screening and subsequent vaccination.
Serology
Antibodies against C. burnetii (IgG against phase 1 and phase 2) were measured in 
1:32 serum dilution, as described [21]. If positive, exact IgG and IgM titres were 
determined. Seropositive patients were informed and ST-reading was cancelled. 
GPs received the results, with interpretation and advice for referral if indicated. 
Weak IgG signals at 1:32 – ‘equivocal’ and possibly false positive – did not result in 
exclusion. Available six months’ post-vaccination samples were measured in the 
same way [22].
Skin test
Trained professionals injected 0.1 mL diluted homologous skin test antigen intra -
dermally in the forearm, as instructed (Q-vax® skin test, CSL, Victoria, Australia) 
[19]. Skin test (ST)-reading at day 7 included measurement – in millimetres – of 
redness, swelling and induration. Any induration or swelling with substantial 
redness – considered positive – led to exclusion. Minimal swelling or local redness 
alone did not preclude vaccination.
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Box 1   Inclusion and exclusion conditions for Q fever vaccination, and coding 
criteria for adverse events following Q fever skin test and vaccination
Inclusion conditions:
1- history of bacterial endocarditis, other infections of the heart excluded
2- heart valve disease or prosthesis, regardless of type
3- aortic aneurysm or prosthesis, carotid stents excluded
4-  congenital heart anomalies, including coarctatio aortae, excluding spontaneous 
closure of VSD and ductus arteriosus Botalli
Exclusion conditions:
1-  age under 15 yrs., pregnancy, incapacity to fulfil requirements, too late referral, 
severe immunodeficiency
2-  history of Q fever infection, positive skin-test or serology, hypersensitivity for 
vaccine components
Coding criteria adverse events:
a- local redness, swelling Vaccination: Skintest:
  1- < 2.5 cm, mild 1 - < 5 mm
  2- 2.5 - < 7.5 cm, moderate  2 - 5 - < 10 mm
  3- 7.5 - < 15cm, pronounced  3 - 10 - < 15 mm
  4- ≥ 15 cm, extensive  4 - ≥ 15 mm
b- local pain  1- pain to the touch, no obstruction of use
  2-  pain on movement, some interference with normal activity
  3- considerable pain in rest, obstruction of use
c- fever  1- 37.5 - < 38.5°C, mild
  2- 38.5 - < 39.5°C, moderate
  3- 39.5 - < 40.5°C, high
  4- ≥ 40.5°C, extreme
d-  other systemic events  1-  easy to endure, minimal discomfort, no impediment
 fatigue, headache,   2- hindrance and some interference with normal activity
 chills, gastrointestinal, 3- considerable impediment of normal functioning,  
 symptoms, muscle  need for treatment 
 pain, joint pain, etc.
e- duration  1- start and resolve within 3 days after vaccination, early  
  2-  start within 3 days and resolve within 6 days after 
vaccination, long
  3- start and resolve day 4-6 after vaccination, late
  4- continuation after day 6, extended
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C. burnetii IFN-γ production-assay
In vitro IFN-γ production after C. burnetii stimulation, measured in a whole-blood 
assay [21], was expressed as continuous variable with cut-off at 32 pg/mL, based on 
previous findings [21]. Outcome did not affect the decision to vaccinate. Available 
post-vaccination samples were measured likewise [22].
Vaccination
After negative skin test and serology, vaccination with Q-vax® vaccine (CSL, Victoria, 
Australia) was performed subcutaneously in the upper arm. This whole-cell vaccine 
contains formaldehyde-inactivated phase 1 Henzerling strain (25 µg/dose) and 
thiomersal (0.01% w/v) [19].
Reporting and registration of adverse events
Safety surveillance, covering the week after skin test and 90 days post-vaccination, 
used diaries, interviews and spontaneous reports. Screened patients should bring 
the diary with registered AE to ST-reading or, in case of cancellation (mostly 
related to positive serology), return it by mail. Vaccinees received two additional 
diaries. The first, for day 0–28 post-vaccination, asked for detailed descriptions of 
local and systemic AE in the first week, with measurements and experienced 
severity. Open questions covered the consecutive three weeks. The second diary 
(month 2–3 post-vaccination), asked questions about illness, medication and 
doctor’s visits, and was returned after 90 days.
 Three telephone interviews, after day 7–28–90 respectively, focused on AE, 
hospital visits and medication, with reminders to return the diaries. Additionally, 
patients and GPs were advised to report AE. Serious AE (SAE) [24] required 
expedited reporting to the Health Care Inspectorate, the National Institute for 
Public Health and Environment and the Netherlands Pharmacovigilance Centre- 
Lareb, and were immediately assessed in order to enhance the safety of the 
campaign.
Data analysis
All AE data were entered in a database including indication, comorbidities, 
medication, and screening/vaccination details. We coded local and systemic AE 
according to severity, based on the highest scores for size and pain combined (local 
AE) or on the highest reported grade (systemic AE) (Box 1) [25–27]. We assessed the 
association with patients’ characteristics, pre-vaccination/post-vaccination test 
outcomes. We used Excel and OpenEpi [28] to compute graphs and to perform 
statistical analysis. 95% confidence intervals (CI) for proportions and their 
differences were calculated and Odds ratios (OR) with CI. Multivariate logistic 
regression in R was used to calculate adjusted OR [29].
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Results
Description of the population
In total, 1786 patients (out of 2741 referred) were screened (1118 male; 63%) [18]. 
Their median age was 67 (range 14–92), similar for both sexes, with 1231 (69%) 
patients being 60 years and over (male 72%, female 64%). Fig. 1 shows the age 
distribution of the population and its sub-groups in more detail. Reported Q fever 
risk-conditions were valvular disease (1273; 73%), aortic aneurysm/prosthesis (375; 
22%), congenital cardiac anomalies  (148;  8%)  and  prior  endocarditis  (56;  3%), 
including multiple risk conditions (109; 6%). For 43 (2%) the risk condition remained 
unclear. Possible immunosuppression included patients on systemic corticoste-
roids (45; 2.5%), other immune-modulating drugs (40; 2.2%), with diabetes (198; 
11%) and/or current cancer (13; 0.7%). Vitamin K-antagonist medication (665; 39%) 
indicated increased bleeding risk.
Pre-vaccination screening
Screening led to exclusion of 389 patients (22%) for positive serology (182) or 
positive ST-reading (207). Another 27 (1.5%) were excluded for other reasons, viz. 
(perceived) contra-indications, benefit-risk imbalance or intercurrent illness. More 
men than women had positive screening-tests (25% vs 17%; OR 1.6, CI 1.3–2.1). All 
together 1370 patients received vaccinations; five of whom despite positive serology, 
due to miscommunication.
Adverse events following skin test
In total, 1602 (90%) patients supplied information on their experiences in the week 
following skin test, with higher response for women than for men (93% vs 88%). 
The response-rate was 97% in vaccinees (1323), and 67% (279) in non-vaccinees, due 
to cancellation of ST-reading because of positive serology or illness. Vaccinees and 
non-vaccinees reported local reactions to skin test (ST-locAE) in 39% and 50%, with 
grade 3–4 AE in 22% and 29%, respectively. Women had higher rates of AE after 
skin test than men (Table 1). Most of these ST-locAE were early with short duration 
(63%; 71% in vaccinees, 33% in non-vaccinees). Not surprisingly, late or prolonged 
local reactions correlated with positive ST-reading (data not shown). Systemic AE 
after skin test (ST-systAE) were reported in 21% and 22% of vaccinees and 
non-vaccinees, with grade 3–4 in 2.2% and 2.6% respectively. ST-systAE were 
mostly non-specific, age-related and/or (aggravated) preexisting complaints. Fever 
was reported by 3.8%, distributed randomly over the week after skin test. All eight 
reported SAE, in seven patients, were considered unrelated to the skin test.
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Figure 1. The age distribution of the population with its sub-groups. Age distribution of (A) 
the screened patients, according to underlying risk conditions; (B) available pre-vaccination 
blood samples, returned skin test diary, immunosuppressive conditions (including diabetes, 
malignancy, systemic corticosteroids or other immunosuppressive drugs), anticoagulants 
and available post-vaccination follow-up samples 6 months after vaccination; (C) the screened 
and vaccinated patients, and returned vaccination diary, separately shown for male and 
female sex.
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Adverse events following vaccination
Seventy-one percent (970) of the 1370 vaccinees returned diaries, with again higher 
response-rates for women (74% vs 68%). Based on diary information, local reactions 
after vaccination (VaclocAE) occurred in 80% (775), of which 21% (208) grade 3–4. 
Overall, 11% lasted beyond day 6 with mild intensity. Systemic AE after vaccination 
(Vac-systAE) occurred in 43% (419), including 5.5% (53) grade 3–4. Vaccinees 
reported fever in 9% (91), all mild/moderate. Women had higher rates of AE than 
men (88% vs 78%; OR 2.2, CI 1.5–3.1), also for the more severe events (Table 1, 
Fig. 2a). Younger age groups had higher reporting rates than older, for both sexes 
(Fig. 2b). Immunosuppression showed an inverse relation with VaclocAE, 
irrespective sex or age group (Fig. 2c). Vaccinees reported bruising at the injection 
site in 12% (107; male 7%, female 18%) with 10 reporting grade 3–4, irrespective of 
anti coagulants.
 The 400 vaccinees who did not return diaries reported fewer AE, with any 
Vac-locAE in 31% (71) and any Vac-systAE in 17% (39) (grade 3–4 14% (32) and 2.7% 
(6), respectively). These data came from telephone interviews (available for 99.2%), 
spontaneous reports and follow-up.
 The five patients who were vaccinated despite positive serology, did not have 
prominent AE; two of them reported no AE at all, the other three only moderate 
Vac-locAE.
 Altogether, 104 SAE (in 89 vaccinees) were reported, with two considered 
possibly related. Both were atypical late and prolonged lumpy local reactions. In 
one, symptoms resolved about 2.5 years after vaccination. In the other, a dimple 
still exists. Needle aspiration and ultrasound excluded abscesses. In either case, 
too deep deposition of the vaccine above the tendon insertion area of the Musculus 
deltoideus may have contributed. The 102 non-related SAE were pre-planned or 
elective hospital interventions for pre-existing conditions, intercurrent infections 
and exacerbations of underlying disease or comorbidity.
Association between local AE and pre-vaccination or post-
vaccination immunological parameters
ST-locAE and Vac-locAE were tested for association with immunological 
parameters separately in univariate analysis. We compared proportions and 
calculated OR (Table 2). Since local AE were associated with sex, age and immuno-
suppression, we performed multivariate analysis as well.
 ST-locAE was associated with pre-vaccination positive serology and high 
IFN-γ values and with positive ST-reading at day 7. For vaccination, positive skin 
test or serology were exclusion criteria; hence association of these positive outcomes 
and Vac-locAE could not be tested. However, the IFN-γ assay did not influence the 
decision to vaccinate. Therefore, association with Vac-locAE could be analyzed for 
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Figure 2. Reported local and systemic AE after skin test and after vaccination, according to 
sex, age and immunosuppression. (A) Proportion of local and systemic AE after skin test and 
vaccination according to sex, and graded for severity, with 95% CI. Grade 3–4 after skin test 
include local AE > 10 mm, while grade 3–4 after vaccination include local AE > 7.5 cm (see 
also Box 1). Fever after vaccination is shown separately; (B) proportion of local and systemic 
AEFI according to age-group and sex; (C) proportion of local AEFI in immunosuppressed 
patients (including diabetes, malignancy, systemic corticosteroids or other immunosuppres-
sive drugs) according to sex and age-group, with 95% CI. Younger male, age < 70 years and 
younger female, age < 60 years.
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all values. Proportions of Vac-locAE increased with higher values of IFN-γ production, 
but OR were non-significant. ST-locAE was strongly associated with Vac-locAE 
(point estimates of adjusted OR ranging from 5.1 to 11.7).
 Association between Local AE and post-vaccination immunological parameters, 
i.e. serology and IFN-γ production were tested univariately as well (Table 3). 
For both these immunological parameters, OR suggested association with Vac- 
locAE, but results were statistically non-significant, possibly because of small 
numbers. In multivariate analysis adjusted for sex, age, immunosuppression and pre- 
vaccination immunological parameters, OR roughly confirmed these associations.
Discussion
This unprecedented Q fever vaccination campaign, in the after-math of the Q fever 
outbreak in the Netherlands, targeted a group with defined high-risk conditions 
for chronic Q fever. The need for pre-vaccination screening and the non-licensed 
vaccine in Europe were the main reasons for choosing a centralized approach. The 
much higher than expected referral rate affected implementation. The lack of 
prevalence data for risk conditions precluded also coverage estimation (manuscript 
in preparation). Compared with previous Australian target-groups, (i.e. healthy 
abattoir workers [30]) our target population involved more women, older age- 
groups, and many co-morbidities/medications. Included risk-groups for vaccination 
fit the recently described risk factors for chronic Q fever in the Netherlands: 
valvular surgery (OR 43.6), aneurysm (OR 25.9) and vascular prosthesis (OR 26.8) 
[13]. Pregnant women, also considered at risk for chronic Q fever [31–33], were 
excluded in this vaccination-campaign because of safety concerns.
 The campaign aimed at individual protection through vaccination of patients 
at high risk for chronic Q fever and was not designed as a study. This resulted in 
several weaknesses in data collection and reports, like limited validation/supple-
mentation of comorbidities and medication, and cancellation of ST-reading when 
serology turned out to be positive. The strength of this study, however, is the high 
response-rate for diaries after skin test and vaccination, and a follow-up of 99.2%. 
This means that any safety signal should have been picked-up. In addition, we 
could study the association between AE, patient characteristics and immunological 
parameters, inclusive of the incorporated IFN-γ production assay.
 ST, measuring cell-mediated immunity, is the primary screening test (interna-
tionally) and is complemented by serology, reflecting humoral immunity [20,34]. 
The discordance of positive skin test and absence of antibodies (207; 12%) confirms 
previous observations [35]. Skin test did not lead to any ST-related SAE. The 3.8% 
with reported fever may reflect the background rate. Although skin test aims to 
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provoke late local reactions in sensitized people, it may result also in early 
inflammatory redness, swelling, pain or bruising, not representing T-cell mediated 
responses. Vaccinees reported ST-locAE in 39%, which were mostly early, mild/
moderate [<10 mm], and short-lived. This illustrates remittance of early ST-locAE, 
resulting in negative ST-reading at day 7. This seven-day timeframe of ST-reading 
(as directed [20]) appears based on a study showing 58 people ST-positive after 7–9 
days, of whom only 43 after 2 days. In 30 others with previous Q fever infection, all 
were ST-positive after 7–9 days, but only 19 after 2 days [36]. Interestingly, our data 
show that self-reported ST-locAE within one week strongly predicted occurrence 
of Vac-locAE, without, however, severe persistent Vac-locAE or systemic hypersen-
sitivity. This association may reflect individual tendency for hyperreaction rather 
than immunological hypersensitivity.
 Intensified surveillance after vaccination revealed no unexpected AE, although 
higher AE rates than previously published [16,20,30]. Rates, however, are not easily 
comparable as studies differ in target population and design of surveillance [27]. 
Here, proportions of reported AE were consistently higher in women than in men, 
both for milder and more pronounced AE. Few publications about AE differentiate 
between sexes and age [37–39]. Yet, we have noted such differences in several 
vaccination programmes for adults and children, depending on age and type of 
event [40]. Here, in addition to sex, age influenced the occurrence of AE after 
vaccination, as did immunosuppression by medication or illness.
 The vaccinees with returned diaries had high reporting-rates for Vac-locAE 
(80%), but the 29% vaccinees without diaries had much lower rates (31%) This is not 
surprising since having AE is an incentive to return the diary. Therefore, these 
rates reflect worst-case and best-case estimates. The average (71%) may be the more 
realistic rate.
 Fever was a relatively rare symptom (9%), with temperatures only moderately 
elevated. This may be because elderly people tend to respond less with high 
temperature to vaccinations or infections [41]. The pre-vaccination IFN-γ 
production, as measured in the whole-blood assay, showed a positive association 
with Vac-locAE, but the observed differences did not reach statistic significance. 
The value of this observation is difficult to interpret, since patients that had any 
other positive parameter of pre-existing immunity (positive serology or ST) were 
not vaccinated (except in five cases of miscommunication, as mentioned before). 
Positive IFN-γ values were overrepresented in non-vaccinees; therefore, the found 
associations are more likely to be underestimated than overestimated. Missing 
values for immunosuppression and for ST-locAE were differential as well, overrep-
resented in the non-vaccinees, who had higher proportions of positive antibody 
titres and of ST-locAE. This may have introduced a bias, with underestimation of 
found associations.
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 We previously published limited immune responses in this old-age group 
with much co-morbidity, with as many as 23% negative serology and IFN-γ values 
after six months [21]. However, despite limited serological responses to vaccination, 
Australian studies have shown high protection in occupationally exposed people 
[30,42–44]. Our data suggest that local AE after skin test and/or vaccination were 
associated with post-vaccination immune responses. Either the local reaction 
stimulates the immune response, or it is a (early) side effect in the process of 
adaptive immune responses itself.
 The safety of Q fever vaccination has been subject of discussion, with severe 
“hypersensitivity” reaction being a major issue [17]. This is assumed to occur after 
vaccination in previously sensitized individuals, hence the stringent pre-vaccina-
tion screening regimen [34,45]. With time, concerns seem to have increased, 
without additional support by reliable data. A recent report on passive surveillance 
of the Australian national Q fever vaccination campaign 2001–2004, showed a very 
low number of reported AEFI (86 AEFI in 48,986 vaccinees; 0.002%). These included 
mostly local reactions, with only one SAE [16].
 Whether pre-vaccination screening has prevented many serious AEFI in the 
Dutch campaign remains an unanswered question, as positive skin test or serology 
were exclusion criteria for vaccination. It may be argued, however, that the 
stringent screening possibly withheld protection from those with low-grade 
reactivity or low titres. Whether the prominent role of serology has contributed to 
justified exclusion, is debatable.
 Of note, only 33.3% (11/33) of the vaccinees with pre-vaccination high IFN-γ 
production, reflecting pre-existing cell-mediated immunity, experienced pronounced 
or extensive local (transient) AE, but anaphylaxis did not occur. The five people 
erroneously vaccinated, all with positive serology and in two borderline ST-reading 
as well, did not have prominent AE. Pre-vaccination equivocal serology was not 
significantly associated with local AE but, interestingly, showed significant and 
strong association with higher post-vaccination serological response. Overall, only 
two reported so-called SAE, with atypical lumpy local reactions, were considered 
causally related, with no suggestion of abscess or granuloma as previously described 
[19,26,46,47]. These two patients had negative serology, negative ST-reading, did 
not report late or extended ST-locAE, and one had negative IFN-γ (for the other no 
sample was available).
 Thus, we conclude that this Q fever vaccination campaign has been safe, with 
a large proportion of vaccinees reporting local injection site reactions after 
vaccination (80%). These local reactions, however, were mostly non-severe and of 
limited duration. We stress the merit of differentiating according to sex, age and 
other covariates in reporting of AEFI. We dispute the base for the stringent requirement 
of pre-vaccination testing, which needs further evaluation in experimental setup. 
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Pre-vaccination screening, which is current practice, hampers appropriate and/or 
efficient use of the vaccine. Development of an effective and less reactogenic 
vaccine could make pre-vaccination screening unnecessary at all.
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Abstract 
Objectives: In the Netherlands, people at risk for chronic Q fever were vaccinated 
against Coxiella burnetii with the inactivated whole cell vaccine Q-vax. We aimed to 
measure the immune responses to C. burnetii six and twelve months after vaccination 
in this relevant population.
Methods: In 260 vaccinees, antibody responses were assessed by immunofluorescence 
assay (IFA), complement fixation test and ELISA. The cellular immune responses 
were assessed by measuring C. burnetii-specific interferon (IFN)-γ production in 
blood. Serological results of 200 individuals with past Q fever were used for 
comparison.
Results: At six months, 46% of vaccinees showed low IFA antibody titres and 67% 
had a positive IFN-γ assay; At twelve months, both were 60%. In contrast, individuals 
with a past Q fever were seropositive in 99.5% at six and twelve months, with relatively 
higher IFA titres. Interestingly, vaccinees with positive IFN-γ assay pre-vaccination, 
showed a higher seroconversion rate than IFN-γ negative vaccinees: 74% vs. 41% 
(p < 0.001).
Conclusions: The immune response after Q-vax vaccination is lower and restricted 
to a smaller proportion than found after past Q fever and than previously described 
after vaccination, suggesting decreased vaccine immunogenicity in this high-risk 
population. A positive IFN-γ assay before vaccination in seronegative vaccinees 
likely points to pre-existing immunity resulting in boosting by vaccination.
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Introduction
Q fever is a zoonosis caused by the intracellular bacterium Coxiella burnetii, which 
has its main reservoir in sheep, goat and cattle.[1] Q fever is endemic in some 
areas,[2] but may also occur in outbreaks.[3-5] Between 2007 and 2010, the Netherlands 
faced the largest Q fever outbreak ever reported,[6] with an estimate of more than 
40,000 infected individuals [7] and more than 4000 notified human cases of acute 
Q fever. Infection may remain asymptomatic or non-specific.[8] If symptoms occur, 
acute Q fever, presenting with fever, pneumonia or hepatitis, rarely causes severe 
disease.[9] However, months till years after first contact, 1-5% of the infected 
individuals may develop chronic infection, mostly endocarditis or vascular wall 
infection,[1] for which longterm antibiotic treatment and often surgery is needed. 
If left untreated, chronic Q fever has a mortality rate as high as 60%.[10] Factors that 
predispose to chronic Q fever are pre-existent valvular or vascular disease,[1] 
conditions that are mainly met in older frail people often suffering from comorbidity. 
In 2009, measures were taken to prevent new human cases, a.o. mandatory vaccination 
of dairy goats and sheep and culling of non-immunized pregnant goats and sheep 
on C. burnetii positive farms. In 2010, it was not clear if these veterinary measures 
were effective enough. Therefore, human vaccination was considered, since that 
may prevent Q fever infection.[11,12] In June 2010, the Dutch health authorities 
decided to offer vaccination to all individuals at risk for chronic Q fever living in 
the area of the epidemic.
 The only Q fever vaccine currently available for human use is Q-vax (CSL 
Biotherapies, Victoria, Australia) an inactivated whole cell vaccine licensed in 
Australia, which contains the phase I Henzerling strain.[13] Vaccination is routinely 
performed in Australian workers who are occupationally exposed to C. burnetii.[14] 
As was shown by various studies, vaccination in these mainly young male 
employees induces humoral and cellular immune responses[15,16] and protects 
against infection.[17,18] However, no data are available on the immune response to 
Q-vax in older adults at risk for chronic Q fever.
 In the present study, we report the antibody responses to Q-vax, as measured 
by various techniques, as well as the in vitro C. burnetii-induced interferon (IFN)-γ 
production at 6 and 12 months after vaccination in 260 vaccinated elderly individuals 
with risk factors for chronic Q fever.
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Material and Methods
Setting
The Dutch Q fever vaccination campaign took place in the spring of 2011 in the 
Municipal Health Service in ’s Hertogenbosch.[19] All vaccine candidates were 
screened one week before vaccination by serology using an immunofluorescence 
assay (Focus Diagnostics, Cypress, USA) and skin testing (Q-vax® Skin Test, CSL 
Biotherapies, Victoria, Australia)[13] according to the manufacturer’s instruction
and as previously described.[20] Simultaneously, an IFN-γ production  assay  was 
performed  to  assess  in  vitro  cell-mediated immunity to C. burnetii.[21] The 
outcome of this test did not affect the decision to vaccinate. Those individuals with 
negative outcome in serology and skin tests were vaccinated. One dose of Q-vax® 
vaccine (lot # 0980-07501) was administered subcutaneously in the upper arm 
according to the product information.[13] Following measures in the veterinary 
sector, the epidemic subsided after 2010. Therefore, in the year after vaccination 
exposure to C. burnetii was unlikely.
Subject enrollment
Following the vaccination campaign, in which 1368 individuals were vaccinated,[20] 
260 vaccinees were included in the study. After obtaining written informed 
consent, blood for microbiological screening was collected approximately 6 and 12 
months after vaccination. Information about morbidity and medication was 
collected in a questionnaire. Control sera were retrieved from a cohort of 371 
anonymous individuals, enrolled in a follow-up study after a natural acute Q fever 
infection in 2009 in the Jeroen Bosch Hospital in ’s-Hertogenbosch. Sera taken 6–7 
months and 12–13 months after natural infection were eligible. From these, the 200 
oldest individuals were evaluated since they matched the vaccinees as close as 
possible. The study was approved by the Central Committee on Research on 
Human Subjects (CCMO).
Microbiological screening
Antibody response measurements 
Serum samples of the vaccinees were aliquoted and tested for anti-C. burnetii phase 
I and phase II antibodies with three methods available for serological screening: 
immunofluorescence assay (IFA), complement fixation test (CFT) and enzyme-linked 
immunosorbent assay (ELISA). Control sera were tested with IFA only.
 A commercially available IFA kit (Focus Diagnostics, Cypress, USA) was used 
according to the manufacturer’s instructions. The assay measures IgM and IgG 
against C. burnetii Nine Mile phase I and II antigens. Seropositivity is described for 
antibody classes separately and overall as any anti-C. burnetii titre ≥1:32.
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 CFT (Virion/Serion, Würzburg, Germany) was performed, according to the 
manufacturer’s instructions, to measure phase II antibodies. After the procedure 
steps, a ready-to-use hemolytic system (Virion/Serion) was used. Dilutions with 
≤50% of hemolysis were defined as positive. A positive result was defined as 
having an endpoint dilution of at least 1:10.
 With ELISA (Virion/Serion), IgG against phase I and II antigens and IgM 
against phase II were measured. IgG phase I and IgM phase II were positive when 
the absorbance was more than 10% above the extinction of the cut-off control. 
Ambiguous results were added to negative  results.
Interferon-gamma  production measurement
Heparinized whole blood was aliquoted into 0.5 ml in separate tubes and incubated 
24 h at 37 oC with C. burnetii antigens (heat-inactivated C. burnetii Nine Mile RSA 
493 phase I, [107 bacteria/mL]), nil or PHA as previously described.[21] IFN-γ was 
measured by ELISA (Pelikine compact, Sanquin, Amsterdam, The Netherlands). 
Net IFN-γ production was expressed as the concentration of IFN-γ in the C. burnetii 
stimulated sample minus that in the negative control sample. The assay was considered 
positive when net IFN-γ production was ≥32 pg/ mL, based on previous findings.[21]
Statistics
Proportions of positive results were calculated and compared among different 
tests using McNemar test. Reciprocal antibody titres were used for comparison. 
Geometric mean antibody titres were calculated and compared using a student 
t-test. A titre <1:32 was assigned 1:16 for calculations. Quantitative IFN-γ production 
(pg/mL) was expressed as mean (±standard error [SE]) per group. Agreement 
between detection of antibody response and IFN-γ response was assessed and the 
kappa (κ) statistic measure was calculated. The proportional Venn diagram was 
drawn using the online DrawVenn application.[22] Logistic regression was used to 
assess the association between absent immune response and the main risk factors 
for  immunosuppression.
Results
Subjects’ characteristics
A total of 260 vaccinees were studied, with a mean age (±standard deviation (SD)) 
of 65.1 (±9.3) years. 66.2% of the vaccinees were male. All had negative serological 
and skin test outcome in pre-vaccination screening. The IFN-γ assay prior to 
vaccination was negative in 197 (76.0%) vaccinees, positive in 42 (16.0%) and 
inconclusive in 21 (8.0%). Table 1 shows the characteristics of the study population 
and the subgroups based on pre-vaccination IFN-γ  production.
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 The mean (±SD) duration between vaccination and blood collection was 6.9 
(±0.6) and 11.8 (±0.4) months respectively. Fig. 1 shows the number of vaccinees 
with blood sampled at six and at twelve months after vaccination and the number 
of results available for serological and IFN-γ assays.
 The control group of 200 individuals with a past natural C. burnetii infection 
had a mean age (±SD) of 57.5 (±10.7) years; 61.5% was male. The serum samples for 
serological follow-up were obtained between 6-7 months and 12-13 months after 
the acute Q fever episode.
Antibody response after vaccination
Results of serological assays are shown in Table 2. At six months, results for all 
serological tests were available of 257 subjects, at twelve months of 227 individuals.
Among the three serological tests, measurement of  anti-C. burnetii IgG antibodies 
with IFA showed the highest proportion of seropositive individuals: at six months 
38.5% IgG against phase I and 34.2% against phase II, while at twelve months this 
was 51.5% and 33.5%, respectively. IgM antibodies were detected in only a small 
proportion. Considering any IgG/IgM IFA titre ≥1:32 as a positive outcome, the 
proportion seropositives was 45.9% at six and 59.9% at twelve months after 
vaccination. The other serological tests were positive in a significantly smaller 
number of subjects: CFT in 16.0% (p < 0.001) at six and 6.6% (p < 0.001) at twelve 
months, ELISA 24.1%  (p  <  0.001)  and 26.9% (p < 0.001), respectively.
 In the control group of 200 patients with a past natural infection, 99.5% showed 
anti-C. burnetii IgG antibodies in the IFA at both six and twelve months after 
infection. Comparison of the IFA IgG titres of the vaccinees and the naturally 
infected individuals showed significantly lower antibody titres for the vaccinees 
(Fig. 2). This was especially the case for IgG anti-phase II. Six months after 
vaccination, the geometric mean reciprocal titres of IgG anti-phase I and anti-phase II 
were 32.7 and 28.2, respectively, compared to 102.9 and 1999.0, six months after 
natural infection (p < 0.0001). Twelve months after vaccination, this was 38.2 and 
26.0 compared to 97.7 and 1531.0 (p < 0.0001), respectively.
IFN-γ production after vaccination
The IFN-γ production assay, measuring a cell-mediated immune response, provided 
positive results in 63% (161/255) of vaccinees at six and in 54% (122/227) at twelve 
months. However, the IFN-γ assay was inconclusive in 13 and 21 subjects at six and 
twelve months, respectively. When only taking into account the conclusive results 
of the IFN-γ test, the proportion positive results was 67% (161/242) at six and 60% 
(123/206) at twelve  months.
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Fig. 3a shows the results of the IFN-γ assay after vaccination stratified according to 
the results of the IFA in patients in whom both tests were performed. Overall, the 
IFN-γ assay showed poor agreement with IFA: Fifty-nine percent ([85+56]/240, 
κ=0.197) after six months and 59% ([80+40]/202, κ=0.155) after twelve months. Only 
35% of the vaccinees had both a detectable antibody and a cell-mediated immune 
response six months after vaccination and 40% twelve months after vaccination 
(Fig. 3b). Twenty-three percent (56/240) of the vaccinees had neither antibody nor 
IFN-γ immune response six months after vaccination, and twelve months after 
vaccination this was still 20%.
 After logistic regression analysis, we found that at six months the absence of a 
detectable IFN-γ response after vaccination was related to use of immunosuppressive 
Table 2   Serological assay and IFN-γ assay outcomes of vaccinated subjects  
6 and 12 months after vaccination
Assay 6 months after  
vaccination,  
No. (%) tested positive a
12 months after  
vaccination,  
No. (%) tested positive a
IFA total b 118 (45.9) 136 (59.9)
IFA, IgG phase I 99 (38.5) 117 (51.5)
IFA, IgG phase II 88 (34.2) 76 (33.5)
IFA, IgM phase I 26 (10.1) 25 (11.0)
IFA, IgM phase II 12 (4.7) 8 (3.5)
CFT, phase II 41 (16.0) 15 (6.6)
ELISA total b 62 (24.1) 61 (26.9)
ELISA IgG phase I 27 (10.5) 34 (15.0)
ELISA IgG phase II 29 (11.3) 35 (15.4)
ELISA IgM phase II 34 (13.2) 15 (6.6)
IFN-γ assay 161 (66.5) 122 (59.5)
Results of all serological assays were available of 257 subjects at six months and of 227 subjects at twelve 
months after vaccination. Results of IFN-γ assay were available of 255 subjects at six months and 227 
subjects at twelve months after vaccination, but only subjects with conclusive results were considered 
(242 and 205 subjects at six and twelve months, respectively).
Abbreviations: IFA, immunofluorescence assay; CFT, complement fixation test; ELISA, enzyme-linked 
immunosorbent assay; IFN-γ, interferon-gamma.
a  Positive is defined as IFA titre of  ≥ 1:32, CFT titre of ≥ 1:10, ELISA IgG phase II titre ≥ 30 U/l, ELISA 
IgG phase I and IgM phase II ≥ extinction, C. burnetii specific IFN-γ production > 32 pg/mL.
b  Either IgG or IgM, either phase I or phase II.
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drugs: the IFN-γ response was absent in 73% (8/11) of the individuals using immuno-
suppressive drugs as compared to 36% (86/242) in individuals not on these drugs 
(p = 0.02). The serological response as measured by IFA was also more frequently 
absent: 82% (9/11) in vaccinees using immunosuppressive drugs compared to 53% 
(129/242) in individuals not on these drugs, although this did not reach statistical 
significance (p = 0.08). Higher age (>75 years) was also associated with an absent 
IFN-γ response: 61% (20/33) in subjects over 75 years of age compared to 34% 
(74/220) in subjects 75 years or younger (p < 0.01). This was not observed for the 
antibody response: 61% (20/33) absent in the older subjects vs. 54% (118/220) in the 
Figure 2. IgG titres against C. burnetii phase I and II antigens in vaccinated subjects as 
compared to individuals with past natural acute Q fever. IgG titres as measured by immuno-
fluorescence (IFA). Percentage of individuals with respective IgG titre are shown for 
vaccinated (gray) and naturally infected individuals (white), six months (not-shaded) and 
twelve months (shaded) after vaccination or natural infection. (A) IgG antibodies against 
C. burnetii phase I, (B) IgG antibodies against C. burnetii phase II.
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younger subjects (p = 0.45). Neither diabetes mellitus nor malignancy had a 
significant effect on cellular or humoral immune response to Q-vax vaccination.
 Excluding the individuals taking immunosuppressive drugs, 22% percent 
(50/231) of the vaccinees had neither antibody nor IFN-γ immune response six 
months after vaccination, and twelve months after vaccination this was 18%.
Figure 3. Results of IFN-γ assay vs. results of IFA in vaccinees 6 and 12 months after 
vaccination. (A) Interferon-gamma (IFN-γ) assay was considered positive when net Coxiella 
burnetii-specific IFN-g production was ≥32 pg/mL. IFN-γ assay was considered inconclusive 
when IFN-γ production in the positive aliquot did not exceed 24 pg/mL in combination with 
absent C. burnetii-specific IFN-γ production. Immunofluorescence assay (IFA) was considered 
positive when anti-C. burnetii antibody titre (either IgG or IgM, either against phase I or II 
organism) was ≥1:32. Results of both the IFN-γ assay and IFA were available of 253 
individuals at 6 months after vaccination and of 223 individuals at 12 months after 
vaccination. (B) Venn-diagram showing overlap between positive results of IFN-γ assay and 
IFA at six and twelve months post-vaccination. Indeterminate results of IFN-γ assay are left 
unconsidered.
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Response to vaccination in subjects with or without pre-vaccination 
IFN-γ production
The 197 vaccinees with a negative IFN-γ assay pre-vaccination, did not significantly 
differ in terms of gender, age and comorbidity from the 42 vaccinees with a positive 
IFN-γ assay pre-vaccination (Table 1). However, as is shown in Table 3, the antibody 
and IFN-γ response after vaccination did differ between these two groups. A 
smaller proportion of vaccinees with a negative IFN-γ test pre-vaccination was 
seropositive at six and twelve months (41% and 57%) as compared to those with 
IFN-γ production pre-vaccination (74% and 83%; p < 0.001). The geometric mean 
reciprocal titre at six months was also significantly lower in the vaccinees with a 
negative IFN-γ test than in those with IFN-γ production pre-vaccination (28.8 vs. 
62.9 and 24.8 vs. 52.2 for IgG against phase I and II, respectively; p < 0.001). Moreover, 
the mean quantitative increase in C. burnetii-specific IFN-γ production from 
pre-vaccination baseline was significantly lower in the vaccinees without pre- 
vaccination IFN-γ production (97 ± 12 pg/mL at six months and 56 ± 6 pg/mL at 
twelve months) than in those with pre-vaccination IFN-γ production to C. burnetii 
(245 ± 114 pg/mL and 166 ± 79 pg/mL) (p < 0.05).
Discussion
In the present study, we showed that the humoral and cellular immune responses 
after Q fever vaccination (Q-vax) in older adults with risk factors for chronic 
Q fever is relatively modest: 46 and 60% had antibodies against C. burnetii, at six 
and twelve months after vaccination, respectively, while 67 and 60% had a positive 
IFN-γ assay at these time points. Overall, 23% of the vaccinees (57/242) did not 
show any immune response at six months, which was associated with the use of 
immunosuppressive drugs and advanced age. The serological titres achieved by 
vaccination are much lower than seen after a natural infection. Likewise, the mean 
IFN-γ production in vaccinees at six months (141 ± 21 pg/mL) was considerably 
lower than previously found in individuals with earlier natural Q fever infection 
(449 ± 82 pg/mL).[21]
 We evaluated three different serological techniques to measure the humoral 
immune response. IFA appeared to be the most sensitive method to detect specific 
antibodies after vaccination. This is in accordance with previous findings, 
suggesting that IFA should be used as the reference serological method for 
detecting natural infection.[23] Also in line with other studies,[16,24] is that 
vaccination is accompanied by emergence of antibodies against both phase I and 
phase II antigens. Although the vaccine is said to contain bacteria expressing phase 
I antigens, this is not surprising. Phase I cells also contain phase II antigens, as the 
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latter are an integral part of the normal phase I bacteria. Therefore, antibodies 
against both phases could be expected,  comparable  to  the  response  after  a 
natural infection (with phase I bacteria). The IgG response against phase II antigens 
seems more consistent over time than the IgG response against phase I antigens. 
The concordance between 6 and 12 months was 86% for IgG anti-phase II, and 77% 
for IgG anti-phase I (data not shown).
 We found a lower humoral and cellular response to Q-vax than previously 
published. The first studies from Australia in abattoir employees, farmers and 
veterinarians reported seroconversion in 65% of the individuals 10e120 days after 
vaccination.[24] Later studies, reviewing the experience from 1981 to 1988 with 
Q-vax in more than 4000 vaccinees, reported a seroconversion rate of 84% up to 3 
months after  vaccination.[16]  Similarly,  Izzo  et  al.  found in a much smaller sized 
study, a seroconversion rate of 80% after 2-4 weeks.[15] Whereas in this latter study 
the number of seropositive individuals declined with time after vaccination, the 
cell-mediated immune response (as measured  by a lymphoproliferation assay) 
remained positive in 95% of vaccinees.[15,16] A recent small sized study from the 
USA reported a positive IFN-γ production assay in 81% (13/16) and a positive 
serology in a similar proportion.[25]
 There are a number of explanations for the observed lower immune response 
in the present study. The higher long-lasting humoral response in Australian 
abattoir workers might be due to boosting by regular exposure to C. burnetii at the 
work site. Our study was performed after the acute Q fever outbreak had subsided, 
implicating that continuous exposure in the community was absent.[19] Probably 
of more importance, however, are the differences in the vaccinated populations. 
The Australian vaccinees were young and healthy abattoir workers, whereas our 
cohort was composed of elderly individuals with cardiovascular disease and other 
types of comorbidity. In fact,  the use of immunosuppressive drugs (4.2%) and an 
age over 75 years old (13.1%) were associated with a diminished cellular vaccine 
response, and in case of immunosuppressive drugs also with the humoral 
response. A blunted IFN-γ immune and humoral response at higher age has been 
reported for other vaccines, e.g., influenza vaccine, and appears to be related to the 
degree of disability and comorbidity.[26,27] In general, the lower vaccine response 
in the elderly is considered a sign of immunosenescence, i.e., the decline in T- and 
B-cell function at older age.[28,29] On the other hand, individuals after a natural 
C. burnetii infection in the control group over 75 years of age (n = 13), had geometric 
mean reciprocal IgG titres against phase I of 2160 and phase II of 1655, which were 
not different from the younger individuals (n = 187). This suggests that exposure to 
presumably large numbers of live C. burnetii, possibly resulting in the persistence 
of non-infective C. burnetii antigens,[30] induces a more pronounced immune 
response than vaccination, even in the elderly. Therefore, it is tempting to speculate 
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that a higher dose of antigen in the vaccine might be needed to induce a more 
robust immune response in older people.
 Chronic Q fever is characterized by very high titres of antibodies against 
C. burnetii, especially towards phase I antigens. Therefore, it can be argued that 
antibodies are not necessarily important for protection.[31]  Nevertheless, it has 
been shown in mice that antibodies contribute in some way to protection against 
C. burnetii infection.[32-34] Cell-mediated immune responses are believed to be 
pivotal in the defense against intracellular pathogens including C. burnetii.
[33,35,36] Thus, measuring cellular immune responses may be relevant to 
understand immune mechanisms in C. burnetii infection. However, our previous 
finding of high IFN-γ production in chronic Q fever [Schoffelen et al., manuscript 
submitted] does not  point to a protective effect either. Thus, a direct relation 
between the humoral and cellular immune response after vaccination and the 
degree of protection will be  difficult to establish.
 Our study population was at risk for severe morbidity and mortality by 
chronic Q fever. This made it highly relevant to offer them protection against 
infection by vaccination. Data from Australia showed a high vaccine efficacy. In 
924 vaccinated abattoir workers there was no evidence of Q fever at 18 months 
post-vaccination[11] and in a review of 4000 vaccinated individuals, there was 
strong suggestion that the eight cases of Q fever after vaccination all occurred in 
individuals vaccinated during the incubation period of natural C. burnetii infection.
[16] Furthermore, a five-year follow-up study demonstrated that only two patients 
from a cohort of 2553 vaccinees developed breakthrough Q fever.[18] Finally, a 
recent meta-analysis by Gefenaite et al., showed an effectiveness of Q-vax of at 
least 97%.[17] Unfortunately, there is no data that demonstrate a relationship 
between the protection and the degree of immune responses, either humoral or 
cellular, after Q-vax vaccination. Because the Q fever epidemic in the Netherlands 
subsided just the year before the vaccination campaign, the present study will also 
be unable to deliver such data.
 In our study, all subjects that were vaccinated had been seronegative as well as 
skin test negative beforehand.[19] Interestingly, the group with C. burnetii-specific 
IFN-γ production before vaccination showed a significantly higher seroconversion 
rate (74%) as compared to the negative IFN-γ production group (41%). The easiest 
explanation for this  phenomenon is that  there  is a  boosting  effect  of  the vaccine 
in these subjects, reflecting previous infection not detected by serology or skin test. 
Alternatively, one could assume that these are high responders and it is non-specific 
IFN-γ production not necessarily a result of previous exposure to C. burnetii. 
However, the control PHA-induced IFN-γ in these individuals did not differ from 
those without C. burnetii-specific IFN-γ response. Assuming that specific IFN-γ 
production is caused by a previous infection, this implies that a positive IFN-γ 
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production could be of additional value in pre-vaccination screening, excluding 
potential vaccinees with pre-existing immunity. It is likely that the IFN-γ test 
identified subjects who had been exposed to C. burnetii, but failed to mount a 
measurable antibody response and skin reaction. This extends the findings of our 
pre-vaccination screening study, in which we compared the IFN-γ test with both 
serology and skin test, and concluded that the IFN-γ test had similar sensitivity 
and specificity as the combination of both other tests and has additional value 
when the other tests have borderline results.[21] To what extent a positive IFN-γ 
response in pre-vaccination screening predicts adverse reaction to vaccination, is 
currently under investigation.
 In conclusion, the antibody and IFN-γ responses after Q fever vaccination in 
an elderly population at risk for chronic Q fever is lower and restricted to a smaller 
proportion of vaccinees than found in a control group with past Q fever and than 
previously described in other vaccinated cohorts. Studies in similar risk groups, 
that remain exposed to C. burnetii after vaccination, are needed to gain insight in 
the relation between humoral and cellular immune responses and vaccine efficacy 
i.e., protection.
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Abstract 
Objectives: The Q fever skin test is used to measure cell-mediated immunity to 
Coxiella burnetii in pre-vaccination screening to exclude individuals with pre-existing 
immunity. We investigated whether this in-vivo test influences subsequent 
measurements of immune response.
Methods: We assessed the humoral and cellular immune responses before, and 
6 and 12 months after skin testing in 63 individuals who were not vaccinated 
because of either a positive skin test or positive serology in screening. IgG anti- 
C. burnetii antibodies were measured using immune-fluorescence assay (IFA). The 
cellular immune response was assessed by measuring in-vitro C. burnetii-specific 
interferon  (IFN)-γ  production  in blood.
Results: Of the 35 subjects with a positive skin test and negative serology, 15/35 
(43%) showed seroconversion at 6 months, and 7/32 (22%) seropositivity at 12 
months. The mean ± SE specific IFN-γ production in this group increased from 185 
± 88 pg/mL (at baseline) to 422 ± 141 pg/mL at 6 months (P = 0.009) and 223 ± 91 pg/mL 
at 12 months (P = 0.17). Of the 28 subjects with positive serology (and unknown skin test 
results), 21/28 (75%) showed an increase in IgG anti-phase I titres at 6 months, and 
11/25 (44%) at 12 months. The mean ± SE specific IFN-γ production was significantly 
increased at 6 months, but not at 12 months.
Conclusions: Q fever skin testing causes higher antibody titres and higher in-vitro 
IFN-γ to C. burnetii, and therefore affects subsequent Q fever diagnostics.
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Introduction
Q fever is caused by Coxiella burnetii, an intracellular Gram-negative bacterium. 
Initial infection often goes unnoticed, but in a minority of cases chronic infection 
develops and can present as endocarditis or vascular wall infection, which leads to 
high morbidity and mortality [1]. Infection is normally diagnosed by serology, by 
measuring IgM and IgG antibodies  against  the  two  different  antigenic  phases  of 
C. burnetii.
 Q fever skin testing is used to measure in vivo cell-mediated immunity to 
C. burnetii. Its use is limited to pre-vaccination screening, to exclude individuals 
with pre-existing immunity who would be at increased risk of hypersensitivity 
reactions to the vaccine [2]. Major drawbacks of the skin test are that it requires 
specialized personnel, needs a second visit to read, and can be troublesome for the 
tested subjects. Even more important, from an immunological point of view and 
with consequences for (epidemiological) follow up, is that in-vivo skin testing, by 
injection of C. burnetii  antigens,  may induce a cellular and humoral immune 
response and thus possibly modifies subsequent immunologic measurements.   
 Between 2007 and 2010, the Netherlands faced the largest Q fever outbreak 
ever reported, with more  than 4000 notified human cases of acute Q fever [3]. In 
June 2010, the Dutch health authorities decided to offer vaccination to all individuals 
at risk for chronic Q fever living in the area  of the epidemic. The resulting screening 
and vaccination took place between January 2011 and July 2011 [4].
 In the current study, we evaluated the impact of skin testing on the 
measurement of both humoral and cellular C. burnetii specific immune responses 
in a group of 63 individuals who were screened in a Q fever vaccination campaign 
and were not subsequently  vaccinated.
Subjects and methods
Setting
The study was performed during a Q fever vaccination campaign in the Netherlands 
(January-July 2011) and the year thereafter. Before Q fever vaccination, all 1786 
eligible individuals were screened by skin testing and Q fever serology: 210 were 
found to be skin test positive (but seronegative) and 181 were seropositive (with 
unknown skin test results, because they were not invited for reading). In accordance 
with the recommendations, both groups were excluded from vaccination because 
of the increased risk of side effects [2]. Individuals from these excluded groups 
were asked to participate in the post-vaccination study. The study was approved 
by the Central Committee on Research on Human Subjects (CCMO).
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 After informed consent, blood was collected just before, and 6 and 12 months 
after skin testing to measure the humoral and cellular specific immune responses 
to C. burnetii.
Q fever skin test
The commercially available Q-vax® skin test (CSL, Australia) was used [5]. It contains 
diluted formaldehyde-inactivated C. burnetii Henzerling strain phase I-antigens 
(10 times lower concentration than in Q-vax® vaccine). One dose of Q-vax skin 
test (lot# 0996-06501) was diluted 30 times and 0.1 mL was administered intra-
cutaneously in the forearm according to the product information [6]. The local 
reaction to the skin test was read after seven days, but only if serology was negative. 
Any localized induration was considered to be positive and led to exclusion from 
vaccination.
Q  fever serology
The humoral immune response was assessed by a commercially available immu-
nofluorescence assay (IFA; Focus Diagnostics, Cypress, USA). A positive serology 
was defined as anti-phase I or phase II C. burnetii IgM/IgG titre ≥1:32. An increase 
of titres was defined by two-fold increase or  more.
C. burnetii specific IFN-γ production
Cellular immune response was assessed by measuring in-vitro C. burnetii specific 
IFN-γ production in whole blood as previously described.[7] Net IFN-γ production 
was expressed as the concentration of IFN-γ in the C. burnetii stimulated sample 
minus that in the negative control sample. The assay was considered positive when 
net IFN-γ production was ≥32 pg/mL, based on previous findings [7].
Statistics
Mean ± standard error (SE) IFN-γ production was calculated and compared using 
a paired samples t-test. Median serological titres were calculated for groups and 
the Wilcoxon matched-pairs signed rank test was used to compare median 
serological titres at different time  points. P < 0.05 was considered significant.
Results
Sixty-three individuals (mean age [±SD] of 66 [±11] years, 76% male) were asked to 
participate in the study: 35/63 with a positive skin test and 28/63 with positive 
serology and unknown skin test results, at screening. These were selected from the 
larger group of eligible individuals, because they lived close to the health care 
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centre where blood was collected. At twelve months, 32/35 and 25/28 of these 
individuals were available for repeated blood tests.
 Individual immune responses at baseline, 6 and 12 months are shown in Fig. 1.
Of the 35 individuals with a positive skin test and negative serology, 15/35 (43%) 
showed seroconversion after 6 months, and 7/32 (22%) were seropositive after 12 
months. The proportions with positive results in the IFN-γ assay were 19/35 (54%) 
at baseline, 26/35 (74%) after 6 months and 22/32 (69%) after 12 months. The mean 
± SE specific IFN-γ production in this group increased from 185 ± 88 pg/mL (at 
baseline) to 422 ± 141 pg/mL at 6 months (P = 0.009) and 223 ± 91 pg/mL at 12 
months (P = 0.17) after skin testing. In the 28 individuals with positive serology in 
pre-vaccination screening, an increase of IgG anti-phase I and II antibody titre was 
observed after the skin test: at 6 months, 21/28 (75%) had an increase in phase I IgG 
titre, 14/28 (50%) in phase II IgG titre; at 12 months, 11/25 (44%) in phase I IgG and 
4/25 (16%) phase II IgG titre. The increase of median titre was 2-fold after 6 months 
(median phase I IgG from 1:64 to 1:128, P = 0.0001; phase II IgG from 1:128 to 1:256, 
P = 0.001) and this significant increase largely disappeared after 12 months (median 
phase I IgG   1:64 P = 0.04; phase II IgG 1:64 P = 0.20). The proportions with positive 
results in the IFN-γ assay were 22/28 (79%) at baseline, 23/28 (82%) after 6 months 
and 22/25 (88%) after 12 months. The IFN-γ production in this group increased 
from 301 ± 100 pg/mL (at baseline) to 918 ± 296 pg/mL at 6 months (P = 0.039) and 
500 ± 271 pg/mL 12 months (P = 0.598) after skin testing.
Discussion
Our results showed that the intracutaneous Q fever test, containing a low dose of 
Q-vax antigen, induces clear C. burnetii-specific  immune  responses  in  about  half 
of the tested individuals with a positive Q fever skin test. In addition, a median 
2-fold increase in antibody titre was found in patients with positive serology in 
pre-vaccination screening. These effects were measurable after 6 months, but 
seemed to wane at 12 months. Since all individuals in this study had evidence of 
pre-existing immunity (either a positive skin test or positive serology), this immune 
response should be considered as a boosting effect.
 Strikingly, the proportion of individuals who seroconverted at 6 months after 
a positive skin test (43%), was almost as high as what was previously reported at 
6 months after Q fever vaccination with a 300 times higher dose of individuals 
with a negative skin test (46%) [8]. In addition, the previously reported mean ± SE 
IFN-γ production in vaccinated individuals was 22 ± 4 pg/mL (at baseline), 141 ± 21 
pg/mL at six months and 94 ± 15 pg/mL at 12 months after Q fever vaccination. 
Thus, while the IFN-γ production was already higher in the skin-test positive 
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subjects than in the vaccinated individuals, vaccination reached similar levels as in 
the skin-test positive subject at baseline, while the latter reached a mean IFN-γ 
production of more than twice as high. In individuals who were seropositive in 
pre-vaccination screening, skin testing also led to a boosting effect, increasing the 
anti-C. burnetii IgG titres as measured after 6, but not after 12 months.
 A similar boosting effect is described for the tuberculin skin test (TST) on 
subsequent interferon-gamma release assay (IGRA) responses, often used in 
combination to diagnose latent tuberculosis[9]. This phenomenon makes it difficult 
for clinicians to discriminate between boosting and conversion of any increase in 
the IGRA response after TST.
 The immunogenetic effect of the Q fever skin test has been described before, 
but has never been quantified. Intracutaneous administration of undiluted Q fever 
whole-cell vaccine has been tried in imprisoned volunteers in the early 1960s [10]. 
The antibody response appeared to be related to the number of doses of vaccine 
given, but was more delayed and reached lower titres than after subcutaneous 
administration. Moreover, five out of six skin test positive individuals, who 
subsequently were not vaccinated, seroconverted in the follow-up. However, the 
problem of repeated injection of whole-cell vaccines, is the increased risk for 
developing adverse reactions. To overcome this problem, Waag et al. used a 
chemical extraction procedure to develop a vaccine with good immunogenicity 
and reduced adverse effects upon serial use. They showed in non-immune 
volunteers that a second subcutaneous vaccination with a chloroform-methanol 
residue phase I vaccine, 3-6 months after a priming subcutaneous dose, can mount 
serological and cellular response, whereas one dose did not [11].
 In this respect, the intracutaneous Q fever test can be seen as a kind of 
vaccination. In rabies prophylaxis, intradermal administration of cell culture 
vaccines is  an accepted alternative to the standard intramuscular route [12]. It only 
takes one-tenth of the dose that is used intramuscularly to obtain an adequate 
humoral response [13]. The effective skin-associated immune response is most 
likely due to the extensive local network of dendritic cells and the skin-draining 
lymph nodes to generate effector T and B cells,  leading  to  long-term  protective 
immunity.
 We believe that clinicians, immunologists and epidemiologists should be 
aware of the phenomenon that individuals who have been skin tested, as is the 
current practice in Q fever pre-vaccination screening, may develop higher anti- 
phase I C. burnetii IgG antibody titres and a more robust in-vitro IFN-γ release. 
This may lead to false diagnosis of re-infection or even possible chronic Q fever. 
We also suggest that an in-vitro test, like the C. burnetii specific IFN-γ production 
assay, should be further investigated as an alternative for the Q fever skin test for 
assessing pre-existing immunity.
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Abstract
Background: In 2011, a unique Q fever vaccination campaign targeted people at 
risk for chronic Q fever in the southeast of the Netherlands. General practitioners 
referred patients with defined cardiovascular risk-conditions (age >15 years). 
Prevalence rates of those risk-conditions were lacking, standing in the way of 
adequate planning and coverage estimation. We aimed to obtain prevalence rates 
retrospectively in order to estimate coverage of the Q fever vaccination campaign.
Methods: With broad search terms for these predefined risk-conditions, we 
extracted patient-records from a large longitudinal general-practice research- 
database in the Netherlands (IPCI-database). After validation of these records, 
obtained prevalence rates (stratified for age and sex) extrapolated to the Q fever 
high-incidence area population, gave an approximation of the size of the targeted 
patient-group. Coverage calculation addressed people actually screened by a 
pre-vaccination Q fever skin test and serology (coverage) and patients referred by 
their general practitioners (adjusted-coverage) in the 2011 campaign.
Results: Our prevalence estimate of any risk-condition was 3.1% (lower-upper 
limits 2.9-3.3%). For heart valve defects, aorta aneurysm/prosthesis, congenital 
anomalies and endocarditis, prevalence was 2.4%, 0.6%, 0.4% and 0.1%, respectively. 
Estimated number of eligible people in the Q fever high-incidence area was 11,724 
(10,965-12,532). With 1330 people screened for vaccination, coverage of the 
vaccination campaign was 11%. For referred people, the adjusted coverage was 
18%. Coverage was lowest among the very-old and highest for people aged 50-70 
years.
Conclusion: The estimated coverage of the vaccination campaign was limited. 
This should be interpreted in the light of the complexity of this target-group with 
much co-morbidity, and of the vaccine that required invasive pre-vaccination 
screening. Calculation of prevalence rates of risk-conditions based on the IPCI- 
database was feasible. This procedure proved an efficient tool for future use, when 
prevalence estimates for policy, implementation or surveillance of subgroup- 
vaccination or other health-care interventions are needed.
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Introduction
In 2007, a large human Q fever outbreak started in the southeast of the Netherlands, 
caused by exposure to goat-farms infected by Coxiella burnetii [1]. Subsequently, the 
annual number of reported human Q fever cases reached a peak of 2354 in 2009. 
The increase of acute Q fever reports was followed by increasing numbers of 
chronic Q fever patients [2]. Chronic Q fever is a severe outcome of C. burnetii 
infection, often presenting itself as endocarditis or vascular infection, and 
needs long-term antibiotic treatment and often surgical intervention [3]. Several 
cardiovascular risk-conditions for chronic Q fever have been identified [4,5], and 
the Health Council (HC) of the Netherlands advised vaccination of people aged 
15 years and over, with these specific risk-conditions in July 2010 [6]. This measure 
was an individual patient-oriented intervention and not a population-targeted 
campaign. The sole available vaccine, only registered in Australia where it is used 
to vaccinate people at occupational risk [7,8], requires pre-vaccination screening 
[9,10], and therefore complicated logistics [11]. The Ministry of Health chose a 
centralized approach, coordinated by the National Institute for Public Health and 
Environment. Efforts to reach the target population concentrated on high-incidence 
areas [Fig. 1] and relied on general practitioners (GPs), and to a lesser extent to 
hospital specialists, for patient referrals. Intake, screening and subsequent vaccination 
was organized at the municipal health clinic in the central high-incidence area. 
The vaccination campaign included intensified safety surveillance [12], immuno -
logical pre-vaccination screening and immunological follow-up [11,13].
 In their advice, the HC did not attempt to quantify the size of the risk-group 
eligible for vaccination and no concise prevalence data of the risk-conditions were 
available according to cardiologists. In the planning phase of the vaccination 
campaign, which should start before the approaching lambing season, it was 
estimated that 100-300 people would respond to the invitation for vaccination 
within the target population, and 1000 was taken as upper limit budget wise. 
The much larger than expected number of referred people (2741) overloaded the 
system and made implementation of the campaign difficult, forcing an up-scaling 
of staff [11]. In the end, 1786 eligible people underwent screening tests between 
January and April 2011.
 The lack of prevalence data of the risk-conditions not only precluded 
determination of the size of the target population, but also of the coverage of the 
vaccination campaign. In order to estimate coverage retrospectively, we needed to 
obtain prevalence estimates of the risk-conditions for chronic Q fever in the 
high-incidence area. To this end, we extracted data on the specific risk-conditions 
from the Integrated Primary Care Information (IPCI)-database, a large longitudinal 
population-based general practice research database in the Netherlands. Here we 
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describe the procedure we followed to arrive at an estimate of the coverage of the 
Q fever vaccination campaign in the Netherlands 2011 [14].
Materials and Methods
IPCI-database
The IPCI-database is a longitudinal general practice research database held by 
Erasmus University Medical Center, Rotterdam. With data collection since 1996, 
Figure 1. Municipalities with their incidence of Q fever in 2009-2010. Q fever high-incidence 
area outlined in black (11).
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this electronic dynamic database presently contains 1.1 million patient-records 
from 437 general practices in the Netherlands [15-17]. It holds comprehensive 
information on medical history and referrals. Included are signs and symptoms, 
diagnoses, International Classification of Primary Care (ICPC)-codes, laboratory 
test results, surgical procedures, medication and hospitalizations.
 The free text fields of the records contain summaries or full discharge letters 
from hospital specialists. Hard copies of letters are available upon request. The 
patient population is representative of the Dutch population, with some under-
representation of elderly people who have moved to nursing homes however [17]. 
Patient-records are anonymous for researchers. IPCI complies with European 
Union guidelines on secondary use of healthcare data for medical research. The 
IPCI- database is valid for pharmaco-epidemiological research and has been used 
in more than 100 peer-reviewed publications. The Supervisory Board of the IPCI- 
database (project number 11/2012) approved the use of IPCI-data for the current 
prevalence estimation. Approval by the ethics committee was not necessary for 
this retrospective study because only anonymous data have been used.
Study population
The source population comprised all patients 15 years and older who were 
registered with one of the GP-practices and actively in follow-up with the GP on 
January 1st 2011 [6]. Due to resource limitations regarding the necessary manual 
validation of extracted patient-records, we sampled 5% of this source population as 
study population. We compared the characteristics of the full source population 
and those of the 5% random sample for consistency in pattern of non-validated 
potential cases.
Risk-conditions and search criteria
Four risk-conditions were defined, based on the HC-advice of eligibility for Q fever 
vaccination [6]. Relevant search terms were entered in a script (syntax) with which 
the database was searched in diagnostic code sections and free text fields [Table 1]. 
Physicians (PEVdB and TS) reviewed the electronic medical records of all potential 
cases in order to assess validity and label the diagnostic certainty. They entered the 
level of diagnostic certainty (definite-probable-possible case or no case) in a 
validation tool with date of first diagnosis or of rejection. Cases could have multiple 
risk-conditions. We did not subdivide the cases according to severity or type of 
defect within the specific risk-conditions, since this was not the scope of our study. 
A random sample of 100 records was crosschecked by independent review (AMV). 
These records and all cases with the lowest level of diagnostic certainty (possible) 
were thereafter checked for consistency, held against strict inclusion criteria, and 
coded following consensus (PEVdB and TS).
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Population of the Q fever high-incidence area and the Q fever 
vaccination campaign
The population distribution of the Q fever high-incidence area as of January 1st 
2011 was retrieved from demographic data from the electronic databank Statline 
(Statistics Netherlands, http://statline.cbs.nl/Statweb). Information on actually 
referred and screened people in the Q fever vaccination campaign was obtained 
from the case report forms of the Q fever vaccination campaign as described 
Table 1   Cardiovascular risk-conditions for chronic Q fever with ICPC-codes, 
search terms and diagnostic certainty levels.
Risk-conditions, ICPC-codesa, search terms and diagnostic certainty levels for IPCI-
databaseb extraction
Risk-conditions 
and ICPC-codesc
1- valvular cardiac disease or prosthesis (symptomless mitral 
valve prolapse excluded) (K83)
2- aortic aneurysm of prosthesis/stent (K99)
3- congenital cardiac anomalies (except spontaneous closure of 
VSD/ASD/OBD or surgical closure without artificial material 
and no residual defect), inclusive of coarctatio aortae (K73)
4- history of endocarditis or rheumatic cardiac disease (K71)
Search terms in 
free text
a- valv*, aort*, aneury*, congenit*, viti*, prosth*, vsd/asd, obd, 
mitra*, tricusp*, stenos*, insuff*, endocardi* and the Dutch 
equivalents, etcetera’s
b- proper names of different (congenital) syndromes like 
Eisenmenger, Fallot, Epstein, Ivemark, Botalli, etcetera’s. All 
these search terms included also possible spelling errors
Level of 
diagnostic 
certainty
1- certain; with discharge letter of specialist or specific diagnostic 
laboratory outcome, or repetitive entries with description and 
specific treatment
2- probable; with only descriptions entered by the general 
practitioner, with the correct ICPC-codes
3- possible; with only (recurrent) ICPC-code, without description 
of condition, or minimal defects with uncertain consequences
4- rejected; if condition could be regarded as variant of normal, 
minimal defects without any consequences, or falling within 
exclusion criteria, as well as conditions excluded by specialist 
examination, or conditions in family members
a  ICPC-codes, International Classification of Primary Care codes
b IPCI-database, Integrated Primary Care Information database
c Qualifying patients were eligible for Q fever vaccination in the campaign of 2011
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previously [12]. Risk-conditions of referred people came from GPs and from the 
potential vaccinees themselves. Postal codes identified referred people living in 
the high-incidence area. Of 2741 potential vaccinees, 955 were excluded for various 
reasons [11]. The remaining 1786 people –of which 1330 from the high-incidence 
area– underwent pre-vaccination screening with skin test and serology, and –if 
negative– were subsequently vaccinated. Logistics and safety surveillance of the Q 
fever vaccination campaign have been described elsewhere [11,12].
Data analysis
After validation and review of extracted patient-records from the IPCI-sample, 
stratified numbers on the four defined risk-conditions according to 10 years’ age 
groups and sex, were used to determine prevalence (N/10,000), with 95% 
Confidence Intervals (95%CI). We did so both for all confirmed cases and for cases 
with definite and probable diagnostic certainty only, with lower and upper limits.
The prevalence estimates for cases with definite and probable diagnostic certainty, 
stratified for age group and sex, served as input for the high-incidence area 
population, to approximate the number of people eligible for Q fever vaccination 
in this region. With this, the coverage of the vaccination campaign was determined 
with minimum and maximum estimates based on the 95% CI of the IPCI-sample 
data. Fig. 2 presents a diagram with the calculation steps. OpenEpi and Excel were 
used for calculations and graphs.
Results
The IPCI-database per January 1st 2011 contained 651,276 people aged 15 years and 
over. The 5% random sample as study population had comparable age and sex 
distribution. The relative age distribution of the populations of the IPCI-sample 
and of the high-incidence area (as obtained from CBS) shows that they were similar 
(with equal median age), though the latter had slightly less people in the age group 
of 20-30 years and more in the 50-60 year olds [Fig. 3].
 The IPCI-study population included 32,571 people [Table 2]. We identified 1966 
patient-records (6%) with one or more ICPC-codes and/or search terms for chronic 
Q fever risk-conditions [Table 1], women (52.7%) slightly outnumbering men 
(47.3%). After review and validation, we rejected 948 extracted patients in all 
(viz. hits for family members with a risk-condition, or medical investigation ruling 
out a specified risk-condition, or non-qualifying diagnoses). This left 1018 (52%) 
cases with one or more confirmed chronic Q fever risk-conditions. Of these, 177 
(17%) had possible diagnostic certainty and 841 definite or probable diagnostic 
certainty [Fig. 4].
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 The majority of confirmed cases from the IPCI-study population (925/1,018; 
91%) had only one defined risk-condition and 9.1% had multiple risk-conditions, 
mostly double and only three triple (male 11.5% and female 7.0%). Valvular disease 
was most prevalent (778; 148 possible), followed by aortic aneurysm or prosthesis 
(183; 10 possible), congenital cardiac anomalies (116; 28 possible) and endocarditis 
(37; 15 possible) [Table 2 and Fig. 4].
 The relative frequencies of the four risk-conditions in the IPCI-study population 
were similar to those in the screened people of the Q fever campaign and the screened 
people from the high-incidence area [Fig. 5A]. However, the screened people were 
younger than the confirmed cases with definite and probable diagnostic certainty 
Figure 2. Flow diagram of calculations leading to coverage estimates. For calculations, 
prevalence of risk-conditions with definite and probable diagnostic certainty from IPCI-study 
population has been used, overall and for subgroups.
Prevalence estimate from IPCI-sample 
for risk-conditions with definite and 
probable diagnostic certainty 
(N/10,000) with 95% CI = X 
 
 
Estimate of number of target patients 
in QF-HI-area, by multiplication of QF-
HI population/10,000 and Prevalence 
estimate/10,000 with lower and upper 
limits, X*Y  =  Z 
Coverage estimate of QF-vaccination 
campaign by dividing screened 
patients by estimated number of target 
patients in QF-HI-area, with lower and 
upper limits, C = P/Z  
Adjusted coverage estimates of QF-
vaccination campaign by 
multiplication Coverage estimate and 
reciprocal of fraction 
screened/referred, with lower and 
upper limits, A = C*T  
Reciprocal of numbers of 
screened (S) divided by  numbers referred (R), R/S = T  
Population number in Q fever  
(QF) high-incidence (HI)-area  
divided by 10,000 = Y 
Screened patients in the QF-
vaccination campaign = P 
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Figure 3. Population distribution of IPCI-database and of Q fever high-incidence area. 
(A) population pyramids for IPCI-database (dark colours) and for Q fever high-incidence 
(HI)- area (light colours), according to sex. (B) Relative age frequencies for IPCI-source 
population (open squares), IPCI-study population (triangles) and for Q fever HI-area (open 
circles).
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from the IPCI-study population. Median (interquartile range) ages were 67 (57-74) 
and 72 (61-81) years for screened people and IPCI-cases, respectively. IPCI-cases 
with possible diagnostic certainty were younger and had a higher proportion of 
women (58% versus 51%). The proportion of men was higher in the referred and 
screened people of the Q fever vaccination campaign from the high-incidence area 
(61%) than in the IPCI-study population cases (48%), for all risk-conditions except 
for congenital heart anomalies [Figs. 4 and 5B].
 The overall prevalence of any risk-condition in the IPCI-study population was 
313 per 10,000 people, increasing with age [Fig. 6]. Only for congenital anomalies, 
prevalence was highest in the youngest age group. Men and women showed almost 
equal overall prevalence rates of 310 and 315 per 10,000, respectively [Table 2]. 
These calculated prevalence rates for the different risk-conditions are within data 
ranges presented in literature [Table 3].
 To get an impression of the proportion of eligible people who were reached in 
the Q fever vaccination campaign (coverage), one should first calculate prevalence 
Figure 4. Flow diagram of results of IPCI-database extraction and validation. Sex distribution 
(male %) included for each step.
651,276  IPCI source population  
(male 48.4% ) 
32,571  (5%) IPCI-sample size   
(male 48.2% ) 
1,966  (6%) potential cases  
(male 47.3%)
1,018  (52 %) confirmed cases  
(male 47.8% )
841 (82.6%) definite + probable cases  
(male 49.1% ) 
• 630 (74.9%) heart valve defect  
• 173 (20.6%) aortic aneurysm/prosthesis  
•   88 (10.5%) congenital heart anomaly  
•   22 (2.6%) history of endocarditis  
 
948  (48%)  rejected cases  
(male 46.7% )
177  (17.4%) possible cases  
(male 41.8% ) 
• 148 (83.6%) heart valve defect  
•   10 (5,6%) aortic aneurysm/prosthesis  
•   28 (15.8%) congenital heart anomaly 
•   15 (8.5%) history of endocarditis  
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estimates for validated IPCI-cases with definite and probable diagnostic certainty 
[Fig. 2]. These prevalence rates were stratified for age group and sex, with an overall 
rate of 258/10,000 [S1 Table ]. Extrapolation of these rates to the population of the Q 
fever-high-incidence area, led to an estimated number of targeted people of 11,724 
Figure 5. Relative frequencies of risk-conditions for chronic Q fever and sex distribution 
in the different populations. (A) Comparison between all screened people of the Q fever 
(QF)-vaccination campaign, screened people from the high-incidence (HI)-area, and cases 
from the IPCI-study population. (B) Sex distribution for different risk-conditions in screened 
people from QF-HI-area and cases from IPCI-study population. The IPCI-study population 
includes cases with definite and probable diagnostic certainty.
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(10,965-12,532) [S2 Table]. If people from municipalities bordering the high-incidence 
area were included in this calculation, the target group would number at least 
15,000 people.
 Overall, only 1330 of this target group from the high incidence area were 
screened for vaccination [Table 4], which resulted in coverage of 11% (1330/11,724) 
with narrow lower and upper limits of 11-12%. For men and women these coverage 
rates were 14% (13%-15%) and 9% (8%-10%), respectively. For the larger group of 
referred people from the high-incidence area, an adjusted coverage rate of 18% 
(limits 16%-18%) was calculated. Coverage was lowest in the oldest age groups, 
with 5% and 1% for the 80-90 year olds and 90 years and older, respectively. The 
highest coverage was in the much larger groups of the 50-60 and 60-70 year olds, 
with 19% and 16% respectively (upper limits of 23% and 19%). Based on the referred 
people in these latter age groups, this would result in an adjusted coverage of 
approximately 30% and 24% (upper limits 34% and 29%) [Table 5].
Figure 6. Age distribution of the defined risk conditions for chronic Q fever. Prevalence 
rates (per 10,000) are estimated from the IPCI-database, per January 1st 2011.
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Discussion
This study aimed to evaluate the quantitative performance of the Q fever 
vaccination campaign in 2011, which targeted people at risk for chronic Q fever. 
Prevalence data for the defined risk-conditions were not available at the time and 
no disease registers exist in the Netherlands. In this retrospective cohort study, we 
identified the number of people with those predefined risk-conditions for chronic 
Q fever in a random sample of a population-based database, from which we 
calculated stratified prevalence estimates. By extrapolation of these prevalence 
data to the population of the high-incidence area of the Q fever epidemic, we 
arrived at an approximation of about 12,000 people with a definite or probable 
cardiovascular condition predisposing to chronic Q fever for this particular area. 
Using the recorded number of people actually screened for Q fever vaccination 
from this area, we estimated the overall coverage to be 11% (upper limit 12%). The 
adjusted coverage estimate, based on the larger group of referred people, was 18%.
 There are several possible explanations for this limited coverage. First, the 
centralized approach, with only one location and limited dates for screening and 
vaccination may have posed a barrier for eligible people. Moreover, potential 
vaccinees had to travel twice because of the required and invasive pre-vaccination 
skin test and serology. As the vaccine was unregistered, information leaflets and 
letters were sent to cardiologists and GPs and to potential vaccinees, in which 
uncertainties were described explicitly; this may have influenced their willingness 
to refer or to be vaccinated. Furthermore, potential vaccinees needed to sign 
multiple consent forms, which may have been another barrier to refer or to consent. 
The necessity to fill in several diaries to record experienced adverse events and the 
intensified safety surveillance with follow-up by telephone may have put off quite 
some referred people. Reasons for secondary withdrawal were, among others, too 
far- unsafe/perceived risk benefit misbalance- intercurrent illness- feeling to be a 
guinea pig- difficult/impossible day/date- lack of transport- etcetera. Some potential 
vaccinees could not walk, were bedridden, or felt they were not at risk because 
they hardly ever left their home. Some other people were excluded because one felt 
they were unable to comply with the requirements of informed consent and 
follow-up. Hence the low coverage in the oldest age groups. Moreover, when the 
vaccination campaign finally took off, the outbreak was already in decline due to 
the effects of consecutive veterinary interventions in the year before; the urgency 
of vaccination was felt less, not only by referring GPs and their patients but also by 
the coordination team of the campaign and its implementers. In December 2010, 
HC decided not to include (new) occupational risk groups because risk of infection 
had sufficiently decreased [18]. This led to the decision not to extend the relative 
short intake period for the Q fever vaccination campaign. In contrast with 
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population based campaigns or programmes, no repeated public education and 
information was launched. To avoid the so-called “worried well” phenomenon, the 
public were not addressed directly. The short time span between informing the 
public and professionals, recruitment of potential vaccinees and the screening and 
vaccination period, posed an obstacle to timely referral and intake. As reported 
[11], GPs had varying degrees of difficulty to identify eligible patients from the files 
depending on their file system specifications and codes. Lastly, the lack of 
prevalence data may have negatively influenced coverage in an indirect way, as 
inadequate logistics for coping with a much larger than expected number of 
indicated patients may have put off some patients, because convenient appointments 
could not easily be made.
 For coverage estimation, we left out all cases labelled as possible from the 
IPCI-study population because many were early cases and of the mildest severity, 
without full clinical work up. GPs might not interpret most of these patients to be 
at high-risk for chronic Q fever; neither would these people think so themselves. 
We calculated coverage for people included in pre-vaccination screening, as this 
group was effectively enrolled, instead of for people referred as the larger group 
that was potentially reached. For this latter group, adjusted coverage would be 
approximately 50% higher. Coverage estimation was based on the Q fever high- 
incidence area (75% of all screened people), for which we had retrieved background 
population numbers.
 The coverage estimates varied somewhat among risk-conditions and age groups. 
The low coverage in the two oldest age decades is not surprising in the light of the 
obstacles and criteria mentioned before. The highest coverage was in the (largest) 
middle age groups, with 19% and 16% for 50-60 and 60-70 years old, respectively. 
Men had higher coverage rates than women. In the light of the higher Q fever risk 
in these specific age groups and in men [19], this is a positive finding. These risk 
factors were included in the HC-advice [6] and in information letters to GPs, possibly 
leading to increased referral. Women were underrepresented in referral and screening 
for Q  fever-vaccination. An explanation might be that they have milder (asymptomatic) 
cardiovascular defects or were less receptive to be referred for vaccination [20].
 In contrast to the well-incorporated Dutch universal childhood vaccination 
programme (over 95% coverage, except for HPV due to concerns about safety and 
necessity) [21][, coverage for other (adult) risk-group vaccination is often disap-
pointingly low, even after official and repeated recommendations [22-26]. The 
annual influenza vaccination programme sticks out comparatively positively but 
for the hepatitis B vaccination for men having sex with men the estimated annual 
coverage of only 1% [27]. Such risk-group targeted vaccinations are also hard to 
monitor, especially if executed in the private sector without disease databases and 
vaccination registers [28].
299
COVERAGE OF THE Q FEVER VACCINATION CAMPAIGN
15
 The calculated prevalence estimates for the four risk-conditions showed that 
overall, 3.1% of the population of 15 years and older had one or more of the defined 
conditions, increasing with age and similar for men and women. One might think 
that prevalence estimates could have been retrieved from literature before the start 
of the vaccination campaign. This could have prevented some of the logistic 
pressures because of the unexpected large influx of referrals. Data on prevalence of 
valvular defects [29-34], aortic aneurysms [35-39], congenital heart anomalies 
[40-45], and endocarditis [46,47] can indeed be found in literature [Table 3]. Some 
publications are quite recent, however, and very few are from the Netherlands [37]. 
There is no reason though, to expect substantial differences in prevalence rates 
between developed countries, but some racial or ethnic differences have been 
described [48], as well as changes over time, better therapeutic procedures and 
higher life expectancy [43].
 The prevalence estimates in this study are the first available in the Netherlands. 
Heart valve defects, as the most common risk-condition presented in 2.4%, with 
peak prevalence of 17.6% in the older age groups. Aortic aneurysm/prosthesis 
occurred in 0.6%, with peak prevalence of 3%. Congenital cardiovascular anomalies 
were a rather small group in the IPCI-study population as well as in the Q fever 
vaccination campaign and were comparatively overrepresented in the youngest 
age group . This may be because patients with the more severe defects may not 
have survived, or recent severe degenerative or acquired symptomatic changes 
may have overshadowed the primary condition. Prevalence estimates for all risk- 
conditions seem to be well in line with the rather scarce reports in literature.
 Observed prevalence rates indicate that a very large group of people in the 
population is at substantial risk of Q fever complications. Not only those living in 
the high-incidence area at the time, but also those living in the proximity of 
infected farms in other areas. Of note, environmental Coxiella burnetii has the 
potential to spread over great distances [49,50]. Seroprevalence studies conducted 
in 2009-2011 have found a large proportion (>10%) of people infected by C .burnetii 
and illustrates the magnitude of the Dutch Q fever outbreak [51]. For the future, 
containing Q fever is of great importance, and relaxation of veterinary measures, 
i.e. mandatory vaccination and tank milk surveillance for Q fever at goat-farms, 
could pose a great hazard for this prevalent risk group. Therefore, veterinary 
measures containing Q fever need to be continued.
 A difficulty for this study was that the risk-conditions searched for in the IPCI- 
database required long string search terms in addition to ICPC-codes and manual 
validation. This was necessary because much information on these risk-conditions 
was captured in unstructured text in GP information systems. Medical expertise 
was necessary to validate the patients, because patient-records had to be assessed 
in medical perspective. With searches based on ICPC-codes alone, a large 
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proportion of qualifying patients would have been missed. Patients with only an 
ICPC-code for risk-condition, qualified for the lowest level of diagnostic certainty 
(possible) at most, because free text substantiation was missing. In addition, some 
patients with an incorrect code would have been included without the free text 
validation. Some miscoding may occur after several consecutive changes in the 
coding system and because of misunderstanding by the coding-assistant. For 
instance, several times, the rheumatic fever code -in Dutch acute rheuma(tic 
disease)- was mistakenly chosen in cases of acute presentation of polyarthritis 
rheumatica. Perusing the free text entries, this could be sorted out in the majority 
of cases. We may have missed less obvious misconceptions, however. In addition, 
not all risk-conditions or targeted interventions had codes that were specific 
enough.
 As the Q fever vaccination campaign was not designed as a study, indications 
for referral, especially in people with multiple risk-conditions, may not have been 
completely reported. On the other hand, checking of people’s eligibility was strict 
and all underlying risk- conditions were critically reviewed, before acceptation for 
pre-vaccination screening. Even so, only a small percentage (2.9%) of referred 
people was rejected because proper indication lacked or because of young age.
 A strength of this study is that the IPCI-study population –which we used to 
calculate prevalence estimates of the risk-conditions– was representative of the 
Dutch population. The existence of population registers enabled us to extrapolate 
these prevalence estimates to the Q fever high-incidence area. The consistency of 
the yield with prevalence data available from literature and the similar relative 
frequencies for the respective risk-conditions in the Q fever vaccination campaign 
and the IPCI-study population inspire confidence. We assume high sensitivity of 
our search strategy with the broad search terms we chose (including spelling 
errors), while we did not come across other terms or synonyms for the conditions 
we were after in the free text of the validated records. In this perspective, the 
relative high proportion of rejections after validation was reassuring. We increased 
specificity through this individual validation of the full extracted patient group 
and subsequent review of all borderline cases with subsequent inclusion or 
rejection. Moreover, the called for risk-conditions had a relative high frequency in 
the general population resulting in precise estimates with small 95% confidence 
intervals.
 In conclusion, the estimated coverage of the Q fever vaccination campaign of 
11-18% was limited, but is understandable if all obstacles are taken into account. 
The IPCI-database extraction for determination of risk-condition prevalence rates 
turned out to be a feasible procedure within a limited time frame. It is fit for future 
use in case background rates are necessary for policymaking, implementation and 
surveillance of (public) health interventions, provided proper and specific (low 
301
COVERAGE OF THE Q FEVER VACCINATION CAMPAIGN
15
level) codes exist for disease (sub)groups. This may be particularly true for the 
planned efforts to launch recommendations on the benefit of vaccinations for 
subgroups in addition to universal vaccination programmes [52-54]. This holds 
even truer for those risk-conditions for which prevalence data are missing, and the 
size of the targeted subgroup needs to be estimated.
Acknowledgements
We thank Marcel de Wilde and Mees Mosseveld for running the scripts and for 
help in defining the database populations and Maria de Ridder for her advice on 
statistical matters. We thank Ben Bom for adapting Fig. 1 that RIVM used to inform 
professionals and the public in the run-up of the Q fever vaccination campaign, 
into an English version for the purpose of papers and presentations on the Q fever 
vaccination campaign.
302
CHAPTER 15
References
1. Karagiannis I, Schimmer B, Van Lier A, Timen A, Schneeberger P, Van Rotterdam B, et al. Investigation 
of a Q fever outbreak in a rural area of The Netherlands. Epidemiol Infect. 2009;137(9):1283-94.
2. van der Hoek W, Schneeberger PM, Oomen T, Wegdam-Blans MC, Dijkstra F, Notermans DW, et al. 
Shifting priorities in the aftermath of a Q fever epidemic in 2007 to 2009 in The Netherlands: from 
acute to chronic infection. Euro Surveill. 2012;17(3):20059.
3. Parker NR, Barralet JH, Bell AM. Q fever. Lancet. 2006;367(9511):679-88.
4. Maurin M, Raoult D. Q fever. Clin Microbiol Rev. 1999;12(4):518-53.
5. Kampschreur LM, Dekker S, Hagenaars JC, Lestrade PJ, Renders NH, de Jager-Leclercq MG, et al. 
Identification of risk factors for chronic Q fever, the Netherlands. Emerg Infect Dis. 2012;18(4):563-70.
6. Human Vaccination Against Q Fever. Publication no 2010/08: Health Council of the Netherlands; 2010.
7. Marmion BP, Ormsbee RA, Kyrkou M, Wright J, Worswick DA, Izzo AA, et al. Vaccine prophylaxis 
of abattoir-associated Q fever: eight years’ experience in Australian abattoirs. Epidemiol Infect. 
1990;104(2):275-87.
8. Gidding HF, Wallace C, Lawrence GL, McIntyre PB. Australia’s national Q fever vaccination 
program. Vaccine. 2009;27(14):2037-41.
9. Q-VAX Q fever vaccine and Q-VAX skin test. Product Information – TGA approved. Australia: CSL 
Biotherapies; 2008.
10. Marmion B. A guide to Q fever and Q fever vaccination. Booklet. Melbourne: CSL Biotherapies; 
2009. Available from: http://meatiesohs.org/files/Q_Fever_booklet.pdf.
11. Isken LD, Kraaij-Dirkzwager M, Vermeer-de Bondt PE, Rümke HC, Wijkmans C, Opstelten W, et al. 
Implementation of a Q fever vaccination program for high-risk patients in the Netherlands. Vaccine. 
2013;31(23):2617-22.
12. Schoffelen T, Wong A, Rümke HC, Netea MG, Timen A, van Deuren M, et al. Adverse events and 
association with age, sex and immunological parameter of Q fever vaccination in patients at risk for 
chronic Q fever in the Netherlands 2011. Vaccine. 2014;32(49):6622-30,
13. Schoffelen T, Herremans T, Sprong T, Nabuurs-Franssen M, Wever PC, Joosten LA, et al. Limited 
humoral and cellular responses to Q fever vaccination in older adults with risk factors for chronic 
Q fever. J Infect. 2013;67(6):565- 73.
14. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening 
the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for 
reporting observational studies. Lancet. 2007;370(9596):1453-7.
15. Lamberts H, Wood M, Hofmans-Okkes IM. International primary care classifications: the effect of 
fifteen years of evolution. Fam Pract. 1992;9(3):330-9.
16. van der Lei J, Duisterhout JS, Westerhof HP, van der Does E, Cromme PV, Boon WM, et al. The introduction 
of computer-based patient records in The Netherlands. Ann Intern Med. 1993;119(10): 1036-41.
17. Vlug AE, van der Lei J, Mosseveld BM, van Wijk MA, van der Linden PD, Sturkenboom MC, et al. 
Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med. 
1999;38(4-5):339-44.
18. Human vaccination against Q fever: second advisory report. publication no 2010/18E: Health 
Council of the Netherlands; 2010.
19. Dijkstra F, van der Hoek W, Wijers N, Schimmer B, Rietveld A, Wijkmans CJ, et al. The 2007–2010 Q 
fever epidemic in The Netherlands: characteristics of notified acute Q fever patients and the 
association with dairy goat farming. FEMS Immunol Med Microbiol. 2012;64(1):3-12.
20. Bults M, Beaujean DJ, Wijkmans CJ, Timen A, Richardus JH, Voeten HA. Why did patients with 
cardiovascular disease in the Netherlands accept Q fever vaccination? Vaccine. 2012;30(23):3369-75.
21. van Lier A, van de Kassteele J, de Hoogh P, Drijfhout I, de Melker H. Vaccine uptake determinants 
in The Netherlands. Eur J Public Health. 2014;24(2):304-9.
22. Reiter PL, Brewer NT. Hepatitis B vaccination among a national sample of gay and bisexual men. 
Sex Transm Dis. 2011;38(3):235-8.
303
COVERAGE OF THE Q FEVER VACCINATION CAMPAIGN
15
23. Byrd KK, Lu PJ, Murphy TV. Baseline hepatitis B vaccination coverage among persons with diabetes 
before implementing a U.S. recommendation for vaccination. Vaccine. 2012;30(23):3376-82.
24. Shen AK, Bridges CB, Tan L. The first national adult immunization summit 2012: implementing 
change through action. Vaccine. 2013;31(2):279-84.
25. Williams WW, Lu PJ, O’Halloran A, Bridges CB, Pilishvili T, Hales CM, et al. Noninfluenza 
vaccination coverage among adults - United States, 2012. MMWR Morb Mortal Wkly Rep. 2014;63(5): 
95-102.
26. Yuen CY, Tarrant M. Determinants of uptake of influenza vaccination among pregnant women - a 
systematic review. Vaccine. 2014;32(36):4602-13.
27. Hahné S, van Houdt R, Koedijk F, van Ballegooijen M, Cremer J, Bruisten S, et al. Selective hepatitis 
B virus vaccination has reduced hepatitis B virus transmission in the Netherlands. PLoS One. 
2013;8(7):e67866.
28. Rasmussen TA, Jørgensen MR, Bjerrum S, Jensen-Fangel S, Støvring H, Østergaard L, et al. Use of 
population based background rates of disease to assess vaccine safety in childhood and mass 
immunisation in Denmark: nationwide population based cohort study. BMJ. 2012;345:e5823.
29. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular 
heart diseases: a population-based study. Lancet. 2006;368(9540):1005-11.
30. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW, et al. A prospective 
survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart 
Disease. Eur Heart J. 2003;24(13):1231-43.
31. Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, et al. Prevalence and clinical determinants 
of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999; 
83(6):897-902.
32. Lindroos M, Kupari M, Heikkilä J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: 
an echocardiographic study of a random population sample. J Am Coll Cardiol. 1993;21(5):1220-5.
33. Vahanian A, Iung B, Himbert D, Nataf P. Changing demographics of valvular heart disease and 
impact on surgical and transcatheter valve therapies. Int J Cardiovasc Imaging. 2011;27(8):1115-22.
34. Boudoulas H. Etiology of valvular heart disease. Expert Rev Cardiovasc Ther. 2003;1(4):523-32.
35. Collin J, Araujo L, Walton J, Lindsell D. Oxford screening programme for abdominal aortic 
aneurysm in men aged 65 to 74 years. Lancet. 1988;2(8611):613-5.
36. Singh K, Bønaa KH, Jacobsen BK, Bjørk L, Solberg S. Prevalence of and risk factors for abdominal 
aortic aneurysms in a population-based study : The Tromsø Study. Am J Epidemiol. 2001;154(3):236-44.
37. van der Graaf Y, Akkersdijk GJ, Hak E, Godaert GL, Eikelboom BC. Results of aortic screening in the 
brothers of patients who had elective aortic aneurysm repair. Br J Surg. 1998;85(6):778-80.
38. Scott RA, Ashton HA, Kay DN. Abdominal aortic aneurysm in 4237 screened patients: prevalence, 
development and management over 6 years. Br J Surg. 1991;78(9):1122-5.
39. Brearley S. Should we screen for abdominal aortic aneurysm? Yes. BMJ. 2008;336(7649):862.
40. Dolk H, Loane M, Garne E, Group ESoCAEW. Congenital heart defects in Europe: prevalence and 
perinatal mortality, 2000 to 2005. Circulation. 2011;123(8):841-9.
41. Hoffman JI, Kaplan S, Liberthson RR. Prevalence of congenital heart disease. Am Heart J. 2004;147(3): 
425-39.
42. Mitchell SC, Korones SB, Berendes HW. Congenital heart disease in 56,109 births. Incidence and 
natural history. Circulation. 1971;43(3):323-32.
43. Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart disease in the general 
population: changing prevalence and age distribution. Circulation. 2007;115(2):163-72.
44. van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, et al. Birth 
prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am 
Coll Cardiol. 2011;58(21):2241-7.
45. van der Bom T, Bouma BJ, Meijboom FJ, Zwinderman AH, Mulder BJ. The prevalence of adult 
congenital heart disease, results from a systematic review and evidence based calculation. Am 
Heart J. 2012;164(4):568-75.
304
CHAPTER 15
46. Fernández-Hidalgo N, Tornos Mas P. Epidemiology of infective endocarditis in Spain in the last 20 
years. Rev Esp Cardiol (Engl Ed). 2013;66(9):728-33.
47. Fedeli U, Schievano E, Buonfrate D, Pellizzer G, Spolaore P. Increasing incidence and mortality of 
infective endocarditis: a population-based study through a record-linkage system. BMC Infect Dis. 
2011;11:48.
48. Patel DK, Green KD, Fudim M, Harrell FE, Wang TJ, Robbins MA. Racial differences in the 
prevalence of severe aortic stenosis. J Am Heart Assoc. 2014;3(3):e000879.
49. Hawker JI, Ayres JG, Blair I, Evans MR, Smith DL, Smith EG, et al. A large outbreak of Q fever in the 
West Midlands: windborne spread into a metropolitan area? Commun Dis Public Health. 
1998;1(3):180-7.
50. Tissot-Dupont H, Amadei MA, Nezri M, Raoult D. Wind in November, Q fever in December. Emerg 
Infect Dis. 2004;10(7):1264-9.
51. Kampschreur LM, Hagenaars JC, Wielders CC, Elsman P, Lestrade PJ, Koning OH, et al. Screening 
for Coxiella burnetii seroprevalence in chronic Q fever high-risk groups reveals the magnitude of the 
Dutch Q fever outbreak. Epidemiol Infect. 2013;141(4):847-51.
52. The individual, collective and public importance of vaccination. publication no 2013/21: Health 
Council of the Netherlands; 2013.
53. Wolfe RM. Update on adult immunizations. J Am Board Fam Med. 2012;25(4):496-510.
54. Verweij M, Houweling H. What is the responsibility of national government with respect to 
vaccination? Vaccine. 2014;32(52:7163-66.
305
COVERAGE OF THE Q FEVER VACCINATION CAMPAIGN
15
306
CHAPTER 15
Supporting Information
Ta
bl
e S
1  
 Ri
sk
-co
nd
iti
on
s f
or
 ch
ro
ni
c Q
 fe
ve
r i
n 
th
e I
PC
I-s
tu
dy
 p
op
ul
at
io
n,
 ac
co
rd
in
g t
o a
ge
 g
ro
up
s f
or
 ca
se
s w
ith
  
d
efi
n
it
e 
of
 p
ro
b
ab
le
 d
ia
g
n
os
ti
c 
ce
rt
ai
n
ty
. D
ist
rib
ut
io
n 
of
 th
e f
ul
l I
PC
I-s
tu
dy
 p
op
ul
at
io
n;
 nu
m
be
r o
f r
isk
- 
co
nd
iti
on
 ca
se
s i
n 
th
e I
PC
I-s
tu
dy
 p
op
ul
at
io
n;
 p
re
va
len
ce
 es
tim
ate
s o
f r
isk
-co
nd
iti
on
s p
er
 10
,00
0 a
cc
or
di
ng
  
to
 se
x, 
as
 ca
lcu
lat
ed
 fr
om
 th
e I
PC
I-s
tu
dy
 p
op
ul
at
io
n,
 w
ith
 lo
we
r a
nd
 u
pp
er
 li
m
its
.
IP
CI
-st
ud
y  
po
pu
la
tio
n 
(n
um
be
r)
15
-2
0
20
-3
0
30
-4
0
40
-5
0
50
-6
0
60
-7
0
70
-8
0
80
-9
0
> 
90
 yr
s
al
l
al
l
21
58
47
08
50
01
62
24
55
09
44
54
28
37
14
47
23
3
32
57
1
m
al
e
10
93
23
54
24
00
30
47
27
28
21
38
13
00
57
9
72
15
71
1
fe
m
al
e
10
65
23
54
26
01
31
77
27
81
23
16
15
37
86
8
16
1
16
86
0
m
al
e%
51
%
50
%
48
%
49
%
50
%
48
%
46
%
40
%
31
%
48
%
Ri
sk
-co
nd
iti
on
s (
nu
m
be
r d
ef
+p
ro
b)
he
ar
t v
al
ve
 d
ef
ec
t
3
8
11
35
49
13
4
19
3
15
9
38
63
0
ao
rti
c a
ne
ur
ys
m
/p
ro
s-
th
es
is 
    
    
  
0
1
0
6
19
37
61
45
4
17
3
co
ng
en
ita
l h
ea
rt 
an
om
-
al
y
14
20
11
18
8
11
3
3
0
88
en
do
ca
rd
iti
s
0
1
2
1
5
7
5
1
0
22
an
y r
isk
 co
nd
iti
on
14
26
22
57
72
17
6
23
6
19
8
40
84
1
m
al
e
5
14
8
26
36
95
12
1
96
12
41
3
fe
m
al
e
9
12
14
31
36
81
11
5
10
2
28
42
8
Pr
ev
al
en
ce
 of
 ri
sk
-co
nd
iti
on
s (
de
f+
pr
ob
) (
/10
,00
0)
he
ar
t v
al
ve
 d
ef
ec
t
14
17
22
56
89
30
1
68
0
10
99
16
31
19
3
m
al
e
9
21
17
46
77
31
8
66
2
10
71
15
28
17
3
fe
m
al
e
19
13
27
66
10
1
28
5
69
6
11
18
16
77
21
2
ao
rta
 an
eu
ry
sm
/p
ro
s-
th
es
is
0
2
0
10
34
83
21
5
31
1
17
2
53
m
al
e
0
4
0
13
51
12
6
37
7
63
9
41
7
86
fe
m
al
e
0
0
0
6
18
43
78
92
62
23
co
ng
en
ita
l h
ea
rt 
an
om
-
al
y
65
42
22
29
15
25
11
21
0
27
m
al
e
46
42
17
30
15
19
15
17
0
25
fe
m
al
e
85
42
27
28
14
30
7
23
0
29
en
do
ca
rd
iti
s
0
2
4
2
9
16
18
7
0
7
m
al
e
0
4
0
0
11
19
15
17
0
7
fe
m
al
e
0
0
8
3
7
13
20
0
0
7
an
y r
isk
-co
nd
iti
on
65
55
44
92
13
1
39
5
83
2
13
68
17
17
25
8
lo
w
er
 li
m
it
37
38
29
71
10
4
34
2
73
6
12
01
12
87
24
2
up
pe
r l
im
it
10
9
81
67
11
9
16
4
45
6
93
9
15
55
22
53
27
6
m
al
e
46
59
33
85
13
2
44
4
93
1
16
58
16
67
26
3
fe
m
al
e
85
51
54
98
12
9
35
0
74
8
11
75
17
39
25
4
307
COVERAGE OF THE Q FEVER VACCINATION CAMPAIGN
15
Ta
bl
e S
1  
 Ri
sk
-co
nd
iti
on
s f
or
 ch
ro
ni
c Q
 fe
ve
r i
n 
th
e I
PC
I-s
tu
dy
 p
op
ul
at
io
n,
 ac
co
rd
in
g t
o a
ge
 g
ro
up
s f
or
 ca
se
s w
ith
  
d
efi
n
it
e 
of
 p
ro
b
ab
le
 d
ia
g
n
os
ti
c 
ce
rt
ai
n
ty
. D
ist
rib
ut
io
n 
of
 th
e f
ul
l I
PC
I-s
tu
dy
 p
op
ul
at
io
n;
 nu
m
be
r o
f r
isk
- 
co
nd
iti
on
 ca
se
s i
n 
th
e I
PC
I-s
tu
dy
 p
op
ul
at
io
n;
 p
re
va
len
ce
 es
tim
ate
s o
f r
isk
-co
nd
iti
on
s p
er
 10
,00
0 a
cc
or
di
ng
  
to
 se
x, 
as
 ca
lcu
lat
ed
 fr
om
 th
e I
PC
I-s
tu
dy
 p
op
ul
at
io
n,
 w
ith
 lo
we
r a
nd
 u
pp
er
 li
m
its
.
IP
CI
-st
ud
y  
po
pu
la
tio
n 
(n
um
be
r)
15
-2
0
20
-3
0
30
-4
0
40
-5
0
50
-6
0
60
-7
0
70
-8
0
80
-9
0
> 
90
 yr
s
al
l
al
l
21
58
47
08
50
01
62
24
55
09
44
54
28
37
14
47
23
3
32
57
1
m
al
e
10
93
23
54
24
00
30
47
27
28
21
38
13
00
57
9
72
15
71
1
fe
m
al
e
10
65
23
54
26
01
31
77
27
81
23
16
15
37
86
8
16
1
16
86
0
m
al
e%
51
%
50
%
48
%
49
%
50
%
48
%
46
%
40
%
31
%
48
%
Ri
sk
-co
nd
iti
on
s (
nu
m
be
r d
ef
+p
ro
b)
he
ar
t v
al
ve
 d
ef
ec
t
3
8
11
35
49
13
4
19
3
15
9
38
63
0
ao
rti
c a
ne
ur
ys
m
/p
ro
s-
th
es
is 
    
    
  
0
1
0
6
19
37
61
45
4
17
3
co
ng
en
ita
l h
ea
rt 
an
om
-
al
y
14
20
11
18
8
11
3
3
0
88
en
do
ca
rd
iti
s
0
1
2
1
5
7
5
1
0
22
an
y r
isk
 co
nd
iti
on
14
26
22
57
72
17
6
23
6
19
8
40
84
1
m
al
e
5
14
8
26
36
95
12
1
96
12
41
3
fe
m
al
e
9
12
14
31
36
81
11
5
10
2
28
42
8
Pr
ev
al
en
ce
 of
 ri
sk
-co
nd
iti
on
s (
de
f+
pr
ob
) (
/10
,00
0)
he
ar
t v
al
ve
 d
ef
ec
t
14
17
22
56
89
30
1
68
0
10
99
16
31
19
3
m
al
e
9
21
17
46
77
31
8
66
2
10
71
15
28
17
3
fe
m
al
e
19
13
27
66
10
1
28
5
69
6
11
18
16
77
21
2
ao
rta
 an
eu
ry
sm
/p
ro
s-
th
es
is
0
2
0
10
34
83
21
5
31
1
17
2
53
m
al
e
0
4
0
13
51
12
6
37
7
63
9
41
7
86
fe
m
al
e
0
0
0
6
18
43
78
92
62
23
co
ng
en
ita
l h
ea
rt 
an
om
-
al
y
65
42
22
29
15
25
11
21
0
27
m
al
e
46
42
17
30
15
19
15
17
0
25
fe
m
al
e
85
42
27
28
14
30
7
23
0
29
en
do
ca
rd
iti
s
0
2
4
2
9
16
18
7
0
7
m
al
e
0
4
0
0
11
19
15
17
0
7
fe
m
al
e
0
0
8
3
7
13
20
0
0
7
an
y r
isk
-co
nd
iti
on
65
55
44
92
13
1
39
5
83
2
13
68
17
17
25
8
lo
w
er
 li
m
it
37
38
29
71
10
4
34
2
73
6
12
01
12
87
24
2
up
pe
r l
im
it
10
9
81
67
11
9
16
4
45
6
93
9
15
55
22
53
27
6
m
al
e
46
59
33
85
13
2
44
4
93
1
16
58
16
67
26
3
fe
m
al
e
85
51
54
98
12
9
35
0
74
8
11
75
17
39
25
4
308
CHAPTER 15
Ta
bl
e S
2  
 Es
tim
at
ed
 n
um
be
rs
 of
 p
eo
pl
e w
ith
 ri
sk
-co
nd
iti
on
s f
or
 ch
ro
ni
c Q
 fe
ve
r i
n 
th
e h
ig
h-
in
cid
en
ce
 ar
ea
. N
um
be
rs
 
sh
ow
n 
p
er
 a
ge
 g
ro
u
p
 a
nd
 s
ex
 b
as
ed
 o
n 
th
e 
p
re
va
le
nc
e 
ra
te
s 
fo
r 
ca
se
s 
w
it
h 
d
efi
n
it
e 
an
d
 p
ro
ba
bl
e 
d
ia
g
no
st
ic
 
ce
rta
in
ty
 fr
om
 th
e I
PC
I-s
tu
dy
 p
op
ul
at
io
n.
El
ig
ib
le
 p
eo
pl
e h
ig
h-
in
cid
en
ce
 ar
ea
(e
sti
m
at
ed
 n
um
be
rs
)
15
-2
0
20
-3
0
30
-4
0
40
-5
0
50
-6
0
60
-7
0
70
-8
0
80
-9
0
>9
0y
rs
al
l
H
ea
rt 
va
lv
e d
efe
ct
47
10
2
15
2
49
8
70
3
19
40
26
62
19
21
39
2
87
82
Lo
w
er
 li
m
it
16
52
85
35
8
53
2
16
42
23
22
16
57
29
2
81
28
Up
pe
r l
im
it
13
8
20
2
27
1
69
1
92
8
22
91
30
48
22
20
51
9
94
90
Ao
rta
 an
eu
ry
sm
/p
ro
sth
es
is
30
13
27
85
27
3
53
6
84
1
54
4
41
24
12
Lo
w
er
 li
m
it
0
2
0
39
17
5
38
9
65
7
40
8
16
20
79
Up
pe
r l
im
it
60
72
53
18
6
42
5
73
7
10
77
72
3
10
4
27
97
Co
ng
en
ita
l h
ea
rt 
an
om
aly
21
9
25
6
15
2
25
6
11
5
15
9
41
36
24
12
27
Lo
w
er
 li
m
it
13
1
16
6
85
16
2
58
89
14
12
0
99
6
Up
pe
r l
im
it
36
7
39
5
27
1
40
4
22
6
28
5
12
1
10
6
47
15
11
En
do
ca
rd
iti
s
30
13
28
14
72
10
1
69
12
24
a
30
7
Lo
w
er
 li
m
it
0
2
8
3
31
49
29
2
0
20
3
Up
pe
r l
im
it
60
72
10
0
81
16
8
20
9
16
1
68
47
46
4
An
y r
isk
 co
nd
iti
on
21
9
33
2
30
3
81
1
10
33
25
49
32
55
23
92
41
3
11
72
4
Lo
w
er
 li
m
it
12
5
22
7
20
0
62
6
82
1
22
04
28
79
21
00
31
0
10
96
5
Up
pe
r l
im
it
36
7
48
6
45
9
10
49
12
99
29
44
36
75
27
19
54
2
12
53
2
M
ale
80
18
4
11
6
38
1
52
8
14
46
16
88
10
43
89
59
22
Lo
w
er
 li
m
it
34
11
0
58
26
1
38
2
11
88
14
23
86
6
52
53
84
Up
pe
r l
im
it
18
6
30
9
22
8
55
7
72
8
17
58
19
96
12
47
14
3
65
13
Fe
m
ale
13
8
14
9
18
4
42
8
50
5
11
17
15
71
13
15
32
6
58
08
Lo
w
er
 li
m
it
73
85
11
0
30
2
36
6
90
2
13
17
10
94
23
1
52
89
Up
pe
r l
im
it
26
1
26
0
30
9
60
6
69
8
13
82
18
70
15
74
45
0
63
76
309
COVERAGE OF THE Q FEVER VACCINATION CAMPAIGN
15

Summary and conclusions
16

313
SUMMARY AND CONCLUSIONS
16
The Q fever outbreak in the Netherlands was the largest ever reported, and afflicted 
many people, especially those suffering from chronic sequelae of Q fever infection. 
The outbreak, however, also offered the opportunity to gain new insights in the 
interaction between C. burnetii and the immune system of the human host. A better 
understanding of host’s immune responses to C. burnetii infection and vaccination 
is important to improve prevention, diagnosis and treatment of the life-threaten-
ing disease chronic Q fever.
In this thesis, studies have been performed to investigate the immunological 
response to C. burnetii in healthy individuals and chronic Q fever patients, to develop 
a new diagnostic tool that adds in the diagnosis of Q fever, to assess the risk of 
immune-modulating drugs on the development chronic Q fever, to investigate the 
safety and immunogenicity of vaccination against C. burnetii in a highly relevant 
population of people at high-risk for chronic Q fever and to determine the coverage 
of this targeted vaccination campaign.
PART I.  Studies on the immune response against C. burnetii  
in (chronic) Q fever
The innate immune system has an essential role in the host defence against invading 
C. burnetii through recognition of the bacterial components and production of 
cytokines to activate anti-microbial mechanisms. Two main pattern recognition 
receptors (PRRs) of the host’s immune cells that recognize bacterial components 
are Toll-like receptors (TLRs) and nucleotide-binding oligomerization domain-like 
receptors (NLRs) NOD1 and NOD2 (1,2). Several reports suggest that TLR4 in mice 
is redundant for anti-C. burnetii responses, as is NOD2, while TLR2 is involved in 
recognition and host responses to avirulent phase II bacteria; TLR2 is however 
dispensable for clearance of phase I C. burnetii in vivo in mice (3-7). Little is known 
about the role of the various PRR for recognition of C. burnetii in humans. In 
Chapter 2, we investigated the role of several TLRs and NOD1 and NOD2, and the 
downstream of TLRs mitogen-activated protein kinases (MAPKs) - p38, JNK, and 
ERK - in the recognition and cytokine response against two C. burnetii phase I 
strains: the reference strain C. burnetii Nine Mile and the Dutch outbreak isolate 
C. burnetii 3262. We found that TLR1, TLR2 and NOD2 are involved in the cytokine 
responses against C. burnetii in human peripheral blood mononuclear cells 
(PBMCs), while TLR4 and NOD1 are not. Inhibition of TLR2, p38, JNK and ERK led 
to decreased cytokine response in C. burnetii-stimulated human PBMCs. PBMCs of 
individuals bearing the NOD2 3020insC mutation, causing loss of function of 
NOD2, had significantly lower cytokine responses to C. burnetii. The same was 
observed in PBMCs of human donors with genetic polymorphisms in TLR1 gene. 
The involvement of NOD2 and TLR1 in cytokine response to C. burnetii was 
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confirmed in experiments in which bone marrow-derived macrophages (BMDM) 
of NOD2 knockout mice and TLR1 knockout mice showed defective IL-6 production 
upon C. burnetii Nine Mile stimulation in vitro. Interestingly, in humans, TLR6 
seemed to be involved in cytokine responses to the Dutch isolate 3262, but not to 
the Nine Mile strain, based on the effect of genetic polymorphisms in the TLR6 
gene on cytokine production. This needs further research, but might be explained 
by different binding sites of the isolate 3262 to TLR6 than the Nine Mile strain. 
C. burnetii 3262 was the predominant genotype found during the Q fever outbreak 
in the Netherlands (8). Based on the fact that it caused such an unprecedented 
outbreak, one can hypothesize that this strain is more virulent than other strains. 
It can be questioned whether extended activation of the immune response by TLR6 is 
beneficial for the infected individual, as enhanced uptake of C. burnetii by monocytes 
and macrophages might favour the intracellular replication of C. burnetii.
Inadequate early recognition and cytokine response to C. burnetii may result in 
inefficient early clearance and increased likelihood to develop chronic Q fever. 
Genetic variants in immune cell receptors such as TLRs and NODs and their 
adaptors have been associated with increased susceptibility to bacterial infections 
(9-13). No study so far has been able to investigate this for chronic C. burnetii 
infection, due to the low prevalence of the disease. In the aftermath of the acute Q 
fever epidemic, a large number of patients with chronic Q fever were observed. In 
Chapter 3, we therefore investigated whether genetic variants in PRRs and adaptor 
proteins are associated with chronic Q fever. Twenty-four single nucleotide 
polymorphisms (SNPs) in genes encoding TLR1, TLR2, TLR4, TLR6, NOD2, 
αvβ3-integrin, CR3, and adaptors MyD88 and TIRAP were genotyped in 139 
chronic Q fever patients and in 220 control individuals with cardiovascular 
risk-factors and previous exposure to C. burnetii without development of chronic Q 
fever. Associations between these SNPs and chronic Q fever were analyzed and 
cytokine production in whole blood stimulation assays was correlated to relevant 
genotypes. These analyses identified polymorphisms TLR1 R80T, NOD2 1007fsX1 
and MYD88 -938C>A to be associated with development of chronic Q fever. 
Individuals carrying the TLR1 80R allele showed increased IL-10 production in 
whole blood upon C. burnetii exposure in vitro, which may contribute to the 
increased risk of chronic Q fever.
In Chapter 4, we investigated the IFN-γ response to C. burnetii in chronic Q fever 
patients. We found, in contrast to what has been generally assumed, that the IFN-γ 
response is not defective in chronic Q fever. We showed that immune cells of 
chronic Q fever patients are not only capable of a high IFN-γ response to C. burnetii, 
but also display up-regulation of genes downstream of the IFN-γ receptor in 
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addition to production of IFN-γ-dependent neopterin. We found that genetic 
polymorphisms in IL12B are associated with the development of chronic Q fever. 
Our findings can be linked to the observation that anti-C. burnetii antibody titers 
are high in chronic Q fever patients. Taken together, this strongly suggests that 
chronic Q fever patients do not have a defective adaptive immune response. More 
likely, the innate immune response, or the link between innate and adaptive 
immune response might be inadequate in these patients to clear the infection with 
C. burnetii in an early phase. We should, however, take into account that we studied 
the immune response of circulating blood mononuclear cells to C. burnetii. It may 
be more relevant to study the local immune response in C. burnetii infected vascular 
walls or valvular tissue. Both vascular and valvular chronic C. burnetii infection 
are mostly low-grade infections in which systemic immune activation is apparently 
not effective in clearing the local infection. The local immunological processes are 
crucial for survival of C. burnetii at predilection sites such as defective cardiac 
valves and aneurysms of the vascular wall. Previous immunohistochemical studies of 
C. burnetii-infected cardiac valves showed small, focal collections of infected 
mononuclear phagocytes (14,15). Characterization of these local immune cells and 
their immunological environment is subject to future research.
PART II.  Detection of C. burnetii infection using cell-mediated 
immune responses
The standard immunological method to detect Q fever is measurement of specific 
antibodies against phase I and phase II C. burnetii. In part II of this thesis, we 
investigated the usefulness of an alternative diagnostic method based on 
cell-mediated immune responses – i.e., by measuring IFN-γ production in blood 
after in vitro exposure to C. burnetii antigens.
An extensive study was performed to investigate the accuracy of this assay in 
diagnosing previous C. burnetii infection (past Q fever); this study is described in 
Chapter 5. The in-vitro IFN-γ production assay was carried out in a group of 1,525 
vaccination candidates. Different formats, using different C. burnetii antigens were 
tested, of which undiluted whole blood culture with Nine Mile antigens showed 
the best performance. All subjects were also screened by Q fever serology and 
skin-test, and these outcomes were related to the IFN-γ production. We performed 
Bayesian analysis that showed that the IFN-γ production assay had similar 
sensitivity and specificity as the combination of serology and skintest to detect 
previous infection with C. burnetii. Agreement between the tests was moderate; 
however, discordant results could not be resolved because there is no gold standard. 
We concluded that the IFN-γ production assay should be considered complimentary 
to Q fever serology.
316
CHAPTER 16
In Chapter 6 we investigated whether the measurement of IFN-γ production in C. 
burnetii-stimulated whole blood, in combination with other cytokines, could be 
used to differentiate a past (cleared) infection from an ongoing infection (chronic 
Q fever) with C. burnetii. We found that high IFN-γ in combination with low IL-2 
production was very specific for chronic Q fever. The relevance of measuring 
IFN-γ/IL-2 production profiles as diagnostic correlate of T-cell responses, has been 
studied outside the field of Q fever. The IFN-γ/IL-2 ratio reflects the type of effector 
and memory CD4+ T-cell response (16). Memory T-lymphocytes can broadly be 
defined as two distinct populations of effector memory T-cells and central memory 
T-cells. IFN-γ is predominately produced by effector T-cells and effector memory 
T-cells, while IL-2 is predominately produced by central memory T-cells. It is 
postulated that high IFN-γ/IL-2 ratio indicates predominance of effector T-cells 
and effector memory T-cells cells, resulting from ongoing immunological 
stimulation by a persistent infection. We concluded that the IFN-γ/IL-2 ratio could 
be used as an additional diagnostic marker in the timely diagnosis and early 
treatment of chronic Q fever to prevent severe morbidity and death.
In Chapter 7 we performed a longitudinal study to assess the applicability of the 
measurement of IFN-γ/IL-2 ratio in the follow-up during treatment of chronic Q fever 
patients. The current clinical, imaging and microbiological parameters to monitor 
the response to treatment are based on experts opinion and small-sized retro -
spective studies (17, 18), and clinicians experience difficulties in decision making 
about when antibiotic treatment can be discontinued. Thus, there is a need for additional 
biomarkers that correlate with treatment success and clearance of infection.
 We measured the C. burnetii-specific IFN-γ and IL-2 production in a whole- 
blood stimulation assay during a period of at least 18 months follow-up of 15 
proven chronic Q fever patients. We observed a trend in which the IFN-γ/IL-2 ratio 
declined when patients experienced a successful outcome of treatment. Patients in 
whom treatment failed, had overall lower IFN-γ/IL-2 ratios, which did not 
significantly decrease. Previous studies in viral infections and tuberculosis have 
correlated the T-cell IFN-γ and IL-2 production to antigen load (19); these studies 
showed that clearance of infection with decreasing antigen load coincides with a 
shift from predominantly IFN-γ secreting CD4+ T-cells to IL-2 secreting CD4+ 
T-cells. Our finding that the IFN-γ/IL-2 ratio declines during successful treatment 
of chronic Q fever, assuming decrease in antigen load, is in accordance with these 
studies. Patients with unsuccessful treatment show lower fluctuating IFN-γ/IL-2 
ratios from the start. They might have bacterial persistence with low antigen 
concentrations, an assumption that is supported by the notion that in most of 
these patients, C. burnetii DNA was not detectable in blood even before start of 
antimicrobial therapy.
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Another IFN-γ production assays has been developed during the Dutch Q fever 
epidemic, which is based on a technique of enzyme-linked immunosorbent 
spotting (Elispot); here antigen-specific IFN-γ secreting cells are detected by 
making them visible at a single-cell level (20). In Chapter 8, we compared the 
results of our IFN-γ production assay with the results of a Coxiella Elispot in a 
group of 16 chronic Q fever patients and 17 healthy control individuals. We found 
that these techniques had similar high sensitivity (14/16, 88%) to discriminate 
patients from controls, but the Coxiella Elispot seemed to be more specific than the 
IFN-γ production assay when Nine Mile was used as stimulating antigen. 
Interestingly, the quantitative outcomes of both assays showed moderate 
correlation. The discrepancies can be explained by the different origins and 
concentrations of stimulating antigens, the different phase variation, or the method 
of inactivation of the antigen stimuli. Moreover, it may well be true that the amount 
of IFN-γ produced and released is not directly related to the number of IFN-γ 
positive T-cells.
 The observations in this study, and in our previous studies of IFN-γ production 
assays in C. burnetii infection, show the potential of measuring cell-mediated 
immune responses for the diagnosis of past or chronic Q fever. IFN-γ based 
assays are already routinely used for detection of immunity to Mycobacterium 
tuberculosis and commercial kits are available for the two types of assays, e.g. the 
QuantiFERON-TB and the T Spot TB (21). These assays have been reported to be at 
least as accurate as the tuberculin skin test to detect exposure to M. tuberculosis.
In Chapter 9 we wanted to investigate the timing and extent of Coxiella-specific 
IFN-γ responses in an acute C. burnetii infection (acute Q fever). For this purpose, 
we used a model in which immunocompetent BALB/c mice were challenged with 
aerosols containing virulent phase I C. burnetii. The production of other cytokines 
was also measured in an effort to identify other potential diagnostic markers for 
acute Q fever. Whole blood incubation proved to be cumbersome in mice; as an 
alternative, splenocyte cultures were used for measurement of C. burnetii induced 
cytokine responses. This model demonstrated that C. burnetii-induced IFN-γ could 
be used to detect acute C. burnetii infection in mice, and this is likely to be the case 
in humans as well. Antigen-specific production of IFN-γ and IFN-γ-induced 
protein-10 (IP-10) were both detectable prior to elevation of specific IgG antibodies. 
This study also showed antigen-specific induction of IL-6, keratinocyte-derived 
cytokine (KC), and monocyte chemotactic protein-1 (MCP-1) from splenocyte 
cultures.
The central position of serology in Q fever diagnostic is undisputable, and serology 
has hitherto been the most widely used immunological measurement for C. burnetii 
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infection. It continues to be extensively validated in Q fever research (22-25). In the 
light of waning antibody titres years after infection, and the ongoing debate of 
cutoff values of serology for diagnosis of chronic Q fever, and the meaning of 
persistently high antibody titers without clinical signs or symptoms of chronic 
Q fever, we conclude that it would be valuable to take into account the more 
relevant cell-mediated immune response as an additional diagnostic tool.
PART III.  Immunosuppressive drugs for rheumatoid arthritis as  
a risk factor for chronic Q fever
Immune suppression is a stated risk factor for development of chronic Q fever, 
which is based on animal studies and on limited human case series. The type of 
immune suppression that increases the risk for chronic Q fever has not been clearly 
defined. We hypothesized that the use of TNF-blockers in patients with rheumatoid 
arthritis (RA) or other inflammatory conditions might specifically increase the risk 
for chronic Q fever, as it does for other infections with intracellular bacteria such 
as M. tuberculosis. In Chapter 10 we describe a study to the prevalence of anti-C. 
burnetii antibodies in RA patients with and without anti-TNF therapy living in the 
Q fever outbreak area. We identified cases of chronic Q fever in these cohorts. We 
found a similar prevalence of C. burnetii infection in RA patients with and without 
TNF-blockers. In the group of patients with TNF-blockers, 12.3% (7/57) of those 
with anti-C. burnetii antibodies were diagnosed with chronic Q fever, compared to 
5.5% (3/55) in the anti-TNF naïve patient group (P=0.32). With this small number of 
cases, and consequently limited power, only a large effect (>four-fold) of anti-TNF 
therapy on the risk for chronic Q fever could have been detected. Interestingly, 
univariate analysis in all C. burnetii-infected RA patients (n=102), suggested that 
corticosteroid use was associated with development of chronic Q fever. Multivariate 
analysis could not be performed, due to low number of cases. Of note, the observed 
prevalence of chronic Q fever in C. burnetii-infected RA patients was considerably 
higher (8,9%) than previously reported in non-selected infected individuals in the 
same area (1,6%) (23). This indicates that RA and its treatment, either with or 
without anti-TNF, may be considered as a risk factor for the  development of 
chronic Q fever. Therefore, we advise that in case of C. burnetii infection, all patients 
with RA should be carefully monitored for progression to chronic Q fever.
In Chapter 11 we present a case history of a RA patient with acute Q fever while 
being treated with anti-TNF agents, who developed chronic Q fever while being 
switched to treatment with the anti-B-cell (anti-CD20) monoclonal antibody 
rituximab. We observed in this patient that the use of anti-TNFα agents for RA in 
the acute phase of Q fever does not seem to impede the C. burnetii-specific 
serological response. However an intact humoral response did not prevent 
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progression to chronic C. burnetii infection, most likely because essential cellular 
immune responses were suppressed in the acute phase of the infection. Even 
though anti-B-cell therapy with rituximab was started after the acute Q fever 
episode, an increase in anti-C. burnetii phase I antibodies was observed, leading to 
the diagnosis of chronic Q fever. We assume that C. burnetii-specific CD20-negative 
memory B-cells are responsible for this rise in antibody titres.
 It is tempting to speculate that B-cell depleting medication during the first 
contact with neo-antigens of C. burnetii would have seriously hampered the 
development of any antibody response and the diagnosis of Q fever based on 
serological titers. In this case, we did not perform IFN-γ production measurements 
in whole blood stimulated with C. burnetii.
PART IV. Prevention of Q fever by vaccination against C. burnetii
Vaccination against C. burnetii can be performed to protect people against Q fever. 
There is one vaccine for human use available worldwide, Q-vax, which is an 
inactivated whole-cell vaccine.
 According to the manufacturer’s protocol, pre-vaccination Q fever screening 
with skin-testing and serology should be performed to exclude people with past 
Q fever who are presumed to have an increased risk for immune-mediated adverse 
events following vaccination. In the Dutch Q fever outbreak, the authorities 
decided to vaccinate people with cardiac valvular/vascular risk factors for chronic 
Q fever living in the Q fever epidemic area. This was a unique decision; C. burnetii 
vaccination has been previously only used in people at occupational risk for C. 
burnetii infection, which comprises an overall younger and healthier population.
In Chapter 12, we describe the safety and adverse events (AE) after Q fever skin 
test and vaccination in the Dutch Q fever vaccination campaign. Vaccination of 
1370 patients did not reveal unexpected AE; however, 80% of vaccinees reported 
local AE, of which 26% were pronounced or extensive. Two causally-related serious 
AE (SAE; 0.1%) were reported, both concerning a persistent subcutaneous injection 
site mass, with no signs of abscess or granuloma formation. Although we cannot 
conclude with certainty, it seems that these were not due to immunological 
responses to the vaccine; rather they were the effect of deposition of the vaccine too 
deep above the tendon insertion area of the M. deltoideus. The occurrence of local 
AE after vaccination was associated with occurrence of local AE after skin-test 
(with negative skin test reading at day 7) and high IFN-γ production pre-vaccination.
 Vaccinees with local AE after skin-test or after vaccination appear to have 
more pronounced post-vaccination immune responses, based on Q fever serology 
and IFN-γ production assay results 6 months after vaccination. We conclude from 
the data collected and analyzed in this study that Q fever vaccination was safe but 
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reactogenic in the high-risk population with valvular/vascular risk factors for 
chronic Q fever. Rates of local AE were higher in women, younger age groups and 
in those with positive immunological parameters before vaccination.
In Chapter 13, we assessed in a random sample of the 260 vaccinees, the post- 
vaccination immune responses to C. burnetii, 6 and 12 months after vaccination. 
At 6 months, we found that 46% of vaccinees showed low anti-C. burnetii antibody 
titres and 67% had a positive IFN-γ production assay result. At twelve months, 
both were 60%. For comparison, serological results of 200 individuals with a 
natural Q fever infection were positive in 99.5% at 6 and 12 months after infection, 
with relatively higher antibody titres. Thus, the immune response after Q-vax 
vaccination is lower and restricted to a smaller proportion than found after a 
natural Q fever infection. Previous studies of on immune responses after 
vaccination in Australian abattoir employees, farmers and veterinarians reported 
higher rates of seroconversion and cellular immune responses after vaccination 
(26-28), suggesting decreased vaccine immunogenicity in our older population 
with risk factors for chronic Q fever.
 Interestingly, in this study we observed that vaccinees with a positive outcome 
in the IFN-γ assay pre-vaccination showed a higher seroconversion rate than IFN-γ 
negative vaccinees: 74% vs. 41% (P<0.001). We conclude from this that a positive 
IFN-γ assay before vaccination in seronegative vaccinees likely points to pre- 
existing immunity resulting in boosting by vaccination.
Chapter 14 focused on the skin test, which, as an in-vivo intracutaneous test, can 
elicit an immune response itself. We showed that the intracutaneous Q fever test, 
containing a low dose of Q-vax antigen, induces clear C. burnetii-specific immune 
responses in about half of the tested individuals with a positive Q fever skin test. 
In addition, a median 2-fold increase in antibody titre was found in patients with 
positive serology in pre-vaccination screening. Since all individuals in this study 
had evidence of pre-existing immunity (either a positive skin test or positive 
serology), this immune response should be considered as a boosting effect of the 
skin test. A similar boosting effect is described for the tuberculin skin test (TST) on 
subsequent interferon-γ release assay (IGRA) responses; these tests are often used 
in combination to diagnose latent tuberculosis (29). This phenomenon makes it 
difficult for clinicians to discriminate between boosting and conversion of any 
increase in the IGRA response after TST. Likewise, clinicians and epidemiologist 
in the field of Q fever should be aware of the phenomenon that individuals who 
have had a skin test, as is the current practice in Q fever pre-vaccination screening, 
may develop higher anti-C. burnetii antibody titres and a more robust in-vitro 
IFN-γ release in follow-up measurements.
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In Chapter 15, we aimed to evaluate the quantitative performance of the Q fever 
vaccination campaign in the Netherlands in 2011, which targeted all people at risk 
for chronic Q fever living in the Q fever epidemic area. Prevalence data for the 
defined risk-conditions were not available at the time and no disease registers exist 
in the Netherlands. As a consequence, it was unclear before and after the vaccination 
campaign, what percentage of the target group had been vaccinated against Q fever. 
In this retrospective cohort study, we set out to estimate the coverage of the 
vaccination. We first identified the number of people with the predefined risk 
conditions for chronic Q fever in a random sample of a population-based database, 
from which we calculated the stratified prevalence estimates. After that, we 
extrapolated these prevalence data to the population of the high-incidence area of 
the Q fever epidemic, and arrived at an approximation of about 12,000 people with a 
definite or probable cardiovascular condition predisposing to chronic Q fever for 
this particular area. Using the recorded number of people actually screened for 
Q fever vaccination from this area, we estimated the overall coverage to be 11%. 
The adjusted coverage estimate, based on the larger  group of referred people, was 
18%. This low estimated coverage should be interpreted in the light of the complexity 
of this target-group with much co-morbidity, and of the vaccination procedure that 
required two visits to a municipal health clinic with an invasive pre-vaccination 
screening. In addition, it is known that coverage for other adult risk-group vaccination 
is often disappointingly low, even after official and repeated recommendations. For 
example, the hepatitis B vaccination for men  having sex with men has an estimated 
annual coverage of only 1% in the Netherlands (30). Since the Q fever epidemic 
waned in subsequent years, the Q fever vaccination was limited to January-April 
2011, and was not continued in the years that followed.
Future perspectives
The studies in this thesis have given us new insights in the immunology of Q fever, 
but many questions are still unanswered and even more new questions have 
arisen. Our future research shall mainly focus on deciphering the innate immune 
response of the host against C. burnetii, and find out which factors predispose 
individuals to inefficient clearance of the infection leading to a chronic infection. 
Even though we found that IFN-γ is not deficient in chronic Q fever patients, we 
wonder whether patients that do not improve during long-term antibiotic treatment 
would benefit from adjunctive immune-stimulatory therapy with IFN-γ at 
pharmacologic dosages. Enhancing the host defence mechanisms by activating 
mononuclear phagocytes, might be beneficial to chronic Q fever patients with low 
IFN-γ production to C. burnetii in vitro in the first place.
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Another important question to be answered is how C. burnetii is able to survive 
inside mononuclear cells at predilection sites such as cardiac valve tissues and 
aneurysm vascular wall. Better understanding the local immunological environment 
in aneurysms infected by C. burnetii and the mechanisms involved in damaging of 
the tissue might be the key to better treatment options for chronic Q fever patients.
In conclusion, by increasing our knowledge on immunological aspects of Q fever, 
we can improve the care for patients suffering from this infectious disease.
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De grote Q-koorts epidemie in Nederland tussen 2007 en 2010 heeft veel mensen 
getroffen, van wie velen nu nog steeds klachten ondervinden. Deze uitbraak heeft 
echter ook de mogelijkheid geboden tot wetenschappelijk onderzoek naar de 
interactie tussen de Q-koorts bacterie - Coxiella burnetii - en het menselijk afweer-
systeem. Meer begrip over deze zogenaamde ‘immunologische’ aspecten van 
Q-koorts zal bijdragen aan betere mogelijkheden om Q-koorts te voorkomen, te 
diagnosticeren en effectief te behandelen.
 Dit proefschrift beschrijft een aantal studies naar de immunologie van 
C. burnetii infectie in het licht van chronische Q-koorts en Q-koorts vaccinatie. In 
deel I bestuderen we de immuun respons tegen C. burnetii bij gezonde vrijwilligers 
en Q-koorts patiënten. In deel II beschrijven we een nieuwe diagnostische test 
voor Q-koorts, die gebaseerd is op immunologische methoden. In deel III onder- 
zoeken we het verband tussen het gebruik van immunomodulerende geneesmiddelen 
bij reumatoïde artritis en de ontwikkeling van chronische Q-koorts. In deel IV 
beschrijven we de veiligheid en immunogeniciteit van vaccinatie tegen C. burnetii 
en de dekkingsgraad van de Nederlandse Q-koorts vaccinatie campagne.
Hoofdstuk 1 is een algemene inleiding over Q-koorts met de nadruk op immuno- 
logische aspecten van C. burnetii infectie. Tevens wordt hierin een overzicht gegeven 
van de inhoud en de doelen van dit proefschrift.
DEEL I.  Studies naar de immuun respons tegen C. burnetii  
bij (chronische) Q-koorts
Het aangeboren immuun systeem beschermt de gastheer tegen C. burnetii door 
herkenning van onderdelen van de bacterie en productie van signaalstoffen – 
cytokines – , waardoor antimicrobiële mechanismen in werking worden gezet. De 
bacteriële componenten worden o.a. herkend door – op immuun cellen aanwezige 
– Toll-like receptoren (TLRs) en nucleotide-binding oligomerization domain-like 
receptoren (NLRs; NOD1 en NOD2) [1,2]. Eerdere studies hebben laten zien dat 
TLR4 bij muizen geen rol van betekenis speelt in de afweer-reactie tegen C. burnetii. 
Hetzelfde geldt voor NOD2. Daarentegen zou TLR2 betrokken zijn bij de 
herkenning en immuun respons tegen de avirulente C. burnetii fase II, terwijl er 
voor het opruimen van de virulente C. burnetii fase I geen tussenkomst van TLR2 
is aangetoond in muisexperimenten [3-7]. Het is nog niet goed bekend of in 
menselijke afweercellen deze receptoren betrokken zijn bij de herkenning van 
C. burnetii. 
 In hoofdstuk 2 onderzochten we de rol van verschillende TLRs, NLRs en van 
de adapter moleculen p38, JNK, en ERK, bij de cytokine respons op C. burnetii van 
humane perifeer bloed mononucleaire cellen (PBMCs). Hiervoor gebruikten we 
twee verschillende C. burnetii stammen: De laboratorium stam ‘Nine Mile’ (de 
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referentie stam) en de ‘3262’ stam, de Nederlandse uitbraak stam. We vonden dat 
TLR1, TLR2 en NOD2 zijn betrokken bij de cytokine respons tegen C. burnetii door 
PBMCs, en TLR4 en NOD1 niet. Blokkade van TLR2, p38, JNK en ERK leidde tot 
een verminderde cytokine respons in C. burnetii-gestimuleerde humane PBMCs. 
PBMCs van individuen met een NOD2 3020insC mutatie, waardoor NOD2 niet 
meer werkt, hadden een significante verminderde cytokine respons tegen C. burnetii. 
Dit laatste werd ook gezien in PBMCs van gezonde vrijwilligers met genetische 
polymorfismen in het TLR1 gen. De betrokkenheid van NOD2 en TLR1 werd 
bevestigd in experimenten met macrofagen verkregen uit beenmerg van muizen. 
Macrofagen van NOD2 knock-out muizen en TLR1 knock-out muizen produceerden 
minder interleukine-6 (IL-6) dan macrofagen van wildtype muizen, wanneer deze 
in vitro werden geïncubeerd met C. burnetii. Verrassend genoeg lijkt het erop dat bij 
mensen TLR6 is betrokken bij de cytokine respons tegen C. burnetii 3262, maar niet 
tegen C. burnetii Nine Mile, gebaseerd op het verschil in effect van genetische 
polymorfisme in het TLR6 gen dat we observeerden tussen beide stammen. Dit 
moet verder worden onderzocht, maar een verklaring zou kunnen zijn dat TLR6 
verschillende bindingsplekken heeft voor 3262 en Nine Mile. C. burnetii 3262 was 
de overheersende stam die werd geïsoleerd tijdens de Nederlandse Q-koorts 
uitbraak [8]. Dat deze stam in staat was om een uitbraak van dergelijke omvang te 
veroorzaken, doet vermoeden dat deze stam virulenter is dan andere stammen. De 
vraag is of een overmatige immuun respons via TLR6 gunstig is voor de gastheer, 
wanneer er meer C. burnetii in monocyten en macrofagen wordt opgenomen, of dat 
er daardoor mogelijk een voordeel is voor C. burnetii voor intracellulaire vermenig-
vuldiging.
Wij veronderstelden dat een inadequate vroege herkenning van C. burnetii bijdraagt 
aan het risico op de ontwikkeling van een persisterende infectie met C. burnetii, 
oftewel chronische Q-koorts. Eerdere studies naar andere bacteriële- en schimmel-
infecties hebben aangetoond dat genetische variatie in TLRs en NLRs en 
bijbehorende adaptors geassocieerd is met verschil in vatbaarheid voor de 
desbetreffende infecties en de klinische uitkomst ervan [9-13]. Tot op heden is er 
nog geen studie verricht die een dergelijk verband voor chronische Q-koorts 
onderzocht, mede vanwege de lage prevalentie van de ziekte. In de nasleep van de 
Nederlandse Q-koorts uitbraak waren er veel chronische Q-koorts patiënten, 
waardoor deze studie mogelijk was. In hoofdstuk 3 beschrijven we de resultaten 
van onze studie naar de associatie tussen genetische variaties in TLRs, NLRs en 
adaptor moleculen en de ontwikkeling van chronische Q-koorts. In deze studie 
werden 24 single nucleotide polymorphisms (SNPs) in de genen voor TLR1, TLR2, 
TLR4, TLR6, NOD2, αvβ3-integrin, CR3, en de adaptors MyD88 en TIRAP 
getypeerd bij 139 chronische Q-koorts patiënten en bij 220 controle individuen 
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met cardiovasculaire risicofactoren voor chronische Q-koorts en blootstelling aan 
C. burnetii echter zonder ontwikkeling van chronische Q-koorts. De associatie 
tussen deze SNPs en chronische Q-koorts werd geanalyseerd en de cytokine 
productie in volbloed stimulatie assays werd gecorreleerd aan de relevante 
genotypes. Dit toonde aan dat de polymorfismen TLR1 R80T, NOD2 1007fsX1 and 
MYD88 -938C>A geassocieerd zijn met chronische Q-koorts. In het bloed van 
individuen met het TLR1 80R risico allel werd in vitro na toevoegen van C. burnetii 
een verhoogde productie van het anti-inflammatoire cytokine IL-10 gevonden, wat 
kan bijdragen aan het risico op een persisterende infectie.
 
In hoofdstuk 4 onderzochten we bij chronische Q-koorts patiënten de IFN-γ 
respons van hun immuun cellen op C. burnetii. We vonden, in tegenstelling tot wat 
algemeen werd aangenomen, dat de IFN-γ respons niet defect is in chronische 
Q-koorts. We toonden aan dat immuun cellen van chronische Q-koorts patiënten 
niet alleen in staat zijn tot een heftigere IFN-γ respons op C. burnetii, maar dat er 
tevens een toegenomen afschrift is van genen stroomafwaarts van de IFN-γ 
receptor, en dat een verhoogde productie plaatsvindt van neopterine, dat IFN-γ 
afhankelijk is. We vonden dat genetische polymorfismen in IL12B geassocieerd 
zijn met de ontwikkeling van chronische Q-koorts. Deze bevindingen gaan samen 
met de observatie dat chronische Q-koorts patiënten hoge anti-C. burnetii antistof 
titers hebben. Dit suggereert dat chronische Q-koorts patiënten niet een defecte 
verworven immuun respons hebben. Het is waarschijnlijker dat de aangeboren 
immuun respons, of de verbinding tussen de aangeboren en de verworven 
immuun respons, bij deze patiënten niet effectief is om de infectie met C. burnetii 
in een vroege fase te bestrijden. Als kanttekening moet worden geplaatst dat we de 
immuun respons van circulerende mononucleaire cellen op C. burnetii hebben 
bestudeerd. Het zou relevant zijn om de locale immuun respons tegen C. burnetii te 
bestuderen in geïnfecteerd vaatweefsel of hartkleppen. Zowel vasculaire als 
valvulaire chronische C. burnetii infecties zijn laaggradige infecties waarbij 
systemische immunologische activatie klaarblijkelijk niet in staat is om de lokale 
infectie effectief te bestrijden. De lokale immunologische processen zijn cruciaal 
voor de overleving van C. burnetii ter plaatse. Eerdere studies waarin immuno- 
histochemie van C. burnetii-geïnfecteerde hartkleppen is verricht, lieten focale 
ophopingen zien van geïnfecteerde mononucleaire cellen [14, 15]. Toekomstig 
onderzoek zal zich richten op het karakteriseren van deze immuun cellen en de 
immuun respons ter plaatse in geïnfecteerd weefsel. 
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DEEL II.  Diagnostiek naar Q-koorts: detectie van cellulaire 
immuun respons tegen C. burnetii 
Serologie is de huidige standaard immunologische test voor Q-koorts; dit houdt in 
dat antistoffen tegen fase I en fase II C. burnetii worden gemeten. In deel II van dit 
proefschrift onderzoeken we een alternatieve diagnostische methode voor 
Q-koorts. Deze methode is gebaseerd op de cellulaire immuun respons, waarbij 
IFN-γ productie in bloed wordt gemeten na in-vitro incubatie met C. burnetii 
antigenen.
Een uitgebreide studie werd verricht naar de nauwkeurigheid van deze methode 
bij het vaststellen van doorgemaakte Q-koorts. Deze studie is beschreven in 
hoofdstuk 5. De in-vitro IFN-γ productie meting (“IFN-γ test”) werd uitgevoerd in 
een groep van 1525 vaccinatie kandidaten. Alle deelnemers werden ook gescreend 
op Q-koorts door middel van serologie en een huidtest, waarvan de uitkomst werd 
vergeleken met die van de IFN-γ test. De IFN-γ test werd op verschillende 
manieren uitgevoerd. Het gebruik van onverdund volbloed geïncubeerd met fase 
I C. burnetii Nine Mile, liet de hoogste nauwkeurigheid zien. Bayesiaanse analyse 
toonde aan dat de IFN-γ test in deze vorm een sensitiviteit en specificiteit heeft 
die vergelijkbaar zijn met de combinatie van serologie en de huidtest, om een 
doorgemaakte Q-koorts aan te tonen. De overeenkomst tussen de uitkomsten van 
de testen was matig. Echter, disconcordante uitkomsten konden niet verder worden 
opgelost bij gebrek aan een gouden standaard. 
In hoofdstuk 6 onderzochten we of het meten van in-vitro IFN-γ productie in 
C. burnetii-gestimuleerd volbloed, in combinatie met het meten van andere cytokines, 
kan differentiëren tussen doorgemaakte Q-koorts (waarbij geen persisterende 
infectie is opgetreden) en chronische Q-koorts. We vonden dat een hoge IFN-γ 
productie in combinatie met een lage IL-2 productie heel specifiek is voor 
chronische Q-koorts. De relevantie van het meten van het IFN-γ/IL-2 productie 
profiel als weerspiegeling van het type T-cel respons is beschreven buiten het veld 
van Q-koorts. De IFN-γ/IL-2 ratio correleert met het type effector en memory 
CD4+ T-cel respons [16]. Memory T-cel lymfocyten worden onderscheiden in twee 
populaties: effector memory T-cellen en central memory T-cellen. IFN-γ wordt 
vooral geproduceerd door effector T-cellen en effector memory T-cellen, terwijl 
IL-2 vooral wordt geproduceerd door central memory T-cellen. Algemeen wordt 
aangenomen dat een hoge IFN-γ/IL-2 ratio duidt op dominantie van effector 
T-cellen en effector memory T-cellen, veroorzaakt door aanhoudende immuno-
logische stimulatie door een persisterende infectie. Een lage IFN-γ/IL-2 ratio wijst 
op activatie van central memory T-cellen die aanwezig zijn na een geklaarde 
infectie. In lijn met deze bevindingen, vonden wij in onze studie dat chronische 
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Q-koorts patiënten zich onderscheiden van individuen met een doorgemaakte 
Q-koorts door een hoge IFN-γ/IL-2 ratio, met een specificiteit van 96%. We 
concludeerden dat de C. burnetii geïnduceerde IFN-γ/IL-2 ratio gebruikt kan 
worden als additionele marker voor de diagnostiek van chronische Q-koorts. 
Tijdige detectie en behandeling van chronische Q-koorts kan ernstige morbiditeit 
en overlijden voorkomen. 
In hoofdstuk 7 hebben we een longitudinale studie verricht om de bruikbaarheid 
vast te stellen van het meten van de in-vitro IFN-γ/IL-2 ratio gedurende de 
behandeling en follow-up van chronische Q-koorts patiënten. De huidige klinische 
en microbiologische parameters voor het monitoren van het effect van behandeling 
zijn gebaseerd op kleine retrospectieve studies en op adviezen van experts [17,18]. 
Vanwege het gebrek aan betrouwbare parameters is het voor behandelend artsen 
moeilijk om te beslissen wanneer antibiotische behandeling kan worden gestopt. 
Er is dus behoefte aan nieuwe biomarkers die correleren met het behandelsucces 
en het klaren van de infectie.
 In deze studie hebben we C. burnetii-specifieke IFN-γ en IL-2 productie 
gemeten in een volbloed stimulatie assay gedurende een follow-up van tenminste 
18 maanden van 15 bewezen chronische Q-koorts patiënten. Er was een duidelijke 
trend te zien waarin de IFN-γ/IL-2 ratio afnam bij patiënten met een succesvolle 
uitkomst van de behandeling. Patiënten bij wie de behandeling faalde, hadden 
over het algemeen aanvankelijk al een lagere IFN-γ/IL-2 ratio die niet verder 
afnam gedurende behandeling. Eerdere studies naar virale infecties en tuberculose 
hebben de correlatie onderzocht tussen de T-cell IFN-γ en IL-2 productie en de 
antigeen last [19]; deze studies hebben laten zien dat klaring van een infectie, 
gepaard gaande met een vermindering van de antigeen last, leidt tot een 
verschuiving van de aanwezigheid van hoofdzakelijk IFN-γ producerende CD4+ 
T-cellen naar IL-2 producerende CD4+ T-cellen. Onze bevinding dat de IFN-γ/IL-2 
ratio afneemt gedurende succesvolle behandeling van chronische Q-koorts, met 
daarbij een aannemelijke afname van de antigeen last, komt daarmee overeen. 
Patiënten met falende therapie hadden zoals gezegd wisselend lage IFN-γ/IL-2 
ratio’s. Bij hen is er blijkbaar sprake van een persisterende infectie met een lage 
antigeen last. Deze veronderstelling wordt ondersteund door het feit dat juist bij de 
meeste van deze patiënten de PCR voor C. burnetii DNA in bloed negatief is, zelfs 
vóór start van antimicrobiële therapie. 
Een andere IFN-γ specifieke test voor Q-koorts die tijdens de Nederlandse Q-koorts 
epidemie is ontwikkeld, is gebaseerd is op de techniek van enzyme-linked 
immunosorbent spotting (Coxiella Elispot). In deze test worden antigeen-specifieke 
IFN-γ producerende immuun cellen gedetecteerd op single-cell niveau [20]. In 
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hoofdstuk 8 hebben we de resultaten van de IFN-γ test vergeleken met die van de 
Coxiella Elispot in een groep van 16 chronische Q-koorts patiënten en 17 gezonde 
controle individuen. In deze groepen hadden de technieken een vergelijkbare hoge 
sensitiviteit (14/16, 88%) voor het onderscheid tussen patiënten en controle 
inidividuen, maar de Coxiella Elispot leek iets specifieker dan de IFN-γ test 
wanneer Nine Mile werd gebruikt als antigeen. Opvallend was dat de uitkomsten 
van de testen een matige correlatie lieten zien. De discrepantie kan worden 
verklaard door verschil in herkomst en concentratie van de antigenen, het fase 
verschil van het Coxiella lipopolysacharide, en het verschil in methode van 
inactivatie van de bacteriën. Bovendien is het zeer aannemelijk dat de hoogte van 
de IFN-γ productie en afgifte van IFN-γ niet direct correleert met de hoeveelheid 
IFN-γ positieve T-cellen. 
De hiervóór beschreven studies met betrekking tot de IFN-γ productie test voor 
het aantonen van C. burnetii infectie, laten de potentie zien van het meten van de 
cellulaire immuun respons voor de diagnose van doorgemaakte en chronische 
Q-koorts. IFN-γ specifieke testen worden reeds routinematig gebruikt voor het 
aantonen van de immuun respons tegen Mycobacterium tuberculosis. Er zijn 
commerciële tests beschikbaar, de QuantiFERON-TB and the T Spot TB [21], die in 
studies minstens zo accuraat blijken te zijn als de tuberculine huidtest (“Mantoux 
test”) voor het aantonen van latente tuberculose.
In hoofdstuk 9 onderzochten we de timing en de hoogte van de C. burnetii-speci-
fieke IFN-γ productie bij een acute C. burnetii infectie (acute Q-fever). Hiervoor 
gebruikten we een muismodel waarin immunocompetente BALB/c muizen werden 
blootgesteld aan aerosolen met virulente fase I C. burnetii. De productie van andere 
cytokines werd ook gemeten om andere potentiële diagnostische markers voor 
acute Q-koorts vast te stellen. Omdat volbloed incubatie bij muizen lastig bleek te zijn, 
werd gekozen voor in-vitro incubatie van splenocyten om C. burnetii-geïnduceerde 
cytokine productie te meten. Dit model liet zien dat C. burnetii-specifieke IFN-γ 
productie gebruikt kan worden om acute Q-koorts aan te tonen bij muizen. Het is 
aannemelijk dat dit ook bij mensen het geval is. C. burnetii-specifieke IFN-γ en 
IFN-γ geïnduceerd proteine-10 (IP-10) waren verhoogd voordat IgG-specifieke 
antistoffen aantoonbaar waren. Deze studie liet in splenocyten van C. burnetii- 
geïnfecteerde muizen ook C. burnetii-specifieke inductie zien van IL-6, evenals 
 keratinocyte-derived cytokine (KC) en monocyte chemotactic protein-1 (MCP-1). 
Tot op heden vervult serologie een centrale rol in de immunologische detectie van 
Q-koorts. Er wordt nog steeds onderzoek verricht ter validatie en optimalisatie 
van Q-koorts serologie [22-25]. In het licht van dalende serologische titers in de 
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jaren na infectie, en het aanhoudende debat over het afkappunt van serologische 
titers in de diagnostiek naar chronische Q-koorts, kan het meten van de cellulaire 
immuun respons – bijvoorbeeld met de IFN-γ test – waarschijnlijk van toegevoegde 
waarde zijn. Onderzoek hiernaar verdient verdere aandacht.
DEEL III.  Immunosuppressiva en reumatoide artritis als 
risicofactoren voor chronische Q-koorts
Immunosuppressie is een risicofactor voor chronische Q-koorts, zoals blijkt uit 
dierstudies en beschrijvingen van infecties bij mensen. Echter, het type immuno-
suppressie dat het risico op chronische Q-koorts verhoogt, is niet goed gedefinieerd. 
Onze hypothese was dat het gebruik van TNF-blokkers (zoals remicade, adalimumab 
en humira) door patiënten met reumatoïde artritis (RA) en andere inflammatoire 
aandoeningen, een specifieke risicofactor is voor chronische Q-koorts. Dit is al 
aangetoond voor andere intracellulaire infecties, met name voor tuberculose. In 
hoofdstuk 10 beschrijven we onze studie naar de prevalentie van anti-C. burnetii 
antistoffen bij RA patiënten met en zonder TNF-blokkers woonachtig in het 
Q-koorts endemisch gebied. In deze cohorten stelden we de diagnose chronische 
Q-koorts vast volgens de algemeen geldende Nederlandse richtlijn. We vonden een 
vergelijkbare prevalentie van C. burnetii infectie bij RA patiënten met en zonder 
TNF-blokkers. In de groep patiënten mét TNF-blokkers bleek 12,3% (7/57) van 
degenen met anti-C. burnetii antistoffen chronische Q-koorts te hebben, vergeleken 
met 5,5% (3/55) in de groep patiënten zonder TNF-blokkers (p=0,32). Vanwege het 
lage aantal chronische Q-koorts patiënten is de power van de studie beperkt en 
zou alleen een groot (>viervoudig) effect van TNF-blokkers op het risico op 
chronische Q-koorts aangetoond kunnen worden. Een interessante bevinding in 
deze studie was dat in een univariaat analyse van alle C. burnetii-geïnfecteerde RA 
patiënten (n=102) een associatie was te zien tussen gebruik van corticosteroïden en 
de ontwikkeling van chronische Q-koorts. Multivariaat analyse kon niet worden 
verricht vanwege het lage aantal chronische Q-koorts patiënten. Opvallend was, 
dat de prevalentie van chronische Q-koorts bij C. burnetii-geïnfecteerde RA patiënten 
veel hoger(8,9%) bleek te zijn dan eerder is gerapporteerd in een niet- geselecteerde 
geïnfecteerde populatie in hetzelfde gebied (1,6%) [23]. Dit impliceert dat RA en de 
behandeling ervan, met of zonder anti-TNF therapie, beschouwd moet worden als 
een risicofactor voor de ontwikkeling van chronische Q-koorts. Ons advies zou 
daarom zijn om in geval van C. burnetii infectie bij een patiënt met RA, zorgvuldige 
follow-up en analyse te verrichten met betrekking tot chronische Q-koorts.
In hoofdstuk 11 presenteren we een casus van een RA patiënt met acute Q-koorts 
tijdens behandeling met TNF-blokkers, die chronische Q-koorts ontwikkelt nadat 
hij is geswitched naar behandeling met anti-B-cell (anti-CD20) monoklonale 
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antilichamen (rituximab). Deze casus leverde een aantal interessante inzichten op. 
We zagen dat bij deze patiënt anti-TNF therapie in de acute fase van Q-koorts de 
ontwikkeling van een serologische respons niet verhindert. Echter, een intacte 
humorale respons heeft de ontwikkeling naar chronische Q-koorts niet voorkomen, 
waarschijnlijk omdat de essentiële cellulaire immuun respons onderdrukt was 
tijdens de acute fase van de infectie. Alhoewel anti-B-cell therapie was ingezet na 
de acute Q-koorts episode, werd een toename van de anti-C. burnetii fase I 
antistoffen geobserveerd, wat leidde tot de diagnose chronische Q-koorts. 
Aangezien CD20-positieve B-cellen op dat moment uitgeschakeld waren door 
rituximab, nemen we aan dat reeds gevormde C. burnetii-specifieke memory 
B-cellen (die CD20-negatief zijn) verantwoordelijk zijn voor deze stijging van de 
antistoftiters. Door depletie van CD20-positieve B-cellen onderdrukt rituximab 
echter de respons op ‘neo-antigenen’. Het is daarom te verwachten dat wanneer 
rituximab zou worden gebruikt op het moment van het eerste contact met C. 
burnetii (tijdens de acute infectie), er wel degelijk een serologische respons wordt 
verhinderd, en daarmee de diagnose van Q-koorts bemoeilijkt zou worden. 
DEEL IV. Preventie van Q-koorts door vaccinatie tegen C. burnetii
Vaccinatie tegen C. burnetii kan mensen bescherming bieden tegen Q-koorts. Er is 
wereldwijd één humaan vaccin beschikbaar: Q-vax® (CSL, Victoria, Australia). Dit 
is een geïnactiveerd whole-cell vaccin. Het protocol van de fabrikant schrijft voor 
dat er pre-vaccinatie screening moet plaatsvinden. Deze screening bestaat uit een 
huidtest en serologie. Beide testen moeten worden verricht om vaccinatiekandida-
ten uit te sluiten met een (asymptomatische of niet-als-zodanig-herkende) 
doorgemaakte Q-koorts. Van deze mensen wordt aangenomen dat ze een hoger 
risico hebben op immunogemedieerde overgevoeligheidsreactie op de vaccinatie. 
Tijdens de Nederlandse Q-koorts uitbraak is door de autoriteiten besloten om 
vaccinatie aan te bieden aan mensen met cardiale en/of vasculaire risicofactoren 
voor chronische Q-koorts woonachtig in het Q-koorts endemisch gebied. Dit was 
een uniek besluit: C. burnetii vaccinatie was tot dan toe alleen toegepast bij mensen 
in Australië met beroepsmatig een verhoogd risico op C. burnetii infectie (o.a. 
slachthuis medewerkers, schaapscheerders, dierenartsen), hetgeen een veel jongere 
en gezondere groep mensen omvat. 
 In hoofdstuk 12 beschrijven we de veiligheid en bijwerkingen van de Q-koorts 
huidtest en vaccinatie in de Nederlandse Q-koorts vaccinatie campagne. Vaccinatie 
van 1370 patiënten liet geen onverwachte bijwerkingen zien. Echter, 80% van alle 
gevaccineerden rapporteerden locale bijwerkingen, waarvan 26% heftig (volgens 
de algemeen geldende classificatie van vaccinatie bijwerkingen). Er werden 2 
ernstige ongewenste voorvallen (serious adverse events ‘SAE’; 0,1%) met een 
oorzakelijk verband vastgesteld. In beide gevallen ging het om een persisterende 
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subcutane zwelling op de injectie-plaats, zonder tekenen van een abces of 
granuloom. Hoewel we het niet met zekerheid kunnen concluderen, gaat het 
waarschijnlijk in beide gevallen niet om een immunologische respons tegen het 
vaccin, maar om een te diepe vaccinatie boven de insertie van de pees van de M. 
deltoïdeus. 
 Het voorkomen van locale bijwerkingen na de vaccinatie was geassocieerd met 
lokale bijwerkingen in de eerste dagen na de huidtest (met een negatieve aflezing 
van de huidtest na 7 dagen) en een hoge pre-vaccinatie C. burnetii-specifieke IFN-γ 
productie. De bijwerkingen vonden relatief meer plaats in vrouwen en bij jongere 
gevaccineerden. Bij gevaccineerden met lokale bijwerkingen na de huidtest en/of 
vaccinatie, was de post-vaccinatie immuun respons sterker (gemeten 6 maanden 
na vaccinatie). We concludeerden dat de Q-koorts vaccinatie veilig, maar reactief 
was in deze hoog-risico populatie met valvulaire / vasculaire risico factoren voor 
chronische Q-koorts. 
In hoofdstuk 13 onderzochten we in een steekproef van 260 gevaccineerden de 
post-vaccinatie immuun respons tegen C. burnetii, 6 en 12 maanden na vaccinatie. 
Na 6 maanden vonden we dat 46% van de gevaccineerden lage anti-C. burnetii 
antistoffen titers had en 67% een positieve IFN-γ test. Na 12 maanden was dit beide 
60%. Ter vergelijking: serologische resultaten van 200 individuen met een natuurlijk 
doorgemaakte Q-koorts infectie waren positief in 99,5% van de gevallen, zowel 
6 als 12 maanden na infectie, met hogere antistoffen titers. De immuun respons na 
Q-koorts vaccinatie is dus lager en beperkt tot een kleiner deel van individuen dan 
na een doorgemaakte Q-koorts infectie. Eerdere studies naar de immuun respons 
op hetzelfde Q-koorts vaccin bij Australische slachthuis medewerkers, schaap - 
boeren en dierenartsen rapporteren een groter percentage seroconversie en 
cellulaire immuun respons na vaccinatie [26-28]. Dit suggereert dat er een 
verminderde immunogeniciteit is van het vaccin in onze oudere populatie met 
risico factoren voor chronische Q-koorts. Een interessante bevinding in deze 
studie was dat gevaccineerden met een positieve uitkomst in de IFN-γ test 
voorafgaand aan de vaccinatie een hoger percentage aan seroconversie lieten zien 
dan gevaccineerden met vooraf een negatieve uitkomst in de IFN-γ test: 74% versus 
41% (P<0.001). Hieruit concludeerden we dat een positieve IFN-γ test voorafgaand 
aan vaccinatie in seronegatieve vaccinatiekandidaten waarschijnlijk duidt op 
pre-existente immuniteit, hetgeen resulteert in een versterkend effect van de 
vaccinatie. 
Hoofdstuk 14 richt zich op de Q-koorts huidtest die, als een in-vivo intracutane 
test, een immuun respons kan uitlokken. We laten zien dat de huidtest, met een 
lage dosis van de Q-vax antigenen, bij ongeveer de helft van de individuen een 
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duidelijke C. burnetii-specifieke immuun respons veroorzaakt (seroconversie en/of 
stijging van de IFN-γ productie). Daarnaast hadden Q-koorts seropositieve 
individuen gemiddeld een verdubbeling van de antistoffen titer door de huidtest. 
Aangezien al deze individuen aanwijzingen hadden voor een pre-existente 
immuniteit tegen C. burnetii (ofwel een positieve huidtest, ofwel seropositiviteit), 
kan dit effect van de huidtest worden beschouwd als boosting. Een soortgelijk 
boosting effect is beschreven van de tuberculine huidtest op herhaaldelijke 
metingen van de interferon-γ release assay (IGRA) respons: deze testen worden 
vaak sequentieel gebruikt voor de diagnose van latente tuberculose [29]. Dit 
fenomeen maakt het lastig voor clinici om het onderscheid te maken tussen 
boosting en conversie bij een toename van de IGRA respons na een tuberculine 
huidtest. Op grond hiervan zouden clinici en epidemiologen op het gebied van 
Q-koorts zich ervan bewust moeten zijn dat individuen die een huidtest hebben 
gehad, zoals gebruikelijk is bij pre-vaccinatie screening, in de daaropvolgende 
metingen een hogere anti-C. burnetii antistoffen titer en een robustere IFN-γ 
productie zullen laten zien.
In hoofdstuk 15 onderzochten we de dekkingsgraad van de Q-koorts vaccinatie 
campagne in Nederland in 2011. De campagne was bedoeld voor alle mensen met 
een risicofactor voor chronische Q-koorts woonachtig in het Q-koorts endemisch 
gebied. Prevalentie data van de gedefinieerde risicofactoren waren niet beschikbaar 
voorafgaand aan de campagne en er bestond geen geschikt registratiesysteem van 
deze aandoeningen in Nederland. Daarom was het vóór de start van de vaccinatie 
campagne lastig om een juiste inschatting te maken van de verwachte opkomst. 
Daarbij bleef het na afloop van de campagne onduidelijk hoeveel procent van de 
doelgroep was gevaccineerd. Het doel van onze retrospectieve cohort studie was 
om een hiervan een schatting te maken. Hiervoor identificeerden we allereerst het 
aantal mensen met de gedefinieerde risicofactoren in een steekproef van een 
Nederlandse huisartsen populatie-database, waaruit we de gestratificeerde 
prevalentie schattingen berekenden. Daarna extrapoleerden we deze prevalentie 
gegevens naar de populatie woonachtig in het Q-koorts epidemisch gebied. Dit 
leidde tot een schatting van ongeveer 12.000 mensen met een zekere of waarschijn-
lijke risicofactor voor chronische Q-koorts. Met behulp van de vaccinatie data van 
het aantal mensen uit dit gebied dat daadwerkelijk gescreened was voor Q-koorts 
vaccinatie, kwamen we tot een schatting van een totale dekkingsgraad van 11%. 
Gecorrigeerd voor het grotere aantal voor vaccinatie verwezen patiënten, was de 
geschatte dekkingsgraad 18%. Deze lage percentages moeten worden gezien in het 
licht van de complexiteit van deze doelgroep met vaak uitgebreide co-morbiditeit, 
en de vaccinatie procedure die een tweetal bezoeken aan een centrale GGD vereiste 
en gepaard ging met een invasieve pre-vaccinatie screeningsmethode. Bovendien 
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is bekend dat de dekkingsgraad van andere vaccinatie campagnes gericht op 
volwassen risico-groepen vaak teleurstellend laag is, zelfs na officiële en herhaaldelijke 
aanbevelingen. De hepatitis B vaccinatie voor mannen die sex hebben met mannen 
heeft bijvoorbeeld een geschatte jaarlijkse dekkingsgraad van 1% in Nederland [30]. 
Aangezien de Q-koorts epidemie in omvang afnam in de jaren na 2011, bleef de 
Q-koorts vaccinatie campagne beperkt tot 2011.
Algemene conclusies en toekomstig onderzoek
Meer kennis over immunologische aspecten van Q-koorts zal ons helpen bij het 
verbeteren van preventie, herkenning en behandeling van patiënten met Q-koorts.
De studies in dit proefschrift hebben nieuwe inzichten opgeleverd over de 
immunologie van Q-koorts, maar er zijn nog veel vragen onbeantwoord gebleven 
en nieuwe vragen ontstaan. 
 Ons toekomstig onderzoek zal zich richten op het verder ontcijferen van de 
aangeboren afweer respons van de gastheer tegen C. burnetii. We zullen verder 
onderzoeken welke factoren in de afweer predisponeren voor inefficiënte klaring 
van de infectie en het ontstaan van chronische Q-koorts. Hoewel we hebben 
gevonden dat de IFN-γ respons niet defect is bij chronische Q-koorts patiënten, 
zouden patiënten die niet opknappen door langdurige antibiotische behandeling, 
gebaat kunnen zijn bij het toevoegen van immuno-stimulerende behandeling met 
IFN-γ. Met name bij chronische Q-koorts patiënten met persisterend lage in-vtro 
IFN-γ productie, zou het verhogen van de verdedigingsmechanismen van het 
afweersysteem door middel van IFN- γ therapie (Immukine) gunstig kunnen zijn.
Een andere belangrijke vraag die nog antwoord behoeft, is hoe C. burnetii in staat 
is om te overleven in mononucleaire fagocyten op predelictie plaatsen zoals 
aangedane hartkleppen en de wand van aneurysmata. Een beter begrip van het 
lokale immunologische milieu in door C. burnetii geïnfecteerde aneurysmata/
hartkleppen, en de betrokken mechanismen die het weefsel beschadigen, vormen 
een mogelijke sleutel tot betere behandelopties voor chronische Q-koorts patiënten. 
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Dankwoord
Dit proefschrift is tot stand gekomen met betrokkenheid van velen. Gelukkig heb 
ik hier de mogelijkheid om hen te noemen en te bedanken.
Om te beginnen wil ik alle patiënten en vrijwilligers die hebben meegedaan aan 
één van de studies in dit proefschrift van harte bedanken. Zonder hun deelname 
was het niet gelukt om dit onderzoek naar Q-koorts uit te voeren. De persoonlijke 
contacten hielden me bij de les over voor wie het onderzoek bedoeld is. Ook in de 
komende jaren zal ik ernaar blijven streven om bij te dragen aan meer kennis over 
Q-koorts en daardoor aan betere zorg voor mensen met Q-koorts.  
Verder zijn er veel mensen dat ik graag wil bedanken voor de samenwerking, de 
steun en de nodige gezelligheid tijdens het tot stand komen van dit proefschrift.
Dr. ir. van Deuren. Beste Marcel, dit proefschrift heb ik vooral samen met jou 
gemaakt. Ik hoop dat je er net zo trots op bent als ik. We hebben er gezamenlijk 
veel tijd aan besteed. Ik waardeer je erg om je wetenschappelijke originaliteit, je 
enorme kennis van de immunologie en je vasthoudendheid. In je begeleiding gaf 
je me veel vrijheid om zelf de juiste weg te vinden, maar als ik advies nodig had 
was je er altijd. Qua koppigheid tijdens onze besprekingen zijn we aan elkaar 
gewaagd zou ik zeggen, maar altijd vanzelfsprekend met humor. Met name onze 
autoritten van hot naar her zijn een levendige herinnering, waarin de gezamenlijke 
interesses de revue passeerden. Dat je daarbij af en toe het gaspedaal vergat in te 
drukken, is je vergeven. Bedankt voor alles!
Prof. dr. Van der Meer. Beste Jos, heel veel dank voor jouw grote inzet in dit 
promotie traject. Je was er altijd op cruciale momenten met ondersteuning en wijze 
raad. Vooral ook bedankt voor je vanzelfsprekende vertrouwen in mij. Wanneer ik 
twijfelde of het wel ging lukken, gaf jij me een extra duwtje in de rug. Ik heb veel 
geleerd van jouw overzicht over de materie en scherpe opmerkingen. Ik ben er 
trots op dat je mijn promotor bent.
Prof. dr. Netea. Beste Mihai, je gaf me als student de kans om op het lab Experimentele 
Geneeskunde te proeven aan immunologisch onderzoek. Ik ben erdoor gegrepen. 
Bedankt voor de kans die je me vervolgens bood om te blijven en een onderzoek 
naar de immunologie van Q-koorts op te starten. Ook al stond je kleine agenda 
volgeschreven met afspraken, je was altijd bereid tot overleg: er was altijd wel een 
gaatje te vinden. Onze discussies waren altijd zeer efficiënt: in een paar stappen 
kwamen we tot de kern van de zaak, zowel het grote plaatje als de details, en in een 
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mum van tijd waren we alweer een paar stappen vooruit. Ik hoop in de toekomst 
nog veel met je te mogen samenwerken.
Dr. Sprong. Beste Tom, ik vind het erg leuk dat je mijn copromotor bent. Ik begon 
als student onder jouw hoede en werd aangestoken door jouw enthousiasme voor 
onderzoek. Je optimisme is onuitputtelijk, ook al had je het vaak te druk om zoveel 
tijd vrij te maken voor onderzoek als je zou willen. In huize Sprong stond echter 
altijd de deur open voor een kop koffie en overleg aan de keukentafel. We lijken in 
best veel opzichten een beetje op elkaar, waaronder onze voorliefde voor Richard 
Dawkins en de kerstverhalen van Aart Staartjes om maar wat te noemen. Alleen is 
bij ons laatste gezamenlijk congres in Berlijn gebleken dat ik je niet kan bijbenen 
met de hoeveelheid bier op een avond. Graag wil ik een herkansing bij het volgende 
ECCMID.
Leden van de manuscript-commissie,  Prof. dr. Verweij, Prof. dr. Hermans en Prof. 
dr. Coutinho: hartelijk bedankt voor het lezen en beoordelen van mijn manuscript. 
Dr. Bleeker-Rovers. Beste Chantal, bedankt voor de prettige samenwerking binnen 
het Q-koorts onderzoek. Het is duidelijk dat de Q-koorts patiënten bij jou in erg 
goede handen zijn. Bovendien is jouw klinische ervaring met Q-koorts erg waardevol 
voor het wetenschappelijk onderzoek op dit gebied. Er zijn nog veel onderzoeks-
vragen onbeantwoord; hopelijk komen we in de komende jaren hiermee verder 
vooruit.
Prof. dr. Joosten. Beste Leo, bedankt voor de mogelijkheden die jij en Mihai mij 
hebben geboden in jullie lab. Zonder jouw inzet was het niet gelukt om het Q-koorts 
onderzoek van de grond te krijgen. Je was gedurende het onderzoek de rots in de 
branding waar het aankwam op algemene kennis, praktische labzaken en zakelijk 
inzicht. Dank voor al je adviezen en je altijd aanwezige humoristische insteek. 
Dr. Van de Vosse. Beste Esther, met heel veel plezier heb ik met jou samengewerkt. 
Je nuchterheid en doortastendheid was een verademing in de wetenschapswereld 
waar alles vaak trager en moeizamer gaat dan je zou willen. Ik heb veel van je 
geleerd met betrekking tot immunologie en genetica van infectieziekten. De paar 
maanden die ik gedeeltelijk op het laboratorium infectieziekten in het LUMC heb 
doorgebracht voor DNA isolatie en SNP analyse zijn onvergetelijk, samen met 
Tanny van der Reijden en Sleutelstad FM. Tanny, bedankt voor je enorme hulp en 
ondersteuning met ‘alle DNA-tjes’.
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Dear professor Raoult, thank you for your hospitality by receiving me at your lab 
in Marseille and allowing me to join you at the outpatient clinic. It was a great 
honour. Sophie Edouard, thank you for showing me around in the lab and 
facilitating the experiments I performed during my stay.
Dear professor Jean-Louis Mege, I am very happy that we met each other in 
Marseille. In our discussions it soon became clear that there was a mutual wish to 
work together on research to the immunology of Q fever. Your visit to Nijmegen 
was the start of our collaboration, of which I am sure will lead to many more 
interesting studies in the future.  
Julien Textoris, thanks a lot for the close collaboration on the analysis of the 
microarray data of C. burnetii infection in patients and healthy individuals. The 
discussions of data that we had via facetime and email are unforgettable. You 
patiently taught me a lot about principal component analysis, pathway analysis of 
gene expression data, and how to use the software that was needed. It was a 
challenge for me, but I really enjoyed it. I hope to meet you again in real-life.    
Dr. Gilbert Kersh. Thank you Gil, for the fruitful collaboration and the great time I 
had at the Q fever lab of the CDC. I had a warm welcome in your group with Josh, 
Kelly, Rachael and Charlie. Among many other things, I particularly enjoyed the 
hamburgers we had for lunch! I hope we can continue the collaboration on Q fever 
research.
Patricia Vermeer-de Bondt. Beste Patricia, wat heb ik veel tijd bij jou op het LCI van 
het Centrum voor Infectieziektebestrijding van het RIVM  doorgebracht om de 
gegevens voor de vaccinatie database te verzamelen, te ordenen en te analyseren. 
En wat waren we kritisch met z’n tweeën. Ik heb veel met en om je moeten lachen. 
En dan waren er ook nog onze talloze stormachtige telefonische- en email-overleg-
gen, ook altijd met een kritische noot. Ik heb met veel plezier met je samengewerkt 
en heel veel van je geleerd! Aura Timen en Leslie Isken, bedankt voor jullie steun 
bij het verkrijgen van de gegevens en jullie bereidheid om samen te werken. 
In het Erasmus MC mochten we voor de schatting van de dekkingsgraad van de 
Q-koorts vaccinatie-campagne gebruik maken van de IPCI database onder leiding 
van Miriam Sturkenboom. Ann Vanrolloghem ben ik veel dank verschuldigd voor 
de geduldige hulp bij het wegwijs worden in de IPCI database. 
De club van het Centraal Veterinair Instituut in Lelystad heeft erg belangrijk 
onderzoek verricht gedurende de Q-koorts epidemie. Annemieke Dinkla, je bent 
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onmisbaar  geweest voor onze immunologische experimenten door het kweken 
van de bacterie. Bedankt voor je bereidheid me te introduceren op een BLS 3 lab. 
Hendrik-Jan Roest en Annemarie Rebel, we hebben fijn samengewerkt en voor mij 
was het ook erg leerzaam om de problematiek eens vanuit veterinair perspectief te 
bekijken. Geiten zijn geen mensen, ook niet als het aankomt op de immunologie 
van Q-koorts. Ik kijk met veel plezier terug op onze meetings met appeltaart in een 
wegrestaurant halverwege tussen Lelystad en Nijmegen.   
Allerbeste Henk Bijlmer en Tineke Herremans: hartelijk dank voor de productieve 
samenwerking vanuit het IDS (voorheen LIS) van het Centrum voor Infectieziekte-
bestrijding van het RIVM bij het onderzoek naar de immuun respons bij Q-koorts 
vaccinatie. Ik hoop dat we elkaar in de toekomst nog regelmatig treffen. Renée van 
Boxtel, bedankt voor de ondersteuning bij de opzet en uitvoering van het post- 
vaccinatie onderzoek. Carola Wouters, je was een onmisbare kracht vanuit het 
secretariaat tijdens de uitvoering van het post-vaccinatie onderzoek: bedankt voor 
je grote inzet!
Clementine Wijkmans en andere medewerkers van de GGD Hart voor Brabant: 
bedankt dat ik deel mocht uitmaken van het uitvoerende team van het Q-koorts 
screening- en vaccinatie programma. Ik heb met bewondering gezien hoe er binnen 
no-time werd opgeschaald toen bleek dat er veel meer deelnemers waren dan 
verwacht. Desondanks bleef er aandacht voor het wetenschappelijk onderzoek dat we 
aan de vaccinatie-campagne hebben gekoppeld en dat is erg waardevol gebleken. 
Beste Hans Rümke, je was vanuit Vaxinostics vanaf het begin betrokken bij de 
opzet en uitvoering van de Q-koorts vaccinatie campagne. Hartelijk dank voor je 
bereidheid om samen te werken aan het onderzoek naar Q-koorts. 
Vanuit ons onderzoek naar de interferon-gamma respons bij C. burnetii infecties, is 
door InnatOss onder leiding van Anja Garritsen een diagnostische Q-koorts test 
(Q-detectTM) ontwikkeld. Ik vind het knap hoe dit is gelukt en ik wens dat het 
bijdraagt aan betere diagnostiek naar Q-koorts. Margot de Vries: het was prettig 
om met je samen te werken bij jouw pionierswerk voor InnatOss.
Marjonne Creemers, Linda Kampschreur en Sonja van Roeden wil ik bedanken voor 
de samenwerking bij het onderzoek naar Q-koorts bij reumatoide artritis. In de Sint 
Maartenskliniek heb ik veel hulp gehad van Joke Vriezenkolk, een ster in logistiek, 
waardoor de uitvoering nagenoeg vlekkeloos verliep. Mashid Fahimnia heeft veel 
werk verzet om mij te helpen met het invullen van de case report forms. Alfons den 
Broeder wil ik graag bedanken voor zijn kritische bijdrage aan de artikelen. 
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Ton de Haan (Radboudumc), hartelijk dank voor je hulp bij de statistische analyse, 
daar waar mijn eigen kennis van statistiek te kort schoot. Ook al benaderden we 
het probleem vanuit verschillende disciplines, het lukte toch aardig goed om 
elkaar in het midden te vinden en te begrijpen. Ik ken niemand anders die in de 
ochtend een kwartiertje te laat komt op de afspraak omdat de ochtendkrant te 
spannend was, maar ik kan me er wel iets bij voorstellen. 
Albert Wong (RIVM), bedankt voor je betrokkenheid en je geduldige uitleg bij het 
analyseren van de gegevens over de Q-koorts vaccinatie. Je zult wel af en toe 
stiekem een diepe zucht hebben geslaakt als Patricia en ik bij je langs waren 
geweest met onze ingewikkelde data, maar daar hebben we gelukkig niets van 
gemerkt.
Veel dank ook aan alle internisten die zich inzetten voor de behandeling van 
Q-koorts patiënten en die hebben meegeholpen om het onderzoek mogelijk te 
maken: Marjolijn Pronk, Yvonne Soethoudt, Monique Leclercq, Jacqueline Buijs, 
Marjo van Kasteren, Shahan Shamelian en Ton Dofferhoff. Gijs Limonard, bedankt 
voor de samenwerking op het gebied van ELISPOT en de interferon-gamma test. 
Ik ben er trots op dat we een lans hebben gebroken voor nieuwe diagnostische 
mogelijkheden voor Q-koorts. 
Eveneens dank aan de arts-microbiologen die betrokken zijn geweest bij de studies 
in dit proefschrift: Marjolijn Wegdam-Blans, Marrigje Nabuurs-Franssen en Peter 
Wever.
De analisten op het lab Medische Microbiologie in het CWZ, waaronder Bea van 
Groezen, Mary Smolders en Dorien van Gülick hebben voor de studies in dit 
proefschrift veel serologische bepalingen verricht, waarvoor veel dank. Het was 
altijd tot in de puntjes georganiseerd, en met grote  vanzelfsprekendheid werden 
bepaalde serologische samples opgediept uit de -80 vriezers.    
Ik wil graag de internisten in het Slingeland ziekenhuis in Doetinchem - Erik, 
Foeke, Inge, Job, Nail, Cees, Aart, Alexandra en Richard - bedanken voor de fijne 
begeleiding sinds ik ben begonnen als internist in opleiding. Na mijn promotie- 
onderzoek had ik nog weinig ervaring in de kliniek en ‘kwam ik uit een reageerbuis’ 
zoals de opleider het verwoordde. Ik werk met veel plezier en leer in een rap tempo. 
Alle mede-A(N)IOS: Kavish, Delia, Lenny, Anke, Marjolein, Joline, Marwi, Doreen, 
Louise, Joris en Inke, bedankt voor de gezellige samenwerking. 
350
CHAPTER 18
Heel veel dank gaat uit naar de analisten van het lab Experimentele Interne 
Geneeskunde in het Radboudumc waar ik de afgelopen jaren heb gewerkt: Trees, 
Liesbeth, Helga, Heidi, Cor, Anneke, Ineke, Magda en Johanna. Jullie vervullen 
een sleutelrol op het lab en zijn onmisbaar voor de continuïteit. Mede dankzij jullie is 
het lab EIG een fijne werkplek. Bedankt voor de interesse die jullie altijd tonen en 
alle gezellige koffiemomenten. Trees en Liesbeth, bedankt voor het mij wegwijs 
maken op het lab, en Trees ook voor je ondersteuning bij het verrichten van 
tientallen interferon-gamma ELISAs. Johanna, jij begon ooit de uitvoering van de 
immunologische Q-koorts experimenten en ik mocht al snel het stokje van je 
overnemen. Helga en Heidi, bedankt voor jullie hulp met alle bestellingen en niet 
te vergeten voor jullie hulp met de bloedafnames in de Sint Maartenskliniek. Cor, 
jij bent niet te missen op het lab! Je hebt me geholpen met tal van zaken, bedankt 
daarvoor en “de Klonten”! 
Alle (ex)collega’s op het lab EIG wil ik bedanken voor de gezellige werksfeer op het 
lab en in de buitenhoek en voor alle leuke activiteiten daarbuiten: Ajeng, Anca, 
Anne J, Anne A, Arjan, Bas B, Bas H, Daniella, Diana, Duby, Edwin, Ekta, Erik, 
Frank, Gosia, Henry, Hinta, Jaap, James, Janna, Jessica, Johanneke, Karin, Kathrin, 
Katharina, Khutso, Kiki, Maartje, Marije, Mark G, Mark S, Martin, Megan, Meta, 
Monique, Rinke, Rob, Ruud, Sanne, Siroon, Suzanne, Tania, Theo, Thijs, Tim, Vesla, 
Will, Xiaowen, Xinhui en Zewen. 
De medewerkers van post blauw op de polikliniek Interne Geneeskunde in het 
Radboudumc wil ik bedanken voor hun medewerking bij de extra bloedafnames 
van deelnemers aan onze studies. Dat verliep altijd feilloos.
De dames van het secretariaat Interne Geneeskunde in het Radboudumc - Helen, 
José, Gonny, Miriam, Sandra en Marijke - ben ik veel dank verschuldigd voor de 
administratieve ondersteuning tijdens het uitvoeren van de verschillende studies. 
Er kwamen nogal wat poststukken en telefoontjes op mijn naam binnen, maar 
jullie hebben deze altijd in goede banen geleid. Ik liep graag binnen voor een 
dropje uit de pot en een gezellig gesprek. 
Bastiaan de Galan, kamergenoot van Marcel, dankjewel voor het geduld dat je 
opbracht als Marcel en ik naast jou weer eens met elkaar zaten te discussiëren, waar 
je soms ongewild bij betrokken werd. Had je ook wel eens stiekem oordopjes in?
Beste Julia, Joris, Lieke, Gabriëlla, Marjolijn, Linda, en andere mede-promovendi 
die onderzoek deden of nog doen naar Q-koorts. Wat goed dat we vanuit heel 
verschillende invalshoeken bijdragen aan meer kennis over Q-koorts. Bedankt 
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voor de prettige contacten en samenwerking. Ruud en Anne J, ik wens jullie veel 
succes en plezier met de voortzetting van het onderzoek naar immunologie en 
Q-koorts in het Radboudumc. Ik vind het erg leuk dat ik jullie daarin mag 
begeleiden. 
Mijn kamergenoten van de Q-room: Stephan, Anne, Siroon, Martin en Megan. Het 
was erg gezellig op onze werkkamer in de buitenhoek en er was altijd wel iemand 
beschikbaar voor serieuze en minder serieuze gesprekken. De combinatie-geur 
van (aangebrande) tosti en (eveneens aangebrande) koffie zal altijd een goede 
herinnering blijven. 
Stephan en Anne, Q-koorts maatjes van het eerste uur, het is voor mij vanzelfsprekend 
dat jullie mijn paranimfen zijn. De afgelopen jaren hebben we gezamenlijk een 
leuke tijd gehad, binnen en buiten het werk. Steef, als vaste ECCMID-maatjes 
hebben we heel wat hotelkamers onveilig gemaakt, ..nou ja vooral jij dan.., en 
hebben we ons tegoed gedaan aan de ‘lokale cuisine’. Je bent een fijne collega! 
Anne, ik heb met heel veel plezier nauw met je samengewerkt. Ik heb bewondering 
voor je positivisme en openheid in alles wat je doet. Ik mis al ons geklets tijdens het 
werken in de flowkast. Ik kom snel een keer bij je langs in Lausanne!
Mijn fijne vrienden, dank voor de gezelligheid en ontspanning buiten het werk. 
Dennis, omdat we al vrienden zijn sinds de kleuterschool, is het altijd als vanouds 
als we samen op pad gaan. Lisanne en Miriam, we zijn al lang vriendinnen en ik 
hoop dat dit nog lang zo blijft, ook met jullie mannen Sten en Sebas. Breg, je bent 
een lieve vriendin en ik leer veel van je optimistische kijk op alles. Nancy, jij maakt 
me altijd aan het lachen! Rianne, Lonneke en Heleen, we hebben samen veel 
plezier beleefd al  sinds onze studietijd en ik kijk elke keer weer naar uit naar 
onze gezamenlijke uitstapjes. Els, Lian, Chantalle en Margriet, jullie zijn fijne 
vriendinnen die ik niet wil missen. Stephan en Tjerk, bedankt voor jullie vriendschap. 
Martijn, Marjanka, Ruben, Marjonne en Rob: de BBQ-kwaliteiten worden alleen 
maar beter met veel oefening, dus ik plan vast de volgende in onze nieuwe tuin. 
Jan en Inge, ik zoek jullie graag op om Indonesisch te koken. Sonja en Stephan, ook 
al is de tussenliggende afstand groot, de wederzijdse bezoekjes zijn altijd weer 
gezellig. Lucas en Ellen, jullie zijn een toffe schoonbroer en schoonzus. 
Piet en Frederiek, bedankt voor jullie belangstelling. Oma, je bent de beste! Je hebt 
inmiddels al veel verdedigingen van (schoon)klein -kinderen bijgewoond. Ik hoop 
dat je dit keer weer komt! Loes en Ronald, dankzij jullie heeft mijn proefschrift een 
mooie kaft gekregen. Heel erg bedankt daarvoor. 
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Joop en Tineke, dankjulliewel voor jullie gastvrijheid in Wittelte. Joop, ik vind het 
leuk dat we elkaar ook tegenkomen op gezamenlijke congressen. In je verstrooidheid 
vergat je eens om bij mijn poster presentatie te komen kijken. Vergeet je niet om 
naar mijn verdediging te komen?!
Mijn lieve zussen Mayke, Lot, Sanne en Rafke en broer Thijs. Als jongste van het 
stel heb ik veel plagerij doorstaan, maar ben ik eigenlijk ook wel het meest verwend. 
We delen fijne jeugdherinneringen en nog steeds delen we veel in elkaars leven. 
Inmiddels ook met mijn leuke zwagers Henry, Michiel, Morten en Paul en mijn 
lieve schoonzus Mayke. Ik realiseer me hoeveel geluk ik heb met zoveel broers 
en zussen. Alle nichtjes en neefjes komen daar nog eens bij. Wat fijn dat jullie er 
altijd zijn!
Lieve pap en mam, ik kan niet uitdrukken hoe belangrijk jullie voor mij zijn. 
Dankjewel voor jullie onvoorwaardelijke steun en betrokkenheid. Bij jullie voelt 
het nog altijd als thuis.  
Marnix, mijn allerliefste, jouw “komt wel goed schatje” klonk steevast als ik weer 
eens zat te mopperen dat iets me waarschijnlijk niet zou gaan lukken. En inderdaad 
kwam het altijd goed. Jij bent voor mij onmisbaar in alle opzichten!
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